crnx-10k_20201231.htm

0001564590-21-016719.txt : 20210330 0001564590-21-016719.hdr.sgml : 20210330 20210330171259 ACCESSION NUMBER: 0001564590-21-016719 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 70 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210330 DATE AS OF CHANGE: 20210330 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Crinetics Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001658247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263744114 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38583 FILM NUMBER: 21787774 BUSINESS ADDRESS: STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-450-6464 MAIL ADDRESS: STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 10-K 1 crnx-10k_20201231.htm 10-K crnx-10k_20201231.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

Form 10-K

(Mark One)

☒	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2020

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-38583

Crinetics Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware		26-3744114
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

10222 Barnes Canyon Road, Bldg. #2, San Diego, California		92121
(Address of principal executive offices)		(Zip code)

Registrant’s telephone number, including area code: (858) 450-6464

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Name of Each Exchange on Which Registered
Common Stock, par value $0.001 per share	Nasdaq Global Select Market

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Securities Exchange Act of 1934.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934). Yes ☐ No ☒

As of June 30, 2020 (the last business day of the registrant’s most recently completed second fiscal quarter), the aggregate market value of the registrant’s common stock held by non-affiliates of the registrant was approximately $505.7 million, based on the closing price of the registrant’s common stock on the Nasdaq Global Select Market on such date of $17.52 per share.

The number of outstanding shares of the registrant’s common stock, par value 0.001 per share, as of February 26, 2021 was 33,028,876.

DOCUMENTS INCORPORATED BY REFERENCE

Certain sections of the registrant’s definitive proxy statement for the 2021 annual meeting of stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after end of the fiscal year covered by this Form 10-K are incorporated by reference into Part III of this Form 10-K.

CRINETICS PHARMACEUTICALS, INC.

FORM 10-K — ANNUAL REPORT

For the Fiscal Year Ended December 31, 2020

Table of Contents

		Page
PART I
Item 1	Business	3
Item 1A	Risk Factors	28
Item 1B	Unresolved Staff Comments	67
Item 2	Properties	67
Item 3	Legal Proceedings	67
Item 4	Mine Safety Disclosures	67

PART II
Item 5	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	68
Item 6	Selected Financial Data	68
Item 7	Management’s Discussion and Analysis of Financial Condition and Results of Operations	69
Item 7A	Quantitative and Qualitative Disclosures About Market Risk	76
Item 8	Financial Statements and Supplementary Data	76
Item 9	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	76
Item 9A	Controls and Procedures	76
Item 9B	Other Information	77

PART III
Item 10	Directors, Executive Officers and Corporate Governance	78
Item 11	Executive Compensation	78
Item 12	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	78
Item 13	Certain Relationships, Related Transactions and Director Independence	78
Item 14	Principal Accounting Fees and Services	78

PART IV
Item 15	Exhibits, Financial Statement Schedules	79
Item 16	Form 10-K Summary	79
	Signatures

PART I

Forward-Looking Statements and Market Data

This annual report on Form 10-K contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this annual report, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations and future results of anticipated products, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. This annual report on Form 10-K also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this annual report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this annual report and are subject to a number of risks, uncertainties and assumptions, including those described in Part I, Item 1A, “Risk Factors.” The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

We use our pending trademark Crinetics in this annual report. This annual report also includes trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, trademarks and tradenames referred to in this annual report appear without the ^® and ™ symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and tradenames.

Summary of Risk Factors

An investment in our securities involves a high degree of risk. You should carefully consider the risks summarized in Item 1A, “Risk Factors,” included in this report. These risks include, but are not limited to, the following:

•

We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.

•

We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.

•

We are early in our development efforts and have only three product candidates in clinical development. All of our other research programs are still in the preclinical or discovery stage. If we are unable to successfully develop product candidates or experience significant delays in doing so, our business will be materially harmed.

•

We cannot assure you that we will be able to successfully develop any product candidates.

•

Preclinical and clinical drug development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results. Our product candidates may not have favorable results in later clinical trials, if any, or receive regulatory approval.

•

Any delays in the commencement or completion, or termination or suspension, of our clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.

•

The COVID-19 pandemic could adversely impact our business, including our drug manufacturing, nonclinical activities and clinical trials.

•

We may find it difficult to enroll patients in our clinical trials given the limited number of patients who have the diseases for which our product candidates are being developed. If we encounter difficulties enrolling subjects in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.

•

Our product candidates are subject to extensive regulation and compliance, which is costly and time consuming and which may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.

•

We face competition from entities that have developed or may develop somatostatin agonist products or other product candidates. If these companies develop technologies or product candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize products may be adversely affected.

•

We rely on third parties for the manufacture of our product candidates for preclinical and clinical development and expect to continue to do so for the foreseeable future. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.

•

Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.

•

We are dependent on the services of our management and other clinical and scientific personnel, and if we are not able to retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer.

•

Our success depends on our ability to protect our intellectual property and our proprietary technologies.

•

The trading price of the shares of our common stock could be highly volatile, and purchasers of our common stock could incur substantial losses.

Item 1. Business

Business Overview

We are a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Endocrine pathways function to maintain homeostasis and commonly use peptide hormones acting through G protein coupled receptors, or GPCRs, to regulate many aspects of physiology including growth, energy, metabolism, gastrointestinal function and stress responses. We have assembled a seasoned team with extensive expertise in drug discovery and development in endocrine GPCRs and built a highly productive drug discovery organization. We have discovered a pipeline of oral nonpeptide (small molecule) new chemical entities that target peptide GPCRs to treat a variety of rare endocrine diseases where treatment options have significant efficacy, safety and/or tolerability limitations. Our product candidates include paltusotine (formerly CRN00808) which is in clinical development for the treatment of acromegaly and neuroendocrine tumors, or NETs, CRN04777, which is in clinical development for congenital hyperinsulinism, or HI, and CRN04894, which is in clinical development for diseases of excess adrenocorticotrophic hormone, or ACTH, including Cushing’s Disease, congenital adrenal hyperplasia, or CAH, and Ectopic ACTH Syndrome, or EAS. We are advancing additional product candidates through preclinical discovery and development studies in parallel. Our vision is to build the leading endocrine company which consistently pioneers new therapeutics to help patients better control their disease and improve their daily lives.

We focus on the discovery and development of oral nonpeptide therapeutics that target peptide GPCRs with well understood biological functions, validated biomarkers and the potential to substantially improve the treatment of endocrine diseases and/or endocrine-related tumors. Our pipeline consists of the following product candidates:

Paltusotine (SST2 Agonist Program)

Paltusotine, our lead product candidate, establishes a new class of oral selective nonpeptide somatostatin receptor type 2, or SST2, agonists designed for the treatment of acromegaly and NETs. Somatostatin is a neuropeptide hormone that broadly inhibits the secretion of other hormones, including growth hormone, or GH, from the pituitary gland. Acromegaly arises from a benign pituitary tumor that secretes excess GH that, in turn, causes excess secretion of insulin-like growth factor-1, or IGF-1, by the liver. This loss of homeostasis in the GH axis results in excess tissue growth and other adverse metabolic effects throughout the body. Approximately 26,000 people in the United States suffer from acromegaly, and depending on surgical success, many are candidates for chronic pharmacological intervention, of which somatostatin peptide analogs are the primary pharmacotherapy. NETs originate from neuroendocrine cells commonly found in the gut, lung or pancreas. Typically, NETs are only diagnosed at a time of extensive metastatic disease and will often progress to liver failure. NETs are present in approximately 171,000 adults in the United States. Most NETs overexpress SST2 receptors and injected depots of peptide somatostatin analogs have become the first-line standard of care for many NETs patients as detailed in National Comprehensive Cancer Network guidelines. In 2020, injected somatostatin peptide drugs accounted for approximately

$3.2 billion in global sales for the treatment of acromegaly, NETs and other uses. These drugs require painful monthly or daily injections and, in the case of somatostatin peptide drugs, often fail to fully control the disease in many acromegaly patients. In July 2020, we announced that the FDA granted orphan drug designation for paltusotine for the treatment of acromegaly.

We have completed two global Phase 2 clinical trials of paltusotine in acromegaly patients, the ACROBAT Evolve, or Evolve, and ACROBAT Edge, or Edge, trials. The Evolve trial was a double-blind, placebo-controlled, randomized withdrawal study designed to evaluate the safety, efficacy, and pharmacokinetics of paltusotine, in subjects with acromegaly whose disease is biochemically controlled by octreotide LAR or lanreotide depot monotherapy. The Edge trial was an open label exploratory study primarily designed to evaluate the safety, efficacy, and pharmacokinetics of paltusotine in subjects with acromegaly that are treated with somatostatin analog monotherapy but whose disease is not biochemically controlled. Patients who completed the Evolve and Edge trials were eligible to enter the ACROBAT Advance trial, which is an open label, long term extension study designed to continue to evaluate the safety and efficacy of paltusotine in patients.

In October 2020, we announced positive topline results from the ACROBAT Phase 2 program in acromegaly. The prespecified primary endpoint in Edge was achieved, showing that once daily oral paltusotine maintained IGF-1 levels at Week 13 in acromegaly patients who were switched from an injected somatostatin receptor ligand, or SRL, depot of either octreotide or lanreotide monotherapy [change in IGF-1 = -0.034 (-0.107, 0.107), median (IQR)]. There were 25 patients enrolled in this prespecified primary analysis population (Group 1). During the four-week washout period after the 13-week treatment period, Group 1 patients showed a meaningful (>20%) and prompt (within two weeks) rise in IGF-1 levels from baseline, which provided evidence regarding the magnitude of therapeutic activity of oral paltusotine in acromegaly patients. Edge also enrolled an additional 22 patients into four different exploratory populations (Groups 2-5).

Enrollment in Evolve was terminated early, enabling data to be available for regulatory interactions on the same timeline as for the Edge study. The reduced sample size did not allow for meaningful statistical comparisons between groups in the randomized withdrawal period. Data from these patients on lower doses of paltusotine were included in the post-hoc dose response analyses in combination with data from patients in the Edge study, most of whom received the higher doses. Post-hoc analyses of patients in Edge (Group 1; n=25) and Evolve (n=13) were conducted in order to explore the effect of paltusotine dose on IGF-1 suppression. These analyses provided evidence of a dose response across the dose range of 10 to 40 mg. Dose-dependent results were observed when evaluating the effect on IGF-1 levels from: 1) switching from injectable SRL to paltusotine, and 2) withdrawing paltusotine during the washout phase. These data inform the selection of doses to be evaluated in future studies. Paltusotine was generally well tolerated among the 60 ACROBAT participants (including both Edge and Evolve), which is consistent with prior clinical findings in healthy volunteers. There were no discontinuations due to drug-related adverse events, no safety signals seen in clinical laboratory analyses, no treatment-related serious adverse events, or SAEs, and no patients required rescue treatments with standard acromegaly medications during treatment. The most common treatment-emergent adverse events (>10%) included: headache, arthralgia, fatigue, peripheral swelling, paresthesia and hyperhidrosis.

Based on feedback from our interactions with the U.S. Food and Drug Administration, or FDA, and other regulators, we have defined our planned Phase 3 development program which will consist of two placebo-controlled clinical trials. We plan to conduct the PATHFNDR-1 trial, which is designed as a double-blind, placebo-controlled, nine-month clinical trial of paltusotine in 52 acromegaly patients with average IGF-1 levels less than or equal to 1.0 times the upper limit of normal, or ULN, and who are on stable doses of SRL monotherapy (octreotide LAR or lanreotide depot). The primary endpoint is the proportion of patients with IGF-1 ≤ 1.0 × ULN at the end of the nine-month treatment period on paltusotine as compared to placebo. We also plan to conduct a second study, the PATHFNDR-2 trial, which is designed as a double-blind, placebo-controlled, twelve-week trial in 74 acromegaly patients with elevated IGF-1 levels who are medication naïve or who are not being treated with pharmacotherapy (untreated patients). The primary endpoint in this study is also the proportion of patients with IGF-1 ≤ 1.0 × ULN at the end of the treatment period on paltusotine as compared to placebo. A new tablet formulation of paltusotine is planned for use in both trials. When evaluated in a Phase 1 pharmacokinetic healthy volunteer study, the tablet formulation had a reduced fasting requirement when compared to the capsule formulation that was used in prior trials and dose proportional exposure was observed up to 80 mg. We plan to initiate our Phase 3 program in the second quarter of 2021 and expect top line data from both studies in 2023. We believe that, if successful, these trials could support registration of paltusotine in the United States and Europe for all acromegaly patients who require pharmacotherapy, including untreated patients and those switching from standard of care.

We were also developing CRN01941, which is an investigational, oral, nonpeptide SST2 agonist, initially in development for the treatment of NETs. We completed a Phase 1 clinical trial in healthy volunteers to examine the safety, tolerability, pharmacokinetics, and pharmacodynamics of CRN01941. Phase 1 data for CRN01941 showed that the compound did not provide an improvement over paltusotine. Therefore, we discontinued development of CRN01941 to focus our resources on development of paltusotine for both acromegaly and NETs. We believe that focusing on paltusotine offers the best path forward for our SST2 franchise. We plan to initiate a Phase 2

trial in patients with NETs complicated by carcinoid syndrome in 2021.

CRN04777 (SST5 Agonist)

CRN04777 is our investigational, oral, nonpeptide somatostatin receptor type 5, or SST5, agonist designed for the treatment of congenital hyperinsulinism, or HI. Congenital HI is a devastating rare genetic disease associated with dysregulated insulin production, in which excess insulin produces life-threatening hypoglycemia (low blood glucose) beginning at birth. This loss of homeostatic control of blood glucose levels can lead to seizures, developmental disorders, learning disabilities, coma and even death. Congenital HI occurs in approximately 1 in 25,000 to 50,000 new births in the United States. We are currently conducting a double-blind, randomized, placebo-controlled Phase 1 study of CRN04777 in healthy volunteers to assess the safety and tolerability of single and multiple doses of CRN04777. In addition, the study is designed to evaluate the potential mechanism of action of CRN04777 by measuring the suppression of insulin secretion in healthy volunteers following stimulation with either glucose or a sulfonylurea, agents that increase the secretion of insulin. We expect preliminary data from the single ascending dose cohorts in mid-2021 and from the multiple ascending dose cohorts in the second half of 2021. In September 2020, we announced that the FDA granted rare pediatric disease designation for CRN04777 for the treatment of congenital HI.

CRN04894 (ACTH Antagonist)

CRN04894 is our investigational, oral, nonpeptide product candidate designed to antagonize ACTH, intended for the treatment of diseases caused by excess ACTH, including Cushing’s disease, CAH, and EAS. Cushing’s disease results from a pituitary tumor that secretes excess ACTH which, in turn, causes the downstream synthesis and over-secretion of cortisol by the adrenal glands. Cortisol is the body’s main stress hormone and excess amounts can cause significant increases in mortality and morbidity. CAH encompasses a set of disorders that are caused by genetic mutations that result in impaired cortisol synthesis. A lack of cortisol leads to a loss of feedback mechanisms and results in persistently high levels of ACTH, which, in turn, causes overstimulation of the adrenal cortex. The resulting adrenal hyperplasia and over-secretion of other steroids (particularly androgens) and steroid precursors can lead to a variety of effects from improper gonadal development to life-threatening dysregulation of mineralocorticoids. EAS is a rare disorder that results from non-pituitary tumors that secrete excessive amounts of ACTH. The supraphysiological degree of ACTH secretion in EAS can vary with effects that range from cushingoid to acutely life-threatening. We are currently conducting a double-blind, randomized, placebo-controlled Phase 1 study of CRN04894 in healthy volunteers to assess the safety and tolerability of single and multiple doses of CRN04894 and to measure the effect of CRN04894 on suppression of cortisol, cortisol precursors, and adrenal androgens following exogenous ACTH stimulation. We expect preliminary data from the single ascending dose cohorts in the first half of 2021 and from the multiple ascending dose cohorts in the second half of 2021.

Research Discovery

Patients with many other debilitating endocrine diseases await new therapeutic options, and we are continuously evaluating where next to deploy our drug discovery efforts. We plan to continue our drug discovery efforts and leverage our expertise in the evaluation of additional conditions including hyperparathyroidism, nonfunctional pituitary adenomas and polycystic kidney disease, among other indications. All of our product candidates have been discovered, characterized and developed internally and are the subject of composition of matter patent applications, including issued U.S. patents covering paltusotine extending to 2037. We have retained worldwide rights to commercialize our product candidates and do not have any royalty obligations. Over time, we intend to sell our products, if approved, through our own commercial organization, which we believe can be of modest size to cover the relatively small number of specialty endocrinologists who treat patients with rare endocrine diseases and endocrine-related tumors.

Our strategy

Our objective is to transform the treatment of rare endocrine diseases and endocrine-related tumors by creating a diversified portfolio of novel therapeutics that will advance the standard of care. To achieve this objective, we are pursuing the following strategy:

•

Focus on rare endocrine diseases and endocrine-related tumors with significant unmet medical need. There are numerous rare endocrine diseases and endocrine-related tumors for which currently available pharmacological therapies (when they exist) have significant limitations in efficacy, safety and/or tolerability. Patients living with these diseases often experience significant morbidity, mortality and/or poor quality of life. We are focused on discovering, developing, and commercializing orally available therapies for multiple rare indications across endocrinology to advance the standard of care for these patients.

•

Rapidly advance multiple product candidates in parallel to clinical proof-of-concept and late-stage development by targeting diseases that require relatively small trials and employ validated biomarkers as clinical endpoints. Phase 1 clinical trials for rare endocrine diseases and endocrine-related tumors can often measure predictive biomarkers in

healthy volunteers and lower the technical risk by providing a predictive measure of efficacy early in clinical development. Clinical trials in these indications often enroll relatively small numbers of trial subjects and use validated biomarkers as registration endpoints, which we believe will allow us to efficiently develop multiple clinical programs in parallel.

•

Continue to expand our therapeutic pipeline for rare endocrine diseases by leveraging the capabilities of our experienced discovery team in the area of peptide hormone GPCRs. Our discovery team has significant expertise in understanding and creating product candidates to influence the dynamic behavior of GPCRs and has developed a number of proprietary methods, techniques and tools that we believe will enable us to efficiently and reliably evaluate newly synthesized molecules. We employ an iterative strategy where compounds are designed, synthesized, and rapidly characterized for pharmacologic and pharmaceutical properties. This approach has led to our current pipeline, and we will continue to invest in creating additional product candidates acting at this important class of targets. Peptide hormone GPCRs regulate many aspects of physiology and are attractive drug targets for treating a broad range of diseases. There are more than 80 known peptide hormones acting at more than 120 known different receptors. With each of our drug discovery programs, our goal is to specifically tailor a product candidate with pharmacologic and pharmaceutical properties highly optimized for its interaction with its specific GPCR target that we anticipate will translate to downstream benefits in our chosen therapeutic applications.

•

Retain commercialization rights to maximize the value of our product candidates. We plan to establish our own commercial organization in major markets and develop a network of third-party distributors in other selected markets. We believe this organization can be focused and modest in size due to the relatively small number of specialty endocrinologists who treat patients suffering from the diseases we target. Therefore, we do not expect that we will require larger pharmaceutical partners for commercialization of our product candidates, although we may consider partnering for certain territories or indications, or for other strategic purposes.

•

Maintain an entrepreneurial, scientifically rigorous, and inclusive corporate culture where employees are fully engaged and strive to bring improved therapeutic options to patients. The patients we seek to treat currently only have options with significant drawbacks and often limited efficacy, safety and/or tolerability. We are passionate about developing new pharmacological therapies to help these patients better control their diseases and to reduce the impact of these diseases on their daily lives. We believe that building a successful and sustainable endocrine company requires not just specific expertise in multiple areas of drug discovery, development, and commercialization, but a team-oriented culture that integrates and harnesses the creative energy, scientific insights and enthusiasm of the entire organization.

The endocrine system

Overview

The endocrine system regulates most of the body’s physiological activities through the actions of hormones, which are chemical and biochemical messengers secreted from different organs that influence growth, gastrointestinal function, maturation and development, reproduction, stress, metabolism and nearly all aspects of homeostasis. Hormones are structurally variable and can be monoamines, steroids, amino acids, peptides, or larger proteins. The endocrine system includes, among other glands and organs, the pituitary gland, hypothalamus, pancreas, adrenal gland, thyroid and parathyroid, ovaries and testes, as well as specialized enteroendocrine cells.

Hormonal secretion is complex, and the body employs several mechanisms to exert positive and negative feedback control to maintain homeostasis. For example, the pituitary gland, which is located behind the eyes at the base of the brain, is sometimes referred to as “the master endocrine gland” because it regulates multiple endocrine systems. Positive and negative control of pituitary hormonal secretion is often dictated by the adjacent hypothalamus, which integrates feedback responses from other areas of the body, including the brain. In the case of GH, its synthesis and secretion are stimulated by growth hormone-releasing hormone, or GHRH, and inhibited by somatostatin, which are both hypothalamic peptides. Another example is the pancreas that secretes insulin and glucagon, which lower and raise blood glucose levels, respectively. Insulin and glucagon secretion are both inhibited by somatostatin, which is also locally produced in and secreted by specific cells in the pancreas.

Hormonal dysregulation can arise from endocrine organ defects, including injury, inflammation, genetic abnormalities, or the growth of tumors derived from endocrine cells. These insults can result in the under-secretion or over-secretion of one or more hormones, disrupting homeostasis and causing disease. For example, several serious clinical disorders, including acromegaly and Cushing’s disease, result from pituitary tumors secreting excess hormones. In the pancreas, genetic defects or cellular dysfunction can give rise to disorders of under-secretion or over-secretion of pancreatic hormones (e.g., hyperinsulinemia).

Peptide hormone GPCRs

Various GPCRs are expressed in every type of cell in the body and their function is to transmit signals from outside the cell across the membrane to signaling pathways within the cell, between cells and between organ systems. Because of these critical actions, the GPCR superfamily is the largest and single most important family of drug targets as highlighted by the large number of approved therapeutics targeting this class. However, most currently available GPCR-targeting drugs act at receptors for which the native ligands are small molecules, such as histamine, adrenaline, and neurotransmitters.

Most peptide hormones bind selectively to specific receptors located on the surface of cells in the target tissue. Receptors for peptide hormones are often GPCRs, which play a central role in many biological processes and are linked to a wide range of disease areas. There are more than 80 known peptide hormones acting at more than 120 known different receptors. Historically, it was assumed that small molecules could not replicate or compete with the complex interactions between peptides and their cognate GPCRs. As such, most drugs developed for peptide GPCRs have been and continue to be peptides themselves, which present manufacturing and formulation difficulties and force patients to undergo frequent injections because peptides generally are not orally bioavailable. We believe our approach to developing novel small molecule product candidates that uniquely engage peptide hormone GPCRs will enable us to generate orally bioavailable, and potentially more selective, effective and better tolerated therapeutics for patients.

The somatostatin receptor family of peptide GPCRs is an illustrative example of the complex and subtle control inherent in endocrine biology and peptide hormone physiology. The peptide hormone somatostatin, which was first isolated over 40 years ago, is produced by a variety of cell types and has pleiotropic effects throughout the body, many of which are related to the inhibition of secretion of other hormones or neurotransmitters, and selective activation of this activity has made somatostatin agonism a well-established, commercially validated mechanism. These effects are mediated by five different somatostatin receptor proteins (SST1, SST2, SST3, SST4, and SST5), which lower levels of cyclic adenosine monophosphate, or cAMP, a key intracellular signaling molecule regulated by GPCR activation. Each of these receptors is expressed in different subsets of tissues. For example, SST2 is the most widely expressed subtype in NETs and is the dominant receptor by which GH secretion is suppressed in the pituitary. The SST5 receptor is expressed by pancreatic islet cells where its activation potently inhibits insulin secretion.

Figure 1. GPCR signaling is determined by many factors, including the binding characteristics of ligands, which dictate the responses of different signaling and regulatory pathways. Selectively favoring one pathway over others is termed biased signaling. Upon activation, GPCRs can also be trafficked into the cell, where they are either targeted for degradation or recycled back to the cell surface.

GPCRs were originally thought to function as simple on-off switches responding to hormones and neurotransmitters but have since been shown to exhibit complex and diverse molecular and cellular behaviors. Many lines of structural and mechanistic research demonstrate that distinct signaling cascades and feedback mechanisms create multi-dimensional pathways with distinct physiological responses. These different responses are based on ligand binding kinetics, receptor regulation and trafficking (Figure 1). Some transduce signals into the cell interior to regulate various cellular functions. Other responses attenuate hormonal signals to prevent overstimulation and include receptor internalization (a removal of the GPCR from the cell surface, which makes it unavailable for external ligands), desensitization and downregulation. The capacity of a GPCR ligand to preferentially affect one of these pathways, such as G-protein signaling, over others, such as receptor downregulation, is termed biased agonism. We believe our understanding of these different signaling pathways enables us to develop oral, small molecule product candidates that not only are highly selective for specific receptor subtypes but also are further custom-tailored to activate specific GPCR properties and ultimately improve patient outcomes.

Our product candidates

All of our product candidates have been discovered and developed internally and we have retained global rights to commercialize our product candidates and have no royalty or licensing obligations. The following table summarizes our product candidate pipeline.

Somatostatin receptor type 2 agonists for the treatment of acromegaly and neuroendocrine tumors

Our lead product, paltusotine, is an oral selective nonpeptide SST2 agonist in clinical development for the treatment of acromegaly. The FDA granted orphan drug designation for paltusotine for the treatment of acromegaly. Results from our Phase 1 trial of paltusotine demonstrated initial clinical proof-of-concept based on observed suppression of GH and IGF-1 secretion in healthy volunteers. In October 2020, we announced positive topline results from the ACROBAT Edge and Evolve Phase 2 trials in acromegaly. The prespecified primary endpoint in Edge was achieved, showing that once daily oral paltusotine maintained IGF-1 levels at Week 13 in acromegaly patients who were switched from an injected somatostatin receptor ligand depot of either octreotide or lanreotide monotherapy. We are currently preparing to initiate our Phase 3 program for paltusotine which we expect to start in the second quarter of 2021. We also plan to initiate a Phase 2 trial in patients with NETs complicated by carcinoid syndrome in 2021.

Acromegaly disease background

Acromegaly is typically caused by a pituitary tumor that secretes excess GH. Pituitary tumors are generally benign adenomas that, in addition to GH secretion, also express membrane receptors for somatostatin. Increased GH secretion results in excess downstream secretion of IGF-1 from the liver. GH and IGF-1 promote tissue growth and have other metabolic effects throughout the body.

The symptoms of acromegaly include abnormal growth of hands and feet and changes in shape of the bones that result in alteration of facial features. Overgrowth of bone and cartilage and thickening of tissue can lead to arthritis, carpal tunnel syndrome, joint aches, enlarged lips, nose and tongue, deepening of voice due to enlarged vocal cords, sleep apnea due to obstruction of airways and enlargement of the heart, liver and other organs. Additional symptoms can include thick, coarse, oily skin, skin tags, excessive sweating and skin odor, fatigue and weakness, headaches, goiter, decreased libido, menstrual abnormalities in women and erectile dysfunction in men. As the tumor grows, it can impinge on the nerves in the optic chiasm leading to visual problems and potentially vision loss. Compression of the surrounding normal pituitary tissues can decrease production of other pituitary hormones, resulting in hypopituitarism. Acromegaly patients experience increased mortality rates, principally due to cardiovascular diseases (diabetes, hypertension), respiratory disease and cerebrovascular diseases.

Acromegaly is often suspected when the patient exhibits enlargement of extremities and an alteration of facial features. Pituitary tumors are also often found during clinical workup for severe headaches, vision changes or incidentally on cranial imaging initiated for other reasons. Elevation of serum IGF-1 levels confirms the suspicion of acromegaly, but a formal diagnosis requires lack of suppression of serum GH levels in response to an oral glucose tolerance test. A magnetic resonance imaging (MRI) or computerized tomography (CT) scan of the pituitary is then used to locate the tumor, determine its size and assess the potential for surgical intervention. It is estimated that there are approximately 26,000 patients in the United States with acromegaly.

Current acromegaly treatments and limitations

The major goals of treatment are to reduce serum GH and normalize IGF-1 levels, ameliorate symptoms and relieve any pressure resulting from the tumor. Surgical removal of the pituitary tumor is the first treatment option and often results in rapid improvement of symptoms. Surgery can be curative if the tumor is small and accessible enough to be fully resected. However, many acromegaly patients turn to pharmacological treatments if they are not candidates for surgery or surgery was unsuccessful. Somatostatin analogs octreotide (marketed as Sandostatin) and lanreotide (marketed as Somatuline) are selective for SST2 receptors and are the preferred first-line pharmacologic treatments. However, these peptides leave many patients inadequately controlled. For example, a meta-analysis published in 2014 by the Journal of Clinical Endocrinology and Metabolism showed that approximately 50% of over 4,000 acromegaly patients treated with octreotide or lanreotide failed to achieve biochemical control. Pegvisomant (marketed as Somavert) is a daily injectable GH receptor antagonist and is generally used in patients resistant to or intolerant of somatostatin analogs. Pasireotide (marketed as Signifor) is a less selective SST receptor agonist that is also used and has activity toward SST5, SST3 and SST2 receptors. However, pasireotide treatment leads to an increase in fasting plasma glucose levels in patients within the first two or three weeks of treatment and a pronounced shift to pre-diabetes and diabetes (as judged by HbA1c levels) within six months due to its insulin-suppressing SST5 activity. Orally administered dopamine agonists, such as cabergoline, are also used, but do not achieve hormone normalization in most patients. For this reason, dopamine agonists are usually used as adjunct to somatostatin analogs. While these currently approved drugs reduce the disease burden, many patients still report acromegaly symptoms despite treatment, particularly at the end of the monthly dosing cycle. In 2020, octreotide capsules (marketed as MYCAPSSA) received marketing approval in the United States for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

Currently available therapies for acromegaly are primarily peptide drugs that require injection, making them both painful and inconvenient. Octreotide and pasireotide are typically a monthly intramuscular injection, lanreotide a monthly deep subcutaneous injection and pegvisomant a daily subcutaneous injection. Patients report pain, swelling and bruising both at the time of injection and for days following injections. In addition, octreotide, lanreotide and pasireotide labels require injections by a trained healthcare provider and are therefore inconvenient for patients. Finally, the reconstitution of octreotide and pasireotide can be complex and prone to error for healthcare providers.

We believe that a once-daily oral nonpeptide somatostatin agonist that reduces excess GH secretion and normalizes IGF-1 levels in acromegaly patients would represent a major clinical advance by eliminating painful injections and reducing the frequency of physician office visits. Additionally, we believe it should allow physicians to more quickly determine optimal dosing regimens compared to existing depot therapies.

Neuroendocrine tumors (NETs) background

NETs arise from cells of the enteroendocrine system in the gastrointestinal tract (approximately 70% of cases) but can also arise from neuroendocrine cells in the lung (approximately 25% of cases) or, more rarely, the pancreas. These tumors are usually slow growing and often initially asymptomatic. Therefore, many patients are only diagnosed at a time of extensive metastatic disease, and these patients can progress to liver failure. In approximately 19% of cases, these tumors are associated with excess secretion of serotonin resulting in carcinoid syndrome, which is characterized by severe diarrhea and flushing. NETs are present in approximately 171,000 adults in the United States, of which approximately 33,000 patients have carcinoid syndrome. While still an orphan disease, NETs are the second most common gastrointestinal malignancy after colon cancer.

Current neuroendocrine tumor treatments and limitations

Most NETs overexpress SST2 receptors and injected depots of peptide somatostatin analogs have become a standard of care for patients with carcinoid syndrome. While somatostatin analogs have been historically indicated primarily for patients with carcinoid syndrome, there is an evolving understanding of the positive impact of somatostatin analog treatment on the broader NETs patient population. For example, lanreotide was approved for the treatment of gastroenteropancreatic NETs based on a long-term study that showed significant improvement in progression free survival. However, many patients eventually become increasingly resistant to somatostatin analogs requiring increased dosage of depot preparations or use short-acting analogs as an add-on therapy. In 2017, the serotonin synthesis inhibitor, telotristat, was approved for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.

The overexpression of SST2 in NETs is also the basis for somatostatin targeted radioimaging of the tumors for diagnosis and staging. Peptide somatostatin analogs modified to incorporate a chelating agent can use their SST2 binding activity to concentrate radioisotopes in tumor tissue that can then be imaged using positron-emission tomography (PET). More recently, this approach has been adapted to deliver the beta particle emitter ¹⁷⁷Lu for anti-tumor activity. A drug using this mechanism, Lutathera, significantly improved progression free survival and led to a substantial reduction in the risk of disease

progression or death when added onto octreotide LAR therapy compared to a double dose of octreotide LAR, in a Phase 3 trial in NET patients who had failed on somatostatin analog therapy. Lutathera was approved in 2018 for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Paltusotine overview and clinical development

Paltusotine, our lead product candidate, pioneers a new class of oral selective nonpeptide SST2 agonists designed for the treatment of acromegaly and is the first agent in its class with reported clinical results. It is designed to reduce excess GH secretion from benign pituitary tumors and normalize IGF-1 levels in patients with acromegaly. In vitro pharmacology studies demonstrated that paltusotine potently stimulated SST2 receptor activity as measured by a decrease in cAMP accumulation in cells expressing the human SST2 receptor (EC₅₀=0.25 nM, the concentration that achieves 50% cAMP inhibition). Analogous experiments using the other SST receptor subtypes showed paltusotine’s selectivity for SST2 was 4,000 times greater than the other SST receptor subtypes.

In addition to somatostatin receptor-directed pharmacology, paltusotine showed little off-target activity in a variety of assays for other GPCRs, enzymes, ion channels and transporters. Based on further in vivo studies in rats and dogs, paltusotine suppressed GH and IGF-1 consistent with its mechanism of action. We conducted 28-day good laboratory practice, or GLP, toxicity studies in rats and dogs and identified no dose-limiting toxicities, which supported moving paltusotine into human clinical trials.

We began a Phase 1, double-blind, placebo-controlled trial in late 2017 to assess the safety, tolerability, PK, and PD of paltusotine in 99 healthy human volunteers. This trial was performed at a single center in Melbourne, Australia. Subjects in the single ascending dose, or SAD, arm (up to 20 mg) were also evaluated for the ability of paltusotine to suppress GH secretion. Because GH secretion is pulsatile during the day, subjects in the first five SAD cohorts were given an intravenous bolus of GHRH (50 µg) to ensure a reliable window of high GH secretion. These GH responses were evaluated on day -1 (the day prior to dosing) and again on day 1 (the day of dosing either paltusotine or placebo). The ability of paltusotine to suppress serum IGF-1 was evaluated in the multiple ascending dose, or MAD, cohorts.

Administration of GHRH on day -1 resulted in a rapid surge of serum GH that lasted approximately 2 hours. In contrast to day -1, the presence of paltusotine in plasma strongly suppressed (approximately 92%) stimulated GH secretion, consistent with the compound’s activity as an SST2 agonist. This response was dose dependent. The first-generation paltusotine capsule achieved approximately 75% of the total plasma exposure (area under the curve, or AUC) of the same dose administered as an oral solution to fasted subjects. However, when the capsule was administered with a standardized high fat meal, plasma AUC was reduced by approximately 83%, suggesting that the first-generation capsule formulation should be taken under fasted conditions. In the drug-drug interaction cohort, repeated dosing of paltusotine resulted in no change in the exposure of the sensitive CYP3A4 reporter midazolam, suggesting that paltusotine is not likely to cause drug interactions by inhibiting the metabolism of other drugs that are primarily metabolized by the major CYP enzymes in the liver.

In the MAD arm, subjects were dosed with paltusotine for seven days (5 mg cohort) or ten days (10-30 mg cohorts) and serum IGF-1 levels were measured each day. In both acromegaly patients and healthy volunteers, sustained suppression of GH release results in lowering of serum IGF-1 levels. However, in contrast to the rapid effects of the GH response, IGF-1 levels are known to decrease more gradually and require several days of exposure to somatostatin agonists to produce an observable effect. As paltusotine concentrations reached steady state, serum IGF-1 concentrations began to decline. This decline reached steady state in approximately seven days. Of note, IGF-1 remained suppressed for several days after the final dose but began to recover as paltusotine plasma concentrations fell.

Paltusotine exhibited a dose-dependent increase in exposure in the dose range of 5 mg to 30 mg and a terminal elimination half-life of 42 to 50 hours, consistent with potential for once daily administration. Suppression of IGF-1 levels for the 10 mg, 20 mg and 30 mg cohorts was similar indicating that the 10 mg dose achieved a maximal response. This degree of IGF-1 suppression by paltusotine was similar to that observed for peptide somatostatin analogs (octreotide, lanreotide) in previously reported healthy volunteer studies. Concentrations of somatostatin analogs in healthy volunteers that result in this level of suppression in healthy volunteers are comparable to the trough concentrations in patients on the highest approved dose. This suggests that drug concentrations that result in maximal suppression of IGF-1 in healthy volunteers translates to meaningful suppression of IGF-1 in acromegaly patients.

The safety and tolerability of paltusotine in the trial was generally consistent with that of approved peptide somatostatin analogs. In the trial, paltusotine resulted in mild gastrointestinal disorders (such as abdominal pain, flatulence, abdominal distension, and diarrhea) in approximately 30% of subjects and mild elevations of pancreatic enzymes in approximately 10% of subjects. One subject experienced moderate abdominal pain after a single 40 mg dose. Additional adverse events included headache, dizziness and cardiac rhythm abnormalities (including nonsustained ventricular tachycardia, or NSVT) which were not dose dependent and also observed in placebo subjects and/or prior to dosing. One serious adverse event of moderate

NSVT was observed following a single 1.25 mg dose and was considered unlikely to be related to paltusotine. Based on the conclusions from this Phase 1 clinical study, we selected 10 mg as the initial dose for our Phase 2 trials.

Following our Phase 1 study, we conducted global Phase 2 clinical trials with paltusotine in acromegaly patients. The first of these, Evolve, was a double-blind, randomized, placebo-controlled trial in patients whose IGF-1 levels were biochemically controlled by octreotide or lanreotide monotherapy. We also conducted a second, open-label exploratory trial, Edge, to evaluate the effects of paltusotine on patients whose IGF-1 levels were not biochemically controlled by octreotide or lanreotide alone. We are also conducting the Advance trial, which is a Phase 2 open label, long term extension study designed to evaluate the safety and efficacy of paltusotine in patients who completed the Evolve or Edge trials.

We announced positive topline results from the ACROBAT Phase 2 program in acromegaly in October 2020. The prespecified primary endpoint in Edge was achieved, showing that once daily oral paltusotine maintained insulin-like growth factor-1, or IGF-1, levels at Week 13 in acromegaly patients who were switched from an injected SRL, depot of either octreotide or lanreotide monotherapy [change in IGF-1 = -0.034 (-0.107, 0.107), median (IQR)]. There were 25 patients enrolled in this prespecified primary analysis population (Group 1). During the four-week washout period after the 13-week treatment period, Group 1 patients showed a meaningful (>20%) and prompt (within two weeks) rise in IGF-1 levels from baseline, which provided evidence regarding the magnitude of therapeutic activity of oral paltusotine in acromegaly patients. Edge also enrolled an additional 22 patients into four different exploratory populations (Groups 2-5).

As previously announced, the enrollment in Evolve was terminated early, enabling data to be available for the end of Phase 2 regulatory interactions on the Edge study. The reduced sample size did not allow for meaningful statistical comparisons between groups in the randomized withdrawal period. Data from these patients on lower doses of paltusotine were included in the post-hoc dose response analyses in combination with data from patients in the Edge study, most of whom received the higher doses.

Post-hoc analyses of patients in Edge (Group 1; n=25) and Evolve (n=13) were conducted to explore the effect of paltusotine dose on IGF-1 suppression. These analyses provided evidence of a dose response across the dose range of 10 to 40 mg. Dose-dependent results were observed when evaluating the effect on IGF-1 levels from: 1) switching from injectable SRL to paltusotine, and 2) withdrawing paltusotine during the washout phase. These data and ongoing exposure response analysis has informed the selection of doses to be included the Phase 3 program.

Paltusotine was generally well tolerated among the 60 ACROBAT participants (including both Edge and Evolve), which is consistent with prior clinical findings in healthy volunteers. There were no discontinuations due to drug-related adverse events, no safety signals seen in clinical laboratory analyses, no treatment-related SAEs, and no patients required rescue treatments with standard acromegaly medications during treatment. The most common treatment-emergent adverse events (>10%) included: headache, arthralgia, fatigue, peripheral swelling, paresthesia, and hyperhidrosis.

Based on feedback from our interactions with the FDA and other regulators, we have defined our planned Phase 3 development program which will consist of two placebo-controlled clinical trials. We plan to conduct PATHFNDR-1, which is designed as a double-blind, placebo-controlled, nine-month clinical trial of paltusotine in 52 acromegaly patients with average IGF-1 levels less than or equal to 1.0 times the upper limit of normal, or ULN, and who are on stable doses of SRL monotherapy (octreotide LAR or lanreotide depot). The primary endpoint is the proportion of patients with IGF-1 ≤ 1.0 × ULN at the end of a nine-month treatment period on paltusotine as compared to placebo. We also plan to conduct a second study, PATHFNDR-2, which is designed as a double-blind, placebo-controlled, twelve-week trial in 74 acromegaly patients with elevated IGF-1 levels, who are medication naïve or who are not being treated with pharmacotherapy (untreated patients). The primary endpoint in this study is also the proportion of patients with IGF-1 ≤ 1.0 × ULN at the end of the treatment period on paltusotine as compared to placebo. A new tablet formulation of paltusotine is planned for use in both trials. When evaluated in a Phase 1 pharmacokinetic healthy volunteer study, the tablet formulation had a reduced fasting requirement compared to the capsule formulation that was used in prior trials and dose proportional exposure was observed up to 80 mg. We plan to initiate our Phase 3 program in the second quarter of 2021 and expect top line data from both studies in 2023. We believe that, if successful, these trials could support registration of paltusotine in the United States and Europe for all acromegaly patients who require pharmacotherapy, including untreated patients and those switching from standard of care. We also plan to initiate a Phase 2 trial in patients with NETs complicated by carcinoid syndrome in 2021.

Somatostatin receptor type 5 agonists for the treatment of hyperinsulinism

We are developing CRN04777, an investigational, oral, selective nonpeptide SST5 receptor agonist that is designed to inhibit the excess insulin secretion associated with congenital and acquired disorders of hyperinsulinism, with our initial focus on congenital HI. CRN04777 is intended to act at the SST5 receptor, which is independent of many of the mutations that cause congenital HI and, therefore, should allow CRN04777 to be broadly applicable to congenital HI patients with the various underlying mutations. We are currently conducting a Phase 1 clinical study with CRN04777 and expect preliminary data from the single ascending dose cohorts in mid- 2021 and from the multiple ascending dose cohorts in the second half of 2021.

In September 2020, we announced that the FDA granted rare pediatric disease designation for CRN04777 for the treatment of congenital HI.

Hyperinsulinism background

Hyperinsulinism is a heterogeneous condition in which dangerously low blood sugar levels are caused by increased insulin secretion from pancreatic ß-cells. The most severe form of hyperinsulinism arises from congenital HI, a disorder whose underlying pathology is driven by genetic mutations in key genes involved in regulating insulin secretion from ß-cells. The incidence of congenital HI is approximately 1 in 30,000 to 50,000 new births in the United States. Hyperinsulinism is one of the most frequent causes of persistent hypoglycemia in neonates and infants. Early diagnosis is vital to prevent neurological complications due to chronic low blood sugar, which can result in apneas, seizures, developmental delays, learning disabilities, epilepsy and even death. Hyperinsulinism can also be a severe complication for patients with insulin secreting tumors (insulinomas). Insulinomas are a specific type of NET derived from pancreatic ß-cells that secrete insulin and cause hypoglycemia. The incidence of insulinomas is 1 to 4 in 1,000,000 persons. In addition, hyperinsulinemic hypoglycemia following meals in patients who have undergone gastric bypass surgery (commonly referred to as Dumping Syndrome) occurs in approximately 10 to 15% of these patients. The number of gastric bypass surgeries continues to increase, from an estimated 158,000 surgeries in 2011 to 252,000 in 2018.

Current treatments and limitations

Maintaining glucose levels through feeding or glucose infusions is the first step in managing congenital HI. Diazoxide is the only approved therapy indicated for hyperinsulinemia. It acts at the ATP-sensitive potassium channels, or K_ATP, that are involved in insulin secretion and inhibits insulin secretion. However, mutations in these channels are present in approximately 55% to 60% of congenital HI patients, which limits the efficacy of the drug in this population. There are also serious side effects of diazoxide, which include hypertrichosis (abnormal and excessive hair growth over much of the body) and pulmonary hypertension, for which the FDA issued a warning regarding its use in infants and children. Octreotide (used off-label) is administered as subcutaneous injections up to six times/day in those who respond poorly to diazoxide. Octreotide is an SST2 agonist, which can suppress both insulin and glucagon secretion. As glucagon is a primary physiologic defense mechanism against hypoglycemia, targeting SST2 is not optimal for congenital HI patients, and octreotide therapy fails for approximately 70% to 75% of patients. Patients who fail pharmacological therapy often progress to partial or nearly complete pancreatectomy, which can result in type I diabetes that must be managed for the remainder of the patient’s life. We believe an orally available SST5 agonist would provide an important new therapeutic option that inhibits insulin secretion while avoiding glucagon suppression, allowing these patients to maintain normal glucose levels and possibly avoid pancreatectomy, the surgical removal of all or a part of the pancreas.

Preclinical development

In the process of discovering paltusotine, we synthesized many other drug-like nonpeptides, some of which also showed activity at other somatostatin receptor subtypes, including SST5. Because activation of SST5 is known to strongly inhibit insulin secretion, we focused on optimizing selective SST5 agonists to identify potential product candidates.

CRN04777 was examined in a rat model of congenital HI (Figure 2). In this model, rats were treated with sulfonylurea glyburide, which promotes insulin release by acting at KATP channels. This activity mimics the K_ATP channel mutations found in about half of congenital HI patients. This high level of insulin produced a decrease of blood glucose in rats. When these rats were then treated with our development candidates, blood glucose levels returned to normal, and at higher doses, even to a hyperglycemic state. Repeat dose experiments demonstrated that insulin continued to be suppressed after seven days. Further, glucagon secretion was not suppressed in these experiments.

Figure 2. Rescue of glyburide-induced hypoglycemia by CRN04777 in rats. To mimic a hypoglycemic state similar to congenital HI, rats were treated with the sulfonylurea glyburide (30 mg/kg, white circles) or vehicle (dashed line). CRN04777 was administered orally two hours after glyburide administration at 3 mg/Kg (white squares), 10 mg/Kg (grey squares) or 30 mg/Kg (black squares). All data are mean ± standard error.

In addition, the drug-like characteristics of CRN04777 met our rigorous internal criteria that we use to determine if a product candidate should enter into preclinical development. This includes extensive evaluation of pharmacology, selectivity, drug interaction potential, oral bioavailability and PK in multiple species, synthetic accessibility and preliminary non-GLP safety assessments including 14-day screening toxicology in rats and cardiovascular safety studies in dogs.

Clinical development

In early 2021, we initiated a double-blind, randomized, placebo-controlled Phase 1 study to evaluate the safety and tolerability of CRN04777 in healthy adult volunteers. In addition, the study is designed to test the potential mechanism of action of CRN04777 by measuring suppression of insulin secretion in healthy volunteers following stimulation with either glucose or a sulfonylurea, agents that increase the secretion of insulin. We expect to report preliminary data from the single ascending dose cohorts in mid-2021 and from the multiple ascending dose cohorts in the second half of 2021.

ACTH antagonists for the treatment of Cushing’s disease and other diseases of ACTH excess

We are developing, CRN04894, an investigational, orally available nonpeptide ACTH antagonist, designed to antagonize adrenocorticotrophic hormone, or ACTH, intended for the treatment of diseases caused by excess ACTH, including Cushing’s disease, CAH, and EAS. We are currently conducting a Phase 1 clinical study with CRN04894 and expect preliminary data from the single ascending dose cohorts in the first half of 2021 and from the multiple ascending dose cohorts in the second half of 2021.

Background on diseases of ACTH excess

Cushing’s syndrome was first described by Harvey Cushing over a century ago and results from a prolonged exposure to elevated levels of glucocorticoids, particularly cortisol. Common signs include growth of fat pads (collarbone, back of neck, face, trunk), excessive sweating, dilation of capillaries, thinning of the skin, muscle weakness, hirsutism, depression/anxiety, hypertension, osteoporosis, insulin resistance and hyperglycemia, heart disease and a range of other metabolic disturbances resulting in high morbidity. While excessive synthetic steroid administration or adrenal tumors can cause ACTH-independent forms of the disease, ACTH dependent Cushing’s syndrome (known as Cushing’s disease) is the most common form accounting for 60-80% of all cases and is most often due to tumors of pituitary corticotroph cells that secrete excess ACTH.

Cushing’s disease is an orphan indication with a prevalence of approximately 10,000 patients in the United States. It presents more commonly in women, and usually between 30 and 50 years of age. Cushing’s disease often takes many years to diagnose and may well be under-diagnosed in the general population as many of its symptoms such as lethargy, depression, obesity, hypertension, hirsutism and menstrual irregularity can be incorrectly attributed to other more common disorders.

CAH encompasses a set of disorders that are caused by genetic mutations that result in impaired cortisol synthesis. This lack of cortisol leads to a breakdown of feedback mechanisms and results in persistently high levels of ACTH, which in turn causes overstimulation of the adrenal cortex. The resulting adrenal hyperplasia and over-secretion of other steroids

(particularly androgens) and steroid precursors can lead to a variety of effects from improper gonadal development to life-threatening dysregulation of mineralocorticoids. CAH is an orphan indication with a prevalence of approximately 27,000 patients in the United States.

EAS is a rare disorder that results from non-pituitary tumors that secrete excessive amounts of ACTH. The supraphysiological degree of ACTH secretion in EAS can vary with effects that range from cushingoid to acutely life-threatening.

Current treatments and limitations

As with acromegaly, first-line therapy for Cushing’s disease is surgery to remove the pituitary tumor if possible. Pharmacological therapy is required when surgery is delayed, contraindicated or unsuccessful. Adrenal enzyme inhibitors (e.g., metyrapone and ketoconazole) prevent the synthesis of cortisol and can improve symptoms but suffer from mechanistic side effects as a result of accumulation of precursor steroids and the resulting lack of negative feedback. For example, metyrapone is associated with hirsutism in women and patients must be monitored carefully to avoid hypoadrenalism. Ketoconazole often requires progressively increasing dosage to maintain disease control, but this is ultimately limited by the hepatotoxicity of the drug. In addition, it is a potent inhibitor of one of the most important drug metabolizing enzymes in the liver, CYP3A4, resulting in the potential for negative drug-interactions as a side effect. Mifepristone, a potent glucocorticoid receptor antagonist, is approved for control of hyperglycemia in Cushing’s syndrome, but is difficult to titrate and has significant liabilities due to its potent anti-progesterone activity. The somatostatin analog, pasireotide, inhibits ACTH secretion, but in a recently published study, only 15-26% of patients in a Phase 3 trial achieved normalization of urinary free cortisol while 73% of patients experienced a hyperglycemia-related adverse event due to the compound’s potent inhibition of insulin secretion. Osilodrostat, a cortisol synthesis inhibitor, received marketing approval in 2020 in the United States for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.

The current treatment algorithm for CAH consists of lifelong daily glucocorticoid supplementation which attempts to balance the inability to synthesize cortisol and alleviate the lack of negative feedback. The inability to precisely dose glucocorticoids can often lead to enduring cycles of over- or under-treatment. Under-treatment can result in adrenal crisis and intramuscular stress doses of glucocorticoid for acute illness are common. CAH patients have a two-fold risk of bone fractures compared to the general population and commonly suffer from hypercholesterolemia, insulin resistance, and hypertension. Compared to the general population, CAH patients have a diminished life expectancy of 7 years, and more than 20% of CAH patients will die of a condition complicated by adrenal crisis. Therefore, we believe a significant unmet medical need exists for improved agents to treat both Cushing’s disease and CAH.

Treatment options for EAS are limited, with the first goal being surgical removal of the tumors, if possible. If surgery is not an option, medical therapy may be used to block cortisol production. And in some cases, adrenalectomy is required if the tumor cannot be located and medical therapy does not fully block the cortisol production.

Preclinical development

ACTH acts through a peptide GPCR called the melanocortin type 2 receptor, or MC2R, that is specifically expressed in the adrenal gland. Activation of MC2 by ACTH results in increased synthesis of cAMP, enhanced synthesis and secretion of cortisol and hypertrophy of adrenal cells. CRN04894 is a potent, selective nonpeptide antagonist of MC2R designed to block ACTH action and prevent its excessive stimulation of the adrenal gland in Cushing’s disease and CAH patients. In vivo proof-of-concept is demonstrated by CRN04894’s capacity to block corticosterone secretion in a rodent ACTH-challenge model, which mimics aspects of Cushing’s disease (Figure 3).



		Figure 3. Suppression of ACTH stimulated corticosterone release in rats by 1 mg/Kg (light grey squares), 3 mg/Kg (dark grey squares) or 10 mg/Kg (black squares) of CRN04894 administered orally, compared to vehicle treated animals (white circles).

Clinical development

In early 2021, we initiated a double-blind, randomized, placebo-controlled Phase 1 study to evaluate the safety and tolerability of single and multiple doses of CRN04894 in healthy adult volunteers. In addition, the study is designed to test the potential mechanism of action of CRN04894 by measuring its ability to suppress cortisol, cortisol precursors, and adrenal androgens following exogenous ACTH stimulation. We expect preliminary data from the single ascending dose cohorts in the first half of 2021 and from the multiple ascending dose cohorts in the second half of 2021.

Competition

The commercialization of new drugs is competitive, and we could face competition from a number of pharmaceutical or biotechnology companies around the world. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects or more convenient than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we do. The key competitive factors affecting the success of all of our programs are likely to be their efficacy, safety and convenience.

With respect to paltusotine, injected peptide somatostatin agonists and GH receptor antagonists are the main medical therapies for acromegaly patients where surgery is unsuccessful. There are three injected somatostatin analogs approved for the treatment of acromegaly: octreotide (marketed by Novartis AG), lanreotide (marketed by Ipsen Biopharmaceuticals, Inc.) and pasireotide (marketed by Novartis). Pegvisomant (marketed by Pfizer Inc.) is a daily injectable growth hormone receptor antagonist and is generally used in patients not fully controlled on somatostatin analogs. Orally administered dopamine agonists, such as bromocriptine and cabergoline, are also used. In 2020, Chiasma, Inc. received marketing approval in the United States for an oral octreotide product, MYCAPSSA, for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. In terms of other products in clinical development, all of them are new formulations of peptide somatostatin agonists or GH receptor antagonists. Other companies developing new pharmaceutical therapies for acromegaly include Camurus AB, Dauntless Pharmaceuticals, Inc., Enesi Pharma Limited, Ionis Pharmaceuticals, Inc./Antisense Therapeutics Ltd., MidaTech Pharma PLC, Aquestive Therapeutics, Inc., and Rani Therapeutics, Inc.

Injected depots of peptide somatostatin analogs are used as therapy for NETs. In adults whose carcinoid syndrome symptoms are inadequately controlled by somatostatin therapy, telotristat ethyl (marketed by TerSera Therapeutics, Inc.) is an orally administered add-on therapy. Targeted therapies everolimus (marketed by Novartis) and sunitinib malate (marketed by Pfizer) are typically only used in patients with high grade tumors which constitute only a small fraction of NETs. In 2018, the FDA approved Novartis’ Lutathera for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors as well as Progenics Pharmaceuticals’ radioactive therapeutic agent for iobenguane scan positive, unresectable, locally advanced, or metastatic pheochromocytoma or paraganglioma for patients who require systemic anticancer therapy. Camurus and ITM Isotopen Technologien are currently engaged in Phase 3 trials of new compounds for use in the treatment of NETs. Other Companies also developing NETs therapeutics include AADi Bioscience, EpicentRx, Inc., Hutchison China MediTech, Ipsen, Merck & Co., Inc., Novartis, Oncoceutics, Inc., Provectus Biopharmaceuticals, RadioMedix, Tarveda Therapeutics, and Xencor.

With respect to CHI, maintaining glucose levels through feeding or glucose infusions is the first step in managing the disease. Diazoxide (marketed by Teva Pharmaceuticals, Inc.) is the only approved therapy indicated for hyperinsulinemia. Octreotide (used off-label) is administered as subcutaneous injections in those who respond poorly to diazoxide. Patients who fail pharmacological therapy often progress to partial or nearly complete pancreatectomy, which can result in type I diabetes that must be managed for the remainder of the patient’s life. Xeris Pharmaceuticals, Inc. received marketing approval for its ready-to-use glucagon in 2019. Companies developing products for potential use in congenital HI include Hanmi Pharmaceuticals and Zealand Pharma A/S with glucagon analogs. Other companies developing products for potential use in congenital HI include Eiger Biopharmaceuticals, Inc. and Rezolute, Inc.

As with acromegaly, first-line therapy for Cushing’s disease is surgery to remove the pituitary tumor if possible. Adrenal enzyme inhibitors (metyrapone, ketoconazole) prevent the synthesis of cortisol and can improve symptoms. Mifepristone (marketed by Corcept Therapeutics, Inc.), a glucocorticoid receptor antagonist, is approved for control of hyperglycemia in Cushing’s syndrome. Osilodrostat (marketed by Recordati), a cortisol synthesis inhibitor, is approved for the treatment of endogenous Cushing’s syndrome. The somatostatin agonist pasireotide is also approved for Cushing’s disease. Strongbridge Biopharma is conducting a Phase 3 clinical trial with levoketoconazole, respectively. Other companies developing products for potential use in Cushing’s disease include Corcept Therapeutics, Inc., and Cyclacel Pharmaceuticals, Inc. Neurocrine Biosciences and Spruce Biosciences are developing CRF receptor antagonists for the treatment of CAH.

There may be other earlier stage clinical programs that, if approved, would compete with our products. Many of our competitors have substantially greater financial, technical and human resources than we have. Additional mergers and acquisitions in the pharmaceutical industry may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances made in the commercial applicability of technologies and greater

availability of capital for investment in these fields. Our success will be based in part on our ability to build and actively manage a portfolio of drugs that addresses unmet medical needs and creates value in patient therapy.

Intellectual property

We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to our business, including seeking, maintaining, and defending our patent rights. We own issued patents and patent applications relating to our product candidates. For example, we own issued patents and patent applications relating to our lead product candidate paltusotine, an issued patent and patent applications relating to our ACTH antagonist product candidate CRN04894, and patent applications relating to our SST5 product candidate CRN04777. Our policy is to seek to protect our proprietary position by, among other methods, filing patent applications in the United States and in jurisdictions outside of the United States directed to our proprietary technology, inventions, improvements, and product candidates that are important to the development and implementation of our business. We also rely on trade secrets and know-how relating to our proprietary technology and product candidates and continuing innovation to develop, strengthen and maintain our proprietary position in the field of endocrinology. We also plan to rely on data exclusivity, market exclusivity and patent term extensions when available. Our commercial success will depend in part on our ability to obtain and maintain patent and other proprietary protection for our technology, inventions, and improvements; to preserve the confidentiality of our trade secrets; to defend and enforce our proprietary rights, including any patents that we may own in the future; and to operate without infringing on the valid and enforceable patents and other proprietary rights of third parties.

As of March 30, 2021, we own four issued U.S. patents, a granted Australian patent, a pending U.S. patent application, and pending patent applications in 19 foreign jurisdictions, including Australia, Brazil, Canada, China, the European Patent Organization, the Eurasian Patent Organization, Hong Kong, India, Indonesia, Israel, Japan, South Korea, Mexico, New Zealand, Singapore, South Africa, Taiwan, Ukraine, and Venezuela with claims directed to our lead product candidate paltusotine and other related compounds, as a composition of matter, as well as claims directed to pharmaceutical compositions and uses of such compounds, including the use of paltusotine, to treat acromegaly, neuroendocrine tumors, and/or pain. The U.S. patents are expected to expire in July 2037, absent any patent term extensions for regulatory delay. Further, we own two U.S. patents, a pending U.S. patent application, and pending patent applications in 19 foreign jurisdictions, including Australia, Brazil, Canada, China, the European Patent Organization, the Eurasian Patent Organization, Hong Kong, India, Indonesia, Israel, Japan, South Korea, Mexico, New Zealand, Singapore, South Africa, Taiwan, Ukraine, and Venezuela with claims directed to crystalline forms (polymorphs) of our lead product candidate paltusotine, as well as claims directed to pharmaceutical compositions, methods of making such crystalline forms and the use of such crystalline forms to treat acromegaly and neuroendocrine tumors. The U.S. patents are expected to expire in January 2039, absent any patent term extensions for regulatory delay. We also own a pending U.S. patent application with claims directed to formulations of our lead product candidate paltusotine and the use of such formulations to treat acromegaly and neuroendocrine tumors. The U.S. patent application, if issued, would be expected to expire in September 2041, absent any patent term adjustments or extensions.

As of March 30, 2021, we own one U.S. patent, a pending U.S. patent application, and pending patent applications in 17 foreign jurisdictions, including Australia, Brazil, Canada, China, the European Patent Organization, the Eurasian Patent Organization, India, Israel, Indonesia, Japan, South Korea, Mexico, New Zealand, Singapore, South Africa, Taiwan, and Ukraine with claims directed to our lead ACTH product candidate CRN04894, as a composition of matter, as well as claims directed to pharmaceutical compositions and uses of CRN04894 to treat Cushing’s disease and other diseases caused by excess ACTH. The U.S. patent is expected to expire in June 2039, absent any patent term extensions for regulatory delay.

As of March 30, 2021, we own a pending U.S. patent application, a pending international patent application, and pending patent applications in 3 foreign jurisdictions, including Argentina, Taiwan, and Venezuela with claims directed to our SST5 product candidate CRN04777 and other related compounds, as a composition of matter, as well as claims directed to pharmaceutical compositions and uses of such compounds, including the use of CRN04777 to treat hyperinsulinemias. The U.S. patent application, if issued, would be expected to expire August 2040, absent any patent term adjustments or extensions.

The other patents and patent applications in our portfolio that we own are directed to various compounds as compositions of matter, pharmaceutical compositions comprising such compounds, and related methods of using such compounds. These issued patents, and any patents that may issue from our pending patent applications are expected to expire between 2036 and 2041, absent any patent term adjustments or extensions. We also possess substantial know-how and trade secrets relating to the development and commercialization of our product candidates, including related manufacturing processes and technology. We also own three trademark registration applications filed at the USPTO, three trademark registration applications filed at the UK IPO, and three trademark registration application filed at the European Union Intellectual Property Office (EUIPO).

With respect to our product candidates and processes we intend to develop and commercialize in the normal course of business, we intend to pursue patent protection covering, when possible, compositions, methods of use, dosing and formulations. We may also pursue patent protection with respect to manufacturing and drug development processes and technologies.

Issued patents can provide protection for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance and the legal term of patents in the countries in which they are obtained. In general, patents issued for applications filed in the United States can provide exclusionary rights for 20 years from the earliest effective filing date. In addition, in certain instances, the term of an issued U.S. patent that covers or claims an FDA approved product can be extended to recapture a portion of the term effectively lost as a result of the FDA regulatory review period, which is called patent term extension. The restoration period cannot be longer than five years and the total patent term, including the restoration period, must not exceed 14 years following FDA approval. The term of patents outside of the United States varies in accordance with the laws of the foreign jurisdiction, but typically is also 20 years from the earliest effective filing date. However, the actual protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent.

The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of claims allowable in patents in the pharmaceutical and biotechnology space has emerged in the United States. The relevant patent laws and their interpretation outside of the United States is also uncertain. Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our technology or product candidates and could affect the value of such intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell or importing products that infringe our intellectual property will depend in part on our success in obtaining and enforcing patent claims that cover our technology, inventions and improvements. We cannot guarantee that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications we may file in the future, nor can we be sure that any patents that may be granted to us in the future will be commercially useful in protecting our products, the methods of use or manufacture of those products. Moreover, even our issued patents do not guarantee us the right to practice our technology in relation to the commercialization of our products. Patent and other intellectual property rights in the pharmaceutical and biotechnology space are evolving and involve many risks and uncertainties. For example, third parties may have blocking patents that could be used to prevent us from commercializing our product candidates and practicing our proprietary technology, and our issued patents may be challenged, invalidated or circumvented, which could limit our ability to stop competitors from marketing related products or could limit the term of patent protection that otherwise may exist for our product candidates. In addition, the scope of the rights granted under any issued patents may not provide us with protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may independently develop similar technologies that are outside the scope of the rights granted under any issued patents. For these reasons, we may face competition with respect to our product candidates. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, before any particular product candidate can be commercialized, any patent protection for such product may expire or remain in force for only a short period following commercialization, thereby reducing the commercial advantage the patent provides.

In addition, most of our intellectual property rights, including those for our lead programs, have been generated through the use of U.S. government funding provided from our Small Business Innovation Research Grants, or SBIR Grants, awarded to us by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, and are therefore subject to certain federal regulations. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future product candidates pursuant to the Bayh-Dole Act of 1980. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party in certain circumstances. The U.S. government also has the right to take title to these inventions if we fail to disclose the invention to the government or fail to file an application to register the intellectual property within specified time limits.

Manufacturing

Manufacturing, testing and storage of our product candidates for nonclinical and clinical studies is conducted at third-party contract manufacturers and distributors. We do not plan to build plants or facilities for development or commercial scale manufacture or storage of our product candidates. To date, the contract manufacturers have met our manufacturing requirements, and we expect them to be capable of providing sufficient quantities of our product candidates to meet estimated full-scale commercial needs. However, the contract manufacturers may be required to increase production scale, or we may need to secure alternate suppliers.

Sales and marketing

We intend to build the commercial infrastructure in major markets to effectively support the commercialization of our product candidates, if and when we believe a regulatory approval of the first of such product candidates in a particular geographic market appears imminent. The commercial infrastructure for orphan products typically consists of a targeted, specialty sales force that calls on a focused group of physicians supported by sales management, medical liaisons, internal sales support, an internal marketing group and distribution support. One challenge unique to commercializing therapies for rare diseases is the difficulty in identifying eligible patients due to the very small and sometimes heterogeneous disease populations.

Additional capabilities important to the orphan marketplace include the management of key accounts, such as managed care organizations, group purchasing organizations, specialty pharmacies and government accounts. To develop the appropriate commercial infrastructure, we will have to invest significant amounts of financial and management resources, some of which will be committed prior to any confirmation that any of our product candidates will be approved.

Where appropriate, we may elect in the future to utilize strategic partners, distributors or contract sales forces to assist in the commercialization of our product candidates. In certain instances, we may consider building our own commercial infrastructure.

Government regulation

Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing and export and import of products such as those we are developing. A new drug must be approved by the FDA through the NDA process before it may be legally marketed in the United States.

U.S. drug development process

In the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act, or the FDCA, and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant to administrative or judicial sanctions. These sanctions could include the FDA’s refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.

The process required by the FDA before a drug may be marketed in the United States generally involves the following:

•	completion of preclinical laboratory tests, animal studies and formulation studies in accordance with GLP regulations and other applicable regulations;

•	submission to the FDA of an IND, which must become effective before human clinical trials may begin;

•	approval by an independent institutional review board, or IRB, or ethics committee at each clinical site before each trial may be initiated;

•	performance of adequate and well-controlled human clinical trials in accordance with good clinical practice, or GCP, regulations to establish the safety and efficacy of the proposed drug for its intended use;

•	submission to the FDA of an NDA after completion of all pivotal trials;

•	satisfactory completion of an FDA advisory committee review, if applicable;

•

satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current GMP, or cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the drug’s identity, strength, quality and purity, and of selected clinical investigation sites to assess compliance with GCP; and

•	FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for use in the United States.

Once a product candidate is identified for development, it enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor must submit

the results of the preclinical tests, together with manufacturing information and analytical data, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. An IND will also include a protocol detailing, among other things, the objectives of the first phase of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated, if the first phase lends itself to an efficacy evaluation. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns about on-going or proposed clinical trials or non-compliance with specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor that the hold has been lifted.

All clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with GCP regulations, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials must be conducted under protocols detailing the objectives of the trial, dosing procedures, subject selection and exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND, and timely safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. An IRB at each institution participating in the clinical trial must review and approve each protocol before a clinical trial commences at that institution and must also approve the information regarding the trial and the consent form that must be provided to each trial subject or his or her legal representative, monitor the study until completed and otherwise comply with IRB regulations. The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB’s requirements or if the drug has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial.

Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:

•

Phase 1: The product candidate is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early indication of its effectiveness. In the case of some products for severe or life-threatening diseases, such as cancer, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. Sponsors sometimes designate their Phase 1 clinical trials as Phase 1a or Phase 1b. Phase 1b clinical trials are typically aimed at confirming dosing, pharmacokinetics and safety in larger number of patients. Some Phase 1b studies evaluate biomarkers or surrogate markers that may be associated with efficacy in patients with specific types of diseases.

•

Phase 2: The product candidate is administered to a limited patient population with a specified disease or condition to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product candidate for specific targeted diseases and to determine dosage tolerance and appropriate dosage. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.

•

Phase 3: The product candidate is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk-benefit ratio of the product candidate and provide, if appropriate, an adequate basis for product labeling.

Post-approval trials, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.

During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase 2 trial to discuss Phase 2 clinical results and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the new drug.

Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.

While the IND is active and before approval, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.

There are also requirements governing the reporting of ongoing clinical trials and completed trial results to public registries. Sponsors of certain clinical trials of FDA-regulated products are required to register and disclose specified clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved.

U.S. review and approval process

The results of product development, preclinical and other non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances. The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product’s identity, strength, quality and purity. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of “filing” of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a “filing” decision after it the application is submitted. The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing.

The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.

After the FDA evaluates an NDA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response Letter, or CRL. An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications. A CRL indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A CRL usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional pivotal Phase 3 trial or other significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a CRL is issued, the sponsor must resubmit the NDA or, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval.

If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. In addition, the FDA may require a sponsor to conduct Phase 4 testing, which involves clinical trials designed to further assess a drug’s safety and effectiveness after NDA approval, and may require testing and surveillance programs to monitor the safety of approved products which have been commercialized. The FDA may also place other conditions on approval including the requirement for a risk evaluation and mitigation strategy, or REMS, to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the NDA without an approved REMS, if required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Marketing approval may be withdrawn for non-compliance with regulatory requirements or if problems occur following initial marketing.

The Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.

Orphan drug designation

Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States or, if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making a drug product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting an NDA. After the FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.

If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or inability to manufacture the product in sufficient quantities. The designation of such drug also entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. However, competitors, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. Orphan exclusivity also could block the approval of one of our product candidates for seven years if a competitor obtains approval of the same drug as defined by the FDA or if our product candidate is determined to be contained within the competitor’s product for the same indication or disease. In addition, if an orphan designated product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan exclusivity.

Expedited development and review programs

The FDA has a fast-track designation program that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. Specifically, new drugs are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. With regard to a fast-track product candidate, the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.

Any product candidate submitted to the FDA for approval, including a product candidate with a fast-track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A product candidate is eligible for priority review if it is designed to treat a serious condition, and if approved, would provide a significant improvement in safety or efficacy compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for priority review in an

effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of the filing date as compared to ten months for review of new molecular entity NDAs under its current PDUFA review goals.

In addition, a product candidate may be eligible for accelerated approval. Drug products intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. Drugs receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required post-marketing trials or if such trials fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.

The Food and Drug Administration Safety and Innovation Act, or FDASIA, established a category of drugs referred to as “breakthrough therapies” that may be eligible to receive breakthrough therapy designation. A sponsor may seek FDA designation of a product candidate as a “breakthrough therapy” if the product candidate is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast-track program features, as well as more intensive FDA interaction and guidance. The Breakthrough Therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met.

Fast track designation, priority review and breakthrough therapy designation do not change the standards for approval but may expedite the development or approval process. Even if a product candidate qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities for our product candidates as appropriate.

Post-approval requirements

Any products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications, certain manufacturing changes and additional labeling claims, are subject to further FDA review and approval. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP regulations and other laws and regulations. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.

The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:

•

restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;

•

fines, warning letters, or untitled letters;

•

clinical holds on clinical studies;

•

refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product approvals;

•

product seizure or detention, or refusal to permit the import or export of products;

•

consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;

•

mandated modification of promotional materials and labeling and the issuance of corrective information;

•

the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or

•

injunctions or the imposition of civil or criminal penalties.

In addition, the FDA closely regulates the marketing, labeling, advertising and promotion of drug products. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product’s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer’s communications on the subject of off-label use of their products.

Marketing exclusivity

Market exclusivity provisions under the FDCA can delay the submission or the approval of certain marketing applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application, or ANDA, or an NDA submitted under Section 505(b)(2), or 505(b)(2) NDA, submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.

Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances.

U.S. coverage and reimbursement

Significant uncertainty exists as to the coverage and reimbursement status of any therapeutic product candidate for which we may seek regulatory approval. Sales in the United States will depend in part on the availability of sufficient coverage and adequate reimbursement from third-party payors, which include government health programs such as Medicare, Medicaid, TRICARE and the Veterans Administration, as well as managed care organizations and private health insurers. Prices at which we or our customers seek reimbursement for our therapeutic product candidates can be subject to challenge, reduction or denial by payors.

The process for determining whether a payor will provide coverage for a product is typically separate from the process for setting the reimbursement rate that the payor will pay for the product. A payor’s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be available. Additionally, in the United States there is no uniform policy among payors for coverage or reimbursement. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies, but also have their own methods and approval processes. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. If coverage and adequate reimbursement are not available, or are available only at limited levels, successful commercialization of, and obtaining a satisfactory financial return on, any product we develop may not be possible.

Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for marketing, we may need to conduct expensive studies in order to demonstrate the medical necessity and cost-effectiveness of any products, which would be in addition to the costs expended to obtain regulatory approvals. Third-party payors may not consider our product candidates to be medically necessary or cost-effective compared to other available therapies, or the rebate percentages required to secure favorable coverage may not yield an adequate margin over cost or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development.

Healthcare reform

In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of drug product candidates, restrict or regulate post-approval activities, and affect the profitable sale of drug product candidates.

Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access.

In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. In March 2010, the Patient Protection and Affordable Care Act, as subsequently amended by as amended by the Health Care and Education Reconciliation Act, collectively the ACA, was passed, which substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA, as amended, among other things: (1) increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations; (2) established an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs; (3) expanded the availability of lower pricing under the 340B drug pricing program by adding new entities to the program; (4) increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; (5) expanded the eligibility criteria for Medicaid programs; (6) created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; (7) created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer’s outpatient drugs to be covered under Medicare Part D; (8) established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and (9) established a Center for Medicare Innovation at the Centers for Medicare & Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drugs.

Since its enactment, there have been judicial, Congressional and executive challenges to certain aspects of the ACA. By way of example, the Tax Cuts and Jobs Act of 2017, or the Tax Act, included a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate.” On December 14, 2018, a U.S. District Court Judge in the Northern District of Texas, or the Texas District Court Judge, ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the ACA are invalid as well. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit affirmed the District Court’s decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court is currently reviewing the case, although it is unclear how the Supreme Court will rule. It is also unclear how other efforts to repeal, challenge or replace the ACA, if any, will impact the ACA

Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year, which was temporarily suspended from May 1, 2020 through March 31, 2021, and reduced payments to several types of Medicare providers. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. The likelihood of implementation of any of these reform initiatives is uncertain, particularly in light of the new Presidential administration. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including

price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.

On May 30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, or Right to Try Act, was signed into law. The law, among other things, provides a federal framework for patients to access certain investigational new drug products that have completed a Phase I clinical trial. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA approval under the FDA expanded access program. The Right to Try Act did not establish any new entitlement or positive right to any party or individual, nor did it create any new mandates, directives, or additional regulations requiring a manufacturer or sponsor of an eligible investigational new drug product to provide expanded access.

U.S. healthcare fraud and abuse laws and compliance requirements

Federal and state healthcare laws and regulations restrict business practices in the biopharmaceutical industry. These laws include anti-kickback and false claims laws and regulations, and transparency laws and regulations.

The federal Anti-Kickback Statute prohibits, among other things, individuals or entities from knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in kind to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation.

The federal civil and criminal false claims laws, including the civil False Claims Act, prohibit, among other things, any individual or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act and the civil monetary penalties statute.

The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal civil and criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program.

The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program, with specific exceptions, to report annually to CMS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other healthcare professionals beginning in 2022, and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members.

Similar state and foreign laws and regulations may also restrict business practices in the biopharmaceutical industry, such as state anti-kickback and false claims laws, which may apply to business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by non- governmental third-party payors, including private insurers, or by patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to physicians, other healthcare providers and entities; state and local laws that require the registration of pharmaceutical sales representatives.

Efforts to ensure compliance with applicable healthcare laws and regulations can involve substantial costs. Violations of healthcare laws can result in significant penalties, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, individual imprisonment, possible exclusion from participation in Medicare, Medicaid and other U.S. healthcare programs, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings, and curtailment or restructuring of operations.

Data Privacy and Security

Numerous state, federal and foreign laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access to, confidentiality and security of personal information, including health-related information. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy laws, and federal and state consumer protection laws and regulations (e.g., Section 5 of the FTC Act), that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our

operations or the operations of our partners. For example, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, imposes certain requirements relating to the privacy, security and transmission of protected health information on HIPAA covered entities, which include certain healthcare provider, health plans and healthcare clearinghouses, and their business associates who conduct certain activities involving protected health information on their behalf. In Europe, the GDPR went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the EEA. In addition, the GDPR increases the scrutiny of transfers of personal data from clinical trial sites located in the EEA to the United States and other jurisdictions that the European Commission does not recognize as having “adequate” data protection laws; in July 2020, the Court of Justice of the European Union limited how organizations could lawfully transfer personal data from the EEA to the United States by invalidating the EU-US Privacy Shield and imposing further restrictions on use of the standard contractual clauses, which could increase our costs and our ability to efficiently process personal data from the EEA. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to €20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Additionally, from January 1, 2021, companies have to comply with the GDPR and the GDPR as incorporated into United Kingdom national law, the latter regime having the ability to separately fine up to the greater of £17.5 million or 4% of global turnover. The relationship between the United Kingdom and the EU in relation to certain aspects of data protection law remains unclear, for example around how data can lawfully be transferred between each jurisdiction, which exposes us to further compliance risk.

Employees and Human Capital Resources

As of February 28, 2021, we had 93 full-time employees, 29 of whom have a Ph.D. or M.D. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good. In addition, we rely on a number of consultants to assist us.

Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integration our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards and cash-based performance bonus awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.

Insurance

We maintain limited product liability insurance coverage for our clinical trials in the amount of $10 million per occurrence and $10 million in the aggregate. However, insurance coverage is becoming increasingly expensive, and we may not be able to obtain or maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability.

About Crinetics

We were formed as a Delaware corporation on November 18, 2008. Our principal executive offices are located at 10222 Barnes Canyon Road, Bldg. #2, San Diego, California 92121, and our telephone number is (858) 450-6464. In January 2017, we formed a wholly-owned Australian subsidiary, Crinetics Australia Pty Ltd, or CAPL, to conduct various preclinical and clinical activities for our product and development candidates in Australia.

Available Information

Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to reports filed pursuant to Sections 13(a) and 15(d) of the Exchange Act are available free of charge on our website at www.crinetics.com, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC. The address of that website is www.sec.gov. The information in or accessible through the SEC and our website are not incorporated into, and are not considered part of, this filing. Further, our references to the URLs for these websites are intended to be inactive textual references only.

Item 1A. Risk Factors

Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with all of the other information included in this Annual Report on Form 10-K, including our consolidated financial statements and related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before making an investment decision to purchase or sell shares of our common stock. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that event, the trading price of our common stock could decline, and you could lose part or all of your investment. The risks described below are not the only ones that we may face, and additional risks or uncertainties not known to us or that we currently deem immaterial may also impair our business and future prospects.

Risks related to our limited operating history, financial position and capital requirements

Pharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We are a clinical-stage pharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. We commenced operations in 2010, and to date, we have focused primarily on organizing and staffing our company, business planning, raising capital, discovering potential product candidates, and conducting preclinical studies and clinical trials. Our approach to the discovery and development of product candidates is unproven, and we do not know whether we will be able to develop any products of commercial value. In addition, only three of our product candidates, paltusotine, CRN04777, and CRN04894 are in clinical development, while our other development programs remain in the preclinical or discovery stages. We have not yet demonstrated an ability to successfully complete any pivotal clinical trials, obtain regulatory approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing pharmaceutical products.

We have incurred significant operating losses since our inception. If our product candidates are not successfully developed and approved, we may never generate any revenue. We have incurred cumulative net losses since our inception and, as of December 31, 2020, we had an accumulated deficit of $167.6 million. Our losses have primarily resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. All of our product candidates will require substantial additional development time and resources before we would be able to apply for or receive regulatory approvals and begin generating revenue from product sales. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase substantially as we continue our development of, seek regulatory approval for and potentially commercialize any approved products.

To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our product candidates, discovering additional product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling any products for which we may obtain regulatory approval. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. In addition, we have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product candidates or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.

The development of biopharmaceutical product candidates is capital-intensive. We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct our ongoing and planned clinical trials of paltusotine, CRN04777, and CRN04894 and continue our research and development activities and conduct preclinical studies for our other development programs, and seek regulatory approval for our current product candidates and any future product candidates, including product candidates that we may develop for hyperparathyroidism, nonfunctional pituitary adenomas

and polycystic kidney disease, among other indications. In addition, if we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Because the outcome of any preclinical study or clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates. Furthermore, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.

We believe that our existing cash, cash equivalents and investment securities will enable us to fund our operations for at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our operating plans and other demands on our cash resources may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings, such as our follow-on public offering completed in April 2020, or other sources, such as strategic collaborations. We do not currently have any active grants nor do we expect grant revenues to be a material source of future revenue. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. For example, in August 2019 we entered into a Sales Agreement, or the Sales Agreement, with SVB Leerink LLC and Cantor Fitzgerald & Co., or the Sales Agents, under which we may, from time to time, sell up to $75.0 million of shares of our common stock through the Sales Agents. However, there can be no assurance that the Sales Agents will be successful in consummating future sales based on prevailing market conditions or in the quantities or at the prices that we deem appropriate. In addition, the Sales Agreement may be terminated by us or the Sales Agents at any time upon ten days’ notice to the other parties, or by either Sales Agent, with respect to itself, at any time in certain circumstances, including the occurrence of a material adverse change. Attempting to secure additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop our product candidates.

Our future capital requirements will depend on many factors, including:

•	the type, number, scope, progress, expansions, results, costs and timing of, our preclinical studies and clinical trials of our product candidates which we are pursuing or may choose to pursue in the future;

•	the costs and timing of manufacturing for our product candidates, including commercial manufacturing if any product candidate is approved;

•	the costs, timing and outcome of regulatory review of our product candidates;

•	the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights;

•	our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company, including enhanced internal controls over financial reporting;

•	the costs associated with hiring additional personnel and consultants as our preclinical and clinical activities increase;

•	the timing and the extent of any Australian Tax Incentive refunds and future grant revenues, if any, that we receive;

•	the costs and timing of establishing or securing sales and marketing capabilities if any product candidate is approved;

•	our ability to achieve sufficient market acceptance, adequate coverage and reimbursement from third-party payors and adequate market share and revenue for any approved products;

•	the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; and

•	costs associated with any products or technologies that we may in-license or acquire.

Identifying potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all.

Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.

Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.

Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through equity offerings, such as our follow-on public offering completed in April 2020 and under the Sales Agreement, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants

limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.

If we raise funds through future collaborations, licenses and other similar arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or that may reduce the value of our common stock.

Risks related to the discovery and development and regulatory approval of our product candidates

We are in the early stages of our development efforts and have only three product candidates, paltusotine, CRN04777, and CRN04894, in clinical development. All of our other development programs are still in the preclinical or drug discovery stage. We have invested substantially all of our efforts and financial resources in developing our current product candidates, potential product candidates and conducting preclinical studies and clinical trials. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates. The success of our product candidates will depend on several factors, including the following:

•	completion of preclinical studies and clinical trials with favorable results;

•	acceptance of INDs by the FDA or acceptance of similar regulatory filing by comparable foreign regulatory authorities for the conduct of clinical trials of our product candidates and our proposed design of future clinical trials;

•	receipt of marketing approvals from applicable regulatory authorities, including NDAs, from the FDA and maintaining such approvals;

•	making arrangements with our third-party manufacturers for, or establishing, commercial manufacturing capabilities;

•	maintaining an acceptable safety profile of our products following approval; and

•	maintaining and growing an organization of scientists and businesspeople who can develop our products and technology.

The success of our business, including our ability to finance our company and generate any revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of paltusotine, as well as our other product candidates, which may never occur. In the future, we may also become dependent on other product candidates that we may develop or acquire; however, given our early stage of development, it may be several years, if at all, before we have demonstrated the safety and efficacy of a treatment sufficient to warrant approval for commercialization. If we are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize our product candidates, we may not be able to generate sufficient revenue to continue our business.

We cannot assure you that we will be able to successfully develop any product candidates.

The success of our business depends primarily upon our ability to discover, develop, and commercialize products created with our internal capabilities, including the experience of our scientists and drug development staff. While we believe we have a highly productive drug discovery and development organization, we have not yet succeeded and may not succeed in demonstrating efficacy and safety for any product candidates in clinical trials or in obtaining marketing approval thereafter. We may be unsuccessful in discovering additional product candidates, moving such product candidates from preclinical studies into clinical development, and any product candidates that we are currently developing may be shown to have harmful side effects or may have other characteristics that may necessitate additional clinical testing or make the product candidates unmarketable or unlikely to receive marketing approval. If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations.

Preclinical and clinical drug development is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the preclinical study or clinical trial process. Despite promising preclinical or clinical results, any product candidate can unexpectedly fail at any stage of preclinical or clinical development. The historical failure rate for product candidates in our industry is high.

The results from preclinical studies or early clinical trials of a product candidate may not predict the results of later clinical trials of the product candidate, and interim results of a clinical trial are not necessarily indicative of final results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having

progressed through preclinical studies and initial clinical trials. In particular, while we have conducted preclinical studies and have obtained Phase 2 results for paltusotine in acromegaly subjects, we do not know how paltusotine will perform in future clinical trials, including as a result of any differences resulting from the use of our new tablet formulation that we will use in our planned Phase 3 clinical trials of paltusotine. It is not uncommon to observe results in clinical trials that are unexpected based on preclinical studies and early clinical trials, and many product candidates fail in clinical trials despite very promising early results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies. Furthermore, although our product candidates all target endocrine diseases and/or endocrine-related tumors, we cannot assure you that our preclinical programs will be able to progress from candidate identification to Phase 1 clinical proof-of-concept in healthy volunteers.

For the foregoing reasons, we cannot be certain that our ongoing and planned clinical trials and preclinical studies will be successful. Any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition and results of operations.

Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical studies to demonstrate the safety and efficacy of the product candidates in humans. Clinical testing is expensive, time consuming and uncertain as to outcome. In addition, we may rely in part on preclinical, clinical and quality data generated by clinical research organizations, or CROs, and other third parties for regulatory submissions for our product candidates. While we have or will have agreements governing these third parties’ services, we have limited influence over their actual performance. If these third parties do not make data available to us, or, if applicable, make regulatory submissions in a timely manner, in each case pursuant to our agreements with them, our development programs may be significantly delayed, and we may need to conduct additional studies or collect additional data independently. In either case, our development costs would increase. We plan to initiate our Phase 3 program of paltusotine in patients with acromegaly in the second quarter of 2021. In addition, we submitted an IND for CRN04894 in 2020 and commenced a Phase 1 clinical trial in the United States in February 2021. We also initiated a Phase 1 clinical trial of CRN04777 in Germany in February 2021. We may conduct clinical trials for any other future product candidates outside the United States. The FDA or comparable foreign regulatory authorities may require us to conduct additional preclinical studies for any product candidate before they allow us to initiate clinical trials under any IND or similar regulatory filing, which may lead to additional delays and increase the costs of our preclinical development programs. Any such delays in the commencement or completion of our ongoing and planned clinical trials for our product candidates could significantly affect our product development costs.

We do not know whether our planned trials will begin on time or be completed on schedule, if at all. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to:

•	the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical studies;

•	obtaining regulatory authorizations to commence a trial or reaching a consensus with regulatory authorities on trial design;

•	any failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;

•	obtaining approval from one or more institutional review boards, or IRBs;

•	IRBs refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial;

•	changes to clinical trial protocol;

•	clinical sites deviating from trial protocol or dropping out of a trial;

•	manufacturing sufficient quantities of product candidate or obtaining sufficient quantities of combination therapies for use in clinical trials;

•	subjects failing to enroll or remain in our trial at the rate we expect, or failing to return for post-treatment follow-up;

•	subjects choosing an alternative treatment for the indication for which we are developing our product candidates, or participating in competing clinical trials;

•	lack of adequate funding to continue the clinical trial;

•	subjects experiencing severe or unexpected drug-related adverse effects;

•	occurrence of serious adverse events in trials of the same class of agents conducted by other companies;

•	selection of clinical end points that require prolonged periods of clinical observation or analysis of the resulting data;

•

a facility manufacturing our product candidates or any of their components being ordered by the FDA or comparable foreign regulatory authorities to temporarily or permanently shut down due to violations of current good manufacturing practice, or cGMP, regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process;

•	any changes to our manufacturing process that may be necessary or desired;

•	third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, good clinical practices, or GCP, or other regulatory requirements;

•	third-party contractors not performing data collection or analysis in a timely or accurate manner; or

•

third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications.

In addition, disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting, or completing our planned and ongoing clinical trials. We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA or comparable foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial.

Further, conducting clinical trials in foreign countries, as we currently are and may continue to do, for our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries.

Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.

If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. Moreover, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues.

In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. We may make formulation or manufacturing changes to our product candidates, in which case we may need to conduct additional preclinical studies to bridge our modified product candidates to earlier versions. Any delays to our clinical trials that occur as a result could shorten any period during which we may have the exclusive right to commercialize our product candidates and our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects significantly.

The COVID-19 pandemic could adversely impact our business, including our drug manufacturing, nonclinical activities and clinical trials.

In December 2019, a novel strain of coronavirus, SARS-CoV-2, and the disease that it causes, COVID-19, were identified in Wuhan, China. This virus continues has spread globally and is present in nearly every country and region in the world, including those in which we have active clinical trial sites. The pandemic and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. In response to the spread of COVID-19, we have closed our offices to all but our lab and a limited number of our other personnel, while the remainder of our employees are continuing their work outside of our offices. As the COVID-19 pandemic continues, we may experience disruptions that could severely impact our business, drug manufacturing, nonclinical activities, and clinical trials, including:

•

delays or difficulties in enrolling volunteers and patients in our clinical trials;

•

delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and staff;

•

diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;

•

interruption of key clinical trial activities, such as clinical trial site monitoring and source data verification, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and clinical study endpoints;

•

interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines;

•

interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems;

•

delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials and interruption in global shipping that may affect the transport of clinical trial materials;

•

interruptions in nonclinical studies due to restricted or limited operations at our laboratory facility or those of our outsourced service providers;

•

limitations on employee resources that would otherwise be focused on the conduct of our nonclinical studies or clinical trials due to sickness of employees or their families or the desire of employees to avoid contact with large groups of people, or other staffing shortages as a result of remote working requirements or otherwise;

•

delays in receiving authorization from local regulatory authorities to initiate our planned clinical trials;

•

changes in local regulations as part of a response to COVID-19 which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue such clinical trials altogether;

•

delays in necessary interactions with local regulators, ethics committees, and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees;

•

refusal of the FDA to accept data from clinical trials in affected geographies outside the United States;

•

interruption or delays to our discovery and development pipeline; and

•

patent office interruption or delays in our ability to timely secure patent coverage for our product candidates.

In addition, the spread of COVID-19 has had and may continue to severely impact the trading price of shares of our common stock and could further severely impact our ability to raise additional capital on a timely basis or at all.

The extent to which the COVID-19 may impact our business, including our drug manufacturing, nonclinical activities, clinical trials, and financial condition will depend on future developments, which are highly uncertain and cannot be predicted with confidence. To the extent the COVID-19 pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this section. In addition, if in the future there is a further outbreak of COVID-19 or a variation thereof, an outbreak of another highly infectious or contagious disease or other health concern, we may be subject to similar risks as posed by COVID-19.

Subject enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility and exclusion criteria for the trial, the design of the clinical trial, the risk that enrolled patients will not complete a clinical trial, our ability to recruit clinical trial investigators with the appropriate competencies and experience, competing clinical trials and clinicians’ and patients’

perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating as well as any drugs under development. We will be required to identify and enroll a sufficient number of subjects for each of our clinical trials. Potential subjects for any planned or ongoing clinical trials may not be adequately diagnosed or identified with the diseases which we are targeting or may not meet the entry criteria for such trials. For example, each of our target indications is an orphan indication and, in particular, our lead product candidate, paltusotine, targets acromegaly, a condition which currently affects approximately 26,000 people in the United States. We also may encounter difficulties in identifying and enrolling subjects with a stage of disease appropriate for our planned or ongoing clinical trials and monitoring such subjects adequately during and after treatment. We may not be able to initiate or continue clinical trials if we are unable to locate a sufficient number of eligible subjects to participate in the clinical trials required by the FDA or comparable foreign regulatory authorities. In addition, the process of finding and diagnosing subjects may prove costly.

The timing of our clinical trials depends, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required follow-up periods. The conditions for which we currently plan to evaluate our product candidates are orphan or rare diseases with limited patient pools from which to draw for clinical trials. The eligibility criteria of our clinical trials, once established, will further limit the pool of available trial participants. If patients are unwilling to participate in our trials for any reason, including the existence of concurrent clinical trials for similar patient populations, if they are unwilling to enroll in a clinical trial with a placebo-controlled design or the availability of approved therapies, or we otherwise have difficulty enrolling a sufficient number of patients, the timeline for recruiting subjects, conducting studies and obtaining regulatory approval of our product candidates may be delayed. Our inability to enroll a sufficient number of subjects for any of our future clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. In addition, we expect to rely on CROs and clinical trial sites to ensure proper and timely conduct of our future clinical trials and, while we intend to enter into agreements governing their services, we will have limited influence over their actual performance.

We cannot assure you that our assumptions used in determining expected clinical trial timelines are correct or that we will not experience delays in enrollment, which would result in the delay of completion of such trials beyond our expected timelines.

Use of our product candidates could be associated with side effects or adverse events, which could severely harm our business, prospects, operating results and financial condition.

As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with our product candidates’ use. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.

Moreover, if our product candidates are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we may elect to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for the product candidate if approved. We may also be required to modify our study plans based on findings in our ongoing clinical trials. For example, the most common adverse events (>10%) observed in our Phase 2 clinical trials of paltusotine were headache, arthralgia, peripheral swelling, back pain and hyperhidrosis. Additionally, while we have not yet completed clinical trials for any of our other product candidates, it is likely that there may be side effects associated with their use. Many compounds that initially showed promise in early stage testing have later been found to cause side effects that prevented further development of the compound. In addition, regulatory authorities may draw different conclusions or require additional testing to confirm these determinations.

It is possible that as we test our product candidates in larger, longer and more extensive clinical trials, including with different dosing regimens and formulations, or as the use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by subjects. If such side effects become known later in development or upon approval, if any, such findings may harm our business, financial condition and prospects significantly.

In addition, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:

•	regulatory authorities may withdraw approvals of such product;

•	we may be required to recall a product or change the way such product is administered to patients;

•	regulatory authorities may require additional warnings on the label, such as a “black box” warning or a contraindication;

•	we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks of such side effects for distribution to patients;

•	we could be sued and held liable for harm caused to patients;

•	the product could become less competitive; and

•	our reputation may suffer.

Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects.

The clinical development, manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of our product candidates are subject to extensive regulation by the FDA in the United States and by comparable foreign regulatory authorities in foreign markets. In the United States, we are not permitted to market our product candidates until we receive regulatory approval from the FDA. The process of obtaining regulatory approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications and patient population. Approval policies or regulations may change, and the FDA has substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates, regulatory approval is never guaranteed. Neither we nor any future collaborator is permitted to market any of our product candidates in the United States until we receive approval of an NDA from the FDA.

Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our potential future collaborators must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe and effective for their intended uses. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and comparable foreign regulatory authorities. For example, while we are planning to conduct two Phase 3 clinical trials of paltusotine in distinct patient populations (patients who are on stable doses of SRL monotherapy and patients who are not being treated with pharmacotherapy), the FDA or comparable foreign regulatory authorities may require additional clinical trials or suggest changes to our planned clinical trials, prior to and in support of the approval of an NDA or equivalent foreign marketing application. The FDA or comparable foreign regulatory authorities, as the case may be, may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval, or may object to elements of our clinical development program.

The FDA or comparable foreign regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including:

•	such authorities may disagree with the design or implementation of our clinical trials;

•	negative or ambiguous results from our clinical trials or results may not meet the level of statistical significance required by the FDA or comparable foreign regulatory agencies for approval;

•	serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates;

•	the population studied in the clinical trial may not be sufficiently broad or representative to assure safety in the full population for which we seek approval;

•	such authorities may not accept clinical data from trials which are conducted at clinical facilities or in countries where the standard of care is potentially different from that of the United States;

•	we may be unable to demonstrate that a product candidate’s clinical and other benefits outweigh its safety risks;

•	such authorities may disagree with our interpretation of data from preclinical studies or clinical trials;

•

such authorities may not agree that the data collected from clinical trials of our product candidates are acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, and such authorities may impose requirements for additional preclinical studies or clinical trials;

•	such authorities may disagree regarding the formulation, labeling and/or the specifications of our product candidates;

•	approval may be granted only for indications that are significantly more limited than what we apply for and/or with other significant restrictions on distribution and use;

•	such authorities may find deficiencies in the manufacturing processes or facilities of our third-party manufacturers with which we or any of our potential future collaborators contract for clinical and commercial supplies; or

•	the approval policies or regulations of such authorities may significantly change in a manner rendering our or any of our potential future collaborators’ clinical data insufficient for approval.

With respect to foreign markets, approval procedures vary among countries and, in addition to the foregoing risks, may involve additional product testing, administrative review periods and agreements with pricing authorities. In addition, events raising questions about the safety of certain marketed pharmaceuticals may result in increased cautiousness by the FDA and comparable foreign regulatory authorities in reviewing new drugs based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us or any of our potential future collaborators from commercializing our product candidates.

Of the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects.

Even if we eventually complete clinical trials and receive approval of an NDA or foreign marketing application for our product candidates, the FDA or comparable foreign regulatory authority may grant approval contingent on the performance of costly additional clinical trials, including Phase 4 clinical trials, and/or the implementation of a REMS, which may be required to ensure safe use of the drug after approval. The FDA or the comparable foreign regulatory authority also may approve a product candidate for a more limited indication or patient population than we originally requested, and the FDA or comparable foreign regulatory authority may not approve the labeling that we believe is necessary or desirable for the successful commercialization of a product. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate and would materially adversely impact our business and prospects.

We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.

Because we have limited financial and managerial resources, we focus on specific product candidates, indications and discovery programs. For example, in April 2020, we announced that Phase 1 data for CRN01941 in healthy volunteers showed that the compound did not represent an improvement over paltusotine. Therefore, we discontinued development of CRN01941 to focus resources on development of paltusotine. As a result, we may forgo or delay pursuit of opportunities with other product candidates that could have had greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through future collaborations, licenses and other similar arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.

We have obtained orphan drug designation from the FDA for paltusotine for the treatment of acromegaly and have received orphan drug designation from the European Medicines Agency, or the EMA, for CRN04777 for the treatment of congenital HI. We also plan to seek orphan drug designations for certain of our other product candidates. However, we may not be able to obtain or maintain orphan drug designations for any of our product candidates, and we may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.

Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a product as an orphan product if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population of greater than 200,000 individuals in the United States, but for which there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the European Union, the European Medicines Agency’s, or the EMA, Committee for Orphan Medicinal Products grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union. We have obtained orphan drug designation for paltusotine in the United States for the treatment of acromegaly, and we intend to seek a similar orphan drug designation in the European Union. We have also obtained orphan drug designation for CRN04777 in Europe for the treatment of congenital HI. We also plan to seek orphan drug designations for certain of our other product candidates. There can be no assurance, however, that the FDA or the EMA’s Committee for Orphan Medicinal Products will grant orphan designation for any indication for which we apply.

In the United States, orphan designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product candidate that has orphan designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including an NDA, to market the same drug for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity. The applicable exclusivity period is ten years in Europe, but such exclusivity period can be reduced to six years if a product no longer meets the criteria for orphan designation or if the product is sufficiently profitable so that market exclusivity is no longer justified.

Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA or comparable foreign regulatory authority can subsequently approve the same drug for the same condition if such regulatory authority concludes that the later drug is clinically superior if it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.

The FDA has granted rare pediatric disease designation for CRN04777 for the treatment of congenital HI, however, there is no guarantee that FDA approval of CRN04777 will result in a priority review voucher.

In 2012, Congress authorized the FDA to award priority review vouchers to sponsors of certain rare pediatric disease product applications. This program is designed to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases. Specifically, under this program, a sponsor who receives an approval for a drug or biologic for a “rare pediatric disease” that meets certain criteria may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor of a rare pediatric disease drug product receiving a priority review voucher may transfer (including by sale) the voucher to another sponsor. The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted the application. The FDA may also revoke any priority review voucher if the rare pediatric disease drug for which the voucher was awarded is not marketed in the U.S. within one year following the date of approval.

The FDA has granted rare pediatric disease designation for CRN04777 for the treatment of congenital HI, however, there is no guarantee that we will be able to obtain a priority review voucher, even if CRN04777 is approved by the FDA. Moreover, Congress included a sunset provision in the statute authorizing the rare pediatric disease priority review voucher program. Specifically, FDA may not award the voucher to sponsors of marketing applications unless either (i) the drug has received rare pediatric disease designation as of September 30, 2024 and is then approved by the FDA no later than September 30, 2026; or (ii) Congress reauthorizes the program. Even though we received rare pediatric disease designation for CRN04777 by the current statutory deadline of September 30, 2024 we may not receive the voucher if we do not obtain approval by September 2026. Even if legislation is enacted that extends the date by which approval of the rare pediatric disease-designated drug must obtain approval to receive a priority review voucher, we may not obtain approval by that date, and even if we do, we may not obtain a priority review voucher.

We have conducted, and continue to conduct, clinical trials for paltusotine and CRN04777 outside of the United States and we may do so for our other product candidates. However, the FDA and other foreign equivalents may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business.

We conducted our initial Phase 1 clinical trials for paltusotine in Australia and we have conducted and plan to conduct additional clinical trials for paltusotine at centers outside of the United States. In addition, our Phase 1 clinical trial of CRN04777 is currently being conducted in Germany. We believe that clinical data generated outside of the United States will be accepted by the FDA and its foreign equivalents outside, and therefore will enable us to commence registration clinical trials in the United States or the European Union, without the need for us to repeat earlier-stage clinical trials. If the FDA, U.K. Medicines and Healthcare Products Regulatory Agency, or MHRA, or other foreign equivalents do not accept any such data, we would likely be required to conduct additional clinical trials, which would be costly and time consuming, and delay aspects of our development plan, which could harm our business.

Although the FDA, MHRA and other foreign equivalents may accept data from clinical trials conducted entirely outside the United States and not under an IND, acceptance of such study data is generally subject to certain conditions. For example, the FDA requires the clinical trial to have been conducted in accordance with GCPs, and the FDA must be able to validate the data from the clinical trial through an onsite inspection if it deems such inspection necessary. In addition, when studies are conducted only at sites outside of the United States, the FDA generally does not provide advance comment on the clinical or nonclinical protocols for the studies, and therefore there is an additional potential risk that the FDA could determine that the study design or protocol for a non-U.S. clinical trial was inadequate, which would likely require us to conduct additional clinical or nonclinical trials.

Conducting trials outside the United States also exposes us to additional risks, including risks associated with:

•	additional foreign regulatory requirements;

•	foreign exchange fluctuations;

•	compliance with foreign manufacturing, customs, shipment and storage requirements;

•	cultural differences in medical practice and clinical research; and

•	diminished protection of intellectual property in some countries.

For example, effective January 31, 2020, the United Kingdom commenced an exit from the European Union, commonly referred to as “Brexit” and, following the expiration of the Brexit transitional period on December 31, 2020, operates under a distinct regulatory regime. European legislation, including on clinical trials (including the impending EU Clinical Trials Regulation, or EU CTR), is no longer directly applicable in the United Kingdom. Current United Kingdom rules on clinical trials are derived from existing European Union legislation (as implemented into United Kingdom law), however going forward there is a risk that United Kingdom rules will diverge from European Union laws. Although regulatory authorities in the United Kingdom have indicated in the Medicines and Medical Devices Bill that new United Kingdom rules will closely align with the European Union legislation, detailed proposals are yet to be published. In addition, already as a result of the United Kingdom ceasing to be part of the European Union, various benefits of membership no longer apply to the United Kingdom, such that, for example, United Kingdom sponsored trials that span several European countries now need to have an individual or organization in the European Union to act as a legal representative, or sponsor; it is unclear whether the United Kingdom will have access to European Union clinical trial databases such as the Clinical Trial Information System (the centralized EU Portal for clinical trial information storage); and additionally, new rules apply to the import of investigational medicinal products from the European Union and European Economic Area to the United Kingdom. As a result, Brexit may create additional administrative burdens including disruptions to and uncertainty surrounding our planned clinical trials and activities in the United Kingdom and the European Union, impacting relationships with our existing and prospective customers, partners, vendors and employees. Although the United Kingdom and European Union have now reached an agreement on their future trading relationship to be implemented in the EU-UK Trade and Cooperation Agreement from January 1, 2021, which includes zero tariffs on goods and provides for regulatory cooperation, the agreement does not cover all regulatory areas regarding supply of medicinal products, which will likely be subject to bilateral discussions going forward which could further change the relationship between the United Kingdom and the European Union in this regard. Changes impacting our ability to conduct business in the United Kingdom or other European Union countries, or changes to the regulatory regime applicable to our operations in those countries (such as with respect to the approval of our product candidates), may have a material adverse impact on our business, financial condition and prospects.

Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.

From time to time, we may publicly disclose preliminary or topline or data from our clinical studies, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our clinical studies. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.

Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, drug candidate or our business. If the topline data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.

Risks related to our reliance on third parties

We rely on third parties to conduct many of our preclinical studies and clinical trials. Any failure by a third party to conduct the clinical trials according to GCPs and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize our product candidates.

We are dependent on third parties to conduct our preclinical studies and clinical trials, including our ongoing clinical trials for paltusotine, CRN04777, CRN04894, and any future clinical trials and preclinical studies for our product candidates. Specifically, we have used and relied on, and intend to continue to use and rely on, medical institutions, clinical investigators, CROs and consultants to conduct our clinical trials in accordance with our clinical protocols and regulatory requirements. These CROs, investigators and other third parties play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. While we have agreements governing the activities of our third-party contractors, we have limited influence over their actual performance. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs or trial sites fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.

There is no guarantee that any such CROs, investigators or other third parties will devote adequate time and resources to such trials or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, or otherwise performs in a substandard manner, our clinical trials may be extended, delayed or terminated. In addition, many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any NDA we submit by the FDA. Any such delay or rejection could prevent us from commercializing our product candidates.

If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties or do so on commercially reasonable terms. Switching or adding additional CROs, investigators and other third parties involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, investigators and other third parties, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.

We do not own or operate manufacturing facilities and have no plans to build our own clinical or commercial scale manufacturing capabilities. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates and related raw materials for preclinical and clinical development, as well as for commercial manufacture if any of our product candidates receive marketing approval. Furthermore, the raw materials for our product candidates are sourced, in some cases, from a single-source supplier. If we were to experience an unexpected loss of supply of any of our product candidates or any of our future product candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials. For example, the extent to which the COVID-19 pandemic impacts our ability to procure sufficient supplies for the development of our products and product candidates will depend on the severity and duration of the spread of the virus, and the actions undertaken to contain COVID-19 or treat its effects.

The facilities used by third-party manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will be conducted after we submit our NDA to the FDA. We do not control the manufacturing process of, and are completely dependent on, third-party manufacturers for compliance with cGMP requirements for manufacture of drug products. If these third-party manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, including requirements related to the manufacturing of high potency compounds, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we have no control over the ability of third-party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products.

In addition, we may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:

•	failure of third-party manufacturers to comply with regulatory requirements and maintain quality assurance;

•	breach of the manufacturing agreement by the third party;

•	failure to manufacture our product according to our specifications;

•	failure to manufacture our product according to our schedule or at all;

•	misappropriation of our proprietary information, including our trade secrets and know-how; and

•	termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.

Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.

Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval, and any related remedial measures may be costly or time-consuming to implement. We do not currently have arrangements in place for redundant supply or a second source for all required raw materials used in the manufacture of our product candidates. If our current third-party manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace them on a timely basis or at all.

Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.

Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.

Because we currently rely on other third parties to manufacture our product candidates and to perform quality testing, we must, at times, share our proprietary technology and confidential information, including trade secrets, with them. We seek to protect our proprietary technology, in part, by entering into confidentiality agreements, consulting agreements or other similar agreements with our advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are intentionally or inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets and despite our efforts to protect our trade secrets, a competitor’s discovery of our proprietary technology and confidential information or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business, financial condition, results of operations and prospects.

Risks related to commercialization of our product candidates

Even if we receive regulatory approval for any product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions on marketing or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.

Following potential approval of any our product candidates, the FDA may impose significant restrictions on a product’s indicated uses or marketing or impose ongoing requirements for potentially costly and time-consuming post-approval studies, post-market surveillance or clinical trials to monitor the safety and efficacy of the product. The FDA may also require a REMS as a condition of approval of our product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our products will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCP requirements for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our products, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:

•	restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls;

•	restrictions on product distribution or use, or requirements to conduct post-marketing studies or clinical trials;

•	fines, restitutions, disgorgement of profits or revenues, warning letters, untitled letters or holds on clinical trials;

•	refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals;

•	product seizure or detention, or refusal to permit the import or export of our products; and

•	injunctions or the imposition of civil or criminal penalties.

The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.

In addition, if any of our product candidates is approved, our product labeling, advertising and promotion will be subject to regulatory requirements and continuing regulatory review. The FDA strictly regulates the promotional claims that may be made about drug products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product’s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off label uses, we may become subject to significant liability. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.

The FDA’s and other regulatory authorities’ policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates.

We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, the results of the 2020 Presidential election may impact our business and industry. Namely, the Trump administration took several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA’s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict whether or how these executive actions will be implemented, or whether they will be rescinded and replaced under a Biden Administration. The policies and priorities of a new administration are unknown and could materially impact the regulations governing our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.

Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved, or commercialized in a timely manner or at all, which could negatively impact our business.

The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, the FDA’s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA’s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs and biologics or modifications to approved drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.

Separately, in response to the COVID-19 pandemic, on March 10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities and products, and on March 18, 2020 the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July 10, 2020, the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.

The commercial success of our product candidates will depend upon the degree of market acceptance of such product candidates by physicians, patients, health care payors and others in the medical community.

Our product candidates may not be commercially successful. Even if any of our product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payors or the medical community. The commercial success of any of our current or future product candidates will depend significantly on the broad adoption and use of the resulting product by physicians and patients for approved indications. The degree of market acceptance of our products will depend on a number of factors, including:

•	demonstration of clinical efficacy and safety compared to other more-established products;

•	the indications for which our product candidates are approved;

•	the limitation of our targeted patient population and other limitations or warnings contained in any FDA-approved labeling;

•	acceptance of a new drug for the relevant indication by healthcare providers and their patients;

•	the pricing and cost-effectiveness of our products, as well as the cost of treatment with our products in relation to alternative treatments and therapies;

•	our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government healthcare programs, including Medicare and Medicaid, private health insurers and other third-party payors;

•	the willingness of patients to pay all, or a portion of, out-of-pocket costs associated with our products in the absence of sufficient third-party coverage and adequate reimbursement;

•	the prevalence and severity of any adverse effects;

•	potential product liability claims;

•	the timing of market introduction of our products as well as competitive drugs;

•	the effectiveness of our or any of our potential future collaborators’ sales and marketing strategies; and

•	unfavorable publicity relating to the product.

If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors or patients, we may not generate sufficient revenue from that product and may not become or remain profitable. Our efforts to educate the medical community and third-party payors regarding the benefits of our products may require significant resources and may never be successful.

The successful commercialization of our product candidates, if approved, will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and favorable pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our products could limit our ability to market those products and decrease our ability to generate revenue.

The availability of coverage and the adequacy of reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as our product candidates, if approved. Our ability to achieve coverage and acceptable levels of reimbursement for our products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize those products. Even if we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the European Union or elsewhere will be available for any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.

Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor may consider our products as substitutable and only offer to reimburse patients for the less expensive product. Even if we are successful in demonstrating improved efficacy or improved convenience of administration with our products, pricing of existing drugs may limit the amount we will be able to charge for our products. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our products and may not be able to obtain a satisfactory financial return on products that we may develop.

There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs will be covered. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse health care providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our products.

Obtaining and maintaining reimbursement status is time-consuming, costly and uncertain. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs. However, no uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely.

Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries has and will continue to put pressure on the pricing and usage of our products. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our products. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.

Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our products. We expect to experience pricing pressures in connection with the sale of any of our products due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.

The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products, product candidates and processes competitive with our product candidates. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may attempt to develop product candidates. In particular, there is intense competition in the field of endocrine disorders. Our competitors include larger and better funded pharmaceutical, biopharmaceutical, biotechnological and therapeutics companies. Moreover, we may also compete with universities and other research institutions who may be active in endocrinology research and could be in direct competition with us. We also compete with these organizations to recruit management, scientists and clinical development personnel, which could negatively affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites, enrolling subjects for clinical trials and in identifying and in-licensing new product candidates. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.

With respect to congenital HI, maintaining glucose levels through feeding or glucose infusions is the first step in managing the disease. Diazoxide (marketed by Teva Pharmaceuticals, Inc.) is the only approved therapy indicated for hyperinsulinemia. Octreotide (used off-label) is administered as subcutaneous injections in those who respond poorly to diazoxide. Patients who fail pharmacological therapy often progress to partial or nearly complete pancreatectomy, which can result in type I diabetes that must be managed for the remainder of the patient’s life. Xeris Pharmaceuticals, Inc. received marketing approval for its ready-to-use glucagon in 2019. Companies developing products for potential use in congenital HI include Hanmi Pharmaceuticals and Zealand Pharma A/S with glucagon analogs. Other companies developing products for potential use in congenital HI include Eiger Biopharmaceuticals, Inc. and Rezolute, Inc.

Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. For example, a competitor could develop another oral formulation of a somatostatin agonist or other technology that could make administration of peptide therapies more convenient. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected.

The number of patients suffering from the rare endocrine diseases that we target, including acromegaly, NETs, diseases associated with excess ACTH, such as Cushing’s Disease, CAH and EAS, and congenital HI is small, and have not been established with precision. If the market opportunities for our products are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.

We focus our research and product development on treatments for orphan and rare diseases. Given the small number of patients who have the diseases that we are targeting, it is critical to our ability to grow and become profitable that we continue to successfully identify patients with these diseases. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our products, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. The effort to identify patients with diseases we seek to treat is in early stages, and we cannot accurately predict the number of patients for whom treatment might be possible. Additionally, the potentially addressable patient population for each of our products may be limited or may not be amenable to treatment with our products, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business. Further, even if we obtain significant market share for our products, because the potential target populations are very small, we may never achieve profitability despite obtaining such significant market share.

We may seek to enter into collaborations, licenses and other similar arrangements of our product and may not be successful in doing so, and even if we are, we may not realize the benefits of such relationships.

We may seek to enter into collaborations, licenses and other similar arrangements for the development or commercialization of our product candidates, due to capital costs required to develop or commercialize the product candidate in such markets. We may not be successful in our efforts to establish such collaborations for our product candidates because our product candidates may be deemed to be at too early of a stage of development for collaborative effort or third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy or significant commercial opportunity. In addition, we face significant competition in seeking appropriate strategic partners, and the negotiation process can be time-consuming and complex. Further, any future collaboration agreements may restrict us from entering into additional agreements with potential collaborators. We cannot be certain that, following a strategic transaction or license, we will achieve an economic benefit that justifies such transaction.

Even if we are successful in our efforts to establish such collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such collaborations if, for example, development or approval of a product candidate is delayed, the safety of a product candidate is questioned, or sales of an approved product are unsatisfactory. We also may not be able to realize the benefit of such collaborations if we are unable to successfully integrate them with our existing operations and company culture.

In addition, any potential future collaborations may be terminable by our strategic partners, and we may not be able to adequately protect our rights under these agreements. Furthermore, strategic partners may negotiate for certain rights to control decisions regarding the development and commercialization of our product candidates, if approved, and may not conduct those activities in the same manner as we do. Any termination of collaborations we enter into in the future, or any delay in entering into collaborations related to our product candidates, could delay the development and commercialization of our product candidates and reduce their competitiveness if they reach the market, which could have a material adverse effect on our business, financial condition and results of operations.

We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue.

We have no internal sales, marketing or distribution capabilities, nor have we commercialized a product. If any of our product candidates ultimately receives regulatory approval, we expect to establish a marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each such product in major markets, which will be expensive and time consuming. We have no prior experience as a company in the marketing, sale and distribution of pharmaceutical products and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may also choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we are not successful in commercializing our products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses.

Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.

Our future growth may depend, in part, on our ability to develop and commercialize our product candidates in foreign markets. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never receive such regulatory approvals for any of our product candidates. To obtain separate regulatory approval in many other countries we must comply with numerous and varying regulatory requirements regarding safety and efficacy and governing, among other things, clinical trials, commercial sales, pricing and distribution of our product candidates. If we obtain regulatory approval of our product candidates and ultimately commercialize our products in foreign markets, we would be subject to additional risks and uncertainties, including:

•	different regulatory requirements for approval of drugs in foreign countries;

•	reduced protection for intellectual property rights;

•	the existence of additional third-party patent rights of potential relevance to our business;

•	unexpected changes in tariffs, trade barriers and regulatory requirements;

•	economic weakness, including inflation, or political instability in particular foreign economies and markets;

•	compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;

•	foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;

•	foreign reimbursement, pricing and insurance regimes;

•	workforce uncertainty in countries where labor unrest is common;

•	production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and

•	business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires.

Risks related to our business operations and industry

Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:

•	the timing and cost of, and level of investment in, research, development, regulatory approval and commercialization activities relating to our product candidates, which may change from time to time;

•	coverage and reimbursement policies with respect to our product candidates, if approved, and potential future drugs that compete with our products;

•	the cost of manufacturing our product candidates, which may vary depending on the quantity of production and the terms of our agreements with third-party manufacturers;

•	expenditures that we may incur to acquire, develop or commercialize additional product candidates and technologies;

•	the level of demand for any approved products, which may vary significantly;

•	future accounting pronouncements or changes in our accounting policies; and

•	the timing and success or failure of preclinical studies or clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners.

The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.

This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide.

Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel. We are highly dependent upon our senior management, particularly our Chief Executive Officer, as well as our senior scientists and other members of our senior management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, initiation or completion of our planned clinical trials or the commercialization of our product candidates. Although we have executed employment agreements or offer letters with each member of our senior management team, these agreements are terminable at will with or without notice and, therefore, we may not be able to retain their services as expected. We do not currently maintain “key person” life insurance on the lives of our executives or any of our employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals.

We will need to expand and effectively manage our managerial, operational, financial and other resources in order to successfully pursue our clinical development and commercialization efforts. We may not be successful in maintaining our unique company culture and continuing to attract or retain qualified management and scientific and clinical personnel in the future due to the intense competition for qualified personnel among pharmaceutical, biotechnology and other businesses, particularly in the San Diego area. Our industry has experienced a high rate of turnover of management personnel in recent years. If we are not able to attract, integrate, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.

We may encounter difficulties in managing our growth and expanding our operations successfully.

As of February 28, 2021, we had 93 full-time employees. As we continue development and pursue the potential commercialization of our product candidates, as well as function as a public company, we will need to expand our financial, development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships with various strategic partners, suppliers and other third parties. Our future financial performance and our ability to develop and commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively.

We conduct certain research and development operations through our Australian wholly-owned subsidiary. If we lose our ability to operate in Australia, or if our subsidiary is unable to receive the research and development tax credit allowed by Australian regulations, our business and results of operations could suffer.

In January 2017, we formed a wholly-owned Australian subsidiary, CAPL, to conduct various preclinical and clinical activities for our product and development candidates in Australia. Due to the geographical distance and lack of employees currently in Australia, as well as our lack of experience operating in Australia, we may not be able to efficiently or successfully monitor, develop and commercialize our lead products in Australia, including conducting clinical trials. Furthermore, we have no assurance that the results of any clinical trials that we conduct for our product candidates in Australia will be accepted by the FDA or foreign regulatory authorities for development and commercialization approvals.

In addition, current Australian tax regulations provide for a refundable research and development tax credit equal to 43.5% of qualified expenditures. If we lose our ability to operate CAPL in Australia, or if we are ineligible or unable to receive the

research and development tax credit, or the Australian government significantly reduces or eliminates the tax credit, our business and results of operation may be adversely affected.

We are subject to various foreign, federal and state healthcare laws and regulations, and our failure to comply with these laws and regulations could harm our results of operations and financial condition.

Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors and customers expose us to broadly applicable federal and state fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute any products for which we obtain marketing approval. Such laws include:

•

the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe or certain rebates), directly or indirectly, overtly or covertly, in cash or in kind, in return for, either the referral of an individual or the purchase, lease, or order, or arranging for or recommending the purchase, lease, or order of any good, facility, item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti- Kickback Statute or specific intent to violate it in order to have committed a violation;

•

the federal false claims, including the civil False Claims Act, which, among other things, impose criminal and civil penalties against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making or causing to be made a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;

•

the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.

•

the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) to report annually to the government information related to payments and other “transfers of value” made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other healthcare professionals (starting in 2022), and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members; and

•

analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by non- governmental third-party payors, including private insurers, or by the patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to physicians, other healthcare providers and entities; state and local laws that require the registration of pharmaceutical sales representatives.

Ensuring that our internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices, including our consulting and advisory board arrangements with physicians and other healthcare providers, some of whom receive stock options as compensation for services provided, do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, disgorgement, individual imprisonment, contractual damages, reputational harm, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve

allegations of non-compliance with these laws, diminished profits and the curtailment or restructuring of our operations. Further, defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusion from government funded healthcare programs and imprisonment. If any of the above occur, it could adversely affect our ability to operate our business and our results of operations.

We are subject to governmental regulation and other legal obligations related to privacy, data protection and information security. Compliance with these requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data, and the failure to comply with such requirements could have a material adverse effect on our business, financial condition or results of operations.

Privacy and data security have become significant issues in the U.S., E.U. and in many other jurisdictions where we may in the future conduct our operations. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues, which may affect our business and may increase our compliance costs and exposure to liability. As we receive, collect, process, use and store personal and confidential data, we are or may be subject to diverse laws and regulations relating to data privacy and security, including, in the U.S., HIPAA and CCPA (defined below), and, in the EU and the EEA, the General Data Protection Regulation, or the GDPR. Compliance with these privacy and data security requirements is rigorous and time-intensive and may increase our cost of doing business, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation and reputational harm, which could materially and adversely affect our business, financial condition and results of operations.

In the U.S., we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their respective implementing regulations, impose, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information held by covered entities and their business associates. We may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA. Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. Even when HIPAA does not apply, according to the Federal Trade Commission or the FTC, failing to take appropriate steps to keep consumers’ personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a company’s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards.

In addition, state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same requirements, thus complicating compliance efforts. By way of example, California enacted the California Consumer Privacy Act, or CCPA, effective January 1, 2020, which gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. Further, the California Privacy Rights Act, or CPRA, recently passed in California. The CPRA will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. In addition, the CCPA has prompted a number of proposals for new federal and state privacy legislation that, if passed, could increase our potential liability, increase our compliance costs and adversely affect our business. If we fail to comply with applicable laws and regulations, we could be subject to penalties or sanctions, including criminal penalties if we knowingly obtain or disclose individually identifiable health information from a covered entity in a manner that is not authorized or permitted by HIPAA or applicable state laws.

In the EEA, the GDPR imposes many requirements for controllers and processors of personal data, including, for example, high standards for obtaining consent from individuals to process their personal data, robust disclosures to individuals and a strong individual data rights regime, short timelines for data breach notifications, limitations on retention and secondary use of information, significant requirements pertaining to health data and pseudonymized (i.e., key-coded) data and obligations when we contract third-party processors in connection with the processing of the personal data. The GDPR allows EU

member states to make additional laws and regulations further limiting the processing of genetic, biometric or health data. Failure to comply with the requirements of the GDPR and the applicable national data protection laws of the EU member states may result in fines of up to €20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other regulatory investigations, reputational damage, orders to cease/ change our processing of our data, enforcement notices, and/ or assessment notices (for a compulsory audit). We may also face civil claims including representative actions and other class action type litigation (where individuals have suffered harm), potentially amounting to significant compensation or damages liabilities, as well as associated costs, diversion of internal resources, and reputational harm.

We are also subject to European Union rules with respect to cross-border transfers of personal data out of the EEA. Recent legal developments in Europe have created complexity and uncertainty regarding transfers of personal data from the EEA to the United States. Most recently, on July 16, 2020, the Court of Justice of the European Union, or CJEU, invalidated the EU-US Privacy Shield Framework, or Privacy Shield, under which personal data could be transferred from the EEA to US entities who had self-certified under the Privacy Shield scheme. While the CJEU upheld the adequacy of the standard contractual clauses (a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism, and potential alternative to the Privacy Shield), it made clear that reliance on them alone may not necessarily be sufficient in all circumstances. Use of the standard contractual clauses must now be assessed on a case-by-case basis taking into account the legal regime applicable in the destination country. The CJEU went on to state that if a competent supervisory authority believes that the standard contractual clauses cannot be complied with in the destination country and the required level of protection cannot be secured by other means, such supervisory authority is under an obligation to suspend or prohibit that transfer. These recent developments may require us to review and amend the legal mechanisms by which we make and/ or receive personal data transfers to/ in the United States. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the standard contractual clauses cannot be used, and/ or start taking enforcement action, we could suffer additional costs, complaints and/ or regulatory investigations or fines, and/ or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.

Additionally, from 1 January 2021, we are subject to the GDPR and also the UK GDPR which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, e.g. fines up to the greater of €20 million (£17.5 million) or 4% of global turnover. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, and it is unclear how UK data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the United Kingdom will be regulated in the long term. Currently there is a four to six-month grace period agreed in the EU and UK Trade and Cooperation Agreement, ending 30 June 2021 at the latest, whilst the parties discuss an adequacy decision in favor of the United Kingdom. However, it is not clear whether (and when) an adequacy decision may be granted by the European Commission enabling data transfers from European Union member states to the United Kingdom long term without additional measures. These changes may lead to additional costs and increase our overall risk exposure, as well as requiring us to find alternative solutions for the compliant transfer of data into the United Kingdom.

Compliance with U.S. and foreign data privacy and security laws, rules and regulations could require us to take on more onerous obligations in our contracts, require us to engage in costly compliance exercises, restrict our ability to collect, use and disclose data, or in some cases, impact our or our partners’ or suppliers’ ability to operate in certain jurisdictions. Each of these constantly evolving laws can be subject to varying interpretations. If we fail to comply with any such laws, rules or regulations, we may face government investigations and/or enforcement actions, fines, civil or criminal penalties, private litigation or adverse publicity that could adversely affect our business, financial condition and results of operations.

Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for and commercialize our product candidates and may affect the prices we may set.

In the United States and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system, including cost-containment measures that may reduce or limit coverage and reimbursement for newly approved drugs and affect our ability to profitably sell any product candidates for which we obtain marketing approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare.

For example, in March 2010, the ACA was enacted in the United States. Among the provisions of the ACA of importance to our potential product candidates, the ACA: established an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents; expanded eligibility criteria for Medicaid programs; increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; created a new Medicare Part D coverage gap discount program; established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research; and

established a Center for Medicare Innovation at the Centers for Medicare and Medicaid Services to test innovative payment and service delivery models to lower Medicare and Medicaid spending.

Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. For example, the Tax Act included a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate.” On December 14, 2018, a U.S. District Court Judge in the Northern District of Texas, or the Texas District Court Judge, ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the ACA are invalid as well. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit affirmed the District Court’s decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court is currently reviewing the case, although it is unclear how the Supreme Court will rule. It is also unclear how other efforts to challenge, repeal or replace the ACA, if any, will impact the ACA or our business.

In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, included reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2021, unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.

Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. The likelihood of implementation of any of these reform initiatives is uncertain, particularly in light of the new Presidential administration.

At the state level, individual states in the United States are also increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates, if approved, or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects.

We expect that these new laws and other healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates, if approved.

If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products.

We face an inherent risk of product liability as a result of the clinical trials of our product candidates and will face an even greater risk if we commercialize our product candidates. For example, we may be sued if our product candidates allegedly cause injury or are found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers

inherent in the product candidate, negligence, strict liability and a breach of warranties. Claims may be brought against us by clinical trial participants, patients or others using, administering or selling products that may be approved in the future, or could be asserted under state consumer protection acts.

If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or cease the commercialization of our products. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:

•	decreased demand for our products;

•	injury to our reputation and significant negative media attention;

•	withdrawal of clinical trial participants;

•	costs to defend the related litigation;

•	a diversion of management’s time and our resources;

•	substantial monetary awards to trial participants or patients;

•	product recalls, withdrawals or labeling, marketing or promotional restrictions;

•	significant negative financial impact;

•	the inability to commercialize our product candidates; and

•	a decline in our stock price.

We currently hold $10 million in product liability insurance coverage in the aggregate. We may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of our product candidates. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies will also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.

We and any of our potential future collaborators will be required to report to regulatory authorities if any of our approved products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business.

If we and any of our potential future collaborators are successful in commercializing our products, the FDA and foreign regulatory authorities would require that we and any of our potential future collaborators report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We and any of our potential future collaborators or CROs may fail to report adverse events within the prescribed timeframe. If we or any of our potential future collaborators or CROs fail to comply with such reporting obligations, the FDA or a foreign regulatory authority could take action, including criminal prosecution, the imposition of civil monetary penalties, seizure of our products or delay in approval or clearance of future products.

Our employees and independent contractors, including principal investigators, CROs, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.

We are exposed to the risk that our employees and independent contractors, including principal investigators, CROs, consultants and vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate: (1) the laws and regulations of the FDA and other similar regulatory requirements, including those laws that require the reporting of true, complete and accurate information to such authorities, manufacturing standards, (2) federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad or (3) laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials, or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business

and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management.

From time to time, we may consider strategic transactions, such as acquisitions of companies, asset purchases and out-licensing or in-licensing of intellectual property, products or technologies. Additional potential transactions that we may consider in the future include a variety of business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Any future transactions could increase our near and long-term expenditures, result in potentially dilutive issuances of our equity securities, including our common stock, or the incurrence of debt, contingent liabilities, amortization expenses or acquired in-process research and development expenses, any of which could affect our financial condition, liquidity and results of operations. Future acquisitions may also require us to obtain additional financing, which may not be available on favorable terms or at all. These transactions may never be successful and may require significant time and attention of management. In addition, the integration of any business that we may acquire in the future may disrupt our existing business and may be a complex, risky and costly endeavor for which we may never realize the full benefits of the acquisition. Accordingly, although there can be no assurance that we will undertake or successfully complete any additional transactions of the nature described above, any additional transactions that we do complete could have a material adverse effect on our business, results of operations, financial condition and prospects.

Risks related to our intellectual property

Our success depends on our ability to protect our intellectual property and our proprietary technologies.

Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our product candidates, proprietary technologies and their uses as well as our ability to operate without infringing upon the proprietary rights of others. We generally seek to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates, proprietary technologies and their uses that are important to our business. Our patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the technology. There can be no assurance that our patent applications will result in patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents issued will not be infringed, designed around or invalidated by third parties. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. This failure to obtain the intellectual property rights relating to our product candidates could have a material adverse effect on our financial condition and results of operations.

Although we own twelve issued patents in the United States as of March 30, 2021, we cannot be certain that the claims in our other U.S. pending patent applications, corresponding international patent applications and patent applications in certain foreign territories will be considered patentable by the United States Patent and Trademark Office, or USPTO, courts in the United States or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our issued patents will not be found invalid or unenforceable if challenged.

The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include but are not limited to the following:

•

the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;

•	patent applications may not result in any patents being issued;

•	patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;

•

our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use and sell our potential product candidates;

•	there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and

•	countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates.

The patent prosecution process is also expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.

In addition, although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, outside scientific collaborators, CROs, third-party manufacturers, consultants, advisors and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.

Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.

If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.

The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our product candidates or which effectively prevent others from commercializing competitive product candidates.

Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we own may be challenged or circumvented by third parties or may be narrowed or invalidated as a result of challenges by third parties. Consequently, we do not know whether our product candidates will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and prospects.

The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third-party pre-issuance submission of prior art to the USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant review, or PGR, and inter partes review, or IPR, or other similar proceedings challenging our owned patent rights. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize our product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, our patents may become subject to post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our priority of invention or other features of patentability with respect to our patents and patent applications. Such challenges may result in loss of patent rights, loss of exclusivity or patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our product candidates. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.

Most of our intellectual property has been discovered through government funded programs and thus may be subject to federal regulations such as “march-in” rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.

Most of our intellectual property rights, including those for our lead programs, have been generated through the use of U.S. government funding provided from SBIR Grants awarded to us prior to 2020 by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, and are therefore subject to certain federal regulations. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future product candidates pursuant to the Bayh-Dole Act of 1980, or Bayh-Dole Act. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as “march-in rights”). The U.S. government also has the right to take title to these inventions if we fail to disclose the invention to the government or fail to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. To the extent any of our future intellectual property is also generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply.

Intellectual property rights do not necessarily address all potential threats to our competitive advantage.

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:

•	others may be able to develop products that are similar to our product candidates but that are not covered by the claims of the patents that we own;

•	we might not have been the first to make the inventions covered by the issued patents or patent application that we own;

•	we might not have been the first to file patent applications covering certain of our inventions;

•	others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;

•	it is possible that our pending patent applications will not lead to issued patents;

•	issued patents that we own may be held invalid or unenforceable, as a result of legal challenges by our competitors;

•	our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;

•	we may not develop additional proprietary technologies that are patentable; and

•	the patents of others may have an adverse effect on our business.

Should any of these events occur, it could significantly harm our business, results of operations and prospects.

Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.

Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our product candidates and products that may be approved in the future, or impair our competitive position. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biopharmaceutical industry, including patent infringement lawsuits, oppositions, reexaminations, IPR proceedings and PGR proceedings before

the USPTO and/or corresponding foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates.

As the biopharmaceutical industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published, we may be unaware of third-party patents that may be infringed by commercialization of any of our product candidates, and we cannot be certain that we were the first to file a patent application related to a product candidate or technology. Moreover, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. There is also no assurance that there is not prior art of which we are aware, but which we do not believe is relevant to our business, which may, nonetheless, ultimately be found to limit our ability to make, use, sell, offer for sale or import our products that may be approved in the future, or impair our competitive position. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Any claims of patent infringement asserted by third parties would be time consuming and could:

•	result in costly litigation that may cause negative publicity;

•	divert the time and attention of our technical personnel and management;

•	cause development delays;

•	prevent us from commercializing any of our product candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law;

•	require us to develop non-infringing technology, which may not be possible on a cost-effective basis;

•	subject us to significant liability to third parties; or

•	require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all, or which might be non-exclusive, which could result in our competitors gaining access to the same technology.

Although no third party has asserted a claim of patent infringement against us as of the date of this Annual Report on Form 10-K, others may hold proprietary rights that could prevent our product candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin commercial activities relating to our products or processes could subject us to potential liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or market our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. Moreover, even if we or our future strategic partners were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we cannot be certain that we could redesign our product candidates or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing our product candidates, which could harm our business, financial condition and operating results. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity and could prohibit us from marketing or otherwise commercializing our product candidates and technology.

Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.

We may be involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court.

Competitors may infringe our intellectual property rights. To prevent infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in a patent infringement proceeding, a court may decide that a patent we own is not valid, is unenforceable and/or is not infringed. If we or any of our potential future collaborators were to initiate legal proceedings against a third party to enforce a patent directed at one of our product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including but not

limited to lack of novelty, obviousness, written description or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution.

Third parties may also raise similar invalidity claims before the USPTO or patent offices abroad, even outside the context of litigation. Such mechanisms include re-examination, PGR, IPR, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation of, cancellation of or amendment to our patents in such a way that they no longer cover our technology or platform, or any product candidates that we may develop. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our technology or platform, or any product candidates that we may develop. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations and prospects.

The outcome following legal assertions of invalidity and/or unenforceability is unpredictable, and prior art could render our patents invalid. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found. There is also no assurance that there is not prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim in our patents and patent applications, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim.

If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Such a loss of patent protection would have a material adverse impact on our business.

Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our own patented product and practicing our own patented technology.

Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline.

During the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing products, programs or intellectual property could be diminished. Accordingly, the market price of shares of our common stock may decline. Such announcements could also harm our reputation or the market for our future products, which could have a material adverse effect on our business.

Derivation proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party.

Derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of derivation proceedings may fail

and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with such proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring our product candidates to market.

Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.

On September 16, 2011, the Leahy-Smith America Invents Act, or Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a “first inventor to file” system in which, assuming that other requirements of patentability are met, the first inventor to file a patent application will be entitled to the patent regardless of whether a third party was first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013 but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to either (1) file any patent application related to our product candidates or (2) invent any of the inventions claimed in our patents or patent applications.

The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including PGR, IPR, and derivation proceedings. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.

Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.

As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the pharmaceutical industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing pharmaceutical patents is costly, time consuming and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property and may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. In addition, Congress or other foreign legislative bodies may pass patent reform legislation that is unfavorable to us.

For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO, or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future.

We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.

We may also be subject to claims that former employees or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on our business. Even if we are successful

in defending against such claims, litigation could result in substantial costs and distraction to management and other employees.

Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.

Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.

If we do not obtain patent term extension for our product candidates, our business may be materially harmed.

Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. A maximum of one patent may be extended per FDA approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of our product candidates. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.

We may not be able to protect our intellectual property rights throughout the world.

Although we have twelve issued patents in the United States as of March 30, 2021 and pending patent applications in the United States and other countries, filing, prosecuting and defending patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our

competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.

Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on our outside patent annuity service to pay these fees when due. Additionally, the USPTO and various foreign patent offices, require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business.

If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.

Even though we have filed three trademark registration applications in the USPTO, we cannot be certain that our registered or unregistered U.S. trademarks or trade names, or the corresponding trademarks or trade names registered in foreign territories, will not be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our financial condition or results of operations.

If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.

In addition, we rely on the protection of our trade secrets, including unpatented know-how, technology and other proprietary information to maintain our competitive position. Although we have taken steps to protect our trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants and advisors, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.

Moreover, third parties may still obtain this information or may come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete with us. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced, and our competitive position would be harmed. If we do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized.

We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.

As is common in the pharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other pharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or

personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees.

Risks related to our common stock

An active, liquid and orderly market for our common stock may not be maintained.

Our common stock only began trading on the Nasdaq Global Select Market, or Nasdaq, in 2018, and we can provide no assurance that we will be able to maintain an active trading market for our common stock. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other businesses or technologies using our shares as consideration, which, in turn, could materially adversely affect our business.

The trading price of the shares of our common stock could be highly volatile, and purchasers of our common stock could incur substantial losses.

Our stock price is likely to be volatile. The stock market in general and the market for stock of pharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at or above the price at which they paid. The market price for our common stock may be influenced by those factors discussed in this “Risk factors” section and many others, including:

•	our ability to enroll subjects in our ongoing and planned clinical trials;

•	results of our clinical trials and preclinical studies, and the results of trials of our competitors or those of other companies in our market sector;

•	regulatory approval of our product candidates, or limitations to specific label indications or patient populations for its use, or changes or delays in the regulatory review process;

•	regulatory developments in the United States and foreign countries;

•	changes in the structure of healthcare payment systems, especially in light of current reforms to the U.S. healthcare system;

•	the success or failure of our efforts to acquire, license or develop additional product candidates;

•	innovations or new products developed by us or our competitors;

•	announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;

•	manufacturing, supply or distribution delays or shortages;

•	any changes to our relationship with any manufacturers, suppliers, future collaborators or other strategic partners;

•	achievement of expected product sales and profitability;

•	variations in our financial results or those of companies that are perceived to be similar to us;

•	market conditions in the pharmaceutical sector and issuance of securities analysts’ reports or recommendations;

•	trading volume of our common stock;

•	an inability to obtain additional funding;

•	sales of our stock by insiders and stockholders;

•	general economic, industry and market conditions or other events or factors, many of which are beyond our control;

•	additions or departures of key personnel; and

•	intellectual property, product liability or other litigation against us.

In addition, in the past, stockholders have initiated class action lawsuits against pharmaceutical companies following periods of volatility in the market prices of these companies’ stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management’s attention and resources, which could have a material adverse effect on our business, financial condition and results of operations.

Our failure to meet the continued listing requirements of the Nasdaq Global Select Market could result in a delisting of our common stock.

If we fail to satisfy the continued listing requirements of the Nasdaq Global Select Market, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq’s listing requirements.

Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to control or significantly influence all matters submitted to stockholders for approval.

Our executive officers, directors and greater than 5% stockholders, in the aggregate, own approximately 58% of our outstanding common stock as of February 26, 2021. As a result, such persons, acting together, have the ability to control or significantly influence all matters submitted to our stockholders for approval, including the election and removal of directors and approval of any significant transaction, as well as our management and business affairs. This concentration of ownership may have the effect of delaying, deferring or preventing a change in control, impeding a merger, consolidation, takeover or other business combination involving us, or discouraging a potential acquiror from making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other stockholders.

We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation, if any, in the price of our common stock.

We have never declared or paid any cash dividend on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, the terms of any future debt agreements may preclude us from paying dividends. Any return to stockholders will therefore be limited to the appreciation of their stock. There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at which stockholders have purchased their shares.

Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.

Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur could significantly reduce the market price of our common stock and impair our ability to raise adequate capital through the sale of additional equity securities.

The holders of 7,240,744 shares of our outstanding common stock, or approximately 22% of our total outstanding common stock as of February 26, 2021, are entitled to rights with respect to the registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule 144 under the Securities Act. Sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.

We are an emerging growth company and a smaller reporting company, and the reduced disclosure requirements applicable to such companies may make our common stock less attractive to investors.

We are an emerging growth company, as defined in the JOBS Act, and a smaller reporting company, as defined under the rules promulgated under the Securities Act. We may remain an emerging growth company until the last day of the fiscal year following the fifth anniversary of the completion of our initial public offering, or IPO. However, if certain events occur prior to the end of such five-year period, including if we become a “large accelerated filer,” our annual gross revenues exceed $1.07 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:

•	not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting;

•	not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements;

•	reduced disclosure obligations regarding executive compensation; and

•	exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

We are also a smaller reporting company, and we will remain a smaller reporting company until the fiscal year following the determination that our voting and non‑voting common shares held by non‑affiliates is more than $250 million measured on the last business day of our second fiscal quarter, or our annual revenues are more than $100 million during the most recently

completed fiscal year and our voting and non‑voting common shares held by non‑affiliates is more than $700 million measured on the last business day of our second fiscal quarter. Similar to emerging growth companies, smaller reporting companies are able to provide simplified executive compensation disclosure and have certain other reduced disclosure obligations, including, among other things, being required to provide only two years of audited financial statements and not being required to provide selected financial data, supplemental financial information or risk factors.

We may choose to take advantage of some, but not all, of the available exemptions for emerging growth companies and smaller reporting companies. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be reduced or more volatile.

Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.

Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could significantly reduce the value of our shares to a potential acquiror or delay or prevent changes in control or changes in our management without the consent of our board of directors. The provisions in our charter documents include the following:

•	a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;

•	no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;

•

the exclusive right of our board of directors, unless the board of directors grants such right to the stockholders, to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;

•	the required approval of at least 66-2/3% of the shares entitled to vote to remove a director for cause, and the prohibition on removal of directors without cause;

•

the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;

•	the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval;

•	the required approval of at least 66-2/3% of the shares entitled to vote to adopt, amend or repeal our amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors;

•	a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;

•	an exclusive forum provision providing that the Court of Chancery of the State of Delaware will be the exclusive forum for certain actions and proceedings;

•	the requirement that a special meeting of stockholders may be called only by the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and

•

advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders’ meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror’s own slate of directors or otherwise attempting to obtain control of us.

We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law. Under Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction.

Our amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, and our amended and restated bylaws provide that the federal district courts shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

Our amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided, however, that this exclusive forum provision would not apply to suits brought to enforce any liability or duty created by the Securities Act or the Exchange Act

or any other claim for which the federal courts have exclusive jurisdiction. Furthermore, our amended and restated bylaws also provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. These provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. Alternatively, if a court were to find this provision in our amended and restated certificate of incorporation and amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.

Our ability to use net operating loss carryforwards and other tax attributes may be limited.

We have incurred substantial losses during our history, do not expect to become profitable in the near future, and may never achieve profitability. To the extent that we continue to incur losses for tax purposes, or NOLs, such NOLs will carry forward to offset future taxable income, if any, until such NOLs expire (if subject to expiration). As of December 31, 2020, we had federal, state and foreign NOLs of approximately $118.2 million, $124.1 million and $1.6 million, respectively. Our federal NOLs that are subject to expiration, and our state NOLs, will begin to expire in 2035, unless previously utilized. Federal NOLs generated in taxable years beginning after December 31, 2017 may be carried forward indefinitely but may only be used to offset 80% of our taxable income in taxable years beginning after December 31, 2020. Our foreign NOLs do not expire. We also have federal and California research and development credit carryforwards totaling $4.5 million and $2.7 million, respectively, available to offset income tax liabilities. The federal research and development tax credits will begin to expire in 2030, unless previously utilized. The California research and development tax credits do not expire. We also have federal Orphan Drug credits totaling $1.4 million which will begin to expire in 2040, unless previously utilized.

Our NOLs and other tax attributes (including tax credits) are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Moreover, in general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an “ownership change” is subject to limitations on its ability to utilize its pre-ownership change NOLs or tax credits to offset future taxable income or income tax liabilities, respectively. For these purposes, an ownership change generally occurs where the aggregate change in stock ownership of one or more stockholders or groups of stockholders owning at least 5% of a corporation’s stock exceeds 50 percentage points over a rolling three-year period. If finalized, Treasury Regulations currently proposed under Section 382 of the Code may further limit our ability to utilize our pre-ownership change NOLs or tax credits if we undergo a such a future ownership change. Similar rules may apply under state or foreign tax laws. We have experienced ownership changes within the meaning of Section 382 of the Code during the fourth quarter of 2015, the first quarter of 2018 and the second quarter of 2020. These ownership changes have subjected, and will continue to subject, our NOLs and tax credits to an annual limitation on their utilization. However, our NOLs and tax credits are not expected to expire unused assuming we have taxable income or income tax liabilities in future periods. Although we do not expect these limitations to constrain utilization of our NOLs or tax credits, such limitations could result in the expiration of our NOLs or tax credits before they can be utilized and, if we are profitable, our future cash flows could be adversely affected due to our increased tax liability. In addition, future changes in our stock ownership, many of which are outside of our control, could result in additional ownership changes and further annual limitations. We have recorded a full valuation allowance related to our NOLs and other deferred tax assets due to the uncertainty of the ultimate realization of the future benefits of those assets.

General risk factors

We and any of our third-party manufacturers and suppliers may use potent chemical agents and hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly.

We and any of our third-party manufacturers or suppliers will use biological materials, potent chemical agents and may use hazardous materials, including chemicals and biological agents and compounds that could be dangerous to human health and safety of the environment. Our operations and the operations of our third-party manufacturers and suppliers also produce hazardous waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our product development efforts. In addition, we cannot eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. In the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.

Although we maintain workers’ compensation insurance for certain costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide

adequate coverage against potential liabilities. We do not maintain insurance for toxic tort claims that may be asserted against us in connection with our storage or disposal of biologic, hazardous or radioactive materials.

In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations, which have tended to become more stringent over time. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions or liabilities, which could materially adversely affect our business, financial condition, results of operations and prospects.

Our internal computer systems, or those of any of our CROs, manufacturers, other contractors or consultants or potential future collaborators, may fail or suffer security breaches, which could result in a material disruption of our product development programs.

Despite the implementation of security measures, our internal computer systems and those of our current and any future CROs and other contractors, consultants and collaborators are vulnerable to damage from computer viruses, cybersecurity threats, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. As a result of the COVID-19 pandemic, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. We also rely on third parties to manufacture our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed.

Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.

Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured. We rely on third- party manufacturers to produce our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers were affected by a man-made or natural disaster or other business interruption. In addition, our corporate headquarters is located in San Diego, California near major earthquake faults and fire zones, and the ultimate impact on us of being located near major earthquake faults and fire zones and being consolidated in a certain geographical area is unknown. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.

We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.

We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department’s Office of Foreign Assets Controls, and anti-corruption and anti-money laundering laws and regulations, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. § 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, clinical research organizations, contractors and other collaborators and partners from authorizing, promising, offering, providing, soliciting or receiving, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties for clinical trials outside of the United States, to sell our products abroad once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the

corrupt or other illegal activities of our employees, agents, clinical research organizations, contractors and other collaborators and partners, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.

We incur significant costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.

As a public company, we incur significant legal, accounting and other expenses. We are subject to the reporting requirements of the Exchange Act, which require, among other things, that we file with the U.S. Securities and Exchange Commission, or SEC, annual, quarterly and current reports with respect to our business and financial condition. In addition, Sarbanes-Oxley, as well as rules subsequently adopted by the SEC, and Nasdaq to implement provisions of Sarbanes-Oxley, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules and regulations in these areas, such as mandatory “say on pay” voting requirements that will apply to us when we cease to be an emerging growth company. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.

The rules and regulations applicable to public companies have increased and may continue to increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will decrease our net income or increase our net loss and may require us to reduce costs in other areas of our business. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.

If securities or industry analysts do not publish research or reports or publish unfavorable research or reports about our business, our stock price and trading volume could decline.

The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us, our business, our market or our competitors. We currently have limited research coverage by securities and industry analysts. If securities or industry analysts do not continue coverage of our company, the trading price for our stock would be negatively impacted. In the event one or more of the analysts who covers us downgrades our stock, our stock price would likely decline. If one or more of these analysts ceases to cover us or fails to regularly publish reports on us, interest in our stock could decrease, which could cause our stock price or trading volume to decline.

If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.

Pursuant to Section 404 of Sarbanes-Oxley, our management is required to report upon the effectiveness of our internal control over financial reporting. When we lose our status as an “emerging growth company,” unless we are no longer an accelerated filer, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we are in process of implementing additional financial and management controls and reporting systems and procedures. If we or, if required, our auditors are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.

Although we have determined that our internal control over financial reporting was effective as of December 31, 2020, we cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begin its Section 404 reviews, investors may lose confidence in the accuracy and completeness of our financial reports, the market

price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.

Changes in tax laws, including as a result of the 2020 United States presidential and congressional elections, may impact our financial condition and results of operations.

New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, or interpreted, changed, modified or applied adversely to us, any of which could adversely affect our business operations and financial performance. In particular, the recent presidential and congressional elections in the United States could result in significant changes in, and uncertainty with respect to, tax legislation, regulation and government policy directly affecting our business or indirectly affecting us because of impacts on our manufacturers and suppliers. For example, the United States government may enact significant changes to the taxation of business entities including, among others, a permanent increase in the corporate income tax rate, an increase in the tax rate applicable to the global intangible low-taxed income and elimination of certain exemptions, and the imposition of minimum taxes or surtaxes on certain types of income. No specific United States tax legislation has been proposed at this time and the likelihood of these changes being enacted or implemented is unclear. We are currently unable to predict whether such changes will occur and, if so, the ultimate impact on our business. To the extent that such changes have a negative impact on us, our suppliers or our customers, including as a result of related uncertainty, these changes may materially and adversely impact our business, financial condition, results of operations and cash flows.

We could be subject to securities class action litigation.

In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management’s attention and resources, which could harm our business.

Item 1B. Unresolved Staff Comments

None.

Item 2. Properties

Our corporate headquarters consists of a 29,499 square foot facility in San Diego, California. We use our corporate headquarters primarily for corporate, research, development, clinical, regulatory, manufacturing and quality functions. Our lease for this facility expires in August 2025, with the option to extend the term of the lease for an additional five years, subject to certain conditions.

We believe that our facilities are adequate to meet our current needs, and that suitable additional alternative spaces will be available in the future on commercially reasonable terms, if required.

Item 3. Legal Proceedings

We are not currently a party to any material legal proceedings. From time to time, we may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.

Item 4. Mine Safety Disclosures

None.

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Market Information

Our common stock is listed on the Nasdaq Global Select Market under the ticker symbol “CRNX.”

Holders of Common Stock

As of February 26, 2021, there were 13 registered holders of record of our common stock. This number was derived from our shareholder records and does not include beneficial owners of our common stock whose shares are held in the name of various dealers, clearing agencies, banks, brokers and other fiduciaries.

Dividend Policy

We have never declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, to finance the operation of our business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors after considering our financial condition, results of operations, capital requirements, business prospects and other factors the board of directors deems relevant, and subject to the restrictions contained in any future financing instruments.

Securities Authorized for Issuance Under Equity Compensation Plans

See Item 12 of Part III of this Annual Report on Form 10-K for information about our equity compensation plans which is incorporated by reference herein.

Recent Sales of Unregistered Securities

None.

Use of Proceeds

On July 17, 2018, the SEC declared effective our registration statement on Form S-1 (File No. 333-225824), as amended, filed in connection with our IPO. The IPO closed on July 20, 2018 and we issued and sold 6,900,000 shares of our common stock at a price to the public of $17.00 per share, which included the exercise in full of the underwriters’ option to purchase additional shares. We received gross proceeds from the IPO of $117.3 million, before deducting underwriting discounts and commissions of approximately $8.2 million and estimated offering expenses of approximately $2.6 million. The managing underwriters of the offering were J.P. Morgan Securities LLC, Leerink Partners LLC and Piper Jaffray & Co. No offering expenses were paid or are payable, directly or indirectly, to our directors or officers, to persons owning 10% or more of any class of our equity securities or to any of our affiliates.

As of December 31, 2020, we have used approximately $57.9 million of the proceeds from our IPO for general corporate purposes, including the development of paltusotine as well as for the preclinical and clinical development of our other development programs. There has been no material change in the planned use of such proceeds from that described in the prospectus for our IPO.

Issuer Repurchases of Equity Securities

None.

Item 6. Selected Financial Data

Not applicable.

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion of our financial condition and results of operations in conjunction with the consolidated financial statements and the notes thereto included elsewhere in this Annual Report on Form 10-K.

Overview

We are a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Endocrine pathways function to maintain homeostasis and commonly use peptide hormones acting through G protein coupled receptors, or GPCRs, to regulate many aspects of physiology including growth, energy, metabolism, gastrointestinal function and stress responses. We have assembled a seasoned team with extensive expertise in drug discovery and development in endocrine GPCRs and built a highly productive drug discovery organization. We have discovered a pipeline of oral nonpeptide (small molecule) new chemical entities that target peptide GPCRs to treat a variety of rare endocrine diseases where treatment options have significant efficacy, safety and/or tolerability limitations. Our product candidates include paltusotine (formerly CRN00808), which is in clinical development for the treatment of acromegaly and neuroendocrine tumors, or NETs, CRN04777, which is in clinical development for congenital hyperinsulinism, or HI, and CRN04894, which is in clinical development for diseases of excess adrenocorticotrophic hormone, or ACTH, including Cushing’s Disease, congenital adrenal hyperplasia, Ectopic ACTH Syndrome. We are advancing additional product candidates through preclinical studies in parallel. Our vision is to build the leading endocrine company which consistently pioneers new therapeutics to help patients better control their disease and improve their daily lives.

We focus on the discovery and development of oral nonpeptide therapeutics that target peptide GPCRs with well-understood biological functions, validated biomarkers and the potential to substantially improve the treatment of endocrine diseases and/or endocrine-related tumors.

To date, we have devoted substantially all of our resources to drug discovery, conducting preclinical studies and clinical trials, obtaining and maintaining patents related to our product candidates, and the provision of general and administrative support for these operations. We have recognized revenues from various research and development grants, but do not have any products approved for sale and have not generated any product sales. We have funded our operations to date primarily through our grant revenues, the private placement of our preferred stock, and sales of our common stock. As of December 31, 2020, we had unrestricted cash, cash equivalents and investment securities of $170.9 million.

We have incurred cumulative net losses since our inception and, as of December 31, 2020, we had an accumulated deficit of $167.6 million. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and preclinical studies and our expenditures on other research and development activities. We expect our expenses and operating losses will increase substantially as we conduct our ongoing and planned clinical trials, continue our research and development activities and conduct preclinical studies, hire additional personnel, protect our intellectual property and incur costs associated with being a public company, including audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and Securities and Exchange Commission, or SEC, requirements, director and officer insurance premiums, and investor relations costs.

We do not expect to generate any revenues from product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our product candidates, which we expect will take a number of years. If we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Accordingly, until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements when needed would have a negative impact on our financial condition and could force us to delay, scale back or discontinue the development of our existing product candidates or our efforts to expand our product pipeline.

Australian operations

In January 2017, we established Crinetics Australia Pty Ltd, or CAPL, a wholly-owned subsidiary which was formed to conduct various preclinical and clinical activities for our product and development candidates. We believe CAPL will be eligible for certain financial incentives made available by the Australian government for research and development expenses. Specifically, the Australian Taxation Office provides for a refundable tax credit in the form of a cash refund equal to 43.5% of qualified research and development expenditures under the Australian Research and Development Tax Incentive Program, or the Australian Tax Incentive, to Australian companies that operate the majority of their research and development activities associated with such projects in Australia. A wholly-owned Australian subsidiary of a non-Australian parent company is eligible to receive the refundable tax credit, provided that the Australian subsidiary retains the rights to the data

and intellectual property generated in Australia, and provided that the total revenues of the parent company and its consolidated subsidiaries during the period for which the refundable tax credit is claimed are less than $20.0 million Australian dollars. If we lose our ability to operate CAPL in Australia, or if we are ineligible or unable to receive the research and development tax credit, or the Australian government significantly reduces or eliminates the tax credit, the actual refund amounts we receive may differ from our estimates.

Financial operations overview

Grant revenues

To date, we have not generated any revenues from the commercial sale of approved products, and we do not expect to generate revenues from the commercial sale of our product candidates for at least the foreseeable future, if ever. Revenues for 2020, 2019 and 2018 were derived from Small Business Innovation Research Grants, or SBIR Grants, awarded to us by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. We do not currently have any active SBIR Grants nor do we expect grant revenues to be a material source of future funding.

Research and development

To date, our research and development expenses have related primarily to discovery efforts and preclinical and clinical development of our product candidates. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.

Research and development expenses include:

•

salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in research and development efforts;

•

external research and development expenses incurred under agreements with contract research organizations, or CROs, investigative sites and consultants to conduct our clinical trials and preclinical and nonclinical studies;

•

costs related to manufacturing our product candidates for clinical trials and preclinical studies, including fees paid to third-party manufacturers;

•

costs related to compliance with regulatory requirements;

•

laboratory supplies; and

•

facilities, depreciation and other allocated expenses for rent, facilities maintenance, insurance, equipment and other supplies.

We recognize the Australian Tax Incentive as a reduction of research and development expense. The amounts are determined based on eligible research and development expenditures. The Australian Tax Incentive is recognized when there is reasonable assurance that the Australian Tax Incentive will be received, the relevant expenditure has been incurred, and the amount of the Australian Tax Incentive can be reliably measured.

Our direct research and development expenses consist principally of external costs, such as fees paid to CROs, investigative sites and consultants in connection with our clinical trials, preclinical and non-clinical studies, and costs related to manufacturing clinical trial materials. The majority of our third-party expenses during the three years ended December 31, 2020 related to the research and development of paltusotine. We deploy our personnel and facility related resources across all of our research and development activities.

Our clinical development costs may vary significantly based on factors such as:

•

per patient trial costs;

•

the number of trials required for approval;

•

the number of sites included in the trials;

•

the countries in which the trials are conducted;

•

the length of time required to enroll eligible patients;

•

the number of patients that participate in the trials;

•

number of doses that patients receive;

•

drop-out or discontinuation rates of patients;

•

potential additional safety monitoring requested by regulatory agencies;

•

the duration of patient participation in the trials and follow-up;

•

the cost and timing of manufacturing our product candidates;

•

the phase of development of our product candidates; and

•

the efficacy and safety profile of our product candidates.

We plan to substantially increase our research and development expenses for the foreseeable future as we continue the development of our product candidates and the discovery of new product candidates. We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of our product candidates due to the inherently unpredictable nature of preclinical and clinical development. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and our ongoing assessments as to each product candidate’s commercial potential. We will need to raise substantial additional capital in the future. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.

General and administrative

General and administrative expenses consist primarily of salaries and employee-related costs, including stock-based compensation, for personnel in executive, finance and other administrative functions. Other significant costs include facility-related costs, legal fees relating to intellectual property and corporate matters, professional fees for accounting and consulting services, insurance costs, and commercial planning expenses. We anticipate that our general and administrative expenses will increase in the future to support our continued research and development activities and, if any of our product candidates receive marketing approval, commercialization activities. We also anticipate increased expenses related to audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums, and investor relations costs associated with operating as a public company.

Critical Accounting Policies and Estimates

Our management’s discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue recognition, accrued expenses and stock-based compensation. We base our estimates on historical experience, known trends and events, and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are described in more detail in Note 2 to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe the following accounting policies and estimates to be most critical to the preparation of our consolidated financial statements.

Australian research and development tax incentive

CAPL is eligible to obtain a cash refund from the Australian Taxation Office for eligible research and development expenditures under the Australian Tax Incentive. The Australian Tax Incentive is recognized as a reduction to research and development expense when there is reasonable assurance that the Australian Tax Incentive will be received, the relevant expenditure has been incurred, and the amount can be reliably measured. Although we do not expect our estimates to be materially different from amounts actually received, if our estimates of the amounts and timing of the receipt of the Australian Tax Incentive differ from actual amounts received, it could result in us reporting amounts that are too high or too low in any particular period.

Accrued expenses

As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued expenses as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The significant estimates in our accrued research and development expenses include the costs incurred for services performed by our vendors in connection with research and development activities for which we have not yet been invoiced.

We base our expenses related to research and development activities on our estimates of the services received and efforts expended pursuant to quotes and contracts with vendors that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows.

There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid expense accordingly. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.

Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.

Operating Leases

The Company determines if an arrangement is a lease at the inception of the arrangement. Leases with a term longer than 12 months that are determined to be operating leases are included in operating lease assets, accrued expenses and other current liabilities and noncurrent operating lease liabilities in the consolidated balance sheets based on the present value of the minimum lease payments called for under the arrangement. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

Stock-based compensation expense

Stock-based compensation expense represents the cost of the estimated grant date fair value of stock option awards and employee stock purchase plan rights amortized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. We estimate the fair value of all stock option grants using the Black-Scholes option pricing model and recognize forfeitures as they occur.

Estimating the fair value of equity awards as of the grant date using valuation models, such as the Black-Scholes option pricing model, is affected by assumptions regarding a number of complex variables, including the expected stock price volatility, the risk-free interest rate, the expected term of stock options, the expected dividend yield and the fair value of the underlying common stock on the date of grant. Changes in the assumptions can materially affect the fair value and ultimately how much stock-based compensation expense is recognized. These inputs are subjective and generally require significant analysis and judgment to develop.

Due to the lack of an adequate history of a public market for the trading of our common stock and a lack of adequate company-specific historical and implied volatility data, we have based our estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. For these analyses, we have selected companies with comparable characteristics to ours, including enterprise value, risk profiles, and position within the industry, and with historical share price information sufficient to meet the expected life of the stock-based awards. We compute the historical volatility data using the daily close prices for the selected companies’ shares during the equivalent period of the calculated expected term of our stock-based awards. We will continue to apply this process until sufficient historical information regarding the volatility of our common stock price becomes available. We have estimated the expected life of our employee stock options using the “simplified” method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon U.S. treasury securities.

Results of Operations

Comparison of the years ended December 31, 2020 and 2019.

The following table summarizes our results of operations for the years ended December 31, 2020 and 2019 (in thousands):

	Year ended December 31,						Dollar
	2020			2019			Change
Grant revenues	$	71		$	1,193		$	(1,122	)
Operating expenses:
Research and development		56,998			41,506			15,492
General and administrative		18,026			13,519			4,507
Total operating expenses		75,024			55,025			19,999
Loss from operations		(74,953	)		(53,832	)		(21,121	)
Other income (expense), net		1,141			3,410			(2,269	)
Net loss	$	(73,812	)	$	(50,422	)	$	(23,390	)

Grant revenues. Grant revenues relate to reimbursable expenses incurred in connection with our SBIR Grants and totaled $71,000 and $1.2 million for the years ended December 31, 2020 and 2019, respectively. Our 2020 and 2019 revenues were primarily associated with research activities for one SBIR Grant, which was completed during the first quarter of 2020. We do not expect grant revenues to be significant in future periods.

Research and development expenses. Research and development expenses were $57.0 million and $41.5 million for the years ended December 31, 2020 and 2019, respectively. The increase was primarily due to increased spending on manufacturing and development activities of $8.4 million associated with our clinical and nonclinical activities for paltusotine and our other clinical and preclinical research programs. Additionally, our 2020 results reflect an increase in costs of $6.3 million primarily due to the hiring of additional personnel (which includes $2.0 million of additional stock-based compensation) and additional expenditures for consulting services of $1.1 million.

General and administrative expenses. General and administrative expenses were $18.0 million and $13.5 million for the years ended December 31, 2020 and 2019, respectively. The increase was primarily due to increases in personnel-related costs of $4.0 million (which includes $2.1 million of additional stock-based compensation) and spending on recruiting costs and pre-commercialization activities of $0.5 million.

Other income (expense). Other income (expense), net was $1.1 million and $3.4 million for the years ended December 31, 2020 and 2019, respectively. The decrease resulted from a reduction of the income generated by our available-for-sale investment securities portfolio due to declining market yields available for such securities.

Comparison of the years ended December 31, 2019 and 2018.

The following table summarizes our results of operations for the years ended December 31, 2019 and 2018 (in thousands):

	Year ended December 31,						Dollar
	2019			2018			Change
Grant revenues	$	1,193		$	2,428		$	(1,235	)
Operating expenses:
Research and development		41,506			24,479			17,027
General and administrative		13,519			6,659			6,860
Total operating expenses		55,025			31,138			23,887
Loss from operations		(53,832	)		(28,710	)		(25,122	)
Other income (expense), net		3,410			1,595			1,815
Net loss	$	(50,422	)	$	(27,115	)	$	(23,307	)

Grant revenues. Grant revenues totaled $1.2 million and $2.4 million for the years ended December 31, 2019 and 2018, respectively. Our 2019 revenues were primarily associated with research activities for one SBIR Grant, while our 2018 revenues were primarily related to research activities for two such grants.

Research and development expenses. Research and development expenses were $41.5 million and $24.5 million for the years ended December 31, 2019 and 2018, respectively. The increase was primarily due to increased spending on manufacturing and development activities of $9.9 million associated with our clinical and nonclinical activities for paltusotine as well as our other clinical and preclinical programs. Additionally, our 2019 results reflect an increase in costs of $4.5 million due to the hiring of additional personnel (which includes $2.1 million of additional stock-based compensation).

General and administrative expenses. General and administrative expenses were $13.5 million and $6.7 million for the years ended December 31, 2019 and 2018, respectively. The increase was primarily due to increases in personnel-related costs of $3.2 million (which includes $1.9 million of additional stock-based compensation), spending on pre-commercialization activities and corporate legal services of $1.6 million, as well as expenses associated with operating as a publicly traded company.

Other income (expense). Other income (expense), net was $3.4 million and $1.6 million for the years ended December 31, 2019 and 2018, respectively. The increase was primarily due to interest income earned on higher cash and investment balances due to the funds raised from investors in 2018.

Cash Flows

We have incurred cumulative net losses and negative cash flows from operations since our inception and anticipate we will continue to incur net losses for the foreseeable future. As of December 31, 2020, we had an accumulated deficit of $167.6 million and unrestricted cash, cash equivalents and investment securities of $170.9 million.

The following table provides information regarding our cash flows for each of the years in the three-year period ended December 31, 2020 (in thousands):

	Years ended December 31,
	2020			2019			2018
Net cash used in operating activities	$	(62,027	)	$	(46,381	)	$	(19,459	)
Net cash provided by (used in) investing activities		217			41,667			(119,458	)
Net cash provided by financing activities		114,571			67			170,198
Net change in cash, cash equivalents and restricted cash	$	52,761		$	(4,647	)	$	31,281

Comparison of the years ended December 31, 2020 and 2019

Operating Activities. Net cash used in operating activities was $62.0 million and $46.4 million for the years ended December 31, 2020 and 2019, respectively. The increase in cash used in operations was primarily attributable to development and manufacturing activities associated with paltusotine as well as our other clinical and preclinical programs, and higher personnel-related costs. The net cash used in operating activities during the year ended December 31, 2020 was primarily due to our net loss of $73.8 million, adjusted for $11.4 million of noncash charges, including stock-based compensation and depreciation expense, and a $0.4 million change in our operating assets and liabilities. The net cash used in operating activities during the year ended December 31, 2019 was primarily due to our net loss of $50.4 million and a $2.1 million change in our operating assets and liabilities, adjusted for $6.2 million of noncash charges, including stock-based compensation and depreciation expense.

Investing activities. Investing activities consist primarily of purchases and maturities of investment securities and, to a lesser extent, the cash outflow associated with purchases of property and equipment. Such activities resulted in net inflows of funds of approximately $0.2 million and $41.7 million during 2020 and 2019, respectively.

Financing activities. Net cash provided by financing activities was $114.6 million and $67,000 for the years ended December 31, 2020 and 2019, respectively. The net cash provided by financing activities during 2020 was primarily the result of the net proceeds of $107.9 million from the sale of shares of common stock in our public offering in April 2020, as well as $6.4 million from the sale of shares in our ATM Offering, as defined below, and $0.3 million from the exercise of common stock options. The net cash provided by financing activities during 2019 was the result of the exercise of stock options, net of stock repurchase activities.

Comparison of the years ended December 31, 2019 and 2018

Operating Activities. Net cash used in operating activities was $46.4 million and $19.5 million for the years ended December 31, 2019 and 2018, respectively. The increase in cash used in operations was primarily attributable to development and manufacturing activities associated with paltusotine as well as our other clinical and preclinical programs, and higher personnel-related costs. The net cash used in operating activities during the year ended December 31, 2019 was primarily due to our net loss of $50.4 million and a $2.1 million change in operating assets and liabilities, adjusted for $6.2 million of noncash charges, including stock-based compensation and depreciation expense. Net cash used in operating activities during the year ended December 31, 2018 was primarily due to our net loss of $27.1 million, adjusted for $2.4 million of noncash charges, primarily for stock-based compensation and depreciation expense, and a $5.3 million change in operating assets and liabilities.

Investing activities. Investing activities consist primarily of purchases and maturities of investment securities and, to a lesser extent, the cash outflow associated with purchases of property and equipment. Such activities resulted in a net inflow of funds of approximately $41.7 million during 2019, compared to approximately $119.5 million used during 2018.

Financing activities. Net cash provided by financing activities was $67,000 and $170.2 million for the years ended December 31, 2019 and 2018, respectively. The net cash provided by financing activities during 2019 was the result of the exercise of stock options, net of stock repurchase activities. The net cash provided by financing activities during 2018 was primarily due to the net proceeds of $63.3 million from the sale of Series B convertible preferred stock, the net proceeds of $106.5 million raised in our initial public offering in July and $0.5 million from the exercise of common stock options.

Liquidity and Capital Resources

At December 31, 2020, we had unrestricted cash, cash equivalents and investment securities of $170.9 million. Based on our current and anticipated level of operations, we believe that our cash, cash equivalents and short-term investments will be sufficient to meet our anticipated obligations for at least one year from the date this Annual Report on Form 10-K is filed with the SEC. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially.

We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect. Additionally, the process of testing product candidates in clinical trials is costly, and the timing of progress and expenses in these trials is uncertain.

Our future capital requirements will depend on many factors, including:

•

the type, number, scope, progress, expansions, results, costs and timing of, our preclinical studies and clinical trials of our product candidates which we are pursuing or may choose to pursue in the future;

•

the costs and timing of manufacturing for our product candidates, including commercial manufacturing if any product candidate is approved;

•

the costs, timing and outcome of regulatory review of our product candidates;

•

the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights;

•

our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company, including enhanced internal controls over financial reporting;

•

the costs associated with hiring additional personnel and consultants as our preclinical and clinical activities increase;

•

the timing and the extent of any Australian Tax Incentive refund and future grant revenues that we receive;

•

the costs and timing of establishing or securing sales and marketing capabilities if any product candidate is approved;

•

our ability to achieve sufficient market acceptance, adequate coverage and reimbursement from third-party payors and adequate market share and revenue for any approved products;

•

the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; and

•

costs associated with any products or technologies that we may in-license or acquire.

Until such time, if ever, as we can generate substantial product revenues to support our cost structure, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, licenses and other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves.

In August 2019, we entered into a Sales Agreement, or the Sales Agreement, with SVB Leerink LLC and Cantor Fitzgerald & Co., or collectively, the Sales Agents, under which we may, from time to time, sell shares of our common stock having an aggregate offering price of up to $75.0 million through the Sales Agents, or the ATM Offering. Sales of our common stock made pursuant to the Sales Agreement will be made directly on or through the Nasdaq Global Select Market under our effective shelf Registration Statement on Form S-3 filed on August 19, 2019 by means of ordinary brokers’ transactions at market prices. Additionally, under the terms of the Sales Agreement, we may also sell shares of our common stock through the Sales Agents, on the Nasdaq Global Select Market or otherwise, at negotiated prices or at prices related to the prevailing market price. We are not obligated to, and we cannot provide any assurances that we will continue to, make any sales of the shares under the Sales Agreement. The Sales Agreement may be terminated by either Sales Agent (with respect to itself) or us at any time upon 10 days’ notice to the other parties, or by either Sales Agent, with respect to itself, at any time in certain circumstances, including the occurrence of a material adverse change. We will pay the Sales Agents a commission for their services in acting as agent in the sale of common stock in an amount equal to 3% of the gross sales price per share sold. During 2020, we issued 275,764 shares of common stock in the ATM Offering for net proceeds of $6.4 million, after deducting commissions.

On April 17, 2020, we completed a public offering of 8,222,500 shares of our common stock at a public offering price of $14.00 per share. We received proceeds of approximately $107.9 million from that offering, net of offering discounts and commissions and offering costs of $7.3 million.

Off-Balance Sheet Arrangements

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable SEC rules.

Item 7A. Quantitative and Qualitative Disclosures about Market Risk

Interest Rate Risk

Our cash, cash equivalents and investment securities consist of cash held in readily available checking and money market accounts, as well as short-term debt securities. We are exposed to market risk related to fluctuations in interest rates and market prices. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of United States interest rates. However, because of the short-term nature of the instruments in our portfolio, a sudden change in market interest rates would not be expected to have a material impact on our financial condition or results of operations.

Foreign Currency

We contract with vendors, CROs and investigational sites in several foreign countries, including countries in South America, Europe and the Asia Pacific. We are therefore subject to fluctuations in foreign currency rates in connection with these agreements. We do not hedge our foreign currency exchange rate risk. To date, we have not incurred any material adverse effects from foreign currency changes on these contracts.

In January 2017, we formed CAPL, a wholly-owned subsidiary in Australia, which exposes us to foreign currency exchange rate risk. The functional currency of CAPL is the United States dollar. Assets and liabilities of our foreign subsidiary that are not denominated in the functional currency are remeasured into U.S. dollars at foreign currency exchange rates in effect at the balance sheet date except for nonmonetary assets and capital accounts, which are remeasured at historical foreign currency exchange rates in effect at the date of transaction. Expenses are generally remeasured at foreign currency exchange rates which approximate average rates in effect during each period. Net realized and unrealized gains and losses from foreign currency transactions and remeasurement are reported in other income (expense), net, in the consolidated statements of operations and totaled approximately $160,000 and $50,000 for the years ended December 31, 2020 and 2019, respectively.

As of December 31, 2020, the impact of a theoretical 10% change in the exchange rate of the Australian dollar would not result in a material gain or loss.

Inflation Risk

Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our results of operations during the periods presented.

Item 8. Financial Statements and Supplementary Data

Our consolidated financial statements and the report of our independent registered accounting firm required pursuant to this item are incorporated by reference herein from the applicable information included in Item 15 of this report and are presented beginning on page F-1.

Item 9. Changes and Disagreements with Accountants on Accounting and Financial Disclosure

None.

Item 9A. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is necessarily required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

As of December 31, 2020, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2020.

Management’s Annual Report on Internal Control over Financial Reporting.

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act. Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Our internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets, (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors, and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements. Because of its inherent limitations, internal controls over financial reporting may not prevent or detect all misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

As of December 31, 2020, our management assessed the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (2013). Based on this assessment, our management concluded that, as of December 31, 2020, our internal control over financial reporting was effective based on those criteria.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting during the quarter ended December 31, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Item 9B. Other Information

None.

PART III

Item 10. Directors, Executive Officers and Corporate Governance.

Information required by this item will be contained in our definitive proxy statement to be filed with the Securities and Exchange Commission in connection with our 2021 Annual Meeting of Stockholders, or the Definitive Proxy Statement, which is expected to be filed not later than 120 days after the end of our fiscal year ended December 31, 2021, under the headings “Election of Directors,” “Corporate Governance,” “Our Executive Officers,” and, if applicable, “Delinquent Section 16(a) Reports,” and is incorporated herein by reference.

Code of Business Conduct and Ethics

We have adopted a Code of Business Conduct and Ethics that applies to our officers, directors and employees, which is available on our website at www.crinetics.com. The Code of Business Conduct and Ethics contains general guidelines for conducting the business of our company consistent with the highest standards of business ethics and is intended to qualify as a “code of ethics” within the meaning of Section 406 of the Sarbanes-Oxley Act of 2002 and Item 406 of Regulation S-K. In addition, we intend to promptly disclose (i) the nature of any amendment to our Code of Business Conduct and Ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions and (ii) the nature of any waiver, including an implicit waiver, from a provision of our code of ethics that is granted to one of these specified officers, the name of such person who is granted the waiver and the date of the waiver on our website in the future.

Item 11. Executive Compensation.

Information required by this item will be contained in our Definitive Proxy Statement under the heading “Executive Compensation and Other Information,” and is incorporated herein by reference.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

Information required by this item will be contained in our Definitive Proxy Statement under the heading “Security Ownership of Certain Beneficial Owners and Management,” and is incorporated herein by reference.

Item 13. Certain Relationships and Related Transactions, and Director Independence.

Information required by this item will be contained in our Definitive Proxy Statement under the headings “Certain Relationships and Related Person Transactions,” “Board Independence” and “Committees of the Board of Directors” and is incorporated herein by reference.

Item 14. Principal Accounting Fees and Services.

Information required by this item will be contained in our Definitive Proxy Statement under the heading “Independent Registered Public Accountants’ Fees,” and is incorporated herein by reference.

PART IV

Item 15. Exhibits, Financial Statement Schedules.

(a)

Documents filed as a part of this report:

(1)	Financial Statements.

The financial statements of Crinetics Pharmaceuticals, Inc., together with the report thereon of BDO USA, LLP, an independent registered public accounting firm, are included in this Annual Report on Form 10-K.

(2)	Financial Statement Schedules.

All schedules are omitted because they are not applicable, or the required information is shown in the financial statements or notes thereto.

(3)

Exhibits.

A list of exhibits to this Annual Report on Form 10-K is set forth on the Exhibit Index immediately preceding the signature page and is incorporated herein by reference.

Item 16. Form 10-K Summary

None.

CRINETICS PHARMACEUTICALS, INC.

INDEX TO FINANCIAL STATEMENTS

	Page
Report of Independent Registered Public Accounting Firm	F-2
Consolidated Balance Sheets	F-3
Consolidated Statements of Operations and Comprehensive Loss	F-4
Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)	F-5
Consolidated Statements of Cash Flows	F-6
Notes to Consolidated Financial Statements	F-7

F-1

Report of Independent Registered Public Accounting Firm

Stockholders and Board of Directors

Crinetics Pharmaceuticals, Inc.

San Diego, California

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of Crinetics Pharmaceuticals, Inc. and its subsidiary (the “Company”) as of December 31, 2020 and 2019, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders’ equity (deficit), and cash flows for each of the three years in the period ended December 31, 2020, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020, in conformity with accounting principles generally accepted in the United States of America.

Change in Accounting Principle

As discussed in Note 2 to the consolidated financial statements, the Company changed its method of accounting for leases in 2019 due to the adoption of Accounting Standards Codification Topic 842, Leases.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ BDO USA, LLP

We have served as the Company’s auditor since 2016.

San Diego, California

March 30, 2021

F-2

CRINETICS PHARMACEUTICALS, INC.

Consolidated Balance Sheets

(In thousands)

	December 31, 2020			December 31, 2019
Assets
Current assets:
Cash and cash equivalents	$	93,087		$	40,326
Investment securities		77,793			78,066
Prepaid expenses and other current assets		6,612			4,947
Total current assets		177,492			123,339
Property and equipment, net		3,181			3,946
Operating lease right-of-use asset		2,232			2,510
Restricted cash		500			500
Other assets		40			82
Total assets	$	183,445		$	130,377

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued expenses	$	5,588		$	5,498
Accrued compensation and related expenses		4,066			2,118
Other current liabilities		835			724
Total current liabilities		10,489			8,340
Operating lease liability, non-current		4,014			4,849
Unvested stock liability		23			49
Total liabilities		14,526			13,238
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.001 par; 10,000 shares authorized, no shares issued or outstanding at December 31, 2020 or 2019		—			—
Common stock and paid-in capital, $0.001 par; 200,000 shares authorized, 33,017 and 33,001 shares issued and outstanding at December 31, 2020; 24,296 and 24,263 shares issued and outstanding at December 31, 2019		336,508			210,793
Accumulated other comprehensive income		25			148
Accumulated deficit		(167,614	)		(93,802	)
Total stockholders’ equity		168,919			117,139
Total liabilities and stockholders’ equity	$	183,445		$	130,377

See the accompanying notes to these consolidated financial statements.

F-3

CRINETICS PHARMACEUTICALS

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except per share data)

	Year ended December 31,
	2020			2019			2018
Grant revenues	$	71		$	1,193		$	2,428
Operating expenses:
Research and development		56,998			41,506			24,479
General and administrative		18,026			13,519			6,659
Total operating expenses		75,024			55,025			31,138
Loss from operations		(74,953	)		(53,832	)		(28,710	)
Other income (expense):
Interest income		991			3,460			1,748
Other income (expense), net		150			(50	)		(153	)
Total other income, net		1,141			3,410			1,595
Net loss		(73,812	)		(50,422	)		(27,115	)
Other comprehensive income (loss):
Unrealized gain (loss) on investment securities		(123	)		87			61
Comprehensive loss	$	(73,935	)	$	(50,335	)	$	(27,054	)
Net loss per share:
Net loss per share - basic and diluted	$	(2.42	)	$	(2.09	)	$	(2.23	)
Weighted average shares - basic and diluted		30,448			24,175			12,142

See the accompanying notes to these consolidated financial statements.

F-4

CRINETICS PHARMACEUTICALS, INC.

Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)

(in thousands)

	Convertible Preferred Stock						Common Stock		Common Stock and Paid-In		Accumulated Other Comprehensive			Accumulated			Total Stockholders’
	Shares			Amount			Shares		Capital		Income			Deficit			Equity (Deficit)
Balance at January 1, 2018		28,763		$	29,700			1,550	$	1,243	$	—		$	(16,265	)	$	(15,022	)
Issuance of Series B convertible preferred, net of costs of $225		19,641			63,275			—		—		—			—			—
Conversion of preferred stock into common stock		(48,404	)		(92,975	)		14,713		92,975		—			—			92,975
Issuance of common stock, net of transaction costs		—			—			6,900		106,472		—			—			106,472
Vesting of shares subject to repurchase		—			—			541		21		—			—			21
Exercise of stock options		—			—			337		231		—			—			231
Stock issued under Stock Purchase Plan		—			—			20		282		—			—			282
Stock-based compensation		—			—			—		2,320		—			—			2,320
Comprehensive income		—			—			—		—		61			—			61
Net loss		—			—			—		—		—			(27,115	)		(27,115	)
Balance at December 31, 2018		-			-			24,061		203,544		61			(43,380	)		160,225
Vesting of shares subject to repurchase		—			—			63		94		—			—			94
Exercise of stock options		—			—			90		126		—			—			126
Stock issued under Stock Purchase Plan		—			—			49		735		—			—			735
Stock-based compensation		—			—			—		6,294		—			—			6,294
Comprehensive income		—			—			—		—		87			—			87
Net loss		—			—			—		—		—			(50,422	)		(50,422	)
Balance at December 31, 2019		—			—			24,263		210,793		148			(93,802	)		117,139
Issuance of common stock, net of transaction costs		—			—			8,499		114,283		—			—			114,283
Vesting of shares subject to repurchase		—			—			17		26		—			—			26
Exercise of stock options		—			—			171		288		—			—			288
Stock issued under Stock Purchase Plan		—			—			51		691		—			—			691
Stock-based compensation		—			—			—		10,427		—			—			10,427
Comprehensive loss		—			—			—		—		(123	)		—			(123	)
Net loss		—			—			—		—		—			(73,812	)		(73,812	)
Balance at December 31, 2020		—		$	—			33,001	$	336,508	$	25		$	(167,614	)	$	168,919

See the accompanying notes to these consolidated financial statements.

F-5

CRINETICS PHARMACEUTICALS, INC.

Consolidated Statements of Cash Flows

(In thousands)

	Year ended December 31,
	2020			2019			2018
Operating activities:
Net loss	$	(73,812	)	$	(50,422	)	$	(27,115	)
Reconciliation of net loss to net cash used in operating activities:
Stock-based compensation		10,427			6,294			2,320
Depreciation and amortization		948			887			471
Noncash lease expense		278			226			—
Accretion of purchase discounts and amortization of premiums on investment securities, net		(227	)		(1,229	)		(433	)
Other, net		(17	)		(4	)		—
Increase (decrease) in cash resulting from changes in:
Prepaid expenses and other assets		(1,623	)		(2,221	)		(1,802	)
Accounts payable and accrued expenses		2,723			696			7,361
Operating lease liability		(724	)		(608	)		—
Deferred rent		—			—			(261	)
Net cash used in operating activities		(62,027	)		(46,381	)		(19,459	)
Investing activities:
Purchases of investment securities		(135,592	)		(108,136	)		(118,399	)
Maturities of investment securities		135,995			150,295			—
Purchases of property and equipment		(186	)		(492	)		(1,059	)
Net cash provided by (used in) investing activities		217			41,667			(119,458	)
Financing activities:
Proceeds from issuance of convertible preferred stock, net of transaction costs		—			—			63,275
Proceeds from issuance of common stock, net of transaction costs		114,283			—			106,472
Proceeds from exercise of stock options		288			126			451
Repurchase of unvested shares		—			(59	)		—
Net cash provided by financing activities		114,571			67			170,198
Net change in cash, cash equivalents and restricted cash		52,761			(4,647	)		31,281
Cash, cash equivalents and restricted cash - beginning of period		40,826			45,473			14,192
Cash, cash equivalents and restricted cash - end of period	$	93,587		$	40,826		$	45,473
Components of cash, cash equivalents and restricted cash:
Cash and cash equivalents	$	93,087		$	40,326		$	44,973
Restricted cash		500			500			500
Cash, cash equivalents and restricted cash at end of period	$	93,587		$	40,826		$	45,473
Non-cash financing activity:
Stock issued under Stock Purchase Plan	$	691		$	735		$	282
Amounts accrued for purchases of property and equipment	$	6		$	112		$	42
Change in unvested stock liability	$	26		$	94		$	21
Tenant improvement allowance	$	—		$	—		$	3,304

See the accompanying notes to these consolidated financial statements.

F-6

CRINETICS PHARMACEUTICALS

Notes to Consolidated Financial Statements

1. ORGANIZATION AND BASIS OF PRESENTATION

Description of Business

Crinetics Pharmaceuticals, Inc. (the “Company”) is a clinical-stage pharmaceutical company incorporated in Delaware on November 18, 2008 and based in San Diego, California. The Company is focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. In January 2017, the Company established a wholly-owned Australian subsidiary, Crinetics Australia Pty Ltd (“CAPL”), in order to conduct various preclinical and clinical activities for its development candidates.

On July 6, 2018, the Company effected a 1-for-3.29 reverse stock split of its common stock. The par value and the authorized shares of the common stock were not adjusted as a result of the reverse stock split. The reverse stock split resulted in an adjustment to the conversion prices of the Company’s Series A and B preferred stock to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying consolidated financial statements and notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented.

Principles of Consolidation and Foreign Currency Transactions

The consolidated financial statements include the accounts of the Company and CAPL. All intercompany accounts and transactions have been eliminated in consolidation. The functional currency of both the Company and CAPL is the U.S. dollar. Assets and liabilities that are not denominated in the functional currency are remeasured into U.S. dollars at foreign currency exchange rates in effect at the balance sheet date except for nonmonetary assets, which are remeasured at historical foreign currency exchange rates in effect at the date of transaction. Net realized and unrealized gains and losses from foreign currency transactions and remeasurement are reported in other income (expense), in the consolidated statements of operations and were not material for all periods presented.

Segment Reporting

Operating segments are identified as components of an enterprise about which discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.

Liquidity and Going Concern

From inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting preclinical studies and clinical trials. The Company has a limited operating history and the sales and income potential of the Company’s business and market are unproven. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company’s cost structure.

As of December 31, 2020, the Company had $170.9 million in unrestricted cash, cash equivalents and investment securities. The Company believes it has sufficient cash to meet its funding requirements for at least the next 12 months from the date of issuance of these financial statements.

The Company has experienced net losses and negative cash flows from operating activities since its inception and has an accumulated deficit of $167.6 million as of December 31, 2020. The Company expects to continue to incur net losses for the foreseeable future and believes it will need to raise substantial additional capital to accomplish its business plan over the next several years. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of equity offerings, debt financings or other sources, including potential collaborations, licenses and other similar arrangements. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned programs. Any of these actions could materially harm the Company’s business, results of operations and future prospects. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future.

COVID-19

The COVID-19 pandemic has caused significant business disruption around the globe. The extent of the impact of COVID-19 on the Company's operational and financial performance will depend on certain developments, including the duration and spread of the pandemic and the impact on the Company's clinical trials, employees and vendors. In response to the spread of COVID-19, the Company has closed its offices to all but its lab and a limited number of its other personnel, while the remainder of its employees are continuing their work outside the Company’s offices. At this point, the degree to which

F-7

COVID-19 may impact the Company's financial condition or future results of operations is uncertain. A prolonged outbreak could have a material adverse impact on financial results and business operations of the Company, including the timing and ability of Company to complete certain clinical trials and other efforts required to advance the development of its drug candidates and raise additional capital.

In response to the pandemic, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) was signed into law on March 27, 2020. The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer’s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The CARES Act has not had a material impact on the Company’s income tax provision for the year ended December 31, 2020.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The Company’s consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The preparation of the Company’s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to accrued amounts receivable under the Australian research and development tax incentive program, accrued expenses and associated research and development expense, the assumptions underlying the determination of the estimated incremental borrowing rate for the determination of the Company’s operating lease right-of-use asset, and the assumptions underlying the determination of the fair value of equity awards for purposes of determining stock-based compensation. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.

Fair Value Measurements

The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level 1: Observable inputs such as quoted prices in active markets.

Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The carrying amounts of the Company’s current financial assets, restricted cash and current financial liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments.

Cash, Cash Equivalents and Restricted Cash

Cash and cash equivalents include cash held in readily available checking and money market accounts, as well as short-term debt securities with maturities of three months or less when purchased. Restricted cash represents cash held as collateral for the Company’s facility lease and is reported as a long-term asset in the accompanying consolidated balance sheets.

Investment Securities

All investments have been classified as “available-for-sale” and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities less than 12 months at the balance sheet date are considered short-term investments. Investments with contractual maturities beyond one year are also classified as short-term due to the Company’s ability to liquidate the investment for use in operations within the next 12 months.

Realized gains and losses on investment securities are included in earnings and are derived using the specific identification method for determining the cost of securities sold. The Company has not realized any significant gains or losses on sales of

F-8

available-for-sale investment securities during any of the periods presented. As all the Company’s investment holdings are in the form of debt securities, unrealized gains and losses that are determined to be temporary in nature are reported as a component of accumulated other comprehensive income. A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the establishment of a new cost basis for the security. Interest income is recognized when earned and is included in investment income, as are the amortization of purchase premiums and accretion of purchase discounts on investment securities.

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investment securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.

Leases

The Company determines if an arrangement is a lease at the inception of the arrangement. Beginning January 1, 2019, leases with a term longer than 12 months that are determined to be operating leases are included in operating lease assets, accrued expenses and other current liabilities and noncurrent operating lease liabilities in the consolidated balance sheets based on the present value of the minimum lease payments called for under the arrangement. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

Property and Equipment, Net

Property and equipment consist of leasehold improvements, and lab and various other equipment. Such assets are stated at cost and depreciated on a straight-line basis over the estimated useful life of the related assets. The Company estimates its useful lives of its lab and other equipment as follows: lab equipment – three to five years; office equipment - three to five years; computer and software – three years. Leasehold improvements are amortized over the estimated useful life of the improvement or the remaining term of the associated lease.

Repairs and maintenance costs are charged to expense as incurred and expenditures that materially extend the useful lives of assets are capitalized.

Impairment of Long-Lived Assets

Long-lived assets consist of property and equipment. An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. The Company has not recognized any impairment losses in any of the periods presented in these consolidated financial statements.

Deferred Rent

The Company’s facility lease includes incentives in the form of rent abatements and leasehold improvement allowances, as well as fixed annual rent escalations. The Company recognizes the aggregate rental expense, after considering incentives and stipulated rent escalations, on a straight-line basis over the lease term. Prior to January 1, 2019, the difference between rent expense and amounts paid under the lease was recorded as deferred rent.

Grant Revenue Recognition

The Company’s grant revenues are derived from Small Business Innovation Research Grants (“SBIR Grants”) from the National Institutes of Health. The Company recognizes SBIR Grant revenue as reimbursable grant costs are incurred up to pre-approved award limits within the budget period. The costs associated with these reimbursements are reflected as a component of research and development expense in the accompanying consolidated statements of operations. Earnings in excess of billings are included as a component of prepaid expenses and other current assets.

Research and Development Expenses

Research and development (“R&D”) expenses consist primarily of salaries, payroll taxes, employee benefits and stock-based compensation for individuals involved in R&D efforts, as well as consulting expenses, third-party R&D expenses, laboratory supplies, clinical materials and overhead, including facilities and depreciation costs, offset by the Australian Tax Incentive

F-9

discussed below. R&D expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in R&D are capitalized until the goods or services are received. Costs incurred under contracts with contract research organizations that conduct and manage the Company’s clinical trials are also included in research and development expenses. The financial terms and activities of these agreements vary from contract to contract and may result in uneven expense levels. Generally, these agreements set forth activities that drive the recording of expenses such as start-up and initiation activities, enrollment and treatment of patients, or the completion of other clinical trial activities. Expenses related to clinical trials are accrued based on estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the amounts that the Company is obligated to pay under its clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the Company adjusts its accruals accordingly on a prospective basis. Revisions to contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain.

Accrued R&D expenses totaled $2.1 million and $2.8 million as of December 31, 2020 and 2019, respectively, and are a component of accounts payable and accrued expenses in the consolidated balance sheets.

Australian Tax Incentive

CAPL is eligible to obtain a cash refund from the Australian Taxation Office for eligible R&D expenditures under the Australian R&D Tax Incentive Program (the “Australian Tax Incentive”). The Australian Tax Incentive is recognized as a reduction to R&D expense when there is reasonable assurance that the relevant expenditure has been incurred, the amount can be reliably measured and that the Australian Tax Incentive will be received. The Company recognized reductions to R&D expense of $0.6 million, $1.0 million and $1.2 million for the years ended December 31, 2020, 2019 and 2018, respectively.

Stock-Based Compensation

Stock-based compensation expense represents the estimated grant date fair value of the Company’s equity awards, consisting of stock options and shares issued under the Company’s Employee Stock Purchase Plan, recognized over the requisite service period of such awards (usually the vesting period) on a straight-line basis. The Company estimates the fair value of equity awards using the Black-Scholes option pricing model on the date of grant and recognizes forfeitures as they occur. For stock awards for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable, or the performance condition has been achieved.

Income Taxes

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.

The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense, and any accrued interest and penalties would be included within the related tax liability. No such costs were recorded during the three years ended December 31, 2020.

Comprehensive Loss

Comprehensive loss is comprised of the Company’s net loss and the unrealized gains on the Company’s investment securities for all periods presented.

F-10

Net Loss Per Share

Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of convertible preferred stock, common stock subject to repurchase, and options outstanding under the Company’s stock option plan. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.

Potentially dilutive securities (in common stock equivalent shares) not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in thousands):

	Year ended December 31,
	2020		2019		2018
Common stock options		4,422		3,127		2,339
Unvested common stock subject to repurchase		16		33		127
Total		4,438		3,160		2,466

Recently Adopted Accounting Pronouncements

ASU 2019-12

In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12, Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes (“ASU 2019-12”). The Board issued this ASU as part of its simplification initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the Company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company has elected to early adopt ASU 2019-12 in the fourth quarter of fiscal 2020; however, there was no cumulative effect to be recognized with the early adoption.

ASU 2018-13

In August 2018, the FASB issued ASU 2018-13, “Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement,” which improves the effectiveness of the disclosures required under ASC 820, “Fair Value Measurements and Disclosures” and modifies the disclosure requirements on fair value measurements, including the consideration of costs and benefits. The Company adopted this standard in 2020; adoption of this standard did not have a material impact on the Company’s consolidated financial statements.

Recent Accounting Pronouncements

ASU 2016-13

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“Topic 326”). Topic 326 amends guidance on reporting credit losses for assets held at amortized cost basis and available for sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available for sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. This ASU update affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. This update is effective for the company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is currently evaluating the impact of the pending adoption of this new standard on its consolidated financial statements.

ASU 2020-06

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of

F-11

liabilities and equity, including convertible instruments and contracts on an entity’s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020, including interim periods within those fiscal years. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The amendment is to be adopted through either a modified retrospective or fully retrospective method of transition. The Company is currently evaluating the potential impact that the adoption of ASU 2020-06 may have on its consolidated financial statements and related disclosures.

3. INVESTMENT SECURITIES

Available-for-sale investment securities consisted of the following as of December 31, 2020 and 2019 (in thousands):

	As of December 31, 2020
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Market Value
Available-for-sale investment securities:
U.S. government and agency obligations	$	74,222	$	6	$	(5	)	$	74,223
Certificates of deposit		2,161		14		—			2,175
Corporate debt securities		1,385		10		—			1,395
Total	$	77,768	$	30	$	(5	)	$	77,793

	As of December 31, 2019
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Market Value
Available-for-sale investment securities:
U.S. government and agency obligations	$	43,275	$	94	$	(1	)	$	43,368
Certificates of deposit		5,931		51		—			5,982
Commercial paper		17,645		—		—			17,645
Corporate debt securities		11,067		7		(3	)		11,071
Total	$	77,918	$	152	$	(4	)	$	78,066

All available-for-sale investment securities held at December 31, 2020 and 2019 had maturity dates of less than 24 months.

None of the Company’s available-for-sale investment securities were in a material unrealized loss position at December 31, 2020. The Company reviewed its investment holdings as of December 31, 2020 and determined that its unrealized losses were not considered to be other-than-temporary based upon (i) the financial strength of the issuing institution and (ii) the fact that no securities have been in an unrealized loss position for twelve months or more. As such, the Company has not recognized any impairment in its financial statements related to its available-for-sale investment securities.

4. FAIR VALUE MEASUREMENTS

The Company holds investment securities that consist of highly liquid, investment grade debt securities. The Company determines the fair value of its investment securities based upon one or more valuations reported by its investment accounting and reporting service provider. The investment service provider values the securities using a hierarchical security pricing model that relies primarily on valuations provided by an industry-recognized valuation service. Such valuations may be based on trade prices in active markets for identical assets or liabilities (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets or liabilities, yield curves, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, and broker and dealer quotes, as well as other relevant economic measures.

F-12

Financial assets measured at fair value on a recurring basis as of December 31, 2020 and 2019 were as follows (in thousands):

	As of December 31, 2020
	Level 1		Level 2		Level 3		Total
Investment securities:
U.S. government and agency obligations	$	60,222	$	14,001	$	—	$	74,223
Certificates of deposit		—		2,175		—		2,175
Corporate debt securities		—		1,395		—		1,395
Total assets measured at fair value	$	60,222	$	17,571	$	—	$	77,793

	As of December 31, 2019
	Level 1		Level 2		Level 3		Total
Investment securities:
U.S. government and agency obligations	$	15,478	$	27,890	$	—	$	43,368
Certificates of deposit		—		5,982		—		5,982
Commercial paper		—		17,645		—		17,645
Corporate debt securities		—		11,071		—		11,071
Total assets measured at fair value	$	15,478	$	62,588	$	—	$	78,066

The Company’s policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no transfers into or out of Level 3 during the years ended December 31, 2020 and 2019.

5. BALANCE SHEET DETAILS

Prepaid expenses and other current assets consisted of the following (in thousands):

	December 31, 2020		December 31, 2019
Prepaid research and development costs	$	3,062	$	2,478
Australian tax incentive receivable		1,720		929
Prepaid insurance		693		648
Interest receivable		113		224
Prepaid expenses and other assets		1,024		668
Total	$	6,612	$	4,947

Property and equipment, net consisted of the following (in thousands):

	December 31, 2020		December 31, 2019
Leasehold improvements	$	3,494	$	3,494
Lab equipment		1,551		1,468
Office equipment		653		567
Computers and software		41		41
Property and equipment at cost		5,739		5,570
Less accumulated depreciation and amortization		2,558		1,624
Total	$	3,181	$	3,946

Depreciation expense was $0.9 million, $0.9 million, and $0.5 million for the three years ended December 31, 2020, 2019 and 2018, respectively.

6. OPERATING LEASE

2018 Operating Lease. In February 2018, as amended in March 2018, the Company entered into a non-cancelable operating lease for a new facility in San Diego, California. The lease has an initial term of seven years which expires in August 2025, and the Company has an option to extend the term of the lease for an additional five years and has a termination option

F-13

subject to early termination fees. The lease is subject to base lease payments and additional charges for common area maintenance and other costs and includes certain lease incentives and tenant improvement allowances. Rent expense is being recognized on a straight-line basis over the term of the lease. The Company’s estimated incremental fully collateralized borrowing rate of 8.0% was used in its present value calculation as the facility lease does not have a stated rate and the implicit rate was not readily determinable.

Under the terms of the lease, the Company provided the lessor with an irrevocable letter of credit in the amount of $0.5 million. The lessor is entitled to draw on the letter of credit in the event of any default by the Company under the terms of the lease.

Future Minimum Payments. As of December 31, 2020, future minimum payments under non-cancellable operating leases were as follows (in thousands):

Year ending December 31,	Minimum Payments
2021	$	1,173
2022		1,208
2023		1,244
2024		1,280
2025		871
Total future minimum lease payments		5,776
Less imputed interest		927
Total operating lease liability		4,849
Less operating lease liability, current		835
Operating lease liability, non-current	$	4,014

Rent expense is recorded on a straight-line basis over the term of the Company’s facility lease. Rent expense was $1.0 million, $1.0 million and $0.6 million for the years ended December 31, 2020, 2019 and 2018, respectively.

Cash paid for amounts included in the measurement of lease liabilities for operating cash flow from operating leases was $1.1 million during each of the years ended December 31, 2020 and 2019.

7. COMMITMENTS AND CONTINGENCIES

Litigation

From time to time, the Company may be subject to various claims and suits arising in the ordinary course of business. The Company does not expect that the resolution of these matters will have a material adverse effect on its financial position or results of operations.

8. CONVERTIBLE PREFERRED STOCK

In April and December 2017, pursuant to a Series A preferred stock purchase agreement entered into in October 2015 which called for an initial closing and, upon the achievement of certain specified milestones, subsequent closings, the Company issued an aggregate of 11,505,268 shares of Series A convertible preferred stock for gross proceeds of $12.0 million, net of offering costs of $40,000. In February and March 2018, the Company issued an aggregate of 19,641,200 shares of its Series B convertible preferred stock for gross proceeds of $63.5 million, net of issuance costs incurred in connection with this offering of $0.2 million.

The holders of the convertible preferred stock were entitled to certain customary preferences, such as dividend and liquidation priority in relationship to the common shareholders, and certain anti-dilution protection. The convertible preferred stock was classified outside of stockholders’ equity (deficit) because the shares contained certain redemption features that were not solely within the control of the Company. In connection with the Company’s initial public offering (“IPO”), the outstanding shares of the Company’s Series A and Series B convertible preferred stock automatically converted into 14,712,571 shares of common stock (see Note 9).

F-14

9. STOCKHOLDERS’ EQUITY

Authorized Shares

In connection with the completion of the Company’s IPO on July 20, 2018, the Company amended and restated its certificate of incorporation to authorize 200,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share.

Public Offerings

The Company completed its IPO in July 2018 whereby it sold 6,900,000 shares of common stock at a price to the public of $17.00 per share. Proceeds from the IPO were approximately $106.5 million, net of underwriting discounts and commissions and offering costs of $10.8 million.

On April 17, 2020, the Company completed a public offering of 8,222,500 shares of its common stock at a public offering price of $14.00 per share. Proceeds from the offering were approximately $107.9 million, net of underwriting discounts and commissions and offering costs of $7.3 million. The shares were registered pursuant to the Company’s Shelf Registration Statement discussed below.

Shelf Registration Statement and ATM Offering

On August 13, 2019, the Company filed a registration statement on Form S-3 (the “Shelf Registration Statement”), covering the offering of up to $300.0 million of common stock, preferred stock, debt securities, warrants and units. The Registration Statement became effective on August 29, 2019.

On August 13, 2019 the Company also entered into a Sales Agreement (the “Sales Agreement”) with SVB Leerink LLC and Cantor Fitzgerald & Co. (collectively, the “Sales Agents”), under which the Company may, from time to time, sell shares of its common stock having an aggregate offering price of up to $75.0 million through the Sales Agents (the “ATM Offering”). The Shelf Registration Statement included a prospectus covering the offering, issuance, and sale of up to $75.0 million of Company common stock from time to time through the ATM Offering. The shares to be sold under the Sales Agreement may be issued and sold pursuant to the Shelf Registration Statement.

During the year ended December 31, 2020, the Company sold a total of 275,764 shares of common stock pursuant to its ATM Offering for net proceeds of $6.4 million, after deducting commissions of $0.2 million.

Shares of Common Stock Subject to Repurchase

In October 2015, in connection with the issuance of the Company’s Series A convertible preferred stock, certain of the Company’s founders entered into stock restriction agreements, whereby 1,914,893 of previously unrestricted shares of common stock became subject to repurchase by the Company upon the stockholder’s termination of employment or service to the Company. The Company’s repurchase rights lapsed as to 765,957 shares of common stock in October 2015, with the remainder scheduled to lapse at the rate of 23,936 shares monthly thereafter such that the shares of common stock would have been fully vested in October 2019. Under the terms of the stock restriction agreements, the shares of common stock were also subject to accelerated vesting upon certain events, such that all of these restricted shares became fully vested upon the closing of the Company’s Series B preferred stock financing in February 2018. The stock restriction agreements resulted in the deemed cancellation and reissuance of shares of common stock and therefore, for accounting purposes, the shares subject to repurchase were not considered to be outstanding until vested. The fair value of these shares as of October 2015 was recognized as compensation expense over the vesting period. The Company recognized stock-based compensation for these awards of $0.4 million during the year ended December 31, 2018.

10. EQUITY INCENTIVE PLANS

2018 Incentive Award Plan

The Company adopted the 2018 Incentive Award Plan (the “2018 Plan”) in July 2018. Under the 2018 Plan, which expires in July 2028, the Company may grant equity-based awards to individuals who are employees, officers, directors or consultants of the Company. Options issued under the 2018 Plan will generally expire ten years from the date of grant and vest over a four-year period. As of December 31, 2020, an aggregate of 1,967,191 shares of common stock were available for issuance under the 2018 Plan.

The 2018 Plan contains a provision that allows annual increases in the number of shares available for issuance on the first day of each calendar year through January 1, 2028 in an amount equal to the lesser of: (i) 5% of the aggregate number of shares of the Company’s common stock outstanding on December 31 of the immediately preceding calendar year, or (ii) such lesser amount determined by the Company. Under this evergreen provision, on January 1, 2021, an additional 1,650,846 shares became available for future issuance under the 2018 Plan.

F-15

2015 Stock Incentive Plan

In February 2015, the Company adopted the Crinetics Pharmaceuticals, Inc. 2015 Stock Incentive Plan (the “2015 Plan”), which provided for the issuance of equity awards to the Company’s employees, members of its board of directors and consultants. In general, options issued under this plan vest over four years and expire after 10 years. Subsequent to the adoption of the 2018 Plan, no additional equity awards can be made under the 2015 Plan.

Certain awards issued under the 2015 Plan allowed for exercise prior to vesting. Shares issued under such early-exercise provisions are subject to repurchase by the Company until they become fully vested. As of December 31, 2020, 15,951 unvested shares issued under early-exercise provisions were subject to repurchase by the Company. The consolidated balance sheet reflects an unvested stock liability of $23,000 and $49,000 as of December 31, 2020 and 2019, respectively.

2018 Employee Stock Purchase Plan

In July 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the “ESPP”). The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. As of December 31, 2020, an aggregate of 614,223 shares of common stock were available for issuance under the ESPP.

The ESPP contains a provision that allows annual increases in the number of shares available for issuance on the first day of each calendar year through January 1, 2028 in an amount equal to the lesser of: (i) 1% of the aggregate number of shares of the Company’s common stock outstanding on December 31 of the immediately preceding calendar year, or (ii) such lesser amount determined by the Company. Under this evergreen provision, on January 1, 2021, an additional 330,169 shares became available for future issuance under the ESPP.

Stock Option Activity

Activity under the Company’s stock option plans during the year ended December 31, 2020 was as follows:

				Weighted-		Weighted-		Aggregate
				Average		Average		Intrinsic
	Options			Exercise		Remaining		Value
	Outstanding			Price		Term		(000’s)
Balance at December 31, 2019		3,127,391		$	11.52
Granted		1,604,470		$	19.16
Exercised		(170,696	)	$	1.68
Forfeited and expired		(139,632	)	$	19.51
Balance at December 31, 2020		4,421,533		$	14.42		8.1	$	15,930
Vested and expected to vest at December 31, 2020		4,421,533		$	14.42		8.1	$	15,930
Exercisable at December 31, 2020		1,957,407		$	11.02		7.4	$	11,766

Aggregate intrinsic value is calculated as the difference between the closing price of the Company’s common stock at December 31, 2020 and the exercise price of stock options that had strike prices below the closing price.

The total intrinsic value of options exercised during 2020, 2019 and 2018 was $2.5 million, $2.0 million and $2.4 million, respectively.

Fair Value of Stock Option Awards

The Company utilizes the Black Scholes option pricing model to value awards under its equity plans. The following table summarizes the weighted average assumptions used to estimate the fair value of stock options granted under the Company’s stock option plans and the shares purchasable under the ESPP during the periods presented:

	Year ended December 31,
Stock Option Awards	2020			2019			2018
Expected option term	6.0 years			5.9 years			6.0 years
Expected volatility		78	%		78	%		70	%
Risk free interest rate		0.8	%		2.3	%		2.8	%
Expected dividend yield		—	%		—	%		—	%

F-16

	Year ended December 31,
ESPP	2020			2019			2018
Expected option term	1.4 years			1.8 years			1.1 years
Expected volatility		84	%		65	%		66	%
Risk free interest rate		0.2	%		2.2	%		2.4	%
Expected dividend yield		—	%		—	%		—	%

The key assumptions used in determining the fair value of equity awards, and the Company’s rationale, were as follows: (i) Expected option term - the expected term represents the period that options are expected to be outstanding and has been estimated using the simplified method, which is an average of the contractual option term and its vesting period; (ii) Expected volatility - the expected volatility assumption is based on volatilities of a peer group of similar companies in the biotechnology industry whose share prices are publicly available; (iii) Risk-free interest rate - the risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities that approximate the expected terms of awards; and (iv) Expected dividend yield - the expected dividend yield assumption is zero as the Company has never paid dividends and has no present intention to do so in the future.

The weighted-average fair value of stock options granted to employees during the years ended December 31, 2020, 2019 and 2018 was $12.83, $16.35 and $4.66 per share, respectively. The weighted-average fair value of awards under the ESPP during the years ended December 31, 2020, 2019 and 2018 was $8.07, $10.59 and $8.15 per share, respectively.

Stock-Based Compensation Expense

Stock-based compensation expense for the equity awards issued by the Company to employees and non-employees for the periods presented below was as follows (in thousands):

	Year ended December 31,
	2020		2019		2018
Included in research and development	$	5,218	$	3,190	$	1,100
Included in general and administrative		5,209		3,104		1,220
Total stock-based compensation expense	$	10,427	$	6,294	$	2,320

Unrecognized stock-based compensation cost related to option awards was $26.9 million as of December 31, 2020, which is expected to be recognized over a remaining weighted-average period of approximately 2.4 years. Unrecognized stock-based compensation cost related to stock purchase rights under the Company’s ESPP was $1.3 million as of December 31, 2020, which is expected to be recognized over a remaining weighted-average period of approximately 1.6 years.

11. INCOME TAXES

The Company is subject to taxation in the United States, various state jurisdictions and Australia; however, as it has operated at a loss since inception, it has not paid income taxes in any of the jurisdictions in which it has operated. At December 31, 2020, the Company had federal, state, and foreign net operating loss (“NOL”) carryforwards of approximately $118.2 million, $124.1 million and $1.6 million, respectively. The federal loss carryforwards generated after 2017 of $111.9 million will carryforward indefinitely and can be used to offset up to 80% of future annual taxable income, while those loss carryforwards generated prior to 2018 begin expiring in 2035, unless previously utilized. State loss carryforwards also begin expiring in 2035, unless previously utilized, while the Company’s foreign loss carryforwards do not expire. The Company also has federal and California R&D credit carryforwards totaling $4.5 million and $2.7 million, respectively. The federal credits begin to expire in 2030 unless previously utilized, while the state credits do not expire. The Company also has federal Orphan Drug credit carryforwards totaling $1.4 million which will begin to expire in 2040 unless previously utilized.

The Company’s NOL and credit carryforwards to offset future taxable income may be subject to a substantial annual limitation as a result of ownership changes that could occur in the future pursuant to Internal Revenue Code Sections 382 and 383. These ownership changes may limit the amount of NOL and credit carryforwards that can be utilized to offset future taxable income and income tax, respectively. In general, an “ownership change” as defined by the tax code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percent of the outstanding stock of a company by certain stockholders or public groups. During 2020, the Company completed a study to assess whether an ownership change within the meaning of Section 382 had occurred for the time period prior to July 15, 2020. The study identified several such ownership changes during the study period, which resulted in limitations on the annual utilization of the Company’s NOL and credit carryforwards, or the “Tax Attribute” carryforwards; however, the study findings also indicated that none of the Company’s Tax Attribute carryforwards generated during the study period would

F-17

expire solely as a result of annual limitations on the utilization of such Tax Attribute carryforwards. Future ownership changes could still occur which might place further limits on the Company’s ability to utilize its Tax Attribute carryforwards.

The Company’s federal income tax returns from 2017 forward, state income tax returns from 2016 forward, and its Australian tax returns beginning in 2018 are subject to examination by tax authorities; however, the Company’s Tax Attribute carryforwards generated in closed years are also subject to examination and remeasurement. No such audits are underway.

Deferred tax assets and liabilities

Net deferred tax assets are comprised of the following as of December 31, 2020 and 2019 (in thousands):

	December 31,
	2020			2019
Deferred tax assets:
Net operating loss carryforwards	$	33,994		$	15,990
Capitalized research expenses		4,231			4,864
R&D and other tax credits		6,881			4,676
Stock-based compensation		3,233			1,343
Lease liability		1,358			1,560
Accrued expenses and other, net		1,932			886
Total deferred tax assets		51,629			29,319
Deferred tax liabilities:
Right-of use asset		(625	)		(702	)
Other deferred tax liabilities		(132	)		(22	)
Net of deferred tax assets and liabilities		50,872			28,595
Less: valuation allowance		(50,872	)		(28,595	)
Net deferred tax assets	$	—		$	—

Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use existing deferred tax assets. Based on the weight of available evidence, including the Company’s history of operating losses, management has determined that it is more likely than not that the Company’s net deferred tax assets will not be realized. Accordingly, a valuation allowance has been established by the Company to fully offset these net deferred tax assets.

Income tax benefit

For the three years in the period ended December 31, 2020, domestic and foreign pre-tax loss were (in thousands):

	Year ended December 31,
	2020			2019			2018
Loss before income taxes - Domestic	$	(71,769	)	$	(48,643	)	$	(25,876	)
Loss before income taxes - Foreign		(2,043	)		(1,779	)		(1,239	)
Loss before income taxes - Consolidated	$	(73,812	)	$	(50,422	)	$	(27,115	)

F-18

A reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate to the loss from operations for the three years in the period ended December 31, 2020 is as follows (in thousands):

	Year ended December 31,
	2020			2019			2018
Expected income tax benefit at federal statutory rate	$	(15,417	)	$	(10,589	)	$	(5,694	)
State income tax benefit, net of federal benefit		(4,886	)		(3,431	)		(1,758	)
Tax effect of
Change in valuation allowance		22,242			16,064			7,724
R&D credit		(2,597	)		(2,485	)		(1,129	)
Federal rate change		—			—			(52	)
Australian tax incentive		215			307			362
Other		443			134			547
Provision for income taxes	$	—		$	—		$	—

Changes to the Company’s unrecognized tax benefits are summarized in the following table (in thousands):

	Year ended December 31,
	2020			2019		2018
Beginning balance	$	886		$	344	$	159
Increase (decrease) for prior year tax positions		(163	)		70		—
Increase (decrease) for current year tax positions		369			472		185
Ending balance	$	1,092		$	886	$	344

Due to the existence of the valuation allowance, future changes in unrecognized tax benefits would not have any effect on the Company’s effective tax rate. The Company does not foresee any material changes to its unrecognized tax benefits within the next twelve months.

F-19

EXHIBIT INDEX

Exhibit

Number

Exhibit Description

Incorporated by Reference

Filed

Herewith

Form

Date

Number

3.1

Amended and Restated Certificate of Incorporation

8-K

7/20/2018

3.1

3.2

Amended and Restated Bylaws

8-K

4/14/2020

3.1

4.1

Specimen Stock Certificate Evidencing the Shares of Common Stock

S-1/A

7/09/2018

4.1

4.2

Amended and Restated Investor Rights Agreement, dated February 9, 2018, by and among the Registrant and certain of its stockholders

S-1

6/22/2018

4.2

4.3

Description of Registered Securities

10.1#

Crinetics Pharmaceuticals, Inc. 2015 Stock Incentive Plan, as amended

S-1/A

7/09/2018

10.1

10.2#

Form of stock option agreement under Crinetics Pharmaceuticals, Inc. 2015 Stock Incentive Plan, as amended

S-1

6/22/2018

10.2

10.3#

Crinetics Pharmaceuticals, Inc. 2018 Incentive Award Plan

S-1/A

7/09/2018

10.3

10.4#

Form of stock option agreement under Crinetics Pharmaceuticals, Inc. 2018 Incentive Award Plan

S-1/A

7/09/2018

10.4

10.5#

Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan and offering document thereunder

S-1/A

7/09/2018

10.5

10.6#

Amended and Restated Employment Agreement, effective as of May 25, 2018, by and between R. Scott Struthers and the Registrant

S-1

6/22/2018

10.6

10.7#

Amended and Restated Employment Agreement, effective as of May 22, 2018, by and between Marc J.S. Wilson and the Registrant

S-1

6/22/2018

10.7

10.8#

Employment Agreement, effective as of June 15, 2018, by and between Alan Krasner, M.D. and the Registrant

S-1/A

7/09/2018

10.8

10.9#

Amended and Restated Employment Agreement, effective as of May 22, 2018, by and between Ajay Madan and the Registrant

10-Q

8/07/2020

10.1

10.10#

Form of Indemnification Agreement for Directors and Officers

S-1/A

7/09/2018

10.9

10.11#

Lease Agreement, dated as of February 21, 2018, by and between 6262 Lusk Investors LLC and the Registrant, as amended

S-1

6/22/2018

10.9

10.12#

Non-Employee Director Compensation Program

S-1/A

7/09/2018

10.11

10.13

Sales Agreement, dated August 13, 2019, among the Company, SVB Leerink LLC and Cantor Fitzgerald & Co.

S-3

8/13/2019

1.2

21.1

List of Subsidiaries of the Registrant

S-1

6/22/2018

21.1

23.1

Consent of BDO USA, LLP, independent registered public accounting firm

31.1

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Exhibit

Number

Exhibit Description

Incorporated by Reference

Filed

Herewith

Form

Date

Number

32.1*

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2*

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags

101.SCH

XBRL Taxonomy Extension Schema Document

101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

XBRL Taxonomy Extension Label Linkbase Document

101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document

#	Indicates management contract or compensatory plan.

These certifications are being furnished solely to accompany this annual report pursuant to 18 U.S.C. Section 1350 and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Company Name

Date: March 30, 2021	By:	/s/ R. Scott Struthers
		R. Scott Struthers, Ph.D.
		President and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

Name	Title	Date

/s/ R. Scott Struthers	President, Chief Executive Officer and Director	March 30, 2021
R. Scott Struthers, Ph.D.	(principal executive officer)

/s/ Marc J.S. Wilson	Chief Financial Officer	March 30, 2021
Marc J.S. Wilson	(principal financial and accounting officer)

/s/ Wendell Wierenga, Ph.D.	Chairman of the Board of Directors	March 30, 2021
Wendell Wierenga, Ph.D.

/s/ Camille Bedrosian	Director	March 30, 2021
Camille Bedrosian

/s/ Matthew K. Fust	Director	March 30, 2021
Matthew K. Fust

/s/ Stephen Kaldor, Ph.D.	Director	March 30, 2021
Stephen Kaldor, Ph.D.

/s/ Weston Nichols, Ph.D.	Director	March 30, 2021
Weston Nichols, Ph.D.

/s/ Stephanie Okey	Director	March 30, 2021
Stephanie Okey

EX-4.3 2 crnx-ex43_10.htm EX-4.3 crnx-ex43_10.htm

Exhibit 4.3

DESCRIPTION OF THE REGISTRANT’S SECURITIES

REGISTERED PURSUANT TO SECTION 12 OF THE

SECURITIES EXCHANGE ACT OF 1934

Crinetics Pharmaceuticals, Inc. (“Crinetics,” “we,” “our” and “us”) has one class of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock.

Description of Common Stock

General

The following summary of the terms of our common stock does not purport to be complete and is subject to and qualified in its entirety by reference to our Amended and Restated Certificate of Incorporation (the “certificate of incorporation”), and Amended and Restated Bylaws (the “bylaws”), which are filed as exhibits to this Annual Report on Form 10-K and are incorporated by reference herein. We encourage you to read our certificate of incorporation and our bylaws for additional information.

Under our certificate of incorporation, the total number of shares of all classes of stock that we have authority to issue is 210,000,000, consisting of 200,000,000 shares of common stock, par value $0.001 per share and 10,000,000 shares of preferred stock, par value $0.001 per share.

Common Stock

Voting Rights

The holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, including the election of directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the outstanding shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they so choose, other than any directors that holders of any preferred stock we may issue may be entitled to elect. Subject to the supermajority votes for some matters, other matters shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter. Our certificate of incorporation and bylaws also provide that our directors may be removed only for cause and only by the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote thereon. In addition, the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote thereon is required to amend or repeal, or to adopt any provision inconsistent with, several of the provisions of our certificate of incorporation.

Dividends

Subject to preferences that may be applicable to any then outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared by the board of directors out of legally available funds.

Liquidation

In the event of our liquidation, dissolution or winding up, the holders of common stock will be entitled to share ratably in the assets legally available for distribution to stockholders after the payment of

or provision for all of our debts and other liabilities, subject to the prior rights of any preferred stock then outstanding.

Rights and Preferences

Holders of common stock have no preemptive or conversion rights or other subscription rights and there are no redemption or sinking funds provisions applicable to the common stock.

The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.

Fully Paid and Nonassessable

All outstanding shares of common stock are duly authorized, validly issued, fully paid and nonassessable.

Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws

Some provisions of Delaware law, our certificate of incorporation and our bylaws contain provisions that could make the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for payment of a premium over the market price for our shares.

These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.

Undesignated Preferred Stock

The ability of our board of directors, without action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to change control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company.

Stockholder Meetings

Our bylaws provide that a special meeting of stockholders may be called only by our chairman of the board of directors, chief executive officer or president, or by a resolution adopted by a majority of our board of directors.

Requirements for Advance Notification of Stockholder Nominations and Proposals

Our bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors.

Elimination of Stockholder Action by Written Consent

Our certificate of incorporation and bylaws eliminate the right of stockholders to act by written consent without a meeting.

Staggered Board of Directors

Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders. This system of electing and removing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.

Removal of Directors

Our certificate of incorporation provides that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two thirds of the total voting power of all of our outstanding voting stock then entitled to vote in the election of directors.

Stockholders Not Entitled to Cumulative Voting

Our certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our preferred stock may be entitled to elect.

Delaware Anti-Takeover Statute

We are subject to Section 203 of the Delaware General Corporation Law. This statute regulating corporate takeovers prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for three years following the date that the stockholder became an interested stockholder, unless:

•

prior to the date of the transaction, the board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;

•

the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (a) shares owned by persons who are directors and also officers and (b) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or

•

on or subsequent to the date of the transaction, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 662/3% of the outstanding voting stock which is not owned by the interested stockholder.

Section 203 defines a business combination to include:

•

any merger or consolidation involving the corporation and the interested stockholder;

•

any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;

•

subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;

•

any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; or

•

the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.

In general, Section 203 defines an interested stockholder as an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by such entity or person.

Choice of Forum

Our certificate of incorporation provides that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for: (1) any derivative action or proceeding brought on our behalf; (2) any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders, creditors or other constituents; (3) any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or our certificate of incorporation or bylaws; (4) any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws; or (5) any action asserting a claim governed by the internal affairs doctrine. This exclusive forum provision would not apply to suits brought to enforce any liability or duty created by the Securities Act of 1933, as amended (the “Securities Act”) or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. Our bylaws provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Our certificate of incorporation also provides that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision. It is possible that a court of law could rule that the choice of forum provisions contained in our certificate of incorporation or bylaws are inapplicable or unenforceable if they are challenged in a proceeding or otherwise.

Amendment of Charter Provisions

The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock, would require approval by holders of at least two thirds of the total voting power of all of our outstanding voting stock.

The provisions of Delaware law, our certificate of incorporation and our bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our board of directors and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.

Listing

Our common stock is listed for trading on the Nasdaq Global Select Market under the symbol “CRNX.”

Transfer Agent and Registrar

The transfer agent and registrar for our common stock is Computershare Trust Company, N.A.

EX-23.1 3 crnx-ex231_8.htm EX-23.1 crnx-ex231_8.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

Crinetics Pharmaceuticals, Inc.

San Diego, California

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-233246) and Form S-8 (No. 333-226234) of Crinetics Pharmaceuticals, Inc., of our report dated March 30, 2021, relating to the consolidated financial statements, which appears in this Annual Report on Form 10-K.

/s/BDO USA, LLP

San Diego, California

March 30, 2021

EX-31.1 4 crnx-ex311_11.htm EX-31.1 crnx-ex311_11.htm

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, R. Scott Struthers, Ph.D., certify that:

I have reviewed this annual report on Form 10-K of Crinetics Pharmaceuticals, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: March 30, 2021				/s/ R. Scott Struthers, Ph.D.
				R. Scott Struthers, Ph.D.
				President and Chief Executive Officer

EX-31.2 5 crnx-ex312_6.htm EX-31.2 crnx-ex312_6.htm

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Marc J.S. Wilson, certify that:

I have reviewed this annual report on Form 10-K of Crinetics Pharmaceuticals, Inc.;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: March 30, 2021				/s/ Marc J.S. Wilson
				Marc J.S. Wilson
				Chief Financial Officer

EX-32.1 6 crnx-ex321_7.htm EX-32.1 crnx-ex321_7.htm

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Crinetics Pharmaceuticals, Inc. (the “Company”) hereby certifies, to his knowledge, that:

(i) the accompanying Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2020 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ R. Scott Struthers, Ph.D.

R. Scott Struthers, Ph.D.

President and Chief Executive Officer

Date: March 30, 2021

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.

EX-32.2 7 crnx-ex322_9.htm EX-32.2 crnx-ex322_9.htm

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Marc J.S. Wilson

Marc J.S. Wilson

Chief Financial Officer

Date: March 30, 2021

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.

GRAPHIC 8 gu3vczyysgco000002.jpg GRAPHIC begin 644 gu3vczyysgco000002.jpg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end GRAPHIC 9 gu3vczyysgco000001.jpg GRAPHIC begin 644 gu3vczyysgco000001.jpg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end GRAPHIC 10 gu3vczyysgco000004.jpg GRAPHIC begin 644 gu3vczyysgco000004.jpg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end GRAPHIC 11 gu3vczyysgco000003.jpg GRAPHIC begin 644 gu3vczyysgco000003.jpg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�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�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end EX-101.INS 12 crnx-20201231.xml XBRL INSTANCE DOCUMENT xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure crnx:Segment crnx:Security 0001658247 2020-01-01 2020-12-31 0001658247 2021-02-26 0001658247 2020-06-30 0001658247 2020-12-31 0001658247 2019-12-31 0001658247 2019-01-01 2019-12-31 0001658247 2018-01-01 2018-12-31 0001658247 us-gaap:ConvertiblePreferredStockMember 2017-12-31 0001658247 crnx:SeriesBConvertiblePreferredStockMember 2018-01-01 2018-12-31 0001658247 us-gaap:ConvertiblePreferredStockMember 2018-01-01 2018-12-31 0001658247 us-gaap:CommonStockMember 2017-12-31 0001658247 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2017-12-31 0001658247 us-gaap:RetainedEarningsMember 2017-12-31 0001658247 2017-12-31 0001658247 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001658247 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001658247 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001658247 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001658247 us-gaap:CommonStockMember 2018-12-31 0001658247 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2018-12-31 0001658247 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001658247 us-gaap:RetainedEarningsMember 2018-12-31 0001658247 2018-12-31 0001658247 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001658247 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001658247 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001658247 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001658247 us-gaap:CommonStockMember 2019-12-31 0001658247 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2019-12-31 0001658247 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001658247 us-gaap:RetainedEarningsMember 2019-12-31 0001658247 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001658247 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001658247 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001658247 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001658247 us-gaap:CommonStockMember 2020-12-31 0001658247 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2020-12-31 0001658247 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001658247 us-gaap:RetainedEarningsMember 2020-12-31 0001658247 us-gaap:CommonStockMember 2018-07-06 2018-07-06 0001658247 srt:MinimumMember 2020-01-01 2020-12-31 0001658247 srt:MinimumMember us-gaap:EquipmentMember 2020-01-01 2020-12-31 0001658247 srt:MaximumMember us-gaap:EquipmentMember 2020-01-01 2020-12-31 0001658247 srt:MinimumMember us-gaap:OfficeEquipmentMember 2020-01-01 2020-12-31 0001658247 srt:MaximumMember us-gaap:OfficeEquipmentMember 2020-01-01 2020-12-31 0001658247 crnx:ComputerAndSoftwareMember 2020-01-01 2020-12-31 0001658247 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2020-12-31 0001658247 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2019-12-31 0001658247 crnx:AustralianResearchAndDevelopmentTaxIncentiveProgramMember us-gaap:AustralianTaxationOfficeMember 2020-01-01 2020-12-31 0001658247 crnx:AustralianResearchAndDevelopmentTaxIncentiveProgramMember us-gaap:AustralianTaxationOfficeMember 2019-01-01 2019-12-31 0001658247 crnx:AustralianResearchAndDevelopmentTaxIncentiveProgramMember us-gaap:AustralianTaxationOfficeMember 2018-01-01 2018-12-31 0001658247 us-gaap:StockOptionMember 2020-01-01 2020-12-31 0001658247 us-gaap:StockOptionMember 2019-01-01 2019-12-31 0001658247 us-gaap:StockOptionMember 2018-01-01 2018-12-31 0001658247 crnx:UnvestedCommonStockSubjectToRepurchaseMember 2020-01-01 2020-12-31 0001658247 crnx:UnvestedCommonStockSubjectToRepurchaseMember 2019-01-01 2019-12-31 0001658247 crnx:UnvestedCommonStockSubjectToRepurchaseMember 2018-01-01 2018-12-31 0001658247 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001658247 us-gaap:CertificatesOfDepositMember 2020-12-31 0001658247 us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001658247 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001658247 us-gaap:CertificatesOfDepositMember 2019-12-31 0001658247 us-gaap:CommercialPaperMember 2019-12-31 0001658247 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001658247 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001658247 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001658247 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001658247 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001658247 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001658247 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001658247 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001658247 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001658247 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001658247 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001658247 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001658247 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001658247 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001658247 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001658247 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001658247 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001658247 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001658247 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001658247 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001658247 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001658247 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001658247 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001658247 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001658247 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001658247 us-gaap:EquipmentMember 2020-12-31 0001658247 us-gaap:EquipmentMember 2019-12-31 0001658247 us-gaap:OfficeEquipmentMember 2020-12-31 0001658247 us-gaap:OfficeEquipmentMember 2019-12-31 0001658247 us-gaap:ComputerEquipmentMember 2020-12-31 0001658247 us-gaap:ComputerEquipmentMember 2019-12-31 0001658247 crnx:TwoThousandEighteenOperatingLeaseMember 2020-12-31 0001658247 crnx:TwoThousandEighteenOperatingLeaseMember 2020-01-01 2020-12-31 0001658247 crnx:TwoThousandEighteenOperatingLeaseMember 2019-01-01 2019-12-31 0001658247 crnx:TwoThousandEighteenOperatingLeaseMember 2018-01-01 2018-12-31 0001658247 crnx:SeriesAConvertiblePreferredStockMember 2017-12-31 0001658247 crnx:SeriesAConvertiblePreferredStockMember 2017-04-01 2017-12-31 0001658247 crnx:SeriesBConvertiblePreferredStockMember 2018-03-31 0001658247 crnx:SeriesBConvertiblePreferredStockMember 2018-02-01 2018-03-31 0001658247 us-gaap:IPOMember crnx:SeriesAAndBConvertiblePreferredStockMember 2018-07-19 2018-07-20 0001658247 us-gaap:IPOMember 2018-07-20 0001658247 us-gaap:CommonStockMember us-gaap:IPOMember 2018-07-01 2018-07-31 0001658247 us-gaap:CommonStockMember us-gaap:IPOMember 2018-07-31 0001658247 us-gaap:IPOMember 2018-07-01 2018-07-31 0001658247 2018-07-31 0001658247 us-gaap:IPOMember us-gaap:CommonStockMember 2020-04-17 2020-04-17 0001658247 us-gaap:IPOMember us-gaap:CommonStockMember 2020-04-17 0001658247 us-gaap:IPOMember 2020-04-17 2020-04-17 0001658247 us-gaap:IPOMember 2020-04-17 0001658247 2019-08-13 0001658247 srt:MaximumMember crnx:SVBLeerinkLLCAndCantorFitzgeraldCoMember 2019-08-13 2019-08-13 0001658247 2019-08-13 2019-08-13 0001658247 crnx:AtTheMarketOfferingMember 2020-01-01 2020-12-31 0001658247 crnx:AtTheMarketOfferingMember 2020-12-31 0001658247 crnx:StockRestrictionAgreementMember 2015-10-01 2015-10-31 0001658247 crnx:StockRestrictionAgreementMember 2018-01-01 2018-12-31 0001658247 crnx:TwoThousandEighteenIncentiveAwardPlanMember 2018-07-01 2018-07-31 0001658247 crnx:TwoThousandEighteenIncentiveAwardPlanMember 2020-01-01 2020-12-31 0001658247 crnx:TwoThousandEighteenIncentiveAwardPlanMember 2020-12-31 0001658247 crnx:TwoThousandEighteenIncentiveAwardPlanMember us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2021-01-01 0001658247 crnx:TwoThousandFifteenStockIncentivePlanMember 2015-02-01 2015-02-28 0001658247 crnx:TwoThousandFifteenStockIncentivePlanMember 2020-01-01 2020-12-31 0001658247 crnx:TwoThousandFifteenStockIncentivePlanMember 2020-12-31 0001658247 crnx:TwoThousandFifteenStockIncentivePlanMember 2019-12-31 0001658247 us-gaap:EmployeeStockMember 2018-07-31 0001658247 us-gaap:CommonStockMember us-gaap:EmployeeStockMember 2020-12-31 0001658247 us-gaap:CommonStockMember us-gaap:EmployeeStockMember 2020-01-01 2020-12-31 0001658247 us-gaap:CommonStockMember us-gaap:EmployeeStockMember us-gaap:SubsequentEventMember 2020-12-30 2021-01-01 0001658247 us-gaap:StockOptionMember 2020-01-01 2020-12-31 0001658247 us-gaap:StockOptionMember 2019-01-01 2019-12-31 0001658247 us-gaap:StockOptionMember 2018-01-01 2018-12-31 0001658247 us-gaap:EmployeeStockMember 2020-01-01 2020-12-31 0001658247 us-gaap:EmployeeStockMember 2019-01-01 2019-12-31 0001658247 us-gaap:EmployeeStockMember 2018-01-01 2018-12-31 0001658247 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001658247 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001658247 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0001658247 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001658247 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001658247 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-12-31 0001658247 us-gaap:EmployeeStockMember 2020-12-31 0001658247 us-gaap:DomesticCountryMember 2020-01-01 2020-12-31 0001658247 us-gaap:DomesticCountryMember us-gaap:EarliestTaxYearMember 2020-01-01 2020-12-31 0001658247 us-gaap:StateAndLocalJurisdictionMember us-gaap:EarliestTaxYearMember 2020-01-01 2020-12-31 0001658247 us-gaap:DomesticCountryMember 2020-12-31 0001658247 stpr:CA 2020-12-31 0001658247 srt:MinimumMember 2020-12-31 0001658247 srt:MaximumMember 2020-01-01 2020-12-31 10-K false 2020-12-31 2020 FY CRNX Crinetics Pharmaceuticals, Inc. 0001658247 --12-31 No Yes No Non-accelerated Filer false true true true 33028876 505700000 Yes Common Stock, par value $0.001 per share NASDAQ 001-38583 DE 26-3744114 10222 Barnes Canyon Road Bldg. #2 San Diego CA 92121 858 450-6464 true false true 93087000 40326000 77793000 78066000 6612000 4947000 177492000 123339000 3181000 3946000 2232000 2510000 500000 500000 40000 82000 183445000 130377000 5588000 5498000 4066000 2118000 835000 724000 10489000 8340000 4014000 4849000 23000 49000 14526000 13238000 336508000 210793000 25000 148000 -167614000 -93802000 168919000 117139000 183445000 130377000 0.001 0.001 10000000 10000000 0 0 0 0 0.001 0.001 200000000 200000000 33017000 24296000 33001000 24263000 71000 1193000 2428000 us-gaap:GrantMember us-gaap:GrantMember us-gaap:GrantMember 56998000 41506000 24479000 18026000 13519000 6659000 75024000 55025000 31138000 -74953000 -53832000 -28710000 991000 3460000 1748000 150000 -50000 -153000 1141000 3410000 1595000 -73812000 -50422000 -27115000 -123000 87000 61000 -73935000 -50335000 -27054000 -2.42 -2.09 -2.23 30448000 24175000 12142000 28763000 29700000 19641000 63275000 -48404000 -92975000 1550000 1243000 -16265000 -15022000 14713000 92975000 92975000 6900000 106472000 106472000 541000 21000 21000 337000 231000 231000 20000 282000 282000 2320000 2320000 61000 61000 -27115000 24061000 203544000 61000 -43380000 160225000 63000 94000 94000 90000 126000 126000 49000 735000 735000 6294000 6294000 87000 87000 -50422000 24263000 210793000 148000 -93802000 8499000 114283000 114283000 17000 26000 26000 171000 288000 288000 51000 691000 691000 10427000 10427000 -123000 -123000 -73812000 33001000 336508000 25000 -167614000 225000 10427000 6294000 2320000 948000 887000 471000 278000 226000 227000 1229000 433000 17000 4000 1623000 2221000 1802000 2723000 696000 7361000 -724000 -608000 -261000 -62027000 -46381000 -19459000 135592000 108136000 118399000 135995000 150295000 186000 492000 1059000 217000 41667000 -119458000 63275000 114283000 106472000 288000 126000 451000 59000 114571000 67000 170198000 52761000 -4647000 31281000 40826000 45473000 14192000 93587000 44973000 500000 500000 500000 691000 735000 282000 6000 112000 42000 26000 94000 21000 3304000 <p style="text-align:center;margin-bottom:0pt;margin-top:6pt;line-height:9pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE Certain sections of the registrant’s definitive proxy statement for the 2021 annual meeting of stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after end of the fiscal year covered by this Form 10-K are incorporated by reference into Part III of this Form 10-K. 1. ORGANIZATION AND BASIS OF PRESENTATION Description of Business Crinetics Pharmaceuticals, Inc. (the “Company”) is a clinical-stage pharmaceutical company incorporated in Delaware on November 18, 2008 and based in San Diego, California. The Company is focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. In January 2017, the Company established a wholly-owned Australian subsidiary, Crinetics Australia Pty Ltd (“CAPL”), in order to conduct various preclinical and clinical activities for its development candidates. On July 6, 2018, the Company effected a 1-for-3.29 reverse stock split of its common stock. The par value and the authorized shares of the common stock were not adjusted as a result of the reverse stock split. The reverse stock split resulted in an adjustment to the conversion prices of the Company’s Series A and B preferred stock to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying consolidated financial statements and notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. Principles of Consolidation and Foreign Currency Transactions The consolidated financial statements include the accounts of the Company and CAPL. All intercompany accounts and transactions have been eliminated in consolidation. The functional currency of both the Company and CAPL is the U.S. dollar. Assets and liabilities that are not denominated in the functional currency are remeasured into U.S. dollars at foreign currency exchange rates in effect at the balance sheet date except for nonmonetary assets, which are remeasured at historical foreign currency exchange rates in effect at the date of transaction. Net realized and unrealized gains and losses from foreign currency transactions and remeasurement are reported in other income (expense), in the consolidated statements of operations and were not material for all periods presented. Segment Reporting Operating segments are identified as components of an enterprise about which discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. Liquidity and Going Concern From inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting preclinical studies and clinical trials. The Company has a limited operating history and the sales and income potential of the Company’s business and market are unproven. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company’s cost structure. As of December 31, 2020, the Company had $170.9 million in unrestricted cash, cash equivalents and investment securities. The Company believes it has sufficient cash to meet its funding requirements for at least the next 12 months from the date of issuance of these financial statements. The Company has experienced net losses and negative cash flows from operating activities since its inception and has an accumulated deficit of $167.6 million as of December 31, 2020. The Company expects to continue to incur net losses for the foreseeable future and believes it will need to raise substantial additional capital to accomplish its business plan over the next several years. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of equity offerings, debt financings or other sources, including potential collaborations, licenses and other similar arrangements. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned programs. Any of these actions could materially harm the Company’s business, results of operations and future prospects. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future. COVID-19 The COVID-19 pandemic has caused significant business disruption around the globe. The extent of the impact of COVID-19 on the Company's operational and financial performance will depend on certain developments, including the duration and spread of the pandemic and the impact on the Company's clinical trials, employees and vendors. In response to the spread of COVID-19, the Company has closed its offices to all but its lab and a limited number of its other personnel, while the remainder of its employees are continuing their work outside the Company’s offices. At this point, the degree to which COVID-19 may impact the Company's financial condition or future results of operations is uncertain. A prolonged outbreak could have a material adverse impact on financial results and business operations of the Company, including the timing and ability of Company to complete certain clinical trials and other efforts required to advance the development of its drug candidates and raise additional capital. In response to the pandemic, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) was signed into law on March 27, 2020.  The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer’s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property.  The CARES Act has not had a material impact on the Company’s income tax provision for the year ended December 31, 2020. 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The Company’s consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The preparation of the Company’s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to accrued amounts receivable under the Australian research and development tax incentive program, accrued expenses and associated research and development expense, the assumptions underlying the determination of the estimated incremental borrowing rate for the determination of the Company’s operating lease right-of-use asset, and the assumptions underlying the determination of the fair value of equity awards for purposes of determining stock-based compensation. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. Fair Value Measurements The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices in active markets. Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The carrying amounts of the Company’s current financial assets, restricted cash and current financial liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. Cash, Cash Equivalents and Restricted Cash Cash and cash equivalents include cash held in readily available checking and money market accounts, as well as short-term debt securities with maturities of three months or less when purchased. Restricted cash represents cash held as collateral for the Company’s facility lease and is reported as a long-term asset in the accompanying consolidated balance sheets. Investment Securities All investments have been classified as “available-for-sale” and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities less than 12 months at the balance sheet date are considered short-term investments. Investments with contractual maturities beyond one year are also classified as short-term due to the Company’s ability to liquidate the investment for use in operations within the next 12 months. Realized gains and losses on investment securities are included in earnings and are derived using the specific identification method for determining the cost of securities sold. The Company has not realized any significant gains or losses on sales of available-for-sale investment securities during any of the periods presented. As all the Company’s investment holdings are in the form of debt securities, unrealized gains and losses that are determined to be temporary in nature are reported as a component of accumulated other comprehensive income. A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the establishment of a new cost basis for the security. Interest income is recognized when earned and is included in investment income, as are the amortization of purchase premiums and accretion of purchase discounts on investment securities. Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investment securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity. Leases The Company determines if an arrangement is a lease at the inception of the arrangement. Beginning January 1, 2019, leases with a term longer than 12 months that are determined to be operating leases are included in operating lease assets, accrued expenses and other current liabilities and noncurrent operating lease liabilities in the consolidated balance sheets based on the present value of the minimum lease payments called for under the arrangement. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Property and Equipment, Net Property and equipment consist of leasehold improvements, and lab and various other equipment. Such assets are stated at cost and depreciated on a straight-line basis over the estimated useful life of the related assets. The Company estimates its useful lives of its lab and other equipment as follows: lab equipment – three to five years; office equipment - three to five years; computer and software – three years. Leasehold improvements are amortized over the estimated useful life of the improvement or the remaining term of the associated lease. Repairs and maintenance costs are charged to expense as incurred and expenditures that materially extend the useful lives of assets are capitalized. Impairment of Long-Lived Assets Long-lived assets consist of property and equipment. An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. The Company has not recognized any impairment losses in any of the periods presented in these consolidated financial statements. Deferred Rent The Company’s facility lease includes incentives in the form of rent abatements and leasehold improvement allowances, as well as fixed annual rent escalations. The Company recognizes the aggregate rental expense, after considering incentives and stipulated rent escalations, on a straight-line basis over the lease term. Prior to January 1, 2019, the difference between rent expense and amounts paid under the lease was recorded as deferred rent. Grant Revenue Recognition The Company’s grant revenues are derived from Small Business Innovation Research Grants (“SBIR Grants”) from the National Institutes of Health. The Company recognizes SBIR Grant revenue as reimbursable grant costs are incurred up to pre-approved award limits within the budget period. The costs associated with these reimbursements are reflected as a component of research and development expense in the accompanying consolidated statements of operations. Earnings in excess of billings are included as a component of prepaid expenses and other current assets. Research and Development Expenses Research and development (“R&D”) expenses consist primarily of salaries, payroll taxes, employee benefits and stock-based compensation for individuals involved in R&D efforts, as well as consulting expenses, third-party R&D expenses, laboratory supplies, clinical materials and overhead, including facilities and depreciation costs, offset by the Australian Tax Incentive discussed below. R&D expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in R&D are capitalized until the goods or services are received. Costs incurred under contracts with contract research organizations that conduct and manage the Company’s clinical trials are also included in research and development expenses. The financial terms and activities of these agreements vary from contract to contract and may result in uneven expense levels. Generally, these agreements set forth activities that drive the recording of expenses such as start-up and initiation activities, enrollment and treatment of patients, or the completion of other clinical trial activities. Expenses related to clinical trials are accrued based on estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the amounts that the Company is obligated to pay under its clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the Company adjusts its accruals accordingly on a prospective basis. Revisions to contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain. Accrued R&D expenses totaled $2.1 million and $2.8 million as of December 31, 2020 and 2019, respectively, and are a component of accounts payable and accrued expenses in the consolidated balance sheets. Australian Tax Incentive CAPL is eligible to obtain a cash refund from the Australian Taxation Office for eligible R&D expenditures under the Australian R&D Tax Incentive Program (the “Australian Tax Incentive”). The Australian Tax Incentive is recognized as a reduction to R&D expense when there is reasonable assurance that the relevant expenditure has been incurred, the amount can be reliably measured and that the Australian Tax Incentive will be received. The Company recognized reductions to R&D expense of $0.6 million, $1.0 million and $1.2 million for the years ended December 31, 2020, 2019 and 2018, respectively. Stock-Based Compensation Stock-based compensation expense represents the estimated grant date fair value of the Company’s equity awards, consisting of stock options and shares issued under the Company’s Employee Stock Purchase Plan, recognized over the requisite service period of such awards (usually the vesting period) on a straight-line basis. The Company estimates the fair value of equity awards using the Black-Scholes option pricing model on the date of grant and recognizes forfeitures as they occur. For stock awards for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable, or the performance condition has been achieved. Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense, and any accrued interest and penalties would be included within the related tax liability. No such costs were recorded during the three years ended December 31, 2020. Comprehensive Loss Comprehensive loss is comprised of the Company’s net loss and the unrealized gains on the Company’s investment securities for all periods presented. Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of convertible preferred stock, common stock subject to repurchase, and options outstanding under the Company’s stock option plan. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive. Potentially dilutive securities (in common stock equivalent shares) not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.28%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,422</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,127</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,339</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested common stock subject to repurchase</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,438</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,160</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,466</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>  </div> Recently Adopted Accounting Pronouncements ASU 2019-12 In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12, Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes (“ASU 2019-12”). The Board issued this ASU as part of its simplification initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the Company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company has elected to early adopt ASU 2019-12 in the fourth quarter of fiscal 2020; however, there was no cumulative effect to be recognized with the early adoption.         ASU 2018-13 In August 2018, the FASB issued ASU 2018-13, “Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement,” which improves the effectiveness of the disclosures required under ASC 820, “Fair Value Measurements and Disclosures” and modifies the disclosure requirements on fair value measurements, including the consideration of costs and benefits. The Company adopted this standard in 2020; adoption of this standard did not have a material impact on the Company’s consolidated financial statements. Recent Accounting Pronouncements ASU 2016-13 In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“Topic 326”). Topic 326 amends guidance on reporting credit losses for assets held at amortized cost basis and available for sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available for sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. This ASU update affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. This update is effective for the company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is currently evaluating the impact of the pending adoption of this new standard on its consolidated financial statements. ASU 2020-06 In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020, including interim periods within those fiscal years. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The amendment is to be adopted through either a modified retrospective or fully retrospective method of transition.  The Company is currently evaluating the potential impact that the adoption of ASU 2020-06 may have on its consolidated financial statements and related disclosures. 3. INVESTMENT SECURITIES Available-for-sale investment securities consisted of the following as of December 31, 2020 and 2019 (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Market <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale investment securities:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government and agency obligations</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,222</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,223</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,161</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,175</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,385</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,395</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,768</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,793</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Market <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale investment securities:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government and agency obligations</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,275</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,368</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,931</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,982</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,645</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,645</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,067</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,071</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,918</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">152</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,066</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> All available-for-sale investment securities held at December 31, 2020 and 2019 had maturity dates of less than 24 months. None of the Company’s available-for-sale investment securities were in a material unrealized loss position at December 31, 2020. The Company reviewed its investment holdings as of December 31, 2020 and determined that its unrealized losses were not considered to be other-than-temporary based upon (i) the financial strength of the issuing institution and (ii) the fact that no securities have been in an unrealized loss position for twelve months or more. As such, the Company has not recognized any impairment in its financial statements related to its available-for-sale investment securities. 4. FAIR VALUE MEASUREMENTS The Company holds investment securities that consist of highly liquid, investment grade debt securities. The Company determines the fair value of its investment securities based upon one or more valuations reported by its investment accounting and reporting service provider. The investment service provider values the securities using a hierarchical security pricing model that relies primarily on valuations provided by an industry-recognized valuation service. Such valuations may be based on trade prices in active markets for identical assets or liabilities (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets or liabilities, yield curves, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, and broker and dealer quotes, as well as other relevant economic measures. Financial assets measured at fair value on a recurring basis as of December 31, 2020 and 2019 were as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Investment securities:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government and agency obligations</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,222</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,001</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,223</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,175</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,175</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,395</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,395</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,222</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,571</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,793</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Investment securities:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government and agency obligations</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,478</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,890</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,368</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,982</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,982</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,645</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,645</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,071</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,071</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,478</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,588</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,066</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div></div> The Company’s policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no transfers into or out of Level 3 during the years ended December 31, 2020 and 2019. 5. BALANCE SHEET DETAILS Prepaid expenses and other current assets consisted of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.82%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid research and development costs</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,062</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,478</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Australian tax incentive receivable</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,720</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">929</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">693</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">648</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest receivable</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.82%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other assets</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,024</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">668</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.82%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,612</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,947</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Property and equipment, net consisted of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,494</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,494</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,551</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,468</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">653</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">567</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers and software</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment at cost</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,739</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,570</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation and amortization</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,558</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,624</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,181</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,946</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Depreciation expense was $0.9 million, $0.9 million, and $0.5 million for the three years ended December 31, 2020, 2019 and 2018, respectively. 6. OPERATING LEASE 2018 Operating Lease. In February 2018, as amended in March 2018, the Company entered into a non-cancelable operating lease for a new facility in San Diego, California. The lease has an initial term of seven years which expires in August 2025, and the Company has an option to extend the term of the lease for an additional five years and has a termination option subject to early termination fees. The lease is subject to base lease payments and additional charges for common area maintenance and other costs and includes certain lease incentives and tenant improvement allowances. Rent expense is being recognized on a straight-line basis over the term of the lease. The Company’s estimated incremental fully collateralized borrowing rate of 8.0% was used in its present value calculation as the facility lease does not have a stated rate and the implicit rate was not readily determinable. Under the terms of the lease, the Company provided the lessor with an irrevocable letter of credit in the amount of $0.5 million. The lessor is entitled to draw on the letter of credit in the event of any default by the Company under the terms of the lease. Future Minimum Payments. As of December 31, 2020, future minimum payments under non-cancellable operating leases were as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.1%; border-bottom:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Minimum <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.1%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,173</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,208</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,244</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,280</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">871</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future minimum lease payments</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,776</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">927</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,849</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less operating lease liability, current</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">835</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability, non-current</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,014</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>  </div> Rent expense is recorded on a straight-line basis over the term of the Company’s facility lease. Rent expense was $1.0 million, $1.0 million and $0.6 million for the years ended December 31, 2020, 2019 and 2018, respectively. Cash paid for amounts included in the measurement of lease liabilities for operating cash flow from operating leases was $1.1 million during each of the years ended December 31, 2020 and 2019. 7. COMMITMENTS AND CONTINGENCIES Litigation From time to time, the Company may be subject to various claims and suits arising in the ordinary course of business. The Company does not expect that the resolution of these matters will have a material adverse effect on its financial position or results of operations. 8. CONVERTIBLE PREFERRED STOCK In April and December 2017, pursuant to a Series A preferred stock purchase agreement entered into in October 2015 which called for an initial closing and, upon the achievement of certain specified milestones, subsequent closings, the Company issued an aggregate of 11,505,268 shares of Series A convertible preferred stock for gross proceeds of $12.0 million, net of offering costs of $40,000. In February and March 2018, the Company issued an aggregate of 19,641,200 shares of its Series B convertible preferred stock for gross proceeds of $63.5 million, net of issuance costs incurred in connection with this offering of $0.2 million. The holders of the convertible preferred stock were entitled to certain customary preferences, such as dividend and liquidation priority in relationship to the common shareholders, and certain anti-dilution protection. The convertible preferred stock was classified outside of stockholders’ equity (deficit) because the shares contained certain redemption features that were not solely within the control of the Company. In connection with the Company’s initial public offering (“IPO”), the outstanding shares of the Company’s Series A and Series B convertible preferred stock automatically converted into 14,712,571 shares of common stock (see Note 9). 9. STOCKHOLDERS’ EQUITY Authorized Shares In connection with the completion of the Company’s IPO on July 20, 2018, the Company amended and restated its certificate of incorporation to authorize 200,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share. Public Offerings The Company completed its IPO in July 2018 whereby it sold 6,900,000 shares of common stock at a price to the public of $17.00 per share. Proceeds from the IPO were approximately $106.5 million, net of underwriting discounts and commissions and offering costs of $10.8 million. On April 17, 2020, the Company completed a public offering of 8,222,500 shares of its common stock at a public offering price of $14.00 per share. Proceeds from the offering were approximately $107.9 million, net of underwriting discounts and commissions and offering costs of $7.3 million. The shares were registered pursuant to the Company’s Shelf Registration Statement discussed below. Shelf Registration Statement and ATM Offering On August 13, 2019, the Company filed a registration statement on Form S-3 (the “Shelf Registration Statement”), covering the offering of up to $300.0 million of common stock, preferred stock, debt securities, warrants and units. The Registration Statement became effective on August 29, 2019. On August 13, 2019 the Company also entered into a Sales Agreement (the “Sales Agreement”) with SVB Leerink LLC and Cantor Fitzgerald & Co. (collectively, the “Sales Agents”), under which the Company may, from time to time, sell shares of its common stock having an aggregate offering price of up to $75.0 million through the Sales Agents (the “ATM Offering”). The Shelf Registration Statement included a prospectus covering the offering, issuance, and sale of up to $75.0 million of Company common stock from time to time through the ATM Offering. The shares to be sold under the Sales Agreement may be issued and sold pursuant to the Shelf Registration Statement. During the year ended December 31, 2020, the Company sold a total of 275,764 shares of common stock pursuant to its ATM Offering for net proceeds of $6.4 million, after deducting commissions of $0.2 million. Shares of Common Stock Subject to Repurchase In October 2015, in connection with the issuance of the Company’s Series A convertible preferred stock, certain of the Company’s founders entered into stock restriction agreements, whereby 1,914,893 of previously unrestricted shares of common stock became subject to repurchase by the Company upon the stockholder’s termination of employment or service to the Company. The Company’s repurchase rights lapsed as to 765,957 shares of common stock in October 2015, with the remainder scheduled to lapse at the rate of 23,936 shares monthly thereafter such that the shares of common stock would have been fully vested in October 2019. Under the terms of the stock restriction agreements, the shares of common stock were also subject to accelerated vesting upon certain events, such that all of these restricted shares became fully vested upon the closing of the Company’s Series B preferred stock financing in February 2018. The stock restriction agreements resulted in the deemed cancellation and reissuance of shares of common stock and therefore, for accounting purposes, the shares subject to repurchase were not considered to be outstanding until vested. The fair value of these shares as of October 2015 was recognized as compensation expense over the vesting period. The Company recognized stock-based compensation for these awards of $0.4 million during the year ended December 31, 2018. 10. EQUITY INCENTIVE PLANS 2018 Incentive Award Plan The Company adopted the 2018 Incentive Award Plan (the “2018 Plan”) in July 2018. Under the 2018 Plan, which expires in July 2028, the Company may grant equity-based awards to individuals who are employees, officers, directors or consultants of the Company. Options issued under the 2018 Plan will generally expire ten years from the date of grant and vest over a four-year period. As of December 31, 2020, an aggregate of 1,967,191 shares of common stock were available for issuance under the 2018 Plan. The 2018 Plan contains a provision that allows annual increases in the number of shares available for issuance on the first day of each calendar year through January 1, 2028 in an amount equal to the lesser of: (i) 5% of the aggregate number of shares of the Company’s common stock outstanding on December 31 of the immediately preceding calendar year, or (ii) such lesser amount determined by the Company. Under this evergreen provision, on January 1, 2021, an additional 1,650,846 shares became available for future issuance under the 2018 Plan. 2015 Stock Incentive Plan In February 2015, the Company adopted the Crinetics Pharmaceuticals, Inc. 2015 Stock Incentive Plan (the “2015 Plan”), which provided for the issuance of equity awards to the Company’s employees, members of its board of directors and consultants. In general, options issued under this plan vest over four years and expire after 10 years. Subsequent to the adoption of the 2018 Plan, no additional equity awards can be made under the 2015 Plan. Certain awards issued under the 2015 Plan allowed for exercise prior to vesting. Shares issued under such early-exercise provisions are subject to repurchase by the Company until they become fully vested. As of December 31, 2020, 15,951 unvested shares issued under early-exercise provisions were subject to repurchase by the Company. The consolidated balance sheet reflects an unvested stock liability of $23,000 and $49,000 as of December 31, 2020 and 2019, respectively. 2018 Employee Stock Purchase Plan In July 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the “ESPP”). The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. As of December 31, 2020, an aggregate of 614,223 shares of common stock were available for issuance under the ESPP. The ESPP contains a provision that allows annual increases in the number of shares available for issuance on the first day of each calendar year through January 1, 2028 in an amount equal to the lesser of: (i) 1% of the aggregate number of shares of the Company’s common stock outstanding on December 31 of the immediately preceding calendar year, or (ii) such lesser amount determined by the Company. Under this evergreen provision, on January 1, 2021, an additional 330,169 shares became available for future issuance under the ESPP.    Stock Option Activity Activity under the Company’s stock option plans during the year ended December 31, 2020 was as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(000’s)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,127,391</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.52</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,604,470</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.16</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(170,696</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.68</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited and expired</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(139,632</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.51</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,421,533</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.42</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,930</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at December 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,421,533</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.42</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,930</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,957,407</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.02</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,766</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Aggregate intrinsic value is calculated as the difference between the closing price of the Company’s common stock at December 31, 2020 and the exercise price of stock options that had strike prices below the closing price. The total intrinsic value of options exercised during 2020, 2019 and 2018 was $2.5 million, $2.0 million and $2.4 million, respectively.  Fair Value of Stock Option Awards The Company utilizes the Black Scholes option pricing model to value awards under its equity plans. The following table summarizes the weighted average assumptions used to estimate the fair value of stock options granted under the Company’s stock option plans and the shares purchasable under the ESPP during the periods presented:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Option Awards</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected option term</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0 years</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9 years</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0 years</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.8</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.8</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table>   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.66%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ESPP</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected option term</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4 years</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8 years</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1 years</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div></div>   The key assumptions used in determining the fair value of equity awards, and the Company’s rationale, were as follows: (i) Expected option term - the expected term represents the period that options are expected to be outstanding and has been estimated using the simplified method, which is an average of the contractual option term and its vesting period; (ii) Expected volatility - the expected volatility assumption is based on volatilities of a peer group of similar companies in the biotechnology industry whose share prices are publicly available; (iii) Risk-free interest rate - the risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities that approximate the expected terms of awards; and (iv) Expected dividend yield - the expected dividend yield assumption is zero as the Company has never paid dividends and has no present intention to do so in the future. The weighted-average fair value of stock options granted to employees during the years ended December 31, 2020, 2019 and 2018 was $12.83, $16.35 and $4.66 per share, respectively. The weighted-average fair value of awards under the ESPP during the years ended December 31, 2020, 2019 and 2018 was $8.07, $10.59 and $8.15 per share, respectively. Stock-Based Compensation Expense Stock-based compensation expense for the equity awards issued by the Company to employees and non-employees for the periods presented below was as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Included in research and development</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,218</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,190</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,100</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Included in general and administrative</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,209</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,104</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,220</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,427</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,294</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,320</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Unrecognized stock-based compensation cost related to option awards was $26.9 million as of December 31, 2020, which is expected to be recognized over a remaining weighted-average period of approximately 2.4 years. Unrecognized stock-based compensation cost related to stock purchase rights under the Company’s ESPP was $1.3 million as of December 31, 2020, which is expected to be recognized over a remaining weighted-average period of approximately 1.6 years. 11. INCOME TAXES The Company is subject to taxation in the United States, various state jurisdictions and Australia; however, as it has operated at a loss since inception, it has not paid income taxes in any of the jurisdictions in which it has operated. At December 31, 2020, the Company had federal, state, and foreign net operating loss (“NOL”) carryforwards of approximately $118.2 million, $124.1 million and $1.6 million, respectively. The federal loss carryforwards generated after 2017 of $111.9 million will carryforward indefinitely and can be used to offset up to 80% of future annual taxable income, while those loss carryforwards generated prior to 2018 begin expiring in 2035, unless previously utilized. State loss carryforwards also begin expiring in 2035, unless previously utilized, while the Company’s foreign loss carryforwards do not expire. The Company also has federal and California R&D credit carryforwards totaling $4.5 million and $2.7 million, respectively. The federal credits begin to expire in 2030 unless previously utilized, while the state credits do not expire. The Company also has federal Orphan Drug credit carryforwards totaling $1.4 million which will begin to expire in 2040 unless previously utilized. The Company’s NOL and credit carryforwards to offset future taxable income may be subject to a substantial annual limitation as a result of ownership changes that could occur in the future pursuant to Internal Revenue Code Sections 382 and 383. These ownership changes may limit the amount of NOL and credit carryforwards that can be utilized to offset future taxable income and income tax, respectively. In general, an “ownership change” as defined by the tax code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percent of the outstanding stock of a company by certain stockholders or public groups. During 2020, the Company completed a study to assess whether an ownership change within the meaning of Section 382 had occurred for the time period prior to July 15, 2020. The study identified several such ownership changes during the study period, which resulted in limitations on the annual utilization of the Company’s NOL and credit carryforwards, or the “Tax Attribute” carryforwards; however, the study findings also indicated that none of the Company’s Tax Attribute carryforwards generated during the study period would expire solely as a result of annual limitations on the utilization of such Tax Attribute carryforwards. Future ownership changes could still occur which might place further limits on the Company’s ability to utilize its Tax Attribute carryforwards. The Company’s federal income tax returns from 2017 forward, state income tax returns from 2016 forward, and its Australian tax returns beginning in 2018 are subject to examination by tax authorities; however, the Company’s Tax Attribute carryforwards generated in closed years are also subject to examination and remeasurement. No such audits are underway. Deferred tax assets and liabilities Net deferred tax assets are comprised of the following as of December 31, 2020 and 2019 (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,994</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,990</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized research expenses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,231</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,864</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&D and other tax credits</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,881</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,676</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,233</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,343</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,358</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,560</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other, net</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,932</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">886</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,629</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,319</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of use asset</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(625</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(702</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other deferred tax liabilities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(132</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net of deferred tax assets and liabilities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,872</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,595</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: valuation allowance</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(50,872</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,595</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use existing deferred tax assets. Based on the weight of available evidence, including the Company’s history of operating losses, management has determined that it is more likely than not that the Company’s net deferred tax assets will not be realized. Accordingly, a valuation allowance has been established by the Company to fully offset these net deferred tax assets. Income tax benefit For the three years in the period ended December 31, 2020, domestic and foreign pre-tax loss were (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes - Domestic</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(71,769</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(48,643</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,876</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes - Foreign</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,043</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,779</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,239</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes - Consolidated</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(73,812</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(50,422</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,115</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div>   A reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate to the loss from operations for the three years in the period ended December 31, 2020 is as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected income tax benefit at federal statutory rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,417</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,589</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,694</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income tax benefit, net of federal benefit</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,886</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,431</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,758</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax effect of</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,242</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,064</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,724</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&D credit</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,597</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,485</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,129</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal rate change</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Australian tax incentive</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">307</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">443</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">547</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Changes to the Company’s unrecognized tax benefits are summarized in the following table (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning balance</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">886</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">344</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase (decrease) for prior year tax positions</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(163</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase (decrease) for current year tax positions</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">369</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">472</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">185</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ending balance</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,092</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">886</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">344</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Due to the existence of the valuation allowance, future changes in unrecognized tax benefits would not have any effect on the Company’s effective tax rate. The Company does not foresee any material changes to its unrecognized tax benefits within the next twelve months. Description of Business Crinetics Pharmaceuticals, Inc. (the “Company”) is a clinical-stage pharmaceutical company incorporated in Delaware on November 18, 2008 and based in San Diego, California. The Company is focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. In January 2017, the Company established a wholly-owned Australian subsidiary, Crinetics Australia Pty Ltd (“CAPL”), in order to conduct various preclinical and clinical activities for its development candidates. On July 6, 2018, the Company effected a 1-for-3.29 reverse stock split of its common stock. The par value and the authorized shares of the common stock were not adjusted as a result of the reverse stock split. The reverse stock split resulted in an adjustment to the conversion prices of the Company’s Series A and B preferred stock to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying consolidated financial statements and notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. Principles of Consolidation and Foreign Currency Transactions The consolidated financial statements include the accounts of the Company and CAPL. All intercompany accounts and transactions have been eliminated in consolidation. The functional currency of both the Company and CAPL is the U.S. dollar. Assets and liabilities that are not denominated in the functional currency are remeasured into U.S. dollars at foreign currency exchange rates in effect at the balance sheet date except for nonmonetary assets, which are remeasured at historical foreign currency exchange rates in effect at the date of transaction. Net realized and unrealized gains and losses from foreign currency transactions and remeasurement are reported in other income (expense), in the consolidated statements of operations and were not material for all periods presented. Segment Reporting Operating segments are identified as components of an enterprise about which discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. Liquidity and Going Concern From inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting preclinical studies and clinical trials. The Company has a limited operating history and the sales and income potential of the Company’s business and market are unproven. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company’s cost structure. As of December 31, 2020, the Company had $170.9 million in unrestricted cash, cash equivalents and investment securities. The Company believes it has sufficient cash to meet its funding requirements for at least the next 12 months from the date of issuance of these financial statements. The Company has experienced net losses and negative cash flows from operating activities since its inception and has an accumulated deficit of $167.6 million as of December 31, 2020. The Company expects to continue to incur net losses for the foreseeable future and believes it will need to raise substantial additional capital to accomplish its business plan over the next several years. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of equity offerings, debt financings or other sources, including potential collaborations, licenses and other similar arrangements. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned programs. Any of these actions could materially harm the Company’s business, results of operations and future prospects. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future. COVID-19 The COVID-19 pandemic has caused significant business disruption around the globe. The extent of the impact of COVID-19 on the Company's operational and financial performance will depend on certain developments, including the duration and spread of the pandemic and the impact on the Company's clinical trials, employees and vendors. In response to the spread of COVID-19, the Company has closed its offices to all but its lab and a limited number of its other personnel, while the remainder of its employees are continuing their work outside the Company’s offices. At this point, the degree to which COVID-19 may impact the Company's financial condition or future results of operations is uncertain. A prolonged outbreak could have a material adverse impact on financial results and business operations of the Company, including the timing and ability of Company to complete certain clinical trials and other efforts required to advance the development of its drug candidates and raise additional capital. In response to the pandemic, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) was signed into law on March 27, 2020.  The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer’s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property.  The CARES Act has not had a material impact on the Company’s income tax provision for the year ended December 31, 2020. Use of Estimates The Company’s consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The preparation of the Company’s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to accrued amounts receivable under the Australian research and development tax incentive program, accrued expenses and associated research and development expense, the assumptions underlying the determination of the estimated incremental borrowing rate for the determination of the Company’s operating lease right-of-use asset, and the assumptions underlying the determination of the fair value of equity awards for purposes of determining stock-based compensation. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. Fair Value Measurements The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices in active markets. Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The carrying amounts of the Company’s current financial assets, restricted cash and current financial liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. Cash, Cash Equivalents and Restricted Cash Cash and cash equivalents include cash held in readily available checking and money market accounts, as well as short-term debt securities with maturities of three months or less when purchased. Restricted cash represents cash held as collateral for the Company’s facility lease and is reported as a long-term asset in the accompanying consolidated balance sheets. Investment Securities All investments have been classified as “available-for-sale” and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities less than 12 months at the balance sheet date are considered short-term investments. Investments with contractual maturities beyond one year are also classified as short-term due to the Company’s ability to liquidate the investment for use in operations within the next 12 months. Realized gains and losses on investment securities are included in earnings and are derived using the specific identification method for determining the cost of securities sold. The Company has not realized any significant gains or losses on sales of available-for-sale investment securities during any of the periods presented. As all the Company’s investment holdings are in the form of debt securities, unrealized gains and losses that are determined to be temporary in nature are reported as a component of accumulated other comprehensive income. A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the establishment of a new cost basis for the security. Interest income is recognized when earned and is included in investment income, as are the amortization of purchase premiums and accretion of purchase discounts on investment securities. Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investment securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity. Leases The Company determines if an arrangement is a lease at the inception of the arrangement. Beginning January 1, 2019, leases with a term longer than 12 months that are determined to be operating leases are included in operating lease assets, accrued expenses and other current liabilities and noncurrent operating lease liabilities in the consolidated balance sheets based on the present value of the minimum lease payments called for under the arrangement. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Property and Equipment, Net Property and equipment consist of leasehold improvements, and lab and various other equipment. Such assets are stated at cost and depreciated on a straight-line basis over the estimated useful life of the related assets. The Company estimates its useful lives of its lab and other equipment as follows: lab equipment – three to five years; office equipment - three to five years; computer and software – three years. Leasehold improvements are amortized over the estimated useful life of the improvement or the remaining term of the associated lease. Repairs and maintenance costs are charged to expense as incurred and expenditures that materially extend the useful lives of assets are capitalized. Impairment of Long-Lived Assets Long-lived assets consist of property and equipment. An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. The Company has not recognized any impairment losses in any of the periods presented in these consolidated financial statements. Deferred Rent The Company’s facility lease includes incentives in the form of rent abatements and leasehold improvement allowances, as well as fixed annual rent escalations. The Company recognizes the aggregate rental expense, after considering incentives and stipulated rent escalations, on a straight-line basis over the lease term. Prior to January 1, 2019, the difference between rent expense and amounts paid under the lease was recorded as deferred rent. Grant Revenue Recognition The Company’s grant revenues are derived from Small Business Innovation Research Grants (“SBIR Grants”) from the National Institutes of Health. The Company recognizes SBIR Grant revenue as reimbursable grant costs are incurred up to pre-approved award limits within the budget period. The costs associated with these reimbursements are reflected as a component of research and development expense in the accompanying consolidated statements of operations. Earnings in excess of billings are included as a component of prepaid expenses and other current assets. Research and Development Expenses Research and development (“R&D”) expenses consist primarily of salaries, payroll taxes, employee benefits and stock-based compensation for individuals involved in R&D efforts, as well as consulting expenses, third-party R&D expenses, laboratory supplies, clinical materials and overhead, including facilities and depreciation costs, offset by the Australian Tax Incentive discussed below. R&D expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in R&D are capitalized until the goods or services are received. Costs incurred under contracts with contract research organizations that conduct and manage the Company’s clinical trials are also included in research and development expenses. The financial terms and activities of these agreements vary from contract to contract and may result in uneven expense levels. Generally, these agreements set forth activities that drive the recording of expenses such as start-up and initiation activities, enrollment and treatment of patients, or the completion of other clinical trial activities. Expenses related to clinical trials are accrued based on estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the amounts that the Company is obligated to pay under its clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the Company adjusts its accruals accordingly on a prospective basis. Revisions to contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain. Accrued R&D expenses totaled $2.1 million and $2.8 million as of December 31, 2020 and 2019, respectively, and are a component of accounts payable and accrued expenses in the consolidated balance sheets. Australian Tax Incentive CAPL is eligible to obtain a cash refund from the Australian Taxation Office for eligible R&D expenditures under the Australian R&D Tax Incentive Program (the “Australian Tax Incentive”). The Australian Tax Incentive is recognized as a reduction to R&D expense when there is reasonable assurance that the relevant expenditure has been incurred, the amount can be reliably measured and that the Australian Tax Incentive will be received. The Company recognized reductions to R&D expense of $0.6 million, $1.0 million and $1.2 million for the years ended December 31, 2020, 2019 and 2018, respectively. Stock-Based Compensation Stock-based compensation expense represents the estimated grant date fair value of the Company’s equity awards, consisting of stock options and shares issued under the Company’s Employee Stock Purchase Plan, recognized over the requisite service period of such awards (usually the vesting period) on a straight-line basis. The Company estimates the fair value of equity awards using the Black-Scholes option pricing model on the date of grant and recognizes forfeitures as they occur. For stock awards for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable, or the performance condition has been achieved. Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense, and any accrued interest and penalties would be included within the related tax liability. No such costs were recorded during the three years ended December 31, 2020. Comprehensive Loss Comprehensive loss is comprised of the Company’s net loss and the unrealized gains on the Company’s investment securities for all periods presented. Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of convertible preferred stock, common stock subject to repurchase, and options outstanding under the Company’s stock option plan. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive. Potentially dilutive securities (in common stock equivalent shares) not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.28%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,422</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,127</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,339</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested common stock subject to repurchase</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,438</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,160</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,466</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Recently Adopted Accounting Pronouncements ASU 2019-12 In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12, Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes (“ASU 2019-12”). The Board issued this ASU as part of its simplification initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the Company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company has elected to early adopt ASU 2019-12 in the fourth quarter of fiscal 2020; however, there was no cumulative effect to be recognized with the early adoption.         ASU 2018-13 In August 2018, the FASB issued ASU 2018-13, “Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement,” which improves the effectiveness of the disclosures required under ASC 820, “Fair Value Measurements and Disclosures” and modifies the disclosure requirements on fair value measurements, including the consideration of costs and benefits. The Company adopted this standard in 2020; adoption of this standard did not have a material impact on the Company’s consolidated financial statements. Recent Accounting Pronouncements ASU 2016-13 In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“Topic 326”). Topic 326 amends guidance on reporting credit losses for assets held at amortized cost basis and available for sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available for sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. This ASU update affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. This update is effective for the company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is currently evaluating the impact of the pending adoption of this new standard on its consolidated financial statements. ASU 2020-06 In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020, including interim periods within those fiscal years. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The amendment is to be adopted through either a modified retrospective or fully retrospective method of transition.  The Company is currently evaluating the potential impact that the adoption of ASU 2020-06 may have on its consolidated financial statements and related disclosures. Available-for-sale investment securities consisted of the following as of December 31, 2020 and 2019 (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Market <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale investment securities:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government and agency obligations</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,222</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,223</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,161</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,175</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,385</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,395</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,768</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,793</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Market <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale investment securities:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government and agency obligations</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,275</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,368</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,931</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,982</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,645</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,645</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,067</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,071</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,918</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">152</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,066</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Financial assets measured at fair value on a recurring basis as of December 31, 2020 and 2019 were as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Investment securities:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government and agency obligations</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,222</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,001</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,223</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,175</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,175</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,395</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,395</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,222</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,571</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,793</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Investment securities:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government and agency obligations</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,478</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,890</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,368</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates of deposit</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,982</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,982</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,645</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,645</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,071</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,071</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,478</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,588</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,066</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Prepaid expenses and other current assets consisted of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.82%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid research and development costs</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,062</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,478</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Australian tax incentive receivable</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,720</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">929</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">693</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">648</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest receivable</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.82%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other assets</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,024</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">668</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.82%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,612</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,947</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Property and equipment, net consisted of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,494</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,494</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,551</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,468</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office equipment</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">653</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">567</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers and software</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment at cost</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,739</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,570</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation and amortization</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,558</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,624</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,181</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,946</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> As of December 31, 2020, future minimum payments under non-cancellable operating leases were as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.1%; border-bottom:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Minimum <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.1%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,173</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,208</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,244</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,280</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">871</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future minimum lease payments</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,776</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">927</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,849</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less operating lease liability, current</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">835</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability, non-current</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,014</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Activity under the Company’s stock option plans during the year ended December 31, 2020 was as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(000’s)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,127,391</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.52</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,604,470</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.16</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(170,696</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.68</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited and expired</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(139,632</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.51</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,421,533</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.42</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,930</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at December 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,421,533</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.42</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,930</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,957,407</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.02</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,766</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The following table summarizes the weighted average assumptions used to estimate the fair value of stock options granted under the Company’s stock option plans and the shares purchasable under the ESPP during the periods presented: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Option Awards</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected option term</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0 years</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9 years</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0 years</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.8</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.8</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.66%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ESPP</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected option term</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4 years</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.8 years</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1 years</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div> Stock-based compensation expense for the equity awards issued by the Company to employees and non-employees for the periods presented below was as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Included in research and development</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,218</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,190</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,100</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Included in general and administrative</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,209</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,104</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,220</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,427</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,294</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,320</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Deferred tax assets and liabilities Net deferred tax assets are comprised of the following as of December 31, 2020 and 2019 (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,994</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,990</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized research expenses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,231</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,864</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&D and other tax credits</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,881</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,676</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,233</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,343</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,358</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,560</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other, net</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,932</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">886</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,629</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,319</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of use asset</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(625</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(702</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other deferred tax liabilities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(132</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net of deferred tax assets and liabilities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,872</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,595</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: valuation allowance</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(50,872</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,595</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Income tax benefit For the three years in the period ended December 31, 2020, domestic and foreign pre-tax loss were (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes - Domestic</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(71,769</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(48,643</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,876</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes - Foreign</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,043</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,779</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,239</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes - Consolidated</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(73,812</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(50,422</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,115</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div>   A reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate to the loss from operations for the three years in the period ended December 31, 2020 is as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected income tax benefit at federal statutory rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,417</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,589</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,694</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income tax benefit, net of federal benefit</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,886</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,431</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,758</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax effect of</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,242</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,064</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,724</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&D credit</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,597</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,485</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,129</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal rate change</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Australian tax incentive</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">307</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">443</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">547</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Changes to the Company’s unrecognized tax benefits are summarized in the following table (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning balance</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">886</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">344</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase (decrease) for prior year tax positions</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(163</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase (decrease) for current year tax positions</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">369</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">472</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">185</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ending balance</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,092</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">886</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">344</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> 1-for-3.29 0.3040 1 170900000 P12M P3Y P5Y P3Y P5Y P3Y 0 0 0 2100000 2800000 600000 1000000 1200000 4422000 3127000 2339000 16000 33000 127000 4438000 3160000 2466000 74222000 2161000 1385000 77768000 6000 14000 10000 30000 5000 5000 74223000 2175000 1395000 77793000 43275000 5931000 17645000 11067000 77918000 94000 51000 7000 152000 1000 3000 4000 43368000 5982000 17645000 11071000 78066000 P24M P24M 0 60222000 14001000 74223000 2175000 2175000 1395000 1395000 60222000 17571000 77793000 15478000 27890000 43368000 5982000 5982000 17645000 17645000 11071000 11071000 15478000 62588000 78066000 0 0 0 0 0 0 0 0 3062000 2478000 1720000 929000 693000 648000 113000 224000 1024000 668000 3494000 3494000 1551000 1468000 653000 567000 41000 41000 5739000 5570000 2558000 1624000 900000 900000 500000 P7Y 2025-08 five years 0.080 500000 1173000 1208000 1244000 1280000 871000 5776000 927000 4849000 us-gaap:OperatingLeaseLiabilityCurrent 835000 1000000 1000000 600000 1100000 1100000 11505268 12000000 40000 19641200 63500000 200000 14712571 200000000 0.001 10000000 0.001 6900000 17.00 106500000 10800000 8222500 14.00 107900000 7300000 300000000 2019-08-29 75000000 75000000 6400000 200000 275764 1914893 765957 23936 400000 2028-07 P10Y P4Y 2028-01-01 0.05 1967191 1650846 P4Y P10Y 15951 23000000000 49000000000 0.20 614223 2028-01-01 330169 3127391 1604470 170696 139632 4421533 4421533 1957407 11.52 19.16 1.68 19.51 14.42 14.42 11.02 P8Y1M6D P8Y1M6D P7Y4M24D 15930000 15930000 11766000 2500000 2000000 2400000 P6Y P5Y10M24D P6Y 0.78 0.78 0.70 0.008 0.023 0.028 P1Y4M24D P1Y9M18D P1Y1M6D 0.84 0.65 0.66 0.002 0.022 0.024 0.00 12.83 16.35 4.66 8.07 10.59 8.15 5218000 3190000 1100000 5209000 3104000 1220000 10427000 6294000 2320000 26900000 1300000 P2Y4M24D P1Y7M6D 118200000 124100000 1600000 111900000 0.80 2035 2035 4500000 2700000 2030 1400 The Company’s NOL and credit carryforwards to offset future taxable income may be subject to a substantial annual limitation as a result of ownership changes that could occur in the future pursuant to Internal Revenue Code Sections 382 and 383. These ownership changes may limit the amount of NOL and credit carryforwards that can be utilized to offset future taxable income and income tax, respectively. In general, an “ownership change” as defined by the tax code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percent of the outstanding stock of a company by certain stockholders or public groups. 0.50 P3Y 33994000 15990000 4231000 4864000 6881000 4676000 3233000 1343000 1358000 1560000 1932000 886000 51629000 29319000 625000 702000 132000 22000 50872000 28595000 50872000 28595000 0 0 -71769000 -48643000 -25876000 -2043000 -1779000 -1239000 -73812000 -50422000 -27115000 -15417000 -10589000 -5694000 -4886000 -3431000 -1758000 22242000 16064000 7724000 2597000 2485000 1129000 0 0 -52000 215000 307000 362000 443000 134000 547000 0 0 0 886000 344000 159000 -163000 70000 0 369000 472000 185000 1092000 EX-101.SCH 13 crnx-20201231.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100060 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Organization and Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Investment Securities link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Balance Sheet Details link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Operating Lease link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Convertible Preferred Stock link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Stockholder's Equity link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Equity Incentive Plans link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Investment Securities (Tables) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Balance Sheet Details (Tables) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Operating Lease (Tables) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Equity Incentive Plans (Tables) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Income Taxes (Tables) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Organization and Basis of Presentation - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share (Details) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Investment Securities - Summary of Available-For-Sale Investment Securities Held by the Company (Details) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Investment Securities - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on Recurring Basis (Details) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Fair Value Measurements - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Balance Sheet Details - Components of Prepaid Expenses and Other Current Assets (Details) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Balance Sheet Details - Components of Property and Equipment, Net (Details) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Balance Sheet Details - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Operating Lease - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Operating Lease - Schedule of Future Minimum Payments Under Non-cancellable Operating Leases (Details) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Operating Lease - Schedule of Future Minimum Payments Under Non-cancellable Operating Leases (Details)2 link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Convertible Preferred Stock - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Stockholder's Equity - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Equity Incentive Plans - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Equity Incentive Plans - Summary of Activity Under Stock Option Plans (Details) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Equity Incentive Plans - Weighted Average Assumptions Used to Estimate Fair Value of Stock Options Granted to Employees (Details) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Equity Incentive Plans - Stock-based Compensation Expense Recognized (Details) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Income Taxes - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)2 link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Income Taxes - Schedule of Domestic and Foreign Pre-Tax Loss (Details) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense (Details) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 14 crnx-20201231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 15 crnx-20201231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 16 crnx-20201231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Deferred tax liabilities right-of-use asset. Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Well-known Seasoned Issuer Entity Well Known Seasoned Issuer Entity Current Reporting Status Entity Current Reporting Status Entity Voluntary Filers Entity Voluntary Filers Entity Filer Category Entity Filer Category Entity Shell Company Entity Shell Company Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity Public Float Entity Public Float Entity Interactive Data Current Entity Interactive Data Current Title of 12(b) Security Security12b Title Security Exchange Name Security Exchange Name Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Document Annual Report Document Annual Report Document Transition Report Document Transition Report ICFR Auditor Attestation Flag Icfr Auditor Attestation Flag Accrued compensation and related expense. Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Investment securities Short Term Investments Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Property and equipment, net Property Plant And Equipment Net Operating lease right-of-use asset Operating Lease Right Of Use Asset Restricted cash Restricted Cash Noncurrent Other assets Other Assets Noncurrent Total assets Assets Liabilities and Stockholders’ Equity Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable and accrued expenses Accounts Payable And Accrued Liabilities Current Accrued compensation and related expenses Accrued Compensation And Related Expense Other current liabilities Other Liabilities Current Total current liabilities Liabilities Current Operating lease liability, non-current Operating Lease Liability Noncurrent Unvested stock liability Deferred Compensation Liability Classified Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 7) Commitments And Contingencies Stockholders’ equity: Stockholders Equity [Abstract] Preferred stock, $0.001 par; 10,000 shares authorized, no shares issued or outstanding at December 31, 2020 or 2019 Preferred Stock Value Common stock and paid-in capital, $0.001 par; 200,000 shares authorized, 33,017 and 33,001 shares issued and outstanding at December 31, 2020; 24,296 and 24,263 shares issued and outstanding at December 31, 2019 Common Stocks Including Additional Paid In Capital Accumulated other comprehensive income Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders’ equity Stockholders Equity Total liabilities and stockholders’ equity Liabilities And Stockholders Equity Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized Preferred Stock Shares Authorized Preferred stock, shares issued Preferred Stock Shares Issued Preferred stock, shares outstanding Preferred Stock Shares Outstanding Common stock and paid-in capital, par value Common Stock Par Or Stated Value Per Share Common stock and paid-in capital, shares authorized Common Stock Shares Authorized Common stock and paid-in capital, shares issued Common Stock Shares Issued Common stock and paid-in capital, shares outstanding Common Stock Shares Outstanding Other income (expense). Income Statement [Abstract] Grant revenues Revenue From Contract With Customer Excluding Assessed Tax Type of Revenue Extensible List Type Of Revenue Extensible List Operating expenses: Operating Expenses [Abstract] Research and development Research And Development Expense General and administrative General And Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income Loss Other income (expense): Nonoperating Income Expense [Abstract] Interest income Investment Income Interest Other income (expense), net Other Income Expense Total other income, net Nonoperating Income Expense Net loss Net Income Loss Other comprehensive income (loss): Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract] Unrealized gain (loss) on investment securities Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Comprehensive loss Comprehensive Income Net Of Tax Net loss per share: Earnings Per Share Basic And Diluted [Abstract] Net loss per share - basic and diluted Earnings Per Share Basic And Diluted Weighted average shares - basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Temporary equity stock issued during period shares new issues. Vesting of shares of common stock value subject to repurchase. Statement Of Stockholders Equity [Abstract] Statement [Table] Statement [Table] Accumulated Other Comprehensive Income Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock Common Stock [Member] Common stock and Paid-In Capital Common Stock Including Additional Paid In Capital [Member] Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income [Member] Accumulated Deficit Retained Earnings [Member] Class of Stock Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] Convertible Preferred Stock Convertible Preferred Stock [Member] Series B convertible preferred stock. Series B Convertible Preferred Stock Series B Convertible Preferred Stock [Member] Statement [Line Items] Statement [Line Items] Temporary equity, Beginning Balance Temporary Equity Carrying Amount Attributable To Parent Temporary equity, Beginning Balance, Shares Temporary Equity Shares Outstanding Beginning Balance, Shares Shares Outstanding Beginning Balance Temporary equity, Issuance of convertible preferred stock, net of costs Temporary Equity Stock Issued During Period Value New Issues Temporary equity, Issuance of convertible preferred stock, net of costs, shares Temporary Equity Stock Issued During Period Shares New Issues Conversion of preferred stock into common stock Stock Issued During Period Value Conversion Of Convertible Securities Conversion of preferred stock into common stock, shares Stock Issued During Period Shares Conversion Of Convertible Securities Issuance of common stock, net of transaction costs Stock Issued During Period Value New Issues Issuance of common stock, net of transaction costs, shares Stock Issued During Period Shares New Issues Vesting of shares subject to repurchase Vesting Of Shares Of Common Stock Value Subject To Repurchase Vesting of shares of common stock shares subject to repurchase. Vesting of shares subject to repurchase, shares Vesting Of Shares Of Common Stock Shares Subject To Repurchase Exercise of stock options Stock Issued During Period Value Stock Options Exercised Exercise of stock options, shares Stock Issued During Period Shares Stock Options Exercised Stock issued under Stock Purchase Plan Stock Issued During Period Value Employee Stock Purchase Plan Issuance of stock under Stock Purchase Plan, shares Stock Issued During Period Shares Employee Stock Purchase Plans Stock-based compensation Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Comprehensive income (loss) Other Comprehensive Income Loss Net Of Tax Net loss Ending Balance Ending Balance, Shares Temporary equity, Ending Balance Temporary equity, Ending Balance, Shares Temporary equity stock issuance costs. Temporary equity convertible preferred stock issuance costs Temporary Equity Stock Issuance Costs Non cash lease expense. Increase (decrease) in operating lease liabilities Payments for repurchase of unvested shares. PurchaseofSharesPursuanttoEmployeeStockPurchasePlan. Change in unvested stock liability. Tenant improvement allowance. Statement Of Cash Flows [Abstract] Operating activities: Net Cash Provided By Used In Operating Activities [Abstract] Reconciliation of net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Stock-based compensation Share Based Compensation Depreciation and amortization Depreciation And Amortization Noncash lease expense Non Cash Lease Expense Accretion of purchase discounts and amortization of premiums on investment securities, net Accretion Amortization Of Discounts And Premiums Investments Other, net Other Noncash Income Expense Increase (decrease) in cash resulting from changes in: Increase Decrease In Operating Capital [Abstract] Prepaid expenses and other assets Increase Decrease In Prepaid Deferred Expense And Other Assets Accounts payable and accrued expenses Increase Decrease In Accounts Payable And Accrued Liabilities Operating lease liability Increase Decrease In Operating Lease Liabilities Deferred rent Increase Decrease In Deferred Liabilities Net cash used in operating activities Net Cash Provided By Used In Operating Activities Investing activities: Net Cash Provided By Used In Investing Activities [Abstract] Purchases of investment securities Payments To Acquire Available For Sale Securities Debt Maturities of investment securities Proceeds From Sale And Maturity Of Available For Sale Securities Purchases of property and equipment Payments To Acquire Property Plant And Equipment Net cash provided by (used in) investing activities Net Cash Provided By Used In Investing Activities Financing activities: Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from issuance of convertible preferred stock, net of transaction costs Proceeds From Issuance Of Convertible Preferred Stock Proceeds from issuance of common stock, net of transaction costs Proceeds From Issuance Of Common Stock Proceeds from exercise of stock options Proceeds From Stock Options Exercised Repurchase of unvested shares Payments For Repurchase Of Unvested Shares Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Net change in cash, cash equivalents and restricted cash Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Cash, cash equivalents and restricted cash - beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Cash, cash equivalents and restricted cash - end of period Components of cash, cash equivalents and restricted cash: Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract] Restricted cash Restricted Cash Non-cash financing activity: Noncash Investing And Financing Items [Abstract] Stock issued under Stock Purchase Plan Purchase Of Shares Pursuant To Employee Stock Purchase Plan Amounts accrued for purchases of property and equipment Capital Expenditures Incurred But Not Yet Paid Change in unvested stock liability Change In Unvested Stock Liability Tenant improvement allowance Tenant Improvement Allowance Documents Incorporated by Reference Documents Incorporated By Reference [Text Block] Organization Consolidation And Presentation Of Financial Statements [Abstract] Organization and Basis of Presentation Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] Accounting Policies [Abstract] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Investments Debt And Equity Securities [Abstract] Investment Securities Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Balance Sheet Details Supplemental Balance Sheet Disclosures [Text Block] Leases [Abstract] Operating Lease Lessee Operating Leases [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Temporary equity disclosure. Temporary Equity Disclosure [Abstract] Convertible Preferred Stock Temporary Equity Disclosure [Text Block] Stockholders Equity Note [Abstract] Stockholders' Equity Stockholders Equity Note Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Equity Incentive Plans Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Description of Business. Description of Business Description Of Business Policy [Text Block] Principles of Consolidation and Foreign Currency Transactions Foreign Currency Transactions And Translations Policy [Text Block] Segment Reporting Segment Reporting Policy Policy [Text Block] Liquidity and going concern. Liquidity and Going Concern Liquidity And Going Concern Policy [Text Block] Unusual Or Infrequent Items Covid19 Pandemic Policy Text Block. COVID-19 Unusual Or Infrequent Items Covid19 Pandemic Policy [Text Block] Use of Estimates Use Of Estimates Fair Value Measurements Fair Value Measurement Policy Policy [Text Block] Cash, Cash Equivalents and Restricted Cash Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy Disclosure of accounting policy for short term investments. Investment Securities Short Term Investments Policy Policy [Text Block] Concentrations of Credit Risk Concentration Risk Credit Risk Leases policy Leases Leases Policy [Text Block] Property and Equipment, Net Property Plant And Equipment Policy [Text Block] Impairment of Long-Lived Assets Impairment Or Disposal Of Long Lived Assets Policy [Text Block] Deferred rent. Deferred Rent Deferred Rent Policy [Text Block] Disclosure of accounting policy for grant revenue recognition. Grant Revenue Recognition Grant Revenue Recognition Policy [Text Block] Research and Development Expense Research And Development Expense Policy Foreign research and development tax incentive. Australian Tax Incentive Foreign Research And Development Tax Incentive Policy Policy [Text Block] Stock-Based Compensation Share Based Compensation Option And Incentive Plans Policy Income Taxes Income Tax Policy [Text Block] Comprehensive Loss Comprehensive Income Policy Policy [Text Block] Net Loss Per Share Earnings Per Share Policy [Text Block] Recent Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Summary of Available-For-Sale Investment Securities Held by the Company Schedule Of Available For Sale Securities Reconciliation Table [Text Block] Schedule of Financial Assets Measured at Fair Value on Recurring Basis Fair Value Assets Measured On Recurring Basis [Text Block] Components of Prepaid Expenses and Other Current Assets Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block] Components of Property and Equipment, Net Property Plant And Equipment [Text Block] Schedule of Future Minimum Payments Under Non-cancellable Operating Leases Operating Leases Of Lessee Disclosure [Text Block] Summary of Activity Under Stock Option Plans Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Weighted Average Assumptions Used to Estimate Fair Value of Stock Options Granted to Employees Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Summary of Stock-based Compensation Expense for the Equity Awards Issued to Employees and Non-Employees Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Schedule of Deferred Tax Assets and Liabilities Schedule Of Deferred Tax Assets And Liabilities Table [Text Block] Schedule of Domestic and Foreign Pre-Tax Loss Schedule Of Income Before Income Tax Domestic And Foreign Table [Text Block] Schedule of Reconciliation of Income Tax Expense Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block] Schedule of Unrecognized Tax Benefits Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block] Organization and basis of presentation. Organization and basis of presentation. Organization And Basis Of Presentation [Table] Organization And Basis Of Presentation [Table] Statistical Measurement Range [Axis] Statistical Measurement Range [Member] Minimum Minimum [Member] Maximum [Member] Maximum [Member] Organization And Basis Of Presentation [Line Items] Organization And Basis Of Presentation [Line Items] Stock reverse stock split Stockholders Equity Reverse Stock Split Stock split conversion ratio Stockholders Equity Note Stock Split Conversion Ratio1 Number of operating segments Number Of Operating Segments Period of sufficient cash to meet its funding requirements. Unrestricted cash, cash equivalents and investments securities Cash Cash Equivalents And Short Term Investments Period of sufficient cash to meet its funding requirements Period Of Sufficient Cash To Meet Its Funding Requirements Accumulated deficit Summary of significant accounting policies. Summary of Significant accounting policies. Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Long-Lived Tangible Asset Property Plant And Equipment By Type [Axis] Long-Lived Tangible Asset Property Plant And Equipment Type [Domain] Lab Equipment Equipment [Member] Office Equipment Office Equipment [Member] Computer and software. Computer and Software Computer And Software [Member] Balance Sheet Location Balance Sheet Location [Axis] Balance Sheet Location Balance Sheet Location [Domain] Accounts Payable And Accrued Expenses Accounts Payable And Accrued Liabilities [Member] Research and Development Arrangement, Contract to Perform for Others, Type Research And Development Arrangement Contract To Perform For Others By Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type Research And Development Arrangement Contract To Perform For Others Type [Domain] Australian research and development tax incentive program. Australian Research and Development Tax Incentive Australian Research And Development Tax Incentive Program [Member] Income Tax Authority, Name Income Tax Authority Name [Axis] Income Tax Authority, Name Income Tax Authority Name [Domain] Australian Taxation Office Australian Taxation Office [Member] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Property and equipment, estimated useful life Property Plant And Equipment Useful Life Impairment losses of long-lived assets Impairment Of Long Lived Assets Held For Use Accrued research and development expenses. Accrued R&D expenses Accrued Research And Development Expenses Tax incentive receivable reduction in research and development expense. Tax incentive receivable, reductions to research and development expense Tax Incentive Receivable Reduction In Research And Development Expense Earnings Per Share [Abstract] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Securities Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities, Name Antidilutive Securities Name [Domain] Common Stock Option Stock Option [Member] Unvested common stock subject to repurchase. Unvested Common Stock Subject To Repurchase Unvested Common Stock Subject To Repurchase [Member] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Potentially dilutive securities excluded from calculation of diluted net loss per share Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Debt Securities Available For Sale [Table] Debt Securities Available For Sale [Table] Investment Type Investment Type [Axis] Investments Investment Type Categorization [Member] U.S. Government and Agency Obligations U S Government Agencies Debt Securities [Member] Certificates of Deposit Certificates Of Deposit [Member] Commercial Paper Commercial Paper [Member] Corporate Debt Securities Corporate Debt Securities [Member] Schedule Of Available For Sale Securities [Line Items] Schedule Of Available For Sale Securities [Line Items] Available-for-sale investment securities, Amortized Cost Available For Sale Debt Securities Amortized Cost Basis Available-for-sale investment securities, Gross Unrealized Gains Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Available-for-sale investment securities, Gross Unrealized Losses Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Available-for-sale investment securities, Fair Market Value Available For Sale Securities Debt Securities Available-for-sale investment securities maturity period, maximum Debt Securities Available For Sale Term Available-for-sale, unrealized loss position, twelve month or more Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Table] Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Table] Asset Class Fair Value By Asset Class [Axis] Asset Class Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] Measurement Frequency Fair Value By Measurement Frequency [Axis] Measurement Frequency Fair Value Measurement Frequency [Domain] Fair Value, Measurements, Recurring Fair Value Measurements Recurring [Member] Fair Value Hierarchy and NAV Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Level 1 Fair Value Inputs Level1 [Member] Level 2 Fair Value Inputs Level2 [Member] Level 3 Fair Value Inputs Level3 [Member] Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Total assets measured at fair value Assets Fair Value Disclosure Fair value assets transferred into level 3 Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 Fair value assets transferred into level 3 Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 Fair value assets transferred into level 3 Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 Fair value assets transferred into level 3 Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 Amount of consideration paid in advance for research and development that provides economic benefits within a future period of one year or the normal operating cycle, if longer. Foreign tax incentive receivable, current. Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract] Prepaid research and development costs Prepaid Research And Development Costs Current Australian tax incentive receivable Foreign Tax Incentive Receivable Current Prepaid insurance Prepaid Insurance Interest receivable Interest Receivable Current Prepaid expenses and other assets Other Assets Current Total Property Plant And Equipment [Abstract] Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Leasehold Improvements Leasehold Improvements [Member] Computers and Software Computer Equipment [Member] Property Plant And Equipment [Line Items] Property Plant And Equipment [Line Items] Property and equipment at cost Property Plant And Equipment Gross Less accumulated depreciation and amortization Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Total Depreciation expense Depreciation Operating lease expiration period. Schedule Of Operating Leased Assets [Table] Schedule Of Operating Leased Assets [Table] Lease Contractual Term Lease Contractual Term [Axis] Lease Contractual Term Lease Contractual Term [Domain] 2018 Operating lease. 2018 Operating Lease Two Thousand Eighteen Operating Lease [Member] Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Operating lease, initial term Lessee Operating Lease Term Of Contract Operating lease expiration period Operating Lease Expiration Period Operating lease, option to extend term Lessee Operating Lease Option To Extend Lessee,operating lease, discount rate Lessee Operating Lease Discount Rate Irrevocable letter of credit Letters Of Credit Outstanding Amount 2021 Lessee Operating Lease Liability Payments Due Next Twelve Months 2022 Lessee Operating Lease Liability Payments Due Year Two 2023 Lessee Operating Lease Liability Payments Due Year Three 2024 Lessee Operating Lease Liability Payments Due Year Four 2025 Lessee Operating Lease Liability Payments Due Year Five Total future minimum lease payments Lessee Operating Lease Liability Payments Due Less imputed interest Lessee Operating Lease Liability Undiscounted Excess Amount Total operating lease liability Operating Lease Liability Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Operating Lease Liability Current Statement Of Financial Position Extensible List Less operating lease liability, current Operating Lease Liability Current Total operating lease liabilities Rent expense Operating Leases Rent Expense Net Cash paid for operating lease liabilities Operating Lease Payments Temporary Equity By Class Of Stock [Table] Temporary Equity By Class Of Stock [Table] Series A convertible preferred stock. Series A Convertible Preferred Stock Series A Convertible Preferred Stock [Member] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] Initial Public Offering I P O [Member] Series A and B convertible preferred stock. Series A and B Convertible Preferred Stock Series A And B Convertible Preferred Stock [Member] Temporary Equity [Line Items] Temporary Equity [Line Items] Convertible preferred stock, shares issued Temporary Equity Shares Issued Net proceeds from issuance of convertible preferred stock Convertible preferred stock, issuance costs Payments Of Stock Issuance Costs Stock issued upon conversion of convertible securities Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table] Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table] Initial Public Offering Counterparty Name Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] SVB Leerink LLC and Cantor Fitzgerald & Co. SVB Leerink LLC and Cantor Fitzgerald & Co. S V B Leerink L L C And Cantor Fitzgerald Co [Member] At-the-market offering. ATM Offering At The Market Offering [Member] Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] Stock restriction agreement. Stock Restriction Agreement Stock Restriction Agreement [Member] Subsidiary Sale Of Stock [Line Items] Subsidiary Sale Of Stock [Line Items] Common stock, shares authorized Offering discounts, commissions and offering costs, net. Sale of common stock Common stock price per share Sale Of Stock Price Per Share Proceeds from issuance initial public offering Proceeds From Issuance Initial Public Offering Offering discounts commissions and offering costs net Offering Discounts Commissions And Offering Costs Net Common stock price per share Proceeds from issuance of common stock, net Maximum amount of common stock preferred stock debt securities warrants and units to be issued. Maximum amount of common stock preferred stock debt securities warrants and units to be issued Maximum Amount Of Common Stock Preferred Stock Debt Securities Warrants And Units To Be Issued Registration statement effective date Document Effective Date Sale of common stock at offering price Sale Of Stock Consideration Received On Transaction Share based compensation arrangement by share based payment award shares of common stock to be lapsed per month thereafter. Unrestricted shares of common stock repurchased Employee Service Share Based Compensation Estimated Quantity Of Shares To Be Repurchased In Following Period Common stock repurchase rights lapsed Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations Common stock repurchase rights to be lapsed monthly thereafter till fully vested in October 2019 Share Based Compensation Arrangement By Share Based Payment Award Shares Of Common Stock To Be Lapsed Thereafter Stock-based compensation expenses Share-based compensation arrangement by share-based payment award expiration date 1. The minimum perentage of annual increase in number of shares available for issuance under share based arrangement. Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] Two thousand eighteen incentive award plan. 2018 Plan Two Thousand Eighteen Incentive Award Plan [Member] Subsequent Event Type Subsequent Event Type [Axis] Subsequent Event Type Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Two thousand fifteen stock incentive plan. 2015 Plan Two Thousand Fifteen Stock Incentive Plan [Member] ESPP Employee Stock [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Plan expiration period Share Based Compensation Arrangement By Share Based Payment Award Expiration Date1 Plan expiration term Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period Vesting period Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 Plan expiration date Share Based Compensation Arrangement By Share Based Payment Award Expiration Date Annual increase in the number of shares available for issuance Sharebased Compensation Arrangement Annual Increase In Number Of Shares Available For Issuance Minimum Percentage Remaining shares available for issuance Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Additional shares available for future issuance Common Stock Capital Shares Reserved For Future Issuance Shares issued under early-exercise provisions subject to repurchase Share Based Compensation Arrangement By Share Based Payment Award Shares To Be Repurchased Next Year Unvested stock liability Deferred Compensation Liability Current And Noncurrent Maximum percentage of eligible compensation to purchase common stock through payroll deductions Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate Shares reserved for issuance, authorized Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Additional shares available for future issuance Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized Share-based compensation arrangement by share-based payment award options forfeited and expired. Options Outstanding, Beginning balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Options Outstanding, Granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Options Outstanding, Exercised Options Outstanding, Forfeited and expired Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited And Expired Options Outstanding, Ending balance Options Outstanding,Vested and expected to vest Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number Options Exercisable, Ending balance Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Weighted-Average Exercise Price, Beginning balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Weighted-Average Exercise Price, Granted Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Weighted Average Exercise Price, Exercised Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price Weighted Average Exercise Price, Forfeited and expired Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price Weighted-Average Exercise Price, Ending balance Weighted-Average Exercise Price, Vested and expected to vest Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price Weighted-Average Exercise Price, Exercisable Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Weighted-Average Remaining Term, Ending balance Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Weighted-Average Remaining Term, Vested and expected to vest Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 Weighted-Average Remaining Term, Exercisable Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 Aggregate Intrinsic Value, Ending balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Aggregate Intrinsic Value, Vested and expected to vest Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value Aggregate Intrinsic Value, Exercisable Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 Total intrinsic value of options exercised Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value Award Type Award Type [Axis] Award Type Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Stock Options Expected option term Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 Expected volatility Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Risk free interest rate Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Expected dividend yield Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate Dividend yield Weighted-average fair value of stock options granted to employees per share Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Included in Research and Development Research And Development Expense [Member] Included in General and Administrative General And Administrative Expense [Member] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Stock-based compensation expense Allocated Share Based Compensation Expense Unrecognized stock-based compensation cost Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options Weighted-average period of unrecognized stock-based compensation cost expected to be recognized over remaining period Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 Operating loss carryforwards expiration year. Deferred tax assets tax credit carry forwards research begin to expire. Percentage of loss carryforwards offset through future taxable income. Federal loss carryforwards. Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Income Tax Authority Income Tax Authority [Axis] Income Tax Authority Income Tax Authority [Domain] Federal Domestic Country [Member] State State And Local Jurisdiction [Member] Tax Period Tax Period [Axis] Tax Period Tax Period [Domain] Earliest Tax Year Earliest Tax Year [Member] Geographical Statement Geographical [Axis] Geographical Segment Geographical [Domain] California CALIFORNIA Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Federal operating loss carryforwards Deferred Tax Assets Operating Loss Carryforwards Domestic State operating loss carryforwards Deferred Tax Assets Operating Loss Carryforwards State And Local Domestic operating loss carryforwards Deferred Tax Assets Operating Loss Carryforwards Foreign Federal loss carryforwards Federal Loss Carryforwards Operating loss carryforwards, future taxable income, offset percentage Percentage Of Loss Carryforwards Offset Through Future Taxable Income Operating loss carryforwards expiration year Operating Loss Carryforwards Expiration Year Research and development credit carryforwards Deferred Tax Assets Tax Credit Carryforwards Research Research and development credit carryforwards, begin to expire Deferred Tax Assets Tax Credit Carry Forwards Research Begin To Expire Research and development credit Carryforwards, Other Deferred Tax Assets Tax Credit Carryforwards Other Period for cumulative change In ownership. Cumulative change in ownership percentage. Operating loss and research and development credit carryforwards, limitations on use Tax Credit Carryforward Limitations On Use Cumulative change in ownership percentage Cumulative Change In Ownership Percentage Period for cumulative change in ownership Period For Cumulative Change In Ownership Deferred tax assets: Components Of Deferred Tax Assets [Abstract] Net operating loss carryforwards Operating Loss Carryforwards Capitalized research expenses Deferred Tax Assets In Process Research And Development R&D and other tax credits Stock-based compensation Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost Lease liability Deferred Tax Liabilities Leasing Arrangements Accrued expenses and other, net Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities Total deferred tax assets Deferred Tax Assets Gross Deferred tax liabilities: Components Of Deferred Tax Liabilities [Abstract] Right-of use asset Deferred Tax Liabilities Right Of Use Asset Other deferred tax liabilities Deferred Tax Liabilities Other Net of deferred tax assets and liabilities Deferred Tax Assets Liabilities Net Less: valuation allowance Deferred Tax Assets Valuation Allowance Net deferred tax assets Deferred Tax Assets Net Loss before income taxes - Domestic Income Loss From Continuing Operations Before Income Taxes Domestic Loss before income taxes - Foreign Income Loss From Continuing Operations Before Income Taxes Foreign Loss before income taxes - Consolidated Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Expected income tax benefit at federal statutory rate Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate State income tax benefit, net of federal benefit Income Tax Reconciliation State And Local Income Taxes Change in valuation allowance Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance R&D credit Income Tax Reconciliation Tax Credits Research Federal rate change Income Tax Reconciliation Change In Enacted Tax Rate Australian tax incentive Income Tax Reconciliation Tax Settlements Foreign Other Income Tax Reconciliation Other Adjustments Provision for income taxes Income Tax Expense Benefit Unrecognized tax benefits increase decrease resulting from prior period tax positions. Beginning balance Unrecognized Tax Benefits Increase (decrease) for prior year tax positions Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions Increase (decrease) for current year tax positions Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions Ending balance EX-101.PRE 17 crnx-20201231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 18 R1.htm IDEA: XBRL DOCUMENT v3.21.1

Document and Entity Information - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2020

Feb. 26, 2021

Jun. 30, 2020

Cover [Abstract]

Document Type 10-K

Amendment Flag false

Document Period End Date Dec. 31, 2020

Document Fiscal Year Focus 2020

Document Fiscal Period Focus FY

Trading Symbol CRNX

Entity Registrant Name Crinetics Pharmaceuticals, Inc.

Entity Central Index Key 0001658247

Current Fiscal Year End Date --12-31

Entity Well-known Seasoned Issuer No

Entity Current Reporting Status Yes

Entity Voluntary Filers No

Entity Filer Category Non-accelerated Filer

Entity Shell Company false

Entity Small Business true

Entity Emerging Growth Company true

Entity Ex Transition Period true

Entity Common Stock, Shares Outstanding 33,028,876

Entity Public Float $ 505.7

Entity Interactive Data Current Yes

Title of 12(b) Security Common Stock, par value $0.001 per share

Security Exchange Name NASDAQ

Entity File Number 001-38583

Entity Incorporation, State or Country Code DE

Entity Tax Identification Number 26-3744114

Entity Address, Address Line One 10222 Barnes Canyon Road

Entity Address, Address Line Two Bldg. #2

Entity Address, City or Town San Diego

Entity Address, State or Province CA

Entity Address, Postal Zip Code 92121

City Area Code 858

Local Phone Number 450-6464

Document Annual Report true

Document Transition Report false

ICFR Auditor Attestation Flag true

Documents Incorporated by Reference
DOCUMENTS INCORPORATED BY REFERENCE

Certain sections of the registrant’s definitive proxy statement for the 2021 annual meeting of stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after end of the fiscal year covered by this Form 10-K are incorporated by reference into Part III of this Form 10-K.

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Area code of city
+ References
No definition available.
+ Details

Name: dei_CityAreaCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Cover page.
+ References
No definition available.
+ Details

Name: dei_CoverAbstract

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true only for a form used as an annual report.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 10-K
-Number 249
-Section 310

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 20-F
-Number 249
-Section 220
-Subsection f

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 40-F
-Number 249
-Section 240
-Subsection f
+ Details

Name: dei_DocumentAnnualReport

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true only for a form used as a transition report.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Forms 10-K, 10-Q, 20-F
-Number 240
-Section 13
-Subsection a-1
+ Details

Name: dei_DocumentTransitionReport

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
Documents incorporated by reference.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-23
+ Details

Name: dei_DocumentsIncorporatedByReferenceTextBlock

Namespace Prefix: dei_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine1

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine2

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the City or Town
+ References
No definition available.
+ Details

Name: dei_EntityAddressCityOrTown

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details

Name: dei_EntityAddressPostalZipCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the state or province.
+ References
No definition available.
+ Details

Name: dei_EntityAddressStateOrProvince

Namespace Prefix: dei_

Data Type: dei:stateOrProvinceItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details

Name: dei_EntityExTransitionPeriod

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.
+ References
No definition available.
+ Details

Name: dei_EntityPublicFloat

Namespace Prefix: dei_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityTaxIdentificationNumber

Namespace Prefix: dei_

Data Type: dei:employerIdItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
No definition available.
+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
No definition available.
+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 10-K
-Number 249
-Section 310

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 20-F
-Number 249
-Section 220
-Subsection f

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 40-F
-Number 249
-Section 240
-Subsection f
+ Details

Name: dei_IcfrAuditorAttestationFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Local phone number for entity.
+ References
No definition available.
+ Details

Name: dei_LocalPhoneNumber

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details

Name: dei_Security12bTitle

Namespace Prefix: dei_

Data Type: dei:securityTitleItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details

Name: dei_SecurityExchangeName

Namespace Prefix: dei_

Data Type: dei:edgarExchangeCodeItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: dei:tradingSymbolItemType

Balance Type: na

Period Type: duration

XML 19 R2.htm IDEA: XBRL DOCUMENT v3.21.1

Consolidated Balance Sheets - USD ($)
$ in Thousands

Dec. 31, 2020

Dec. 31, 2019

Current assets:

Cash and cash equivalents $ 93,087 $ 40,326

Investment securities 77,793 78,066

Prepaid expenses and other current assets 6,612 4,947

Total current assets 177,492 123,339

Property and equipment, net 3,181 3,946

Operating lease right-of-use asset 2,232 2,510

Restricted cash 500 500

Other assets 40 82

Total assets 183,445 130,377

Current liabilities:

Accounts payable and accrued expenses 5,588 5,498

Accrued compensation and related expenses 4,066 2,118

Other current liabilities 835 724

Total current liabilities 10,489 8,340

Operating lease liability, non-current 4,014 4,849

Unvested stock liability 23 49

Total liabilities 14,526 13,238

Commitments and contingencies (Note 7)

Stockholders’ equity:

Preferred stock, $0.001 par; 10,000 shares authorized, no shares issued or outstanding at December 31, 2020 or 2019

Common stock and paid-in capital, $0.001 par; 200,000 shares authorized, 33,017 and 33,001 shares issued and outstanding at December 31, 2020; 24,296 and 24,263 shares issued and outstanding at December 31, 2019 336,508 210,793

Accumulated other comprehensive income 25 148

Accumulated deficit (167,614) (93,802)

Total stockholders’ equity 168,919 117,139

Total liabilities and stockholders’ equity $ 183,445 $ 130,377

X

- Definition
Accrued compensation and related expense.
+ References
No definition available.
+ Details

Name: crnx_AccruedCompensationAndRelatedExpense

Namespace Prefix: crnx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(4))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(3))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of par value plus amounts in excess of par value or issuance value for common stock issued.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770
+ Details

Name: us-gaap_CommonStocksIncludingAdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).
+ References
No definition available.
+ Details

Name: us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of noncurrent assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 210
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580
+ Details

Name: us-gaap_RestrictedCashNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(4))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(5))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1)(g))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 20 R3.htm IDEA: XBRL DOCUMENT v3.21.1

Consolidated Balance Sheets (Parenthetical) - $ / shares

Dec. 31, 2020

Dec. 31, 2019

Statement Of Financial Position [Abstract]

Preferred stock, par value $ 0.001 $ 0.001

Preferred stock, shares authorized 10,000,000 10,000,000

Preferred stock, shares issued 0 0

Preferred stock, shares outstanding 0 0

Common stock and paid-in capital, par value $ 0.001 $ 0.001

Common stock and paid-in capital, shares authorized 200,000,000 200,000,000

Common stock and paid-in capital, shares issued 33,017,000 24,296,000

Common stock and paid-in capital, shares outstanding 33,001,000 24,263,000

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 21 R4.htm IDEA: XBRL DOCUMENT v3.21.1

Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Income Statement [Abstract]

Grant revenues $ 71 $ 1,193 $ 2,428

Type of Revenue Extensible List us-gaap:GrantMember us-gaap:GrantMember us-gaap:GrantMember

Operating expenses:

Research and development $ 56,998 $ 41,506 $ 24,479

General and administrative 18,026 13,519 6,659

Total operating expenses 75,024 55,025 31,138

Loss from operations (74,953) (53,832) (28,710)

Other income (expense):

Interest income 991 3,460 1,748

Other income (expense), net 150 (50) (153)

Total other income, net 1,141 3,410 1,595

Net loss (73,812) (50,422) (27,115)

Other comprehensive income (loss):

Unrealized gain (loss) on investment securities (123) 87 61

Comprehensive loss $ (73,935) $ (50,335) $ (27,054)

Net loss per share:

Net loss per share - basic and diluted $ (2.42) $ (2.09) $ (2.23)

Weighted average shares - basic and diluted 30,448 24,175 12,142

X

- Definition
Other income (expense).
+ References
No definition available.
+ Details

Name: crnx_OtherIncomeExpense

Namespace Prefix: crnx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(22))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(24))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(26))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7(b))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599
+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.
+ References
No definition available.
+ Details

Name: us-gaap_TypeOfRevenueExtensibleList

Namespace Prefix: us-gaap_

Data Type: srt-types:extensibleListItemType

Balance Type: na

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 22 R5.htm IDEA: XBRL DOCUMENT v3.21.1

Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)
$ in Thousands

Total

Convertible Preferred Stock

Series B Convertible Preferred Stock

Common Stock

Common stock and Paid-In Capital

Accumulated Other Comprehensive Income

Accumulated Deficit

Temporary equity, Beginning Balance at Dec. 31, 2017 $ 29,700

Temporary equity, Beginning Balance, Shares at Dec. 31, 2017 28,763,000

Beginning Balance, Shares at Dec. 31, 2017 1,550,000

Beginning Balance at Dec. 31, 2017 $ (15,022) $ 1,243 $ (16,265)

Temporary equity, Issuance of convertible preferred stock, net of costs $ 63,275

Temporary equity, Issuance of convertible preferred stock, net of costs, shares 19,641,000

Conversion of preferred stock into common stock 92,975 $ (92,975) 92,975

Conversion of preferred stock into common stock, shares (48,404,000) 14,713,000

Issuance of common stock, net of transaction costs 106,472 106,472

Issuance of common stock, net of transaction costs, shares 6,900,000

Vesting of shares subject to repurchase 21 21

Vesting of shares subject to repurchase, shares 541,000

Exercise of stock options 231 231

Exercise of stock options, shares 337,000

Stock issued under Stock Purchase Plan 282 282

Issuance of stock under Stock Purchase Plan, shares 20,000

Stock-based compensation 2,320 2,320

Comprehensive income (loss) 61 $ 61

Net loss (27,115) (27,115)

Ending Balance at Dec. 31, 2018 160,225 203,544 61 (43,380)

Ending Balance, Shares at Dec. 31, 2018 24,061,000

Vesting of shares subject to repurchase 94 94

Vesting of shares subject to repurchase, shares 63,000

Exercise of stock options 126 126

Exercise of stock options, shares 90,000

Stock issued under Stock Purchase Plan 735 735

Issuance of stock under Stock Purchase Plan, shares 49,000

Stock-based compensation 6,294 6,294

Comprehensive income (loss) 87 87

Net loss (50,422) (50,422)

Ending Balance at Dec. 31, 2019 117,139 210,793 148 (93,802)

Ending Balance, Shares at Dec. 31, 2019 24,263,000

Issuance of common stock, net of transaction costs 114,283 114,283

Issuance of common stock, net of transaction costs, shares 8,499,000

Vesting of shares subject to repurchase 26 26

Vesting of shares subject to repurchase, shares 17,000

Exercise of stock options $ 288 288

Exercise of stock options, shares 170,696 171,000

Stock issued under Stock Purchase Plan $ 691 691

Issuance of stock under Stock Purchase Plan, shares 51,000

Stock-based compensation 10,427 10,427

Comprehensive income (loss) (123) (123)

Net loss (73,812) (73,812)

Ending Balance at Dec. 31, 2020 $ 168,919 $ 336,508 $ 25 $ (167,614)

Ending Balance, Shares at Dec. 31, 2020 33,001,000

X

- Definition
Temporary equity stock issued during period shares new issues.
+ References
No definition available.
+ Details

Name: crnx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: crnx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Vesting of shares of common stock shares subject to repurchase.
+ References
No definition available.
+ Details

Name: crnx_VestingOfSharesOfCommonStockSharesSubjectToRepurchase

Namespace Prefix: crnx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Vesting of shares of common stock value subject to repurchase.
+ References
No definition available.
+ Details

Name: crnx_VestingOfSharesOfCommonStockValueSubjectToRepurchase

Namespace Prefix: crnx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-30)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued during the period as a result of an employee stock purchase plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The gross value of stock issued during the period upon the conversion of convertible securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of stock options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.
+ References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityCarryingAmountAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27)(b))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_TemporaryEquitySharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Value of new stock classified as temporary equity issued during the period.
+ References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 23 R6.htm IDEA: XBRL DOCUMENT v3.21.1

Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)
$ in Thousands
12 Months Ended

Dec. 31, 2018

USD ($)

Statement Of Stockholders Equity [Abstract]

Temporary equity convertible preferred stock issuance costs $ 225

X

- Definition
Temporary equity stock issuance costs.
+ References
No definition available.
+ Details

Name: crnx_TemporaryEquityStockIssuanceCosts

Namespace Prefix: crnx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfStockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 24 R7.htm IDEA: XBRL DOCUMENT v3.21.1

Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Operating activities:

Net loss $ (73,812) $ (50,422) $ (27,115)

Reconciliation of net loss to net cash used in operating activities:

Stock-based compensation 10,427 6,294 2,320

Depreciation and amortization 948 887 471

Noncash lease expense 278 226

Accretion of purchase discounts and amortization of premiums on investment securities, net (227) (1,229) (433)

Other, net (17) (4)

Increase (decrease) in cash resulting from changes in:

Prepaid expenses and other assets (1,623) (2,221) (1,802)

Accounts payable and accrued expenses 2,723 696 7,361

Operating lease liability (724) (608)

Deferred rent (261)

Net cash used in operating activities (62,027) (46,381) (19,459)

Investing activities:

Purchases of investment securities (135,592) (108,136) (118,399)

Maturities of investment securities 135,995 150,295

Purchases of property and equipment (186) (492) (1,059)

Net cash provided by (used in) investing activities 217 41,667 (119,458)

Financing activities:

Proceeds from issuance of convertible preferred stock, net of transaction costs 63,275

Proceeds from issuance of common stock, net of transaction costs 114,283 106,472

Proceeds from exercise of stock options 288 126 451

Repurchase of unvested shares (59)

Net cash provided by financing activities 114,571 67 170,198

Net change in cash, cash equivalents and restricted cash 52,761 (4,647) 31,281

Cash, cash equivalents and restricted cash - beginning of period 40,826 45,473 14,192

Cash, cash equivalents and restricted cash - end of period 93,587 40,826 45,473

Components of cash, cash equivalents and restricted cash:

Cash and cash equivalents 93,087 40,326 44,973

Restricted cash 500 500 500

Cash, cash equivalents and restricted cash - end of period 93,587 40,826 45,473

Non-cash financing activity:

Stock issued under Stock Purchase Plan 691 735 282

Amounts accrued for purchases of property and equipment 6 112 42

Change in unvested stock liability $ 26 $ 94 21

Tenant improvement allowance $ 3,304

X

- Definition
Change in unvested stock liability.
+ References
No definition available.
+ Details

Name: crnx_ChangeInUnvestedStockLiability

Namespace Prefix: crnx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Increase (decrease) in operating lease liabilities
+ References
No definition available.
+ Details

Name: crnx_IncreaseDecreaseInOperatingLeaseLiabilities

Namespace Prefix: crnx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Non cash lease expense.
+ References
No definition available.
+ Details

Name: crnx_NonCashLeaseExpense

Namespace Prefix: crnx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Payments for repurchase of unvested shares.
+ References
No definition available.
+ Details

Name: crnx_PaymentsForRepurchaseOfUnvestedShares

Namespace Prefix: crnx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
PurchaseofSharesPursuanttoEmployeeStockPurchasePlan.
+ References
No definition available.
+ Details

Name: crnx_PurchaseOfSharesPursuantToEmployeeStockPurchasePlan

Namespace Prefix: crnx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Tenant improvement allowance.
+ References
No definition available.
+ Details

Name: crnx_TenantImprovementAllowance

Namespace Prefix: crnx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Future cash outflow to pay for purchases of fixed assets that have occurred.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586
+ Details

Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInDeferredLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_OtherNoncashIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562
+ Details

Name: us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562
+ Details

Name: us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow from exercise of option under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(1)(a))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(2))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910
+ Details

Name: us-gaap_RestrictedCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 25 R8.htm IDEA: XBRL DOCUMENT v3.21.1

Organization and Basis of Presentation
12 Months Ended

Dec. 31, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Organization and Basis of Presentation
1. ORGANIZATION AND BASIS OF PRESENTATION

Description of Business

Crinetics Pharmaceuticals, Inc. (the “Company”) is a clinical-stage pharmaceutical company incorporated in Delaware on November 18, 2008 and based in San Diego, California. The Company is focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. In January 2017, the Company established a wholly-owned Australian subsidiary, Crinetics Australia Pty Ltd (“CAPL”), in order to conduct various preclinical and clinical activities for its development candidates.

On July 6, 2018, the Company effected a 1-for-3.29 reverse stock split of its common stock. The par value and the authorized shares of the common stock were not adjusted as a result of the reverse stock split. The reverse stock split resulted in an adjustment to the conversion prices of the Company’s Series A and B preferred stock to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying consolidated financial statements and notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented.

Principles of Consolidation and Foreign Currency Transactions

The consolidated financial statements include the accounts of the Company and CAPL. All intercompany accounts and transactions have been eliminated in consolidation. The functional currency of both the Company and CAPL is the U.S. dollar. Assets and liabilities that are not denominated in the functional currency are remeasured into U.S. dollars at foreign currency exchange rates in effect at the balance sheet date except for nonmonetary assets, which are remeasured at historical foreign currency exchange rates in effect at the date of transaction. Net realized and unrealized gains and losses from foreign currency transactions and remeasurement are reported in other income (expense), in the consolidated statements of operations and were not material for all periods presented.

Segment Reporting

Operating segments are identified as components of an enterprise about which discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.

Liquidity and Going Concern

From inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting preclinical studies and clinical trials. The Company has a limited operating history and the sales and income potential of the Company’s business and market are unproven. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company’s cost structure.

As of December 31, 2020, the Company had $170.9 million in unrestricted cash, cash equivalents and investment securities. The Company believes it has sufficient cash to meet its funding requirements for at least the next 12 months from the date of issuance of these financial statements.

The Company has experienced net losses and negative cash flows from operating activities since its inception and has an accumulated deficit of $167.6 million as of December 31, 2020. The Company expects to continue to incur net losses for the foreseeable future and believes it will need to raise substantial additional capital to accomplish its business plan over the next several years. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of equity offerings, debt financings or other sources, including potential collaborations, licenses and other similar arrangements. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned programs. Any of these actions could materially harm the Company’s business, results of operations and future prospects. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future.

COVID-19

The COVID-19 pandemic has caused significant business disruption around the globe. The extent of the impact of COVID-19 on the Company's operational and financial performance will depend on certain developments, including the duration and spread of the pandemic and the impact on the Company's clinical trials, employees and vendors. In response to the spread of COVID-19, the Company has closed its offices to all but its lab and a limited number of its other personnel, while the remainder of its employees are continuing their work outside the Company’s offices. At this point, the degree to which COVID-19 may impact the Company's financial condition or future results of operations is uncertain. A prolonged outbreak could have a material adverse impact on financial results and business operations of the Company, including the timing and ability of Company to complete certain clinical trials and other efforts required to advance the development of its drug candidates and raise additional capital.

In response to the pandemic, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) was signed into law on March 27, 2020. The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer’s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The CARES Act has not had a material impact on the Company’s income tax provision for the year ended December 31, 2020.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R9.htm IDEA: XBRL DOCUMENT v3.21.1

Summary of Significant Accounting Policies
12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The Company’s consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The preparation of the Company’s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to accrued amounts receivable under the Australian research and development tax incentive program, accrued expenses and associated research and development expense, the assumptions underlying the determination of the estimated incremental borrowing rate for the determination of the Company’s operating lease right-of-use asset, and the assumptions underlying the determination of the fair value of equity awards for purposes of determining stock-based compensation. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.

Fair Value Measurements

The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level 1: Observable inputs such as quoted prices in active markets.

Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The carrying amounts of the Company’s current financial assets, restricted cash and current financial liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments.

Cash, Cash Equivalents and Restricted Cash

Cash and cash equivalents include cash held in readily available checking and money market accounts, as well as short-term debt securities with maturities of three months or less when purchased. Restricted cash represents cash held as collateral for the Company’s facility lease and is reported as a long-term asset in the accompanying consolidated balance sheets.

Investment Securities

All investments have been classified as “available-for-sale” and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities less than 12 months at the balance sheet date are considered short-term investments. Investments with contractual maturities beyond one year are also classified as short-term due to the Company’s ability to liquidate the investment for use in operations within the next 12 months.

Realized gains and losses on investment securities are included in earnings and are derived using the specific identification method for determining the cost of securities sold. The Company has not realized any significant gains or losses on sales of available-for-sale investment securities during any of the periods presented. As all the Company’s investment holdings are in the form of debt securities, unrealized gains and losses that are determined to be temporary in nature are reported as a component of accumulated other comprehensive income. A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the establishment of a new cost basis for the security. Interest income is recognized when earned and is included in investment income, as are the amortization of purchase premiums and accretion of purchase discounts on investment securities.

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investment securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.

Leases

The Company determines if an arrangement is a lease at the inception of the arrangement. Beginning January 1, 2019, leases with a term longer than 12 months that are determined to be operating leases are included in operating lease assets, accrued expenses and other current liabilities and noncurrent operating lease liabilities in the consolidated balance sheets based on the present value of the minimum lease payments called for under the arrangement. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

Property and Equipment, Net

Property and equipment consist of leasehold improvements, and lab and various other equipment. Such assets are stated at cost and depreciated on a straight-line basis over the estimated useful life of the related assets. The Company estimates its useful lives of its lab and other equipment as follows: lab equipment – three to five years; office equipment - three to five years; computer and software – three years. Leasehold improvements are amortized over the estimated useful life of the improvement or the remaining term of the associated lease.

Repairs and maintenance costs are charged to expense as incurred and expenditures that materially extend the useful lives of assets are capitalized.

Impairment of Long-Lived Assets

Long-lived assets consist of property and equipment. An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. The Company has not recognized any impairment losses in any of the periods presented in these consolidated financial statements.

Deferred Rent

The Company’s facility lease includes incentives in the form of rent abatements and leasehold improvement allowances, as well as fixed annual rent escalations. The Company recognizes the aggregate rental expense, after considering incentives and stipulated rent escalations, on a straight-line basis over the lease term. Prior to January 1, 2019, the difference between rent expense and amounts paid under the lease was recorded as deferred rent.

Grant Revenue Recognition

The Company’s grant revenues are derived from Small Business Innovation Research Grants (“SBIR Grants”) from the National Institutes of Health. The Company recognizes SBIR Grant revenue as reimbursable grant costs are incurred up to pre-approved award limits within the budget period. The costs associated with these reimbursements are reflected as a component of research and development expense in the accompanying consolidated statements of operations. Earnings in excess of billings are included as a component of prepaid expenses and other current assets.

Research and Development Expenses

Research and development (“R&D”) expenses consist primarily of salaries, payroll taxes, employee benefits and stock-based compensation for individuals involved in R&D efforts, as well as consulting expenses, third-party R&D expenses, laboratory supplies, clinical materials and overhead, including facilities and depreciation costs, offset by the Australian Tax Incentive discussed below. R&D expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in R&D are capitalized until the goods or services are received. Costs incurred under contracts with contract research organizations that conduct and manage the Company’s clinical trials are also included in research and development expenses. The financial terms and activities of these agreements vary from contract to contract and may result in uneven expense levels. Generally, these agreements set forth activities that drive the recording of expenses such as start-up and initiation activities, enrollment and treatment of patients, or the completion of other clinical trial activities. Expenses related to clinical trials are accrued based on estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the amounts that the Company is obligated to pay under its clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the Company adjusts its accruals accordingly on a prospective basis. Revisions to contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain.

Accrued R&D expenses totaled $2.1 million and $2.8 million as of December 31, 2020 and 2019, respectively, and are a component of accounts payable and accrued expenses in the consolidated balance sheets.

Australian Tax Incentive

CAPL is eligible to obtain a cash refund from the Australian Taxation Office for eligible R&D expenditures under the Australian R&D Tax Incentive Program (the “Australian Tax Incentive”). The Australian Tax Incentive is recognized as a reduction to R&D expense when there is reasonable assurance that the relevant expenditure has been incurred, the amount can be reliably measured and that the Australian Tax Incentive will be received. The Company recognized reductions to R&D expense of $0.6 million, $1.0 million and $1.2 million for the years ended December 31, 2020, 2019 and 2018, respectively.

Stock-Based Compensation

Stock-based compensation expense represents the estimated grant date fair value of the Company’s equity awards, consisting of stock options and shares issued under the Company’s Employee Stock Purchase Plan, recognized over the requisite service period of such awards (usually the vesting period) on a straight-line basis. The Company estimates the fair value of equity awards using the Black-Scholes option pricing model on the date of grant and recognizes forfeitures as they occur. For stock awards for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable, or the performance condition has been achieved.

Income Taxes

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.

The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense, and any accrued interest and penalties would be included within the related tax liability. No such costs were recorded during the three years ended December 31, 2020.

Comprehensive Loss

Comprehensive loss is comprised of the Company’s net loss and the unrealized gains on the Company’s investment securities for all periods presented.

Net Loss Per Share

Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of convertible preferred stock, common stock subject to repurchase, and options outstanding under the Company’s stock option plan. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.

Potentially dilutive securities (in common stock equivalent shares) not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in thousands):

Year ended December 31,

2020

2019

2018

Common stock options

4,422

3,127

2,339

Unvested common stock subject to repurchase

16

33

127

Total

4,438

3,160

2,466

Recently Adopted Accounting Pronouncements

ASU 2019-12

In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12, Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes (“ASU 2019-12”). The Board issued this ASU as part of its simplification initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the Company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company has elected to early adopt ASU 2019-12 in the fourth quarter of fiscal 2020; however, there was no cumulative effect to be recognized with the early adoption.

ASU 2018-13

In August 2018, the FASB issued ASU 2018-13, “Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement,” which improves the effectiveness of the disclosures required under ASC 820, “Fair Value Measurements and Disclosures” and modifies the disclosure requirements on fair value measurements, including the consideration of costs and benefits. The Company adopted this standard in 2020; adoption of this standard did not have a material impact on the Company’s consolidated financial statements.

Recent Accounting Pronouncements

ASU 2016-13

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“Topic 326”). Topic 326 amends guidance on reporting credit losses for assets held at amortized cost basis and available for sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available for sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. This ASU update affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. This update is effective for the company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is currently evaluating the impact of the pending adoption of this new standard on its consolidated financial statements.

ASU 2020-06

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020, including interim periods within those fiscal years. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The amendment is to be adopted through either a modified retrospective or fully retrospective method of transition. The Company is currently evaluating the potential impact that the adoption of ASU 2020-06 may have on its consolidated financial statements and related disclosures.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R10.htm IDEA: XBRL DOCUMENT v3.21.1

Investment Securities
12 Months Ended

Dec. 31, 2020

Investments Debt And Equity Securities [Abstract]

Investment Securities
3. INVESTMENT SECURITIES

Available-for-sale investment securities consisted of the following as of December 31, 2020 and 2019 (in thousands):

As of December 31, 2020

Amortized

Cost

Gross

Unrealized

Gains

Gross

Unrealized

Losses

Fair

Market

Value

Available-for-sale investment securities:

U.S. government and agency obligations

$

74,222

$

6

$

(5

)

$

74,223

Certificates of deposit

2,161

14

—

2,175

Corporate debt securities

1,385

10

—

1,395

Total

$

77,768

$

30

$

(5

)

$

77,793

As of December 31, 2019

Amortized

Cost

Gross

Unrealized

Gains

Gross

Unrealized

Losses

Fair

Market

Value

Available-for-sale investment securities:

U.S. government and agency obligations

$

43,275

$

94

$

(1

)

$

43,368

Certificates of deposit

5,931

51

—

5,982

Commercial paper

17,645

—

—

17,645

Corporate debt securities

11,067

7

(3

)

11,071

Total

$

77,918

$

152

$

(4

)

$

78,066

All available-for-sale investment securities held at December 31, 2020 and 2019 had maturity dates of less than 24 months.

None of the Company’s available-for-sale investment securities were in a material unrealized loss position at December 31, 2020. The Company reviewed its investment holdings as of December 31, 2020 and determined that its unrealized losses were not considered to be other-than-temporary based upon (i) the financial strength of the issuing institution and (ii) the fact that no securities have been in an unrealized loss position for twelve months or more. As such, the Company has not recognized any impairment in its financial statements related to its available-for-sale investment securities.

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for investments in certain debt and equity securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-URI http://asc.fasb.org/subtopic&trid=2209399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-URI http://asc.fasb.org/subtopic&trid=2324412

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-URI http://asc.fasb.org/topic&trid=2196928

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 320
-URI http://asc.fasb.org/subtopic&trid=2176304
+ Details

Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R11.htm IDEA: XBRL DOCUMENT v3.21.1

Fair Value Measurements
12 Months Ended

Dec. 31, 2020

Fair Value Disclosures [Abstract]

Fair Value Measurements
4. FAIR VALUE MEASUREMENTS

The Company holds investment securities that consist of highly liquid, investment grade debt securities. The Company determines the fair value of its investment securities based upon one or more valuations reported by its investment accounting and reporting service provider. The investment service provider values the securities using a hierarchical security pricing model that relies primarily on valuations provided by an industry-recognized valuation service. Such valuations may be based on trade prices in active markets for identical assets or liabilities (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets or liabilities, yield curves, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, and broker and dealer quotes, as well as other relevant economic measures.

Financial assets measured at fair value on a recurring basis as of December 31, 2020 and 2019 were as follows (in thousands):

As of December 31, 2020

Level 1

Level 2

Level 3

Total

Investment securities:

U.S. government and agency obligations

$

60,222

$

14,001

$

—

$

74,223

Certificates of deposit

—

2,175

—

2,175

Corporate debt securities

—

1,395

—

1,395

Total assets measured at fair value

$

60,222

$

17,571

$

—

$

77,793

As of December 31, 2019

Level 1

Level 2

Level 3

Total

Investment securities:

U.S. government and agency obligations

$

15,478

$

27,890

$

—

$

43,368

Certificates of deposit

—

5,982

—

5,982

Commercial paper

—

17,645

—

17,645

Corporate debt securities

—

11,071

—

11,071

Total assets measured at fair value

$

15,478

$

62,588

$

—

$

78,066

The Company’s policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no transfers into or out of Level 3 during the years ended December 31, 2020 and 2019.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R12.htm IDEA: XBRL DOCUMENT v3.21.1

Balance Sheet Details
12 Months Ended

Dec. 31, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Balance Sheet Details
5. BALANCE SHEET DETAILS

Prepaid expenses and other current assets consisted of the following (in thousands):

December 31,

2020

December 31,

2019

Prepaid research and development costs

$

3,062

$

2,478

Australian tax incentive receivable

1,720

929

Prepaid insurance

693

648

Interest receivable

113

224

Prepaid expenses and other assets

1,024

668

Total

$

6,612

$

4,947

Property and equipment, net consisted of the following (in thousands):

December 31,

2020

December 31,

2019

Leasehold improvements

$

3,494

$

3,494

Lab equipment

1,551

1,468

Office equipment

653

567

Computers and software

41

41

Property and equipment at cost

5,739

5,570

Less accumulated depreciation and amortization

2,558

1,624

Total

$

3,181

$

3,946

Depreciation expense was $0.9 million, $0.9 million, and $0.5 million for the three years ended December 31, 2020, 2019 and 2018, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-URI http://asc.fasb.org/topic&trid=2122208
+ Details

Name: us-gaap_SupplementalBalanceSheetDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R13.htm IDEA: XBRL DOCUMENT v3.21.1

Operating Lease
12 Months Ended

Dec. 31, 2020

Leases [Abstract]

Operating Lease
6. OPERATING LEASE

2018 Operating Lease. In February 2018, as amended in March 2018, the Company entered into a non-cancelable operating lease for a new facility in San Diego, California. The lease has an initial term of seven years which expires in August 2025, and the Company has an option to extend the term of the lease for an additional five years and has a termination option subject to early termination fees. The lease is subject to base lease payments and additional charges for common area maintenance and other costs and includes certain lease incentives and tenant improvement allowances. Rent expense is being recognized on a straight-line basis over the term of the lease. The Company’s estimated incremental fully collateralized borrowing rate of 8.0% was used in its present value calculation as the facility lease does not have a stated rate and the implicit rate was not readily determinable.

Under the terms of the lease, the Company provided the lessor with an irrevocable letter of credit in the amount of $0.5 million. The lessor is entitled to draw on the letter of credit in the event of any default by the Company under the terms of the lease.

Future Minimum Payments. As of December 31, 2020, future minimum payments under non-cancellable operating leases were as follows (in thousands):

Year ending December 31,

Minimum

Payments

2021

$

1,173

2022

1,208

2023

1,244

2024

1,280

2025

871

Total future minimum lease payments

5,776

Less imputed interest

927

Total operating lease liability

4,849

Less operating lease liability, current

835

Operating lease liability, non-current

$

4,014

Rent expense is recorded on a straight-line basis over the term of the Company’s facility lease. Rent expense was $1.0 million, $1.0 million and $0.6 million for the years ended December 31, 2020, 2019 and 2018, respectively.

Cash paid for amounts included in the measurement of lease liabilities for operating cash flow from operating leases was $1.1 million during each of the years ended December 31, 2020 and 2019.

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-URI http://asc.fasb.org/subtopic&trid=77888251
+ Details

Name: us-gaap_LesseeOperatingLeasesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R14.htm IDEA: XBRL DOCUMENT v3.21.1

Commitments and Contingencies
12 Months Ended

Dec. 31, 2020

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies
7. COMMITMENTS AND CONTINGENCIES

Litigation

From time to time, the Company may be subject to various claims and suits arising in the ordinary course of business. The Company does not expect that the resolution of these matters will have a material adverse effect on its financial position or results of operations.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R15.htm IDEA: XBRL DOCUMENT v3.21.1

Convertible Preferred Stock
12 Months Ended

Dec. 31, 2020

Temporary Equity Disclosure [Abstract]

Convertible Preferred Stock
8. CONVERTIBLE PREFERRED STOCK

In April and December 2017, pursuant to a Series A preferred stock purchase agreement entered into in October 2015 which called for an initial closing and, upon the achievement of certain specified milestones, subsequent closings, the Company issued an aggregate of 11,505,268 shares of Series A convertible preferred stock for gross proceeds of $12.0 million, net of offering costs of $40,000. In February and March 2018, the Company issued an aggregate of 19,641,200 shares of its Series B convertible preferred stock for gross proceeds of $63.5 million, net of issuance costs incurred in connection with this offering of $0.2 million.

The holders of the convertible preferred stock were entitled to certain customary preferences, such as dividend and liquidation priority in relationship to the common shareholders, and certain anti-dilution protection. The convertible preferred stock was classified outside of stockholders’ equity (deficit) because the shares contained certain redemption features that were not solely within the control of the Company. In connection with the Company’s initial public offering (“IPO”), the outstanding shares of the Company’s Series A and Series B convertible preferred stock automatically converted into 14,712,571 shares of common stock (see Note 9).

X

- Definition
Temporary equity disclosure.
+ References
No definition available.
+ Details

Name: crnx_TemporaryEquityDisclosureTextBlock

Namespace Prefix: crnx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 33 R16.htm IDEA: XBRL DOCUMENT v3.21.1

Stockholder's Equity
12 Months Ended

Dec. 31, 2020

Stockholders Equity Note [Abstract]

Stockholders' Equity
9. STOCKHOLDERS’ EQUITY

Authorized Shares

In connection with the completion of the Company’s IPO on July 20, 2018, the Company amended and restated its certificate of incorporation to authorize 200,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share.

Public Offerings

The Company completed its IPO in July 2018 whereby it sold 6,900,000 shares of common stock at a price to the public of $17.00 per share. Proceeds from the IPO were approximately $106.5 million, net of underwriting discounts and commissions and offering costs of $10.8 million.

On April 17, 2020, the Company completed a public offering of 8,222,500 shares of its common stock at a public offering price of $14.00 per share. Proceeds from the offering were approximately $107.9 million, net of underwriting discounts and commissions and offering costs of $7.3 million. The shares were registered pursuant to the Company’s Shelf Registration Statement discussed below.

Shelf Registration Statement and ATM Offering

On August 13, 2019, the Company filed a registration statement on Form S-3 (the “Shelf Registration Statement”), covering the offering of up to $300.0 million of common stock, preferred stock, debt securities, warrants and units. The Registration Statement became effective on August 29, 2019.

On August 13, 2019 the Company also entered into a Sales Agreement (the “Sales Agreement”) with SVB Leerink LLC and Cantor Fitzgerald & Co. (collectively, the “Sales Agents”), under which the Company may, from time to time, sell shares of its common stock having an aggregate offering price of up to $75.0 million through the Sales Agents (the “ATM Offering”). The Shelf Registration Statement included a prospectus covering the offering, issuance, and sale of up to $75.0 million of Company common stock from time to time through the ATM Offering. The shares to be sold under the Sales Agreement may be issued and sold pursuant to the Shelf Registration Statement.

During the year ended December 31, 2020, the Company sold a total of 275,764 shares of common stock pursuant to its ATM Offering for net proceeds of $6.4 million, after deducting commissions of $0.2 million.

Shares of Common Stock Subject to Repurchase

In October 2015, in connection with the issuance of the Company’s Series A convertible preferred stock, certain of the Company’s founders entered into stock restriction agreements, whereby 1,914,893 of previously unrestricted shares of common stock became subject to repurchase by the Company upon the stockholder’s termination of employment or service to the Company. The Company’s repurchase rights lapsed as to 765,957 shares of common stock in October 2015, with the remainder scheduled to lapse at the rate of 23,936 shares monthly thereafter such that the shares of common stock would have been fully vested in October 2019. Under the terms of the stock restriction agreements, the shares of common stock were also subject to accelerated vesting upon certain events, such that all of these restricted shares became fully vested upon the closing of the Company’s Series B preferred stock financing in February 2018. The stock restriction agreements resulted in the deemed cancellation and reissuance of shares of common stock and therefore, for accounting purposes, the shares subject to repurchase were not considered to be outstanding until vested. The fair value of these shares as of October 2015 was recognized as compensation expense over the vesting period. The Company recognized stock-based compensation for these awards of $0.4 million during the year ended December 31, 2018.

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R17.htm IDEA: XBRL DOCUMENT v3.21.1

Equity Incentive Plans
12 Months Ended

Dec. 31, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Equity Incentive Plans
10. EQUITY INCENTIVE PLANS

2018 Incentive Award Plan

The Company adopted the 2018 Incentive Award Plan (the “2018 Plan”) in July 2018. Under the 2018 Plan, which expires in July 2028, the Company may grant equity-based awards to individuals who are employees, officers, directors or consultants of the Company. Options issued under the 2018 Plan will generally expire ten years from the date of grant and vest over a four-year period. As of December 31, 2020, an aggregate of 1,967,191 shares of common stock were available for issuance under the 2018 Plan.

The 2018 Plan contains a provision that allows annual increases in the number of shares available for issuance on the first day of each calendar year through January 1, 2028 in an amount equal to the lesser of: (i) 5% of the aggregate number of shares of the Company’s common stock outstanding on December 31 of the immediately preceding calendar year, or (ii) such lesser amount determined by the Company. Under this evergreen provision, on January 1, 2021, an additional 1,650,846 shares became available for future issuance under the 2018 Plan.

2015 Stock Incentive Plan

In February 2015, the Company adopted the Crinetics Pharmaceuticals, Inc. 2015 Stock Incentive Plan (the “2015 Plan”), which provided for the issuance of equity awards to the Company’s employees, members of its board of directors and consultants. In general, options issued under this plan vest over four years and expire after 10 years. Subsequent to the adoption of the 2018 Plan, no additional equity awards can be made under the 2015 Plan.

Certain awards issued under the 2015 Plan allowed for exercise prior to vesting. Shares issued under such early-exercise provisions are subject to repurchase by the Company until they become fully vested. As of December 31, 2020, 15,951 unvested shares issued under early-exercise provisions were subject to repurchase by the Company. The consolidated balance sheet reflects an unvested stock liability of $23,000 and $49,000 as of December 31, 2020 and 2019, respectively.

2018 Employee Stock Purchase Plan

In July 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the “ESPP”). The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. As of December 31, 2020, an aggregate of 614,223 shares of common stock were available for issuance under the ESPP.

The ESPP contains a provision that allows annual increases in the number of shares available for issuance on the first day of each calendar year through January 1, 2028 in an amount equal to the lesser of: (i) 1% of the aggregate number of shares of the Company’s common stock outstanding on December 31 of the immediately preceding calendar year, or (ii) such lesser amount determined by the Company. Under this evergreen provision, on January 1, 2021, an additional 330,169 shares became available for future issuance under the ESPP.

Stock Option Activity

Activity under the Company’s stock option plans during the year ended December 31, 2020 was as follows:

Weighted-

Weighted-

Aggregate

Average

Average

Intrinsic

Options

Exercise

Remaining

Value

Outstanding

Price

Term

(000’s)

Balance at December 31, 2019

3,127,391

$

11.52

Granted

1,604,470

$

19.16

Exercised

(170,696

)

$

1.68

Forfeited and expired

(139,632

)

$

19.51

Balance at December 31, 2020

4,421,533

$

14.42

8.1

$

15,930

Vested and expected to vest at December 31, 2020

4,421,533

$

14.42

8.1

$

15,930

Exercisable at December 31, 2020

1,957,407

$

11.02

7.4

$

11,766

Aggregate intrinsic value is calculated as the difference between the closing price of the Company’s common stock at December 31, 2020 and the exercise price of stock options that had strike prices below the closing price.

The total intrinsic value of options exercised during 2020, 2019 and 2018 was $2.5 million, $2.0 million and $2.4 million, respectively.

Fair Value of Stock Option Awards

The Company utilizes the Black Scholes option pricing model to value awards under its equity plans. The following table summarizes the weighted average assumptions used to estimate the fair value of stock options granted under the Company’s stock option plans and the shares purchasable under the ESPP during the periods presented:

Year ended December 31,

Stock Option Awards

2020

2019

2018

Expected option term

6.0 years

5.9 years

6.0 years

Expected volatility

78

%

78

%

70

%

Risk free interest rate

0.8

%

2.3

%

2.8

%

Expected dividend yield

—

%

—

%

—

%

Year ended December 31,

ESPP

2020

2019

2018

Expected option term

1.4 years

1.8 years

1.1 years

Expected volatility

84

%

65

%

66

%

Risk free interest rate

0.2

%

2.2

%

2.4

%

Expected dividend yield

—

%

—

%

—

%

The key assumptions used in determining the fair value of equity awards, and the Company’s rationale, were as follows: (i) Expected option term - the expected term represents the period that options are expected to be outstanding and has been estimated using the simplified method, which is an average of the contractual option term and its vesting period; (ii) Expected volatility - the expected volatility assumption is based on volatilities of a peer group of similar companies in the biotechnology industry whose share prices are publicly available; (iii) Risk-free interest rate - the risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities that approximate the expected terms of awards; and (iv) Expected dividend yield - the expected dividend yield assumption is zero as the Company has never paid dividends and has no present intention to do so in the future.

The weighted-average fair value of stock options granted to employees during the years ended December 31, 2020, 2019 and 2018 was $12.83, $16.35 and $4.66 per share, respectively. The weighted-average fair value of awards under the ESPP during the years ended December 31, 2020, 2019 and 2018 was $8.07, $10.59 and $8.15 per share, respectively.

Stock-Based Compensation Expense

Stock-based compensation expense for the equity awards issued by the Company to employees and non-employees for the periods presented below was as follows (in thousands):

Year ended December 31,

2020

2019

2018

Included in research and development

$

5,218

$

3,190

$

1,100

Included in general and administrative

5,209

3,104

1,220

Total stock-based compensation expense

$

10,427

$

6,294

$

2,320

Unrecognized stock-based compensation cost related to option awards was $26.9 million as of December 31, 2020, which is expected to be recognized over a remaining weighted-average period of approximately 2.4 years. Unrecognized stock-based compensation cost related to stock purchase rights under the Company’s ESPP was $1.3 million as of December 31, 2020, which is expected to be recognized over a remaining weighted-average period of approximately 1.6 years.

X

- Definition
The entire disclosure for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R18.htm IDEA: XBRL DOCUMENT v3.21.1

Income Taxes
12 Months Ended

Dec. 31, 2020

Income Tax Disclosure [Abstract]

Income Taxes
11. INCOME TAXES

The Company is subject to taxation in the United States, various state jurisdictions and Australia; however, as it has operated at a loss since inception, it has not paid income taxes in any of the jurisdictions in which it has operated. At December 31, 2020, the Company had federal, state, and foreign net operating loss (“NOL”) carryforwards of approximately $118.2 million, $124.1 million and $1.6 million, respectively. The federal loss carryforwards generated after 2017 of $111.9 million will carryforward indefinitely and can be used to offset up to 80% of future annual taxable income, while those loss carryforwards generated prior to 2018 begin expiring in 2035, unless previously utilized. State loss carryforwards also begin expiring in 2035, unless previously utilized, while the Company’s foreign loss carryforwards do not expire. The Company also has federal and California R&D credit carryforwards totaling $4.5 million and $2.7 million, respectively. The federal credits begin to expire in 2030 unless previously utilized, while the state credits do not expire. The Company also has federal Orphan Drug credit carryforwards totaling $1.4 million which will begin to expire in 2040 unless previously utilized.

The Company’s NOL and credit carryforwards to offset future taxable income may be subject to a substantial annual limitation as a result of ownership changes that could occur in the future pursuant to Internal Revenue Code Sections 382 and 383. These ownership changes may limit the amount of NOL and credit carryforwards that can be utilized to offset future taxable income and income tax, respectively. In general, an “ownership change” as defined by the tax code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percent of the outstanding stock of a company by certain stockholders or public groups. During 2020, the Company completed a study to assess whether an ownership change within the meaning of Section 382 had occurred for the time period prior to July 15, 2020. The study identified several such ownership changes during the study period, which resulted in limitations on the annual utilization of the Company’s NOL and credit carryforwards, or the “Tax Attribute” carryforwards; however, the study findings also indicated that none of the Company’s Tax Attribute carryforwards generated during the study period would expire solely as a result of annual limitations on the utilization of such Tax Attribute carryforwards. Future ownership changes could still occur which might place further limits on the Company’s ability to utilize its Tax Attribute carryforwards.

The Company’s federal income tax returns from 2017 forward, state income tax returns from 2016 forward, and its Australian tax returns beginning in 2018 are subject to examination by tax authorities; however, the Company’s Tax Attribute carryforwards generated in closed years are also subject to examination and remeasurement. No such audits are underway.

Deferred tax assets and liabilities

Net deferred tax assets are comprised of the following as of December 31, 2020 and 2019 (in thousands):

December 31,

2020

2019

Deferred tax assets:

Net operating loss carryforwards

$

33,994

$

15,990

Capitalized research expenses

4,231

4,864

R&D and other tax credits

6,881

4,676

Stock-based compensation

3,233

1,343

Lease liability

1,358

1,560

Accrued expenses and other, net

1,932

886

Total deferred tax assets

51,629

29,319

Deferred tax liabilities:

Right-of use asset

(625

)

(702

)

Other deferred tax liabilities

(132

)

(22

)

Net of deferred tax assets and liabilities

50,872

28,595

Less: valuation allowance

(50,872

)

(28,595

)

Net deferred tax assets

$

—

$

—

Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use existing deferred tax assets. Based on the weight of available evidence, including the Company’s history of operating losses, management has determined that it is more likely than not that the Company’s net deferred tax assets will not be realized. Accordingly, a valuation allowance has been established by the Company to fully offset these net deferred tax assets.

Income tax benefit

For the three years in the period ended December 31, 2020, domestic and foreign pre-tax loss were (in thousands):

Year ended December 31,

2020

2019

2018

Loss before income taxes - Domestic

$

(71,769

)

$

(48,643

)

$

(25,876

)

Loss before income taxes - Foreign

(2,043

)

(1,779

)

(1,239

)

Loss before income taxes - Consolidated

$

(73,812

)

$

(50,422

)

$

(27,115

)

A reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate to the loss from operations for the three years in the period ended December 31, 2020 is as follows (in thousands):

Year ended December 31,

2020

2019

2018

Expected income tax benefit at federal statutory rate

$

(15,417

)

$

(10,589

)

$

(5,694

)

State income tax benefit, net of federal benefit

(4,886

)

(3,431

)

(1,758

)

Tax effect of

Change in valuation allowance

22,242

16,064

7,724

R&D credit

(2,597

)

(2,485

)

(1,129

)

Federal rate change

—

—

(52

)

Australian tax incentive

215

307

362

Other

443

134

547

Provision for income taxes

$

—

$

—

$

—

Changes to the Company’s unrecognized tax benefits are summarized in the following table (in thousands):

Year ended December 31,

2020

2019

2018

Beginning balance

$

886

$

344

$

159

Increase (decrease) for prior year tax positions

(163

)

70

—

Increase (decrease) for current year tax positions

369

472

185

Ending balance

$

1,092

$

886

$

344

Due to the existence of the valuation allowance, future changes in unrecognized tax benefits would not have any effect on the Company’s effective tax rate. The Company does not foresee any material changes to its unrecognized tax benefits within the next twelve months.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R19.htm IDEA: XBRL DOCUMENT v3.21.1

Summary of Significant Accounting Policies (Policies)
12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Description of Business
Description of Business

Crinetics Pharmaceuticals, Inc. (the “Company”) is a clinical-stage pharmaceutical company incorporated in Delaware on November 18, 2008 and based in San Diego, California. The Company is focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. In January 2017, the Company established a wholly-owned Australian subsidiary, Crinetics Australia Pty Ltd (“CAPL”), in order to conduct various preclinical and clinical activities for its development candidates.

On July 6, 2018, the Company effected a 1-for-3.29 reverse stock split of its common stock. The par value and the authorized shares of the common stock were not adjusted as a result of the reverse stock split. The reverse stock split resulted in an adjustment to the conversion prices of the Company’s Series A and B preferred stock to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying consolidated financial statements and notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented.

Principles of Consolidation and Foreign Currency Transactions
Principles of Consolidation and Foreign Currency Transactions

The consolidated financial statements include the accounts of the Company and CAPL. All intercompany accounts and transactions have been eliminated in consolidation. The functional currency of both the Company and CAPL is the U.S. dollar. Assets and liabilities that are not denominated in the functional currency are remeasured into U.S. dollars at foreign currency exchange rates in effect at the balance sheet date except for nonmonetary assets, which are remeasured at historical foreign currency exchange rates in effect at the date of transaction. Net realized and unrealized gains and losses from foreign currency transactions and remeasurement are reported in other income (expense), in the consolidated statements of operations and were not material for all periods presented.

Segment Reporting
Segment Reporting

Operating segments are identified as components of an enterprise about which discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.

Liquidity and Going Concern
Liquidity and Going Concern

From inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting preclinical studies and clinical trials. The Company has a limited operating history and the sales and income potential of the Company’s business and market are unproven. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company’s cost structure.

As of December 31, 2020, the Company had $170.9 million in unrestricted cash, cash equivalents and investment securities. The Company believes it has sufficient cash to meet its funding requirements for at least the next 12 months from the date of issuance of these financial statements.

The Company has experienced net losses and negative cash flows from operating activities since its inception and has an accumulated deficit of $167.6 million as of December 31, 2020. The Company expects to continue to incur net losses for the foreseeable future and believes it will need to raise substantial additional capital to accomplish its business plan over the next several years. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of equity offerings, debt financings or other sources, including potential collaborations, licenses and other similar arrangements. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned programs. Any of these actions could materially harm the Company’s business, results of operations and future prospects. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future.

COVID-19
COVID-19

The COVID-19 pandemic has caused significant business disruption around the globe. The extent of the impact of COVID-19 on the Company's operational and financial performance will depend on certain developments, including the duration and spread of the pandemic and the impact on the Company's clinical trials, employees and vendors. In response to the spread of COVID-19, the Company has closed its offices to all but its lab and a limited number of its other personnel, while the remainder of its employees are continuing their work outside the Company’s offices. At this point, the degree to which COVID-19 may impact the Company's financial condition or future results of operations is uncertain. A prolonged outbreak could have a material adverse impact on financial results and business operations of the Company, including the timing and ability of Company to complete certain clinical trials and other efforts required to advance the development of its drug candidates and raise additional capital.

In response to the pandemic, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) was signed into law on March 27, 2020. The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer’s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The CARES Act has not had a material impact on the Company’s income tax provision for the year ended December 31, 2020.

Use of Estimates
Use of Estimates

The Company’s consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The preparation of the Company’s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to accrued amounts receivable under the Australian research and development tax incentive program, accrued expenses and associated research and development expense, the assumptions underlying the determination of the estimated incremental borrowing rate for the determination of the Company’s operating lease right-of-use asset, and the assumptions underlying the determination of the fair value of equity awards for purposes of determining stock-based compensation. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.

Fair Value Measurements
Fair Value Measurements

The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level 1: Observable inputs such as quoted prices in active markets.

Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The carrying amounts of the Company’s current financial assets, restricted cash and current financial liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments.

Cash, Cash Equivalents and Restricted Cash
Cash, Cash Equivalents and Restricted Cash

Cash and cash equivalents include cash held in readily available checking and money market accounts, as well as short-term debt securities with maturities of three months or less when purchased. Restricted cash represents cash held as collateral for the Company’s facility lease and is reported as a long-term asset in the accompanying consolidated balance sheets.

Investment Securities
Investment Securities

All investments have been classified as “available-for-sale” and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities less than 12 months at the balance sheet date are considered short-term investments. Investments with contractual maturities beyond one year are also classified as short-term due to the Company’s ability to liquidate the investment for use in operations within the next 12 months.

Realized gains and losses on investment securities are included in earnings and are derived using the specific identification method for determining the cost of securities sold. The Company has not realized any significant gains or losses on sales of available-for-sale investment securities during any of the periods presented. As all the Company’s investment holdings are in the form of debt securities, unrealized gains and losses that are determined to be temporary in nature are reported as a component of accumulated other comprehensive income. A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the establishment of a new cost basis for the security. Interest income is recognized when earned and is included in investment income, as are the amortization of purchase premiums and accretion of purchase discounts on investment securities.

Concentrations of Credit Risk
Concentrations of Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investment securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.

Leases
Leases

The Company determines if an arrangement is a lease at the inception of the arrangement. Beginning January 1, 2019, leases with a term longer than 12 months that are determined to be operating leases are included in operating lease assets, accrued expenses and other current liabilities and noncurrent operating lease liabilities in the consolidated balance sheets based on the present value of the minimum lease payments called for under the arrangement. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

Property and Equipment, Net
Property and Equipment, Net

Property and equipment consist of leasehold improvements, and lab and various other equipment. Such assets are stated at cost and depreciated on a straight-line basis over the estimated useful life of the related assets. The Company estimates its useful lives of its lab and other equipment as follows: lab equipment – three to five years; office equipment - three to five years; computer and software – three years. Leasehold improvements are amortized over the estimated useful life of the improvement or the remaining term of the associated lease.

Repairs and maintenance costs are charged to expense as incurred and expenditures that materially extend the useful lives of assets are capitalized.

Impairment of Long-Lived Assets
Impairment of Long-Lived Assets

Long-lived assets consist of property and equipment. An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. The Company has not recognized any impairment losses in any of the periods presented in these consolidated financial statements.

Deferred Rent
Deferred Rent

The Company’s facility lease includes incentives in the form of rent abatements and leasehold improvement allowances, as well as fixed annual rent escalations. The Company recognizes the aggregate rental expense, after considering incentives and stipulated rent escalations, on a straight-line basis over the lease term. Prior to January 1, 2019, the difference between rent expense and amounts paid under the lease was recorded as deferred rent.

Grant Revenue Recognition
Grant Revenue Recognition

The Company’s grant revenues are derived from Small Business Innovation Research Grants (“SBIR Grants”) from the National Institutes of Health. The Company recognizes SBIR Grant revenue as reimbursable grant costs are incurred up to pre-approved award limits within the budget period. The costs associated with these reimbursements are reflected as a component of research and development expense in the accompanying consolidated statements of operations. Earnings in excess of billings are included as a component of prepaid expenses and other current assets.

Research and Development Expense
Research and Development Expenses

Research and development (“R&D”) expenses consist primarily of salaries, payroll taxes, employee benefits and stock-based compensation for individuals involved in R&D efforts, as well as consulting expenses, third-party R&D expenses, laboratory supplies, clinical materials and overhead, including facilities and depreciation costs, offset by the Australian Tax Incentive discussed below. R&D expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in R&D are capitalized until the goods or services are received. Costs incurred under contracts with contract research organizations that conduct and manage the Company’s clinical trials are also included in research and development expenses. The financial terms and activities of these agreements vary from contract to contract and may result in uneven expense levels. Generally, these agreements set forth activities that drive the recording of expenses such as start-up and initiation activities, enrollment and treatment of patients, or the completion of other clinical trial activities. Expenses related to clinical trials are accrued based on estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. If the amounts that the Company is obligated to pay under its clinical trial agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the Company adjusts its accruals accordingly on a prospective basis. Revisions to contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain.

Accrued R&D expenses totaled $2.1 million and $2.8 million as of December 31, 2020 and 2019, respectively, and are a component of accounts payable and accrued expenses in the consolidated balance sheets.

Australian Tax Incentive
Australian Tax Incentive

CAPL is eligible to obtain a cash refund from the Australian Taxation Office for eligible R&D expenditures under the Australian R&D Tax Incentive Program (the “Australian Tax Incentive”). The Australian Tax Incentive is recognized as a reduction to R&D expense when there is reasonable assurance that the relevant expenditure has been incurred, the amount can be reliably measured and that the Australian Tax Incentive will be received. The Company recognized reductions to R&D expense of $0.6 million, $1.0 million and $1.2 million for the years ended December 31, 2020, 2019 and 2018, respectively.

Stock-Based Compensation
Stock-Based Compensation

Stock-based compensation expense represents the estimated grant date fair value of the Company’s equity awards, consisting of stock options and shares issued under the Company’s Employee Stock Purchase Plan, recognized over the requisite service period of such awards (usually the vesting period) on a straight-line basis. The Company estimates the fair value of equity awards using the Black-Scholes option pricing model on the date of grant and recognizes forfeitures as they occur. For stock awards for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable, or the performance condition has been achieved.

Income Taxes
Income Taxes

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.

The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense, and any accrued interest and penalties would be included within the related tax liability. No such costs were recorded during the three years ended December 31, 2020.

Comprehensive Loss
Comprehensive Loss

Comprehensive loss is comprised of the Company’s net loss and the unrealized gains on the Company’s investment securities for all periods presented.

Net Loss Per Share
Net Loss Per Share

Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of convertible preferred stock, common stock subject to repurchase, and options outstanding under the Company’s stock option plan. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.

Potentially dilutive securities (in common stock equivalent shares) not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in thousands):

Year ended December 31,

2020

2019

2018

Common stock options

4,422

3,127

2,339

Unvested common stock subject to repurchase

16

33

127

Total

4,438

3,160

2,466

Recent Accounting Pronouncements
Recently Adopted Accounting Pronouncements

ASU 2019-12

In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12, Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes (“ASU 2019-12”). The Board issued this ASU as part of its simplification initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness. The main provision that impacts the Company is the removal of the exception to the incremental approach of intra-period tax allocation when there is a loss from continuing operations and income or gain from other items (for example, discontinued operations and other comprehensive income). ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company has elected to early adopt ASU 2019-12 in the fourth quarter of fiscal 2020; however, there was no cumulative effect to be recognized with the early adoption.

ASU 2018-13

In August 2018, the FASB issued ASU 2018-13, “Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement,” which improves the effectiveness of the disclosures required under ASC 820, “Fair Value Measurements and Disclosures” and modifies the disclosure requirements on fair value measurements, including the consideration of costs and benefits. The Company adopted this standard in 2020; adoption of this standard did not have a material impact on the Company’s consolidated financial statements.

Recent Accounting Pronouncements

ASU 2016-13

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“Topic 326”). Topic 326 amends guidance on reporting credit losses for assets held at amortized cost basis and available for sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available for sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. This ASU update affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. This update is effective for the company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is currently evaluating the impact of the pending adoption of this new standard on its consolidated financial statements.

ASU 2020-06

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020, including interim periods within those fiscal years. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The amendment is to be adopted through either a modified retrospective or fully retrospective method of transition. The Company is currently evaluating the potential impact that the adoption of ASU 2020-06 may have on its consolidated financial statements and related disclosures.

X

- Definition
Deferred rent.
+ References
No definition available.
+ Details

Name: crnx_DeferredRentPolicyTextBlock

Namespace Prefix: crnx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of Business.
+ References
No definition available.
+ Details

Name: crnx_DescriptionOfBusinessPolicyTextBlock

Namespace Prefix: crnx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Foreign research and development tax incentive.
+ References
No definition available.
+ Details

Name: crnx_ForeignResearchAndDevelopmentTaxIncentivePolicyPolicyTextBlock

Namespace Prefix: crnx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for grant revenue recognition.
+ References
No definition available.
+ Details

Name: crnx_GrantRevenueRecognitionPolicyTextBlock

Namespace Prefix: crnx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Leases policy
+ References
No definition available.
+ Details

Name: crnx_LeasesPolicyTextBlock

Namespace Prefix: crnx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Liquidity and going concern.
+ References
No definition available.
+ Details

Name: crnx_LiquidityAndGoingConcernPolicyTextBlock

Namespace Prefix: crnx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for short term investments.
+ References
No definition available.
+ Details

Name: crnx_ShortTermInvestmentsPolicyPolicyTextBlock

Namespace Prefix: crnx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Unusual Or Infrequent Items Covid19 Pandemic Policy Text Block.
+ References
No definition available.
+ Details

Name: crnx_UnusualOrInfrequentItemsCovid19PandemicPolicyTextBlock

Namespace Prefix: crnx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(1)(a))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586
+ Details

Name: us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for comprehensive income.
+ References
No definition available.
+ Details

Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for credit risk.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788
+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-URI http://asc.fasb.org/topic&trid=2175825

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 05
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.CC)
-URI http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742
+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for segment reporting.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599
+ Details

Name: us-gaap_SegmentReportingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(f)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901
+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R20.htm IDEA: XBRL DOCUMENT v3.21.1

Investment Securities (Tables)
12 Months Ended

Dec. 31, 2020

Investments Debt And Equity Securities [Abstract]

Summary of Available-For-Sale Investment Securities Held by the Company Available-for-sale investment securities consisted of the following as of December 31, 2020 and 2019 (in thousands):

As of December 31, 2020

Amortized

Cost

Gross

Unrealized

Gains

Gross

Unrealized

Losses

Fair

Market

Value

Available-for-sale investment securities:

U.S. government and agency obligations

$

74,222

$

6

$

(5

)

$

74,223

Certificates of deposit

2,161

14

—

2,175

Corporate debt securities

1,385

10

—

1,395

Total

$

77,768

$

30

$

(5

)

$

77,793

As of December 31, 2019

Amortized

Cost

Gross

Unrealized

Gains

Gross

Unrealized

Losses

Fair

Market

Value

Available-for-sale investment securities:

U.S. government and agency obligations

$

43,275

$

94

$

(1

)

$

43,368

Certificates of deposit

5,931

51

—

5,982

Commercial paper

17,645

—

—

17,645

Corporate debt securities

11,067

7

(3

)

11,071

Total

$

77,918

$

152

$

(4

)

$

78,066

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R21.htm IDEA: XBRL DOCUMENT v3.21.1

Fair Value Measurements (Tables)
12 Months Ended

Dec. 31, 2020

Fair Value Disclosures [Abstract]

Schedule of Financial Assets Measured at Fair Value on Recurring Basis
Financial assets measured at fair value on a recurring basis as of December 31, 2020 and 2019 were as follows (in thousands):

As of December 31, 2020

Level 1

Level 2

Level 3

Total

Investment securities:

U.S. government and agency obligations

$

60,222

$

14,001

$

—

$

74,223

Certificates of deposit

—

2,175

—

2,175

Corporate debt securities

—

1,395

—

1,395

Total assets measured at fair value

$

60,222

$

17,571

$

—

$

77,793

As of December 31, 2019

Level 1

Level 2

Level 3

Total

Investment securities:

U.S. government and agency obligations

$

15,478

$

27,890

$

—

$

43,368

Certificates of deposit

—

5,982

—

5,982

Commercial paper

—

17,645

—

17,645

Corporate debt securities

—

11,071

—

11,071

Total assets measured at fair value

$

15,478

$

62,588

$

—

$

78,066

X

- Definition
Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 39 R22.htm IDEA: XBRL DOCUMENT v3.21.1

Balance Sheet Details (Tables)
12 Months Ended

Dec. 31, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Components of Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consisted of the following (in thousands):

December 31,

2020

December 31,

2019

Prepaid research and development costs

$

3,062

$

2,478

Australian tax incentive receivable

1,720

929

Prepaid insurance

693

648

Interest receivable

113

224

Prepaid expenses and other assets

1,024

668

Total

$

6,612

$

4,947

Components of Property and Equipment, Net
Property and equipment, net consisted of the following (in thousands):

December 31,

2020

December 31,

2019

Leasehold improvements

$

3,494

$

3,494

Lab equipment

1,551

1,468

Office equipment

653

567

Computers and software

41

41

Property and equipment at cost

5,739

5,570

Less accumulated depreciation and amortization

2,558

1,624

Total

$

3,181

$

3,946

X

- Definition
Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R23.htm IDEA: XBRL DOCUMENT v3.21.1

Operating Lease (Tables)
12 Months Ended

Dec. 31, 2020

Leases [Abstract]

Schedule of Future Minimum Payments Under Non-cancellable Operating Leases As of December 31, 2020, future minimum payments under non-cancellable operating leases were as follows (in thousands):

Year ending December 31,

Minimum

Payments

2021

$

1,173

2022

1,208

2023

1,244

2024

1,280

2025

871

Total future minimum lease payments

5,776

Less imputed interest

927

Total operating lease liability

4,849

Less operating lease liability, current

835

Operating lease liability, non-current

$

4,014

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 1,3)
-URI http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41499-112717

Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121555522&loc=d3e12069-110248

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121549808&loc=d3e36991-112694
+ Details

Name: us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R24.htm IDEA: XBRL DOCUMENT v3.21.1

Equity Incentive Plans (Tables)
12 Months Ended

Dec. 31, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Activity Under Stock Option Plans
Activity under the Company’s stock option plans during the year ended December 31, 2020 was as follows:

Weighted-

Weighted-

Aggregate

Average

Average

Intrinsic

Options

Exercise

Remaining

Value

Outstanding

Price

Term

(000’s)

Balance at December 31, 2019

3,127,391

$

11.52

Granted

1,604,470

$

19.16

Exercised

(170,696

)

$

1.68

Forfeited and expired

(139,632

)

$

19.51

Balance at December 31, 2020

4,421,533

$

14.42

8.1

$

15,930

Vested and expected to vest at December 31, 2020

4,421,533

$

14.42

8.1

$

15,930

Exercisable at December 31, 2020

1,957,407

$

11.02

7.4

$

11,766

Weighted Average Assumptions Used to Estimate Fair Value of Stock Options Granted to Employees The following table summarizes the weighted average assumptions used to estimate the fair value of stock options granted under the Company’s stock option plans and the shares purchasable under the ESPP during the periods presented:

Year ended December 31,

Stock Option Awards

2020

2019

2018

Expected option term

6.0 years

5.9 years

6.0 years

Expected volatility

78

%

78

%

70

%

Risk free interest rate

0.8

%

2.3

%

2.8

%

Expected dividend yield

—

%

—

%

—

%

Year ended December 31,

ESPP

2020

2019

2018

Expected option term

1.4 years

1.8 years

1.1 years

Expected volatility

84

%

65

%

66

%

Risk free interest rate

0.2

%

2.2

%

2.4

%

Expected dividend yield

—

%

—

%

—

%

Summary of Stock-based Compensation Expense for the Equity Awards Issued to Employees and Non-Employees
Stock-based compensation expense for the equity awards issued by the Company to employees and non-employees for the periods presented below was as follows (in thousands):

Year ended December 31,

2020

2019

2018

Included in research and development

$

5,218

$

3,190

$

1,100

Included in general and administrative

5,209

3,104

1,220

Total stock-based compensation expense

$

10,427

$

6,294

$

2,320

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901
+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R25.htm IDEA: XBRL DOCUMENT v3.21.1

Income Taxes (Tables)
12 Months Ended

Dec. 31, 2020

Income Tax Disclosure [Abstract]

Schedule of Deferred Tax Assets and Liabilities
Deferred tax assets and liabilities

Net deferred tax assets are comprised of the following as of December 31, 2020 and 2019 (in thousands):

December 31,

2020

2019

Deferred tax assets:

Net operating loss carryforwards

$

33,994

$

15,990

Capitalized research expenses

4,231

4,864

R&D and other tax credits

6,881

4,676

Stock-based compensation

3,233

1,343

Lease liability

1,358

1,560

Accrued expenses and other, net

1,932

886

Total deferred tax assets

51,629

29,319

Deferred tax liabilities:

Right-of use asset

(625

)

(702

)

Other deferred tax liabilities

(132

)

(22

)

Net of deferred tax assets and liabilities

50,872

28,595

Less: valuation allowance

(50,872

)

(28,595

)

Net deferred tax assets

$

—

$

—

Schedule of Domestic and Foreign Pre-Tax Loss
Income tax benefit

For the three years in the period ended December 31, 2020, domestic and foreign pre-tax loss were (in thousands):

Year ended December 31,

2020

2019

2018

Loss before income taxes - Domestic

$

(71,769

)

$

(48,643

)

$

(25,876

)

Loss before income taxes - Foreign

(2,043

)

(1,779

)

(1,239

)

Loss before income taxes - Consolidated

$

(73,812

)

$

(50,422

)

$

(27,115

)

Schedule of Reconciliation of Income Tax Expense

A reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate to the loss from operations for the three years in the period ended December 31, 2020 is as follows (in thousands):

Year ended December 31,

2020

2019

2018

Expected income tax benefit at federal statutory rate

$

(15,417

)

$

(10,589

)

$

(5,694

)

State income tax benefit, net of federal benefit

(4,886

)

(3,431

)

(1,758

)

Tax effect of

Change in valuation allowance

22,242

16,064

7,724

R&D credit

(2,597

)

(2,485

)

(1,129

)

Federal rate change

—

—

(52

)

Australian tax incentive

215

307

362

Other

443

134

547

Provision for income taxes

$

—

$

—

$

—

Schedule of Unrecognized Tax Benefits
Changes to the Company’s unrecognized tax benefits are summarized in the following table (in thousands):

Year ended December 31,

2020

2019

2018

Beginning balance

$

886

$

344

$

159

Increase (decrease) for prior year tax positions

(163

)

70

—

Increase (decrease) for current year tax positions

369

472

185

Ending balance

$

1,092

$

886

$

344

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of income before income tax between domestic and foreign jurisdictions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
+ Details

Name: us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the change in unrecognized tax benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 55
-Paragraph 217
-URI http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319
+ Details

Name: us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R26.htm IDEA: XBRL DOCUMENT v3.21.1

Organization and Basis of Presentation - Additional Information (Details)
12 Months Ended

Jul. 06, 2018

Dec. 31, 2020

USD ($)

Segment

Dec. 31, 2019

USD ($)

Organization And Basis Of Presentation [Line Items]

Number of operating segments | Segment 1

Unrestricted cash, cash equivalents and investments securities $ 170,900,000

Accumulated deficit $ 167,614,000 $ 93,802,000

Minimum

Organization And Basis Of Presentation [Line Items]

Period of sufficient cash to meet its funding requirements 12 months

Common Stock

Organization And Basis Of Presentation [Line Items]

Stock reverse stock split 1-for-3.29

Stock split conversion ratio 0.3040

X

- Definition
Organization and basis of presentation.
+ References
No definition available.
+ Details

Name: crnx_OrganizationAndBasisOfPresentationLineItems

Namespace Prefix: crnx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Period of sufficient cash to meet its funding requirements.
+ References
No definition available.
+ Details

Name: crnx_PeriodOfSufficientCashToMeetItsFundingRequirements

Namespace Prefix: crnx_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CashCashEquivalentsAndShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599
+ Details

Name: us-gaap_NumberOfOperatingSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770
+ Details

Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1

Namespace Prefix: us-gaap_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770
+ Details

Name: us-gaap_StockholdersEquityReverseStockSplit

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 44 R27.htm IDEA: XBRL DOCUMENT v3.21.1

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)
12 Months Ended

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Summary Of Significant Accounting Policies [Line Items]

Impairment losses of long-lived assets $ 0 $ 0 $ 0

Australian Research and Development Tax Incentive | Australian Taxation Office

Summary Of Significant Accounting Policies [Line Items]

Tax incentive receivable, reductions to research and development expense 600,000 1,000,000 $ 1,200,000

Accounts Payable And Accrued Expenses

Summary Of Significant Accounting Policies [Line Items]

Accrued R&D expenses $ 2,100,000 $ 2,800,000

Computer and Software

Summary Of Significant Accounting Policies [Line Items]

Property and equipment, estimated useful life 3 years

Minimum | Lab Equipment

Summary Of Significant Accounting Policies [Line Items]

Property and equipment, estimated useful life 3 years

Minimum | Office Equipment

Summary Of Significant Accounting Policies [Line Items]

Property and equipment, estimated useful life 3 years

Maximum [Member] | Lab Equipment

Summary Of Significant Accounting Policies [Line Items]

Property and equipment, estimated useful life 5 years

Maximum [Member] | Office Equipment

Summary Of Significant Accounting Policies [Line Items]

Property and equipment, estimated useful life 5 years

X

- Definition
Accrued research and development expenses.
+ References
No definition available.
+ Details

Name: crnx_AccruedResearchAndDevelopmentExpenses

Namespace Prefix: crnx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Summary of significant accounting policies.
+ References
No definition available.
+ Details

Name: crnx_SummaryOfSignificantAccountingPoliciesLineItems

Namespace Prefix: crnx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tax incentive receivable reduction in research and development expense.
+ References
No definition available.
+ Details

Name: crnx_TaxIncentiveReceivableReductionInResearchAndDevelopmentExpense

Namespace Prefix: crnx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228
+ Details

Name: us-gaap_ImpairmentOfLongLivedAssetsHeldForUse

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=crnx_AustralianResearchAndDevelopmentTaxIncentiveProgramMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=crnx_ComputerAndSoftwareMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 R28.htm IDEA: XBRL DOCUMENT v3.21.1

Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share (Details) - shares
shares in Thousands
12 Months Ended

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]

Potentially dilutive securities excluded from calculation of diluted net loss per share 4,438 3,160 2,466

Common Stock Option

Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]

Potentially dilutive securities excluded from calculation of diluted net loss per share 4,422 3,127 2,339

Unvested Common Stock Subject To Repurchase

Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]

Potentially dilutive securities excluded from calculation of diluted net loss per share 16 33 127

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=crnx_UnvestedCommonStockSubjectToRepurchaseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 46 R29.htm IDEA: XBRL DOCUMENT v3.21.1

Investment Securities - Summary of Available-For-Sale Investment Securities Held by the Company (Details) - USD ($)
$ in Thousands

Dec. 31, 2020

Dec. 31, 2019

Schedule Of Available For Sale Securities [Line Items]

Available-for-sale investment securities, Amortized Cost $ 77,768 $ 77,918

Available-for-sale investment securities, Gross Unrealized Gains 30 152

Available-for-sale investment securities, Gross Unrealized Losses (5) (4)

Available-for-sale investment securities, Fair Market Value 77,793 78,066

U.S. Government and Agency Obligations

Schedule Of Available For Sale Securities [Line Items]

Available-for-sale investment securities, Amortized Cost 74,222 43,275

Available-for-sale investment securities, Gross Unrealized Gains 6 94

Available-for-sale investment securities, Gross Unrealized Losses (5) (1)

Available-for-sale investment securities, Fair Market Value 74,223 43,368

Certificates of Deposit

Schedule Of Available For Sale Securities [Line Items]

Available-for-sale investment securities, Amortized Cost 2,161 5,931

Available-for-sale investment securities, Gross Unrealized Gains 14 51

Available-for-sale investment securities, Fair Market Value 2,175 5,982

Commercial Paper

Schedule Of Available For Sale Securities [Line Items]

Available-for-sale investment securities, Amortized Cost 17,645

Available-for-sale investment securities, Fair Market Value 17,645

Corporate Debt Securities

Schedule Of Available For Sale Securities [Line Items]

Available-for-sale investment securities, Amortized Cost 1,385 11,067

Available-for-sale investment securities, Gross Unrealized Gains 10 7

Available-for-sale investment securities, Gross Unrealized Losses (3)

Available-for-sale investment securities, Fair Market Value $ 1,395 $ 11,071

X

- Definition
Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (aa)
-URI http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 47 R30.htm IDEA: XBRL DOCUMENT v3.21.1

Investment Securities - Additional Information (Details) - Security

Dec. 31, 2020

Dec. 31, 2019

Investments Debt And Equity Securities [Abstract]

Available-for-sale investment securities maturity period, maximum 24 months 24 months

Available-for-sale, unrealized loss position, twelve month or more 0

X

- Definition
Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 50
-Paragraph 4
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455
+ Details

Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_DebtSecuritiesAvailableForSaleTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 48 R31.htm IDEA: XBRL DOCUMENT v3.21.1

Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)
$ in Thousands

Dec. 31, 2020

Dec. 31, 2019

Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]

Total assets measured at fair value $ 77,793 $ 78,066

Level 1

Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]

Total assets measured at fair value 60,222 15,478

Level 2

Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]

Total assets measured at fair value 17,571 62,588

Certificates of Deposit

Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]

Total assets measured at fair value 2,175 5,982

Certificates of Deposit | Level 2

Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]

Total assets measured at fair value 2,175 5,982

Corporate Debt Securities

Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]

Total assets measured at fair value 1,395 11,071

Corporate Debt Securities | Level 2

Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]

Total assets measured at fair value 1,395 11,071

U.S. Government and Agency Obligations

Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]

Total assets measured at fair value 74,223 43,368

U.S. Government and Agency Obligations | Level 1

Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]

Total assets measured at fair value 60,222 15,478

U.S. Government and Agency Obligations | Level 2

Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]

Total assets measured at fair value $ 14,001 27,890

Commercial Paper

Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]

Total assets measured at fair value 17,645

Commercial Paper | Level 2

Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]

Total assets measured at fair value $ 17,645

X

- Definition
Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_AssetsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 49 R32.htm IDEA: XBRL DOCUMENT v3.21.1

Fair Value Measurements - Additional Information (Details) - USD ($)
12 Months Ended

Dec. 31, 2020

Dec. 31, 2019

Fair Value Disclosures [Abstract]

Fair value assets transferred into level 3 $ 0 $ 0

Fair value assets transferred into level 3 0 0

Fair value assets transferred into level 3 0 0

Fair value assets transferred into level 3 $ 0 $ 0

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 50 R33.htm IDEA: XBRL DOCUMENT v3.21.1

Balance Sheet Details - Components of Prepaid Expenses and Other Current Assets (Details) - USD ($)
$ in Thousands

Dec. 31, 2020

Dec. 31, 2019

Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]

Prepaid research and development costs $ 3,062 $ 2,478

Australian tax incentive receivable 1,720 929

Prepaid insurance 693 648

Interest receivable 113 224

Prepaid expenses and other assets 1,024 668

Total $ 6,612 $ 4,947

X

- Definition
Foreign tax incentive receivable, current.
+ References
No definition available.
+ Details

Name: crnx_ForeignTaxIncentiveReceivableCurrent

Namespace Prefix: crnx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of consideration paid in advance for research and development that provides economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
No definition available.
+ Details

Name: crnx_PrepaidResearchAndDevelopmentCostsCurrent

Namespace Prefix: crnx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InterestReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of current assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765
+ Details

Name: us-gaap_PrepaidInsurance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 51 R34.htm IDEA: XBRL DOCUMENT v3.21.1

Balance Sheet Details - Components of Property and Equipment, Net (Details) - USD ($)
$ in Thousands

Dec. 31, 2020

Dec. 31, 2019

Property Plant And Equipment [Line Items]

Property and equipment at cost $ 5,739 $ 5,570

Less accumulated depreciation and amortization 2,558 1,624

Total 3,181 3,946

Leasehold Improvements

Property Plant And Equipment [Line Items]

Property and equipment at cost 3,494 3,494

Lab Equipment

Property Plant And Equipment [Line Items]

Property and equipment at cost 1,551 1,468

Office Equipment

Property Plant And Equipment [Line Items]

Property and equipment at cost 653 567

Computers and Software

Property Plant And Equipment [Line Items]

Property and equipment at cost $ 41 $ 41

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 52 R35.htm IDEA: XBRL DOCUMENT v3.21.1

Balance Sheet Details - Additional Information (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Property Plant And Equipment [Abstract]

Depreciation expense $ 0.9 $ 0.9 $ 0.5

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 53 R36.htm IDEA: XBRL DOCUMENT v3.21.1

Operating Lease - Additional Information (Details) - 2018 Operating Lease - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Operating Leased Assets [Line Items]

Operating lease, initial term 7 years

Operating lease expiration period 2025-08

Operating lease, option to extend term five years

Lessee,operating lease, discount rate 8.00%

Irrevocable letter of credit $ 0.5

Rent expense 1.0 $ 1.0 $ 0.6

Cash paid for operating lease liabilities $ 1.1 $ 1.1

X

- Definition
Operating lease expiration period.
+ References
No definition available.
+ Details

Name: crnx_OperatingLeaseExpirationPeriod

Namespace Prefix: crnx_

Data Type: xbrli:gYearMonthItemType

Balance Type: na

Period Type: duration

X

- Definition
Discount rate used by lessee to determine present value of operating lease payments.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseDiscountRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseOptionToExtend

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseTermOfContract

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.
+ References
No definition available.
+ Details

Name: us-gaap_LettersOfCreditOutstandingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 5
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeasePayments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingLeasedAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41499-112717
+ Details

Name: us-gaap_OperatingLeasesRentExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_LeaseContractualTermAxis=crnx_TwoThousandEighteenOperatingLeaseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 54 R37.htm IDEA: XBRL DOCUMENT v3.21.1

Operating Lease - Schedule of Future Minimum Payments Under Non-cancellable Operating Leases (Details) - USD ($)
$ in Thousands

Dec. 31, 2020

Dec. 31, 2019

Leases [Abstract]

2021 $ 1,173

2022 1,208

2023 1,244

2024 1,280

2025 871

Total future minimum lease payments 5,776

Less imputed interest 927

Total operating lease liability $ 4,849

Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Less operating lease liability, current

Less operating lease liability, current $ 835

Operating lease liability, non-current 4,014 $ 4,849

Total operating lease liabilities $ 4,849

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Indicates line item in statement of financial position that includes current operating lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList

Namespace Prefix: us-gaap_

Data Type: srt-types:extensibleListItemType

Balance Type: na

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 55 R38.htm IDEA: XBRL DOCUMENT v3.21.1

Convertible Preferred Stock - Additional Information (Details) - USD ($)
2 Months Ended 9 Months Ended 12 Months Ended

Jul. 20, 2018

Mar. 31, 2018

Dec. 31, 2017

Dec. 31, 2018

Temporary Equity [Line Items]

Net proceeds from issuance of convertible preferred stock $ 63,275,000

Series A Convertible Preferred Stock

Temporary Equity [Line Items]

Convertible preferred stock, shares issued 11,505,268

Net proceeds from issuance of convertible preferred stock $ 12,000,000

Convertible preferred stock, issuance costs $ 40,000

Series B Convertible Preferred Stock

Temporary Equity [Line Items]

Convertible preferred stock, shares issued 19,641,200

Net proceeds from issuance of convertible preferred stock $ 63,500,000

Convertible preferred stock, issuance costs $ 200,000

Series A and B Convertible Preferred Stock | Initial Public Offering

Temporary Equity [Line Items]

Stock issued upon conversion of convertible securities 14,712,571

X

- Definition
The cash outflow for cost incurred directly with the issuance of an equity security.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-30)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27)(b))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_TemporaryEquitySharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=crnx_SeriesAConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=crnx_SeriesBConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=crnx_SeriesAAndBConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 56 R39.htm IDEA: XBRL DOCUMENT v3.21.1

Stockholder's Equity - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended

Apr. 17, 2020

Aug. 13, 2019

Jul. 31, 2018

Oct. 31, 2015

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Jul. 20, 2018

Subsidiary Sale Of Stock [Line Items]

Common stock, shares authorized 200,000,000 200,000,000

Common stock and paid-in capital, par value $ 0.001 $ 0.001

Preferred stock, shares authorized 10,000,000 10,000,000

Preferred stock, par value $ 0.001 $ 0.001

Offering discounts commissions and offering costs net $ 10,800

Proceeds from issuance of common stock, net $ 75,000 $ 114,283 $ 106,472

Maximum amount of common stock preferred stock debt securities warrants and units to be issued 300,000

Registration statement effective date Aug. 29, 2019

Common stock and paid-in capital, shares issued 33,017,000 24,296,000

Stock-based compensation expenses $ 10,427 $ 6,294 $ 2,320

Stock Restriction Agreement

Subsidiary Sale Of Stock [Line Items]

Unrestricted shares of common stock repurchased 1,914,893

Common stock repurchase rights lapsed 765,957

Common stock repurchase rights to be lapsed monthly thereafter till fully vested in October 2019 23,936

Stock-based compensation expenses $ 400

SVB Leerink LLC and Cantor Fitzgerald & Co. | Maximum [Member]

Subsidiary Sale Of Stock [Line Items]

Sale of common stock at offering price $ 75,000

Common Stock

Subsidiary Sale Of Stock [Line Items]

Sale of common stock 8,499,000 6,900,000

Issuance of common stock, net of transaction costs, shares 8,499,000 6,900,000

Initial Public Offering

Subsidiary Sale Of Stock [Line Items]

Common stock, shares authorized 200,000,000

Common stock and paid-in capital, par value $ 0.001

Preferred stock, shares authorized 10,000,000

Preferred stock, par value $ 0.001

Proceeds from issuance initial public offering $ 106,500

Offering discounts commissions and offering costs net $ 7,300

Proceeds from issuance of common stock, net $ 107,900

Initial Public Offering | Common Stock

Subsidiary Sale Of Stock [Line Items]

Sale of common stock 8,222,500 6,900,000

Common stock price per share $ 14.00 $ 17.00

Issuance of common stock, net of transaction costs, shares 8,222,500 6,900,000

Common stock price per share $ 14.00 $ 17.00

ATM Offering

Subsidiary Sale Of Stock [Line Items]

Offering discounts commissions and offering costs net $ 200

Proceeds from issuance of common stock, net $ 6,400

Common stock and paid-in capital, shares issued 275,764

X

- Definition
Maximum amount of common stock preferred stock debt securities warrants and units to be issued.
+ References
No definition available.
+ Details

Name: crnx_MaximumAmountOfCommonStockPreferredStockDebtSecuritiesWarrantsAndUnitsToBeIssued

Namespace Prefix: crnx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Offering discounts, commissions and offering costs, net.
+ References
No definition available.
+ Details

Name: crnx_OfferingDiscountsCommissionsAndOfferingCostsNet

Namespace Prefix: crnx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Share based compensation arrangement by share based payment award shares of common stock to be lapsed per month thereafter.
+ References
No definition available.
+ Details

Name: crnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesOfCommonStockToBeLapsedThereafter

Namespace Prefix: crnx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases.
+ References
No definition available.
+ Details

Name: dei_DocumentEffectiveDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares to be repurchased in accordance with a policy to use treasury stock to satisfy share-award conversions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (l)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationEstimatedQuantityOfSharesToBeRepurchasedInFollowingPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow associated with the amount received from entity's first offering of stock to the public.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Cash received on stock transaction after deduction of issuance costs.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(4)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_SubsidiarySaleOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TypeOfArrangementAxis=crnx_StockRestrictionAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=crnx_SVBLeerinkLLCAndCantorFitzgeraldCoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=crnx_AtTheMarketOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 57 R40.htm IDEA: XBRL DOCUMENT v3.21.1

Equity Incentive Plans - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 12 Months Ended

Jan. 01, 2021

Jul. 31, 2018

Feb. 28, 2015

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Total intrinsic value of options exercised $ 2.5 $ 2.0 $ 2.4

Dividend yield 0.00%

Weighted-average fair value of stock options granted to employees per share $ 12.83 $ 16.35 $ 4.66

Unrecognized stock-based compensation cost $ 26.9

Weighted-average period of unrecognized stock-based compensation cost expected to be recognized over remaining period 2 years 4 months 24 days

ESPP

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Maximum percentage of eligible compensation to purchase common stock through payroll deductions 20.00%

Weighted-average fair value of stock options granted to employees per share $ 8.07 $ 10.59 $ 8.15

Unrecognized stock-based compensation cost $ 1.3

Weighted-average period of unrecognized stock-based compensation cost expected to be recognized over remaining period 1 year 7 months 6 days

2018 Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Plan expiration period 2028-07

Plan expiration term 10 years

Vesting period 4 years

Plan expiration date Jan. 01, 2028

Annual increase in the number of shares available for issuance 5.00%

Remaining shares available for issuance 1,967,191

2015 Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Plan expiration term 10 years

Vesting period 4 years

Shares issued under early-exercise provisions subject to repurchase 15,951

Unvested stock liability $ 23,000.0 $ 49,000.0

Common Stock | ESPP

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Plan expiration date Jan. 01, 2028

Shares reserved for issuance, authorized 614,223

Common Stock | Subsequent Event | ESPP

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Additional shares available for future issuance 330,169

Common Stock | 2018 Plan | Subsequent Event

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Additional shares available for future issuance 1,650,846

X

- Definition
Share-based compensation arrangement by share-based payment award expiration date 1.
+ References
No definition available.
+ Details

Name: crnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate1

Namespace Prefix: crnx_

Data Type: xbrli:gYearMonthItemType

Balance Type: na

Period Type: duration

X

- Definition
The minimum perentage of annual increase in number of shares available for issuance under share based arrangement.
+ References
No definition available.
+ Details

Name: crnx_SharebasedCompensationArrangementAnnualIncreaseInNumberOfSharesAvailableForIssuanceMinimumPercentage

Namespace Prefix: crnx_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate number of common shares reserved for future issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cost to be recognized for option under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Date the equity-based award expires, in CCYY-MM-DD format.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of additional shares authorized for issuance under share-based payment arrangement.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares authorized for issuance under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
An entity expecting to repurchase shares in the following period, generally discloses an estimate of the amount or range of shares to be repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (l)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesToBeRepurchasedNextYear

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=crnx_TwoThousandEighteenIncentiveAwardPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=crnx_TwoThousandFifteenStockIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 58 R41.htm IDEA: XBRL DOCUMENT v3.21.1

Equity Incentive Plans - Summary of Activity Under Stock Option Plans (Details)
$ / shares in Units, $ in Thousands
12 Months Ended

Dec. 31, 2020

USD ($)

$ / shares

shares

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Options Outstanding, Beginning balance | shares 3,127,391

Options Outstanding, Granted | shares 1,604,470

Options Outstanding, Exercised | shares (170,696)

Options Outstanding, Forfeited and expired | shares (139,632)

Options Outstanding, Ending balance | shares 4,421,533

Options Outstanding,Vested and expected to vest | shares 4,421,533

Options Exercisable, Ending balance | shares 1,957,407

Weighted-Average Exercise Price, Beginning balance | $ / shares $ 11.52

Weighted-Average Exercise Price, Granted | $ / shares 19.16

Weighted Average Exercise Price, Exercised | $ / shares 1.68

Weighted Average Exercise Price, Forfeited and expired | $ / shares 19.51

Weighted-Average Exercise Price, Ending balance | $ / shares 14.42

Weighted-Average Exercise Price, Vested and expected to vest | $ / shares 14.42

Weighted-Average Exercise Price, Exercisable | $ / shares $ 11.02

Weighted-Average Remaining Term, Ending balance 8 years 1 month 6 days

Weighted-Average Remaining Term, Vested and expected to vest 8 years 1 month 6 days

Weighted-Average Remaining Term, Exercisable 7 years 4 months 24 days

Aggregate Intrinsic Value, Ending balance | $ $ 15,930

Aggregate Intrinsic Value, Vested and expected to vest | $ 15,930

Aggregate Intrinsic Value, Exercisable | $ $ 11,766

X

- Definition
Share-based compensation arrangement by share-based payment award options forfeited and expired.
+ References
No definition available.
+ Details

Name: crnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedAndExpired

Namespace Prefix: crnx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price of options that were either forfeited or expired.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)-(4)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 59 R42.htm IDEA: XBRL DOCUMENT v3.21.1

Equity Incentive Plans - Weighted Average Assumptions Used to Estimate Fair Value of Stock Options Granted to Employees (Details)
12 Months Ended

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Expected dividend yield 0.00%

ESPP

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Expected option term 1 year 4 months 24 days 1 year 9 months 18 days 1 year 1 month 6 days

Expected volatility 84.00% 65.00% 66.00%

Risk free interest rate 0.20% 2.20% 2.40%

Stock Options

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Expected option term 6 years 5 years 10 months 24 days 6 years

Expected volatility 78.00% 78.00% 70.00%

Risk free interest rate 0.80% 2.30% 2.80%

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_StockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 60 R43.htm IDEA: XBRL DOCUMENT v3.21.1

Equity Incentive Plans - Stock-based Compensation Expense Recognized (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Stock-based compensation expense $ 10,427 $ 6,294 $ 2,320

Included in Research and Development

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Stock-based compensation expense 5,218 3,190 1,100

Included in General and Administrative

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Stock-based compensation expense $ 5,209 $ 3,104 $ 1,220

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 61 R44.htm IDEA: XBRL DOCUMENT v3.21.1

Income Taxes - Additional Information (Details) - USD ($)
12 Months Ended

Dec. 31, 2020

Dec. 31, 2019

Operating Loss Carryforwards [Line Items]

Federal operating loss carryforwards $ 118,200,000

State operating loss carryforwards 124,100,000

Domestic operating loss carryforwards 1,600,000

Federal loss carryforwards 111,900,000

Research and development credit carryforwards 6,881,000 $ 4,676,000

Research and development credit Carryforwards, Other $ 1,400

Operating loss and research and development credit carryforwards, limitations on use The Company’s NOL and credit carryforwards to offset future taxable income may be subject to a substantial annual limitation as a result of ownership changes that could occur in the future pursuant to Internal Revenue Code Sections 382 and 383. These ownership changes may limit the amount of NOL and credit carryforwards that can be utilized to offset future taxable income and income tax, respectively. In general, an “ownership change” as defined by the tax code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percent of the outstanding stock of a company by certain stockholders or public groups.

Minimum

Operating Loss Carryforwards [Line Items]

Cumulative change in ownership percentage 50.00%

Maximum [Member]

Operating Loss Carryforwards [Line Items]

Period for cumulative change in ownership 3 years

California

Operating Loss Carryforwards [Line Items]

Research and development credit carryforwards $ 2,700,000

Federal

Operating Loss Carryforwards [Line Items]

Operating loss carryforwards, future taxable income, offset percentage 80.00%

Research and development credit carryforwards $ 4,500,000

Research and development credit carryforwards, begin to expire 2030

Federal | Earliest Tax Year

Operating Loss Carryforwards [Line Items]

Operating loss carryforwards expiration year 2035

State | Earliest Tax Year

Operating Loss Carryforwards [Line Items]

Operating loss carryforwards expiration year 2035

X

- Definition
Cumulative change in ownership percentage.
+ References
No definition available.
+ Details

Name: crnx_CumulativeChangeInOwnershipPercentage

Namespace Prefix: crnx_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Deferred tax assets tax credit carry forwards research begin to expire.
+ References
No definition available.
+ Details

Name: crnx_DeferredTaxAssetsTaxCreditCarryForwardsResearchBeginToExpire

Namespace Prefix: crnx_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Federal loss carryforwards.
+ References
No definition available.
+ Details

Name: crnx_FederalLossCarryforwards

Namespace Prefix: crnx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Operating loss carryforwards expiration year.
+ References
No definition available.
+ Details

Name: crnx_OperatingLossCarryforwardsExpirationYear

Namespace Prefix: crnx_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of loss carryforwards offset through future taxable income.
+ References
No definition available.
+ Details

Name: crnx_PercentageOfLossCarryforwardsOffsetThroughFutureTaxableIncome

Namespace Prefix: crnx_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Period for cumulative change In ownership.
+ References
No definition available.
+ Details

Name: crnx_PeriodForCumulativeChangeInOwnership

Namespace Prefix: crnx_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319
+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingLossCarryforwardsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of the limitation related to use of the tax credit carryforward.
+ References
No definition available.
+ Details

Name: us-gaap_TaxCreditCarryforwardLimitationsOnUse

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=stpr_CA

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 62 R45.htm IDEA: XBRL DOCUMENT v3.21.1

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands

Dec. 31, 2020

Dec. 31, 2019

Deferred tax assets:

Net operating loss carryforwards $ 33,994 $ 15,990

Capitalized research expenses 4,231 4,864

R&D and other tax credits 6,881 4,676

Stock-based compensation 3,233 1,343

Lease liability 1,358 1,560

Accrued expenses and other, net 1,932 886

Total deferred tax assets 51,629 29,319

Deferred tax liabilities:

Right-of use asset (625) (702)

Other deferred tax liabilities (132) (22)

Net of deferred tax assets and liabilities 50,872 28,595

Less: valuation allowance (50,872) (28,595)

Net deferred tax assets $ 0 $ 0

X

- Definition
Deferred tax liabilities right-of-use asset.
+ References
No definition available.
+ Details

Name: crnx_DeferredTaxLiabilitiesRightOfUseAsset

Namespace Prefix: crnx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ComponentsOfDeferredTaxAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319
+ Details

Name: us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsLiabilitiesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxLiabilitiesLeasingArrangements

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxLiabilitiesOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319
+ Details

Name: us-gaap_OperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 63 R46.htm IDEA: XBRL DOCUMENT v3.21.1

Income Taxes - Schedule of Domestic and Foreign Pre-Tax Loss (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Loss before income taxes - Domestic $ (71,769) $ (48,643) $ (25,876)

Loss before income taxes - Foreign (2,043) (1,779) (1,239)

Loss before income taxes - Consolidated $ (73,812) $ (50,422) $ (27,115)

X

- Definition
The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.3)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.3)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 64 R47.htm IDEA: XBRL DOCUMENT v3.21.1

Income Taxes - Schedule of Reconciliation of Income Tax Expense (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Expected income tax benefit at federal statutory rate $ (15,417) $ (10,589) $ (5,694)

State income tax benefit, net of federal benefit (4,886) (3,431) (1,758)

Change in valuation allowance 22,242 16,064 7,724

R&D credit (2,597) (2,485) (1,129)

Federal rate change 0 0 (52)

Australian tax incentive 215 307 362

Other 443 134 547

Provision for income taxes $ 0 $ 0 $ 0

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120406818&loc=d3e32059-109318

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationOtherAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationTaxCreditsResearch

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax settlement.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationTaxSettlementsForeign

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 65 R48.htm IDEA: XBRL DOCUMENT v3.21.1

Income Taxes - Schedule of Unrecognized Tax Benefits (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Beginning balance $ 886 $ 344 $ 159

Increase (decrease) for prior year tax positions (163) 70 0

Increase (decrease) for current year tax positions 369 472 185

Ending balance $ 1,092 $ 886 $ 344

X

- Definition
Unrecognized tax benefits increase decrease resulting from prior period tax positions.
+ References
No definition available.
+ Details

Name: crnx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions

Namespace Prefix: crnx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of unrecognized tax benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 10B
-URI http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

EXCEL 66 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.crinetics.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Consolidated Balance Sheets Sheet http://www.crinetics.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.crinetics.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.crinetics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 100040 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) Sheet http://www.crinetics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) Statements 5 false false R6.htm 100050 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) Sheet http://www.crinetics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) Statements 6 false false R7.htm 100060 - Statement - Consolidated Statements of Cash Flows Sheet http://www.crinetics.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 100070 - Disclosure - Organization and Basis of Presentation Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentation Organization and Basis of Presentation Notes 8 false false R9.htm 100080 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 100090 - Disclosure - Investment Securities Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureInvestmentSecurities Investment Securities Notes 10 false false R11.htm 100100 - Disclosure - Fair Value Measurements Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 100110 - Disclosure - Balance Sheet Details Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureBalanceSheetDetails Balance Sheet Details Notes 12 false false R13.htm 100120 - Disclosure - Operating Lease Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureOperatingLease Operating Lease Notes 13 false false R14.htm 100130 - Disclosure - Commitments and Contingencies Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 100140 - Disclosure - Convertible Preferred Stock Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStock Convertible Preferred Stock Notes 15 false false R16.htm 100150 - Disclosure - Stockholder's Equity Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureStockholderSEquity Stockholder's Equity Notes 16 false false R17.htm 100160 - Disclosure - Equity Incentive Plans Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureEquityIncentivePlans Equity Incentive Plans Notes 17 false false R18.htm 100170 - Disclosure - Income Taxes Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 18 false false R19.htm 100180 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.crinetics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 19 false false R20.htm 100190 - Disclosure - Investment Securities (Tables) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureInvestmentSecuritiesTables Investment Securities (Tables) Tables http://www.crinetics.com/20201231/taxonomy/role/DisclosureInvestmentSecurities 20 false false R21.htm 100200 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.crinetics.com/20201231/taxonomy/role/DisclosureFairValueMeasurements 21 false false R22.htm 100210 - Disclosure - Balance Sheet Details (Tables) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsTables Balance Sheet Details (Tables) Tables http://www.crinetics.com/20201231/taxonomy/role/DisclosureBalanceSheetDetails 22 false false R23.htm 100220 - Disclosure - Operating Lease (Tables) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureOperatingLeaseTables Operating Lease (Tables) Tables http://www.crinetics.com/20201231/taxonomy/role/DisclosureOperatingLease 23 false false R24.htm 100230 - Disclosure - Equity Incentive Plans (Tables) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansTables Equity Incentive Plans (Tables) Tables http://www.crinetics.com/20201231/taxonomy/role/DisclosureEquityIncentivePlans 24 false false R25.htm 100240 - Disclosure - Income Taxes (Tables) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://www.crinetics.com/20201231/taxonomy/role/DisclosureIncomeTaxes 25 false false R26.htm 100250 - Disclosure - Organization and Basis of Presentation - Additional Information (Details) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails Organization and Basis of Presentation - Additional Information (Details) Details 26 false false R27.htm 100260 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Summary of Significant Accounting Policies - Additional Information (Details) Details 27 false false R28.htm 100270 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share (Details) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInCalculationOfDilutedNetLossPerShareDetails Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share (Details) Details 28 false false R29.htm 100280 - Disclosure - Investment Securities - Summary of Available-For-Sale Investment Securities Held by the Company (Details) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureInvestmentSecuritiesSummaryOfAvailableForSaleInvestmentSecuritiesHeldByCompanyDetails Investment Securities - Summary of Available-For-Sale Investment Securities Held by the Company (Details) Details 29 false false R30.htm 100290 - Disclosure - Investment Securities - Additional Information (Details) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureInvestmentSecuritiesAdditionalInformationDetails Investment Securities - Additional Information (Details) Details 30 false false R31.htm 100300 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on Recurring Basis (Details) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on Recurring Basis (Details) Details 31 false false R32.htm 100310 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 32 false false R33.htm 100320 - Disclosure - Balance Sheet Details - Components of Prepaid Expenses and Other Current Assets (Details) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsComponentsOfPrepaidExpensesAndOtherCurrentAssetsDetails Balance Sheet Details - Components of Prepaid Expenses and Other Current Assets (Details) Details 33 false false R34.htm 100330 - Disclosure - Balance Sheet Details - Components of Property and Equipment, Net (Details) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsComponentsOfPropertyAndEquipmentNetDetails Balance Sheet Details - Components of Property and Equipment, Net (Details) Details 34 false false R35.htm 100340 - Disclosure - Balance Sheet Details - Additional Information (Details) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails Balance Sheet Details - Additional Information (Details) Details 35 false false R36.htm 100350 - Disclosure - Operating Lease - Additional Information (Details) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureOperatingLeaseAdditionalInformationDetails Operating Lease - Additional Information (Details) Details 36 false false R37.htm 100360 - Disclosure - Operating Lease - Schedule of Future Minimum Payments Under Non-cancellable Operating Leases (Details) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureOperatingLeaseScheduleOfFutureMinimumPaymentsUnderNonCancellableOperatingLeasesDetails Operating Lease - Schedule of Future Minimum Payments Under Non-cancellable Operating Leases (Details) Details 37 false false R38.htm 100380 - Disclosure - Convertible Preferred Stock - Additional Information (Details) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureConvertiblePreferredStockAdditionalInformationDetails Convertible Preferred Stock - Additional Information (Details) Details 38 false false R39.htm 100390 - Disclosure - Stockholder's Equity - Additional Information (Details) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureStockholderSEquityAdditionalInformationDetails Stockholder's Equity - Additional Information (Details) Details 39 false false R40.htm 100400 - Disclosure - Equity Incentive Plans - Additional Information (Details) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails Equity Incentive Plans - Additional Information (Details) Details 40 false false R41.htm 100410 - Disclosure - Equity Incentive Plans - Summary of Activity Under Stock Option Plans (Details) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails Equity Incentive Plans - Summary of Activity Under Stock Option Plans (Details) Details 41 false false R42.htm 100420 - Disclosure - Equity Incentive Plans - Weighted Average Assumptions Used to Estimate Fair Value of Stock Options Granted to Employees (Details) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedToEmployeesDetails Equity Incentive Plans - Weighted Average Assumptions Used to Estimate Fair Value of Stock Options Granted to Employees (Details) Details 42 false false R43.htm 100430 - Disclosure - Equity Incentive Plans - Stock-based Compensation Expense Recognized (Details) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureEquityIncentivePlansStockBasedCompensationExpenseRecognizedDetails Equity Incentive Plans - Stock-based Compensation Expense Recognized (Details) Details 43 false false R44.htm 100440 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 44 false false R45.htm 100450 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) Details 45 false false R46.htm 100470 - Disclosure - Income Taxes - Schedule of Domestic and Foreign Pre-Tax Loss (Details) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDomesticAndForeignPreTaxLossDetails Income Taxes - Schedule of Domestic and Foreign Pre-Tax Loss (Details) Details 46 false false R47.htm 100480 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense (Details) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseDetails Income Taxes - Schedule of Reconciliation of Income Tax Expense (Details) Details 47 false false R48.htm 100490 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details) Sheet http://www.crinetics.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails Income Taxes - Schedule of Unrecognized Tax Benefits (Details) Details 48 false false All Reports Book All Reports crnx-20201231.xml crnx-20201231.xsd crnx-20201231_cal.xml crnx-20201231_def.xml crnx-20201231_lab.xml crnx-20201231_pre.xml http://xbrl.sec.gov/dei/2020-01-31 http://xbrl.sec.gov/stpr/2018-01-31 http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true true ZIP 71 0001564590-21-016719-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-016719-xbrl.zip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end

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2020	Feb. 26, 2021	Jun. 30, 2020
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Trading Symbol	CRNX
Entity Registrant Name	Crinetics Pharmaceuticals, Inc.
Entity Central Index Key	0001658247
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		33,028,876
Entity Public Float			$ 505.7
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Entity File Number	001-38583
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-3744114
Entity Address, Address Line One	10222 Barnes Canyon Road
Entity Address, Address Line Two	Bldg. #2
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	858
Local Phone Number	450-6464
Document Annual Report	true
Document Transition Report	false
ICFR Auditor Attestation Flag	true
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Certain sections of the registrant’s definitive proxy statement for the 2021 annual meeting of stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after end of the fiscal year covered by this Form 10-K are incorporated by reference into Part III of this Form 10-K.

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 93,087	$ 40,326
Investment securities	77,793	78,066
Prepaid expenses and other current assets	6,612	4,947
Total current assets	177,492	123,339
Property and equipment, net	3,181	3,946
Operating lease right-of-use asset	2,232	2,510
Restricted cash	500	500
Other assets	40	82
Total assets	183,445	130,377
Current liabilities:
Accounts payable and accrued expenses	5,588	5,498
Accrued compensation and related expenses	4,066	2,118
Other current liabilities	835	724
Total current liabilities	10,489	8,340
Operating lease liability, non-current	4,014	4,849
Unvested stock liability	23	49
Total liabilities	14,526	13,238
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.001 par; 10,000 shares authorized, no shares issued or outstanding at December 31, 2020 or 2019
Common stock and paid-in capital, $0.001 par; 200,000 shares authorized, 33,017 and 33,001 shares issued and outstanding at December 31, 2020; 24,296 and 24,263 shares issued and outstanding at December 31, 2019	336,508	210,793
Accumulated other comprehensive income	25	148
Accumulated deficit	(167,614)	(93,802)
Total stockholders’ equity	168,919	117,139
Total liabilities and stockholders’ equity	$ 183,445	$ 130,377

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock and paid-in capital, par value	$ 0.001	$ 0.001
Common stock and paid-in capital, shares authorized	200,000,000	200,000,000
Common stock and paid-in capital, shares issued	33,017,000	24,296,000
Common stock and paid-in capital, shares outstanding	33,001,000	24,263,000

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Grant revenues	$ 71	$ 1,193	$ 2,428
Type of Revenue Extensible List	us-gaap:GrantMember	us-gaap:GrantMember	us-gaap:GrantMember
Operating expenses:
Research and development	$ 56,998	$ 41,506	$ 24,479
General and administrative	18,026	13,519	6,659
Total operating expenses	75,024	55,025	31,138
Loss from operations	(74,953)	(53,832)	(28,710)
Other income (expense):
Interest income	991	3,460	1,748
Other income (expense), net	150	(50)	(153)
Total other income, net	1,141	3,410	1,595
Net loss	(73,812)	(50,422)	(27,115)
Other comprehensive income (loss):
Unrealized gain (loss) on investment securities	(123)	87	61
Comprehensive loss	$ (73,935)	$ (50,335)	$ (27,054)
Net loss per share:
Net loss per share - basic and diluted	$ (2.42)	$ (2.09)	$ (2.23)
Weighted average shares - basic and diluted	30,448	24,175	12,142

Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Convertible Preferred Stock	Series B Convertible Preferred Stock	Common Stock	Common stock and Paid-In Capital	Accumulated Other Comprehensive Income	Accumulated Deficit
Temporary equity, Beginning Balance at Dec. 31, 2017		$ 29,700
Temporary equity, Beginning Balance, Shares at Dec. 31, 2017		28,763,000
Beginning Balance, Shares at Dec. 31, 2017				1,550,000
Beginning Balance at Dec. 31, 2017	$ (15,022)				$ 1,243		$ (16,265)
Temporary equity, Issuance of convertible preferred stock, net of costs			$ 63,275
Temporary equity, Issuance of convertible preferred stock, net of costs, shares			19,641,000
Conversion of preferred stock into common stock	92,975	$ (92,975)			92,975
Conversion of preferred stock into common stock, shares		(48,404,000)		14,713,000
Issuance of common stock, net of transaction costs	106,472				106,472
Issuance of common stock, net of transaction costs, shares				6,900,000
Vesting of shares subject to repurchase	21				21
Vesting of shares subject to repurchase, shares				541,000
Exercise of stock options	231				231
Exercise of stock options, shares				337,000
Stock issued under Stock Purchase Plan	282				282
Issuance of stock under Stock Purchase Plan, shares				20,000
Stock-based compensation	2,320				2,320
Comprehensive income (loss)	61					$ 61
Net loss	(27,115)						(27,115)
Ending Balance at Dec. 31, 2018	160,225				203,544	61	(43,380)
Ending Balance, Shares at Dec. 31, 2018				24,061,000
Vesting of shares subject to repurchase	94				94
Vesting of shares subject to repurchase, shares				63,000
Exercise of stock options	126				126
Exercise of stock options, shares				90,000
Stock issued under Stock Purchase Plan	735				735
Issuance of stock under Stock Purchase Plan, shares				49,000
Stock-based compensation	6,294				6,294
Comprehensive income (loss)	87					87
Net loss	(50,422)						(50,422)
Ending Balance at Dec. 31, 2019	117,139				210,793	148	(93,802)
Ending Balance, Shares at Dec. 31, 2019				24,263,000
Issuance of common stock, net of transaction costs	114,283				114,283
Issuance of common stock, net of transaction costs, shares				8,499,000
Vesting of shares subject to repurchase	26				26
Vesting of shares subject to repurchase, shares				17,000
Exercise of stock options	$ 288				288
Exercise of stock options, shares	170,696			171,000
Stock issued under Stock Purchase Plan	$ 691				691
Issuance of stock under Stock Purchase Plan, shares				51,000
Stock-based compensation	10,427				10,427
Comprehensive income (loss)	(123)					(123)
Net loss	(73,812)						(73,812)
Ending Balance at Dec. 31, 2020	$ 168,919				$ 336,508	$ 25	$ (167,614)
Ending Balance, Shares at Dec. 31, 2020				33,001,000

Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2018 USD ($)
Statement Of Stockholders Equity [Abstract]
Temporary equity convertible preferred stock issuance costs	$ 225

Organization and Basis of Presentation - Additional Information (Details)		12 Months Ended
	Jul. 06, 2018	Dec. 31, 2020 USD ($) Segment	Dec. 31, 2019 USD ($)
Organization And Basis Of Presentation [Line Items]
Number of operating segments \| Segment		1
Unrestricted cash, cash equivalents and investments securities		$ 170,900,000
Accumulated deficit		$ 167,614,000	$ 93,802,000
Minimum
Organization And Basis Of Presentation [Line Items]
Period of sufficient cash to meet its funding requirements		12 months
Common Stock
Organization And Basis Of Presentation [Line Items]
Stock reverse stock split	1-for-3.29
Stock split conversion ratio	0.3040

Investment Securities - Summary of Available-For-Sale Investment Securities Held by the Company (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale investment securities, Amortized Cost	$ 77,768	$ 77,918
Available-for-sale investment securities, Gross Unrealized Gains	30	152
Available-for-sale investment securities, Gross Unrealized Losses	(5)	(4)
Available-for-sale investment securities, Fair Market Value	77,793	78,066
U.S. Government and Agency Obligations
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale investment securities, Amortized Cost	74,222	43,275
Available-for-sale investment securities, Gross Unrealized Gains	6	94
Available-for-sale investment securities, Gross Unrealized Losses	(5)	(1)
Available-for-sale investment securities, Fair Market Value	74,223	43,368
Certificates of Deposit
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale investment securities, Amortized Cost	2,161	5,931
Available-for-sale investment securities, Gross Unrealized Gains	14	51
Available-for-sale investment securities, Fair Market Value	2,175	5,982
Commercial Paper
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale investment securities, Amortized Cost		17,645
Available-for-sale investment securities, Fair Market Value		17,645
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale investment securities, Amortized Cost	1,385	11,067
Available-for-sale investment securities, Gross Unrealized Gains	10	7
Available-for-sale investment securities, Gross Unrealized Losses		(3)
Available-for-sale investment securities, Fair Market Value	$ 1,395	$ 11,071

Investment Securities - Additional Information (Details) - Security	Dec. 31, 2020	Dec. 31, 2019
Investments Debt And Equity Securities [Abstract]
Available-for-sale investment securities maturity period, maximum	24 months	24 months
Available-for-sale, unrealized loss position, twelve month or more	0

Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Total assets measured at fair value	$ 77,793	$ 78,066
Level 1
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Total assets measured at fair value	60,222	15,478
Level 2
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Total assets measured at fair value	17,571	62,588
Certificates of Deposit
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Total assets measured at fair value	2,175	5,982
Certificates of Deposit \| Level 2
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Total assets measured at fair value	2,175	5,982
Corporate Debt Securities
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Total assets measured at fair value	1,395	11,071
Corporate Debt Securities \| Level 2
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Total assets measured at fair value	1,395	11,071
U.S. Government and Agency Obligations
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Total assets measured at fair value	74,223	43,368
U.S. Government and Agency Obligations \| Level 1
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Total assets measured at fair value	60,222	15,478
U.S. Government and Agency Obligations \| Level 2
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Total assets measured at fair value	$ 14,001	27,890
Commercial Paper
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Total assets measured at fair value		17,645
Commercial Paper \| Level 2
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Total assets measured at fair value		$ 17,645

Fair Value Measurements - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Fair value assets transferred into level 3	$ 0	$ 0
Fair value assets transferred into level 3	0	0
Fair value assets transferred into level 3	0	0
Fair value assets transferred into level 3	$ 0	$ 0

Balance Sheet Details - Components of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid research and development costs	$ 3,062	$ 2,478
Australian tax incentive receivable	1,720	929
Prepaid insurance	693	648
Interest receivable	113	224
Prepaid expenses and other assets	1,024	668
Total	$ 6,612	$ 4,947

Balance Sheet Details - Components of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Property and equipment at cost	$ 5,739	$ 5,570
Less accumulated depreciation and amortization	2,558	1,624
Total	3,181	3,946
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment at cost	3,494	3,494
Lab Equipment
Property Plant And Equipment [Line Items]
Property and equipment at cost	1,551	1,468
Office Equipment
Property Plant And Equipment [Line Items]
Property and equipment at cost	653	567
Computers and Software
Property Plant And Equipment [Line Items]
Property and equipment at cost	$ 41	$ 41

Operating Lease - Schedule of Future Minimum Payments Under Non-cancellable Operating Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
2021	$ 1,173
2022	1,208
2023	1,244
2024	1,280
2025	871
Total future minimum lease payments	5,776
Less imputed interest	927
Total operating lease liability	$ 4,849
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Less operating lease liability, current
Less operating lease liability, current	$ 835
Operating lease liability, non-current	4,014	$ 4,849
Total operating lease liabilities	$ 4,849

Convertible Preferred Stock - Additional Information (Details) - USD ($)		2 Months Ended	9 Months Ended	12 Months Ended
	Jul. 20, 2018	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2018
Temporary Equity [Line Items]
Net proceeds from issuance of convertible preferred stock				$ 63,275,000
Series A Convertible Preferred Stock
Temporary Equity [Line Items]
Convertible preferred stock, shares issued			11,505,268
Net proceeds from issuance of convertible preferred stock			$ 12,000,000
Convertible preferred stock, issuance costs			$ 40,000
Series B Convertible Preferred Stock
Temporary Equity [Line Items]
Convertible preferred stock, shares issued		19,641,200
Net proceeds from issuance of convertible preferred stock		$ 63,500,000
Convertible preferred stock, issuance costs		$ 200,000
Series A and B Convertible Preferred Stock \| Initial Public Offering
Temporary Equity [Line Items]
Stock issued upon conversion of convertible securities	14,712,571

Stockholder's Equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended		12 Months Ended
	Apr. 17, 2020	Aug. 13, 2019	Jul. 31, 2018	Oct. 31, 2015	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Jul. 20, 2018
Subsidiary Sale Of Stock [Line Items]
Common stock, shares authorized					200,000,000	200,000,000
Common stock and paid-in capital, par value					$ 0.001	$ 0.001
Preferred stock, shares authorized					10,000,000	10,000,000
Preferred stock, par value					$ 0.001	$ 0.001
Offering discounts commissions and offering costs net			$ 10,800
Proceeds from issuance of common stock, net		$ 75,000			$ 114,283		$ 106,472
Maximum amount of common stock preferred stock debt securities warrants and units to be issued		300,000
Registration statement effective date					Aug. 29, 2019
Common stock and paid-in capital, shares issued					33,017,000	24,296,000
Stock-based compensation expenses					$ 10,427	$ 6,294	$ 2,320
Stock Restriction Agreement
Subsidiary Sale Of Stock [Line Items]
Unrestricted shares of common stock repurchased				1,914,893
Common stock repurchase rights lapsed				765,957
Common stock repurchase rights to be lapsed monthly thereafter till fully vested in October 2019							23,936
Stock-based compensation expenses							$ 400
SVB Leerink LLC and Cantor Fitzgerald & Co. \| Maximum [Member]
Subsidiary Sale Of Stock [Line Items]
Sale of common stock at offering price		$ 75,000
Common Stock
Subsidiary Sale Of Stock [Line Items]
Sale of common stock					8,499,000		6,900,000
Issuance of common stock, net of transaction costs, shares					8,499,000		6,900,000
Initial Public Offering
Subsidiary Sale Of Stock [Line Items]
Common stock, shares authorized								200,000,000
Common stock and paid-in capital, par value								$ 0.001
Preferred stock, shares authorized								10,000,000
Preferred stock, par value								$ 0.001
Proceeds from issuance initial public offering			$ 106,500
Offering discounts commissions and offering costs net	$ 7,300
Proceeds from issuance of common stock, net	$ 107,900
Initial Public Offering \| Common Stock
Subsidiary Sale Of Stock [Line Items]
Sale of common stock	8,222,500		6,900,000
Common stock price per share	$ 14.00		$ 17.00
Issuance of common stock, net of transaction costs, shares	8,222,500		6,900,000
Common stock price per share	$ 14.00		$ 17.00
ATM Offering
Subsidiary Sale Of Stock [Line Items]
Offering discounts commissions and offering costs net					$ 200
Proceeds from issuance of common stock, net					$ 6,400
Common stock and paid-in capital, shares issued					275,764

Equity Incentive Plans - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions		1 Months Ended		12 Months Ended
	Jan. 01, 2021	Jul. 31, 2018	Feb. 28, 2015	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total intrinsic value of options exercised				$ 2.5	$ 2.0	$ 2.4
Dividend yield				0.00%
Weighted-average fair value of stock options granted to employees per share				$ 12.83	$ 16.35	$ 4.66
Unrecognized stock-based compensation cost				$ 26.9
Weighted-average period of unrecognized stock-based compensation cost expected to be recognized over remaining period				2 years 4 months 24 days
ESPP
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum percentage of eligible compensation to purchase common stock through payroll deductions		20.00%
Weighted-average fair value of stock options granted to employees per share				$ 8.07	$ 10.59	$ 8.15
Unrecognized stock-based compensation cost				$ 1.3
Weighted-average period of unrecognized stock-based compensation cost expected to be recognized over remaining period				1 year 7 months 6 days
2018 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Plan expiration period		2028-07
Plan expiration term		10 years
Vesting period		4 years
Plan expiration date				Jan. 01, 2028
Annual increase in the number of shares available for issuance				5.00%
Remaining shares available for issuance				1,967,191
2015 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Plan expiration term			10 years
Vesting period			4 years
Shares issued under early-exercise provisions subject to repurchase				15,951
Unvested stock liability				$ 23,000.0	$ 49,000.0
Common Stock \| ESPP
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Plan expiration date				Jan. 01, 2028
Shares reserved for issuance, authorized				614,223
Common Stock \| Subsequent Event \| ESPP
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Additional shares available for future issuance	330,169
Common Stock \| 2018 Plan \| Subsequent Event
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Additional shares available for future issuance	1,650,846

Equity Incentive Plans - Summary of Activity Under Stock Option Plans (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020 USD ($) $ / shares shares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options Outstanding, Beginning balance \| shares	3,127,391
Options Outstanding, Granted \| shares	1,604,470
Options Outstanding, Exercised \| shares	(170,696)
Options Outstanding, Forfeited and expired \| shares	(139,632)
Options Outstanding, Ending balance \| shares	4,421,533
Options Outstanding,Vested and expected to vest \| shares	4,421,533
Options Exercisable, Ending balance \| shares	1,957,407
Weighted-Average Exercise Price, Beginning balance \| $ / shares	$ 11.52
Weighted-Average Exercise Price, Granted \| $ / shares	19.16
Weighted Average Exercise Price, Exercised \| $ / shares	1.68
Weighted Average Exercise Price, Forfeited and expired \| $ / shares	19.51
Weighted-Average Exercise Price, Ending balance \| $ / shares	14.42
Weighted-Average Exercise Price, Vested and expected to vest \| $ / shares	14.42
Weighted-Average Exercise Price, Exercisable \| $ / shares	$ 11.02
Weighted-Average Remaining Term, Ending balance	8 years 1 month 6 days
Weighted-Average Remaining Term, Vested and expected to vest	8 years 1 month 6 days
Weighted-Average Remaining Term, Exercisable	7 years 4 months 24 days
Aggregate Intrinsic Value, Ending balance \| $	$ 15,930
Aggregate Intrinsic Value, Vested and expected to vest \| $	15,930
Aggregate Intrinsic Value, Exercisable \| $	$ 11,766

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating Loss Carryforwards [Line Items]
Federal operating loss carryforwards	$ 118,200,000
State operating loss carryforwards	124,100,000
Domestic operating loss carryforwards	1,600,000
Federal loss carryforwards	111,900,000
Research and development credit carryforwards	6,881,000	$ 4,676,000
Research and development credit Carryforwards, Other	$ 1,400
Operating loss and research and development credit carryforwards, limitations on use	The Company’s NOL and credit carryforwards to offset future taxable income may be subject to a substantial annual limitation as a result of ownership changes that could occur in the future pursuant to Internal Revenue Code Sections 382 and 383. These ownership changes may limit the amount of NOL and credit carryforwards that can be utilized to offset future taxable income and income tax, respectively. In general, an “ownership change” as defined by the tax code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percent of the outstanding stock of a company by certain stockholders or public groups.
Minimum
Operating Loss Carryforwards [Line Items]
Cumulative change in ownership percentage	50.00%
Maximum [Member]
Operating Loss Carryforwards [Line Items]
Period for cumulative change in ownership	3 years
California
Operating Loss Carryforwards [Line Items]
Research and development credit carryforwards	$ 2,700,000
Federal
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, future taxable income, offset percentage	80.00%
Research and development credit carryforwards	$ 4,500,000
Research and development credit carryforwards, begin to expire	2030
Federal \| Earliest Tax Year
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards expiration year	2035
State \| Earliest Tax Year
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards expiration year	2035

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets:
Net operating loss carryforwards	$ 33,994	$ 15,990
Capitalized research expenses	4,231	4,864
R&D and other tax credits	6,881	4,676
Stock-based compensation	3,233	1,343
Lease liability	1,358	1,560
Accrued expenses and other, net	1,932	886
Total deferred tax assets	51,629	29,319
Deferred tax liabilities:
Right-of use asset	(625)	(702)
Other deferred tax liabilities	(132)	(22)
Net of deferred tax assets and liabilities	50,872	28,595
Less: valuation allowance	(50,872)	(28,595)
Net deferred tax assets	$ 0	$ 0